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ABSTRACT 
The very elderly, are the fastest growing group worldwide and at high risk from 
dementia. Estimated prevalence rates double from 20 percent[%] at 80 to 40% at 90 
years. Identification of risk factors therefore becomes important. 
It is hypothesised that risk factors for incident cognitive decline/dementia in the very 
elderly will be similar to those of younger populations. 
In this thesis I assess the impact of various baseline risk factors on change in cognitive 
score and development of cognitive decline/possible dementia over two year follow-up. 
Risk factors were explored via literature review. The strongest evidence was available 
for blood pressure; (higher pressure increases risk), education; (higher education 
decreases risk), age and gender (older persons, women at higher risk). However, there 
are no studies specifically examining impact of risk factors in those ?.80 years and many 
of the findings in the literature relate to midlife. 
After a two year follow-up of 909 participants from the Hypertension in the very 
Elderly Trial, multivariate analysis showed that a greater fall in cognitive function 
associated with increasing age (p=0.031), lower educational level (p=0.004) and higher 
haemoglobin[Hb] (p=0.002). When the analyses were restricted to patients with a 
baseline MMSE score >23, lower education (p<0.0001) and higher Hb (p<0.0001) 
remained with orthostatic hypotension emerging as a risk factor (p=0.017). 
When incident cognitive decline (falling MMSE score >3 points in a year or to <24) 
was assessed, high Hb (13.8% increase in risk per gm/dl increase) and age (8.1% 
increase for each additional year) were risk factors. Other associations included a higher 
HDL-cholesterol, being Chinese and not taking non-steroidal anti-inflammatory drugs. 
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These results demonstrate that risk factors seen in younger populations are not 
necessarily those of the very elderly. It provides risk indicators for clinicians some of 
which may be modifiable and predictive in a prospective study 
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1. Chapter 1: Introduction and objectives of thesis 
Dementia is a distressing condition and has huge implications for the affected 
individual, carer and society alike. Dementia and cognitive decline are largely 
conditions of the elderly and especially the very elderly. As the world population ages 
the number of dementia cases will rise substantially. Anything that could aid either the 
understanding or the reduction in risk of cognitive decline or dementia is of huge 
importance. In this thesis I evaluate the literature relating to risk factors for dementia 
and cognitive decline and research their impact in a very elderly high risk, hypertensive 
group. I focus on modifiable risks and review the literature using meta-analytitic 
techniques where appropriate. The introduction is divided into three subsections 
covering the definitions of dementia, its epidemiology, and a summary of the multiple 
risk factors described in the literature. Chapter two follows on from this with a detailed 
analysis of individual risk factors and the strength of evidence available for each. After 
this I evaluate the cognitive tests and describe the methods used to carry out an 
international two year cohort study of very elderly hypertensive individuals, (chapters 
three and four); present the results, chapter five, discuss and explore their implications, 
chapters six and seven. 
1.1. Dementia: definitions of dementia 
The word dementia stems from the Latin demens, 'without mind' [1] and was 
used by the Romans as a synonym for madness [2]. Dementia has been defined more 
recently as 'a loss of intellectual capacity to the extent that normal social and 
occupational functions can no longer be carried out' [3]. Classic features of dementia 
include arnnestic memory impairment, deterioration of language, visuospatial deficits 
and motor and sensory abnormalities. Functional and behavioural disturbances increase 
as the disorder progresses and the loss of daily function, such as use of public transport, 
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deteriorates to loss of basic skills such as eating and grooming [4]. Cognitive decline 
manifests as a decline in some cognitive domains and is likely to occur before diagnosis 
of full dementia. Mild cognitive impairment is sometimes categorised as an initial form 
of early dementia or as a separate disorder with a recent definition proposed as 'patients 
with memory complaints insufficient to interfere with everyday function but with 
evidence of impairment on memory tests' (>1.5 SD below normal) 'and preservation of 
other cognitive abilities' [Thompson]. This raises further questions as to the tests that 
should used to define memory impairment and how to define interference with everyday 
function, however, what is commonly agreed in the literature is that a substantial 
number although not all cases are estimated to progress to dementia [5,6]. 
The identification of cognitive decline and dementia cases are subject to 
methodological issues in that definitions of cognitive impairment vary and different 
diagnostic tools for dementia may produce different results [7,8,9]. Other issues that 
may affect case identification include the level of detail available and use of standard 
medical reports, different cultural understandings of impairment and different lifestyle, 
regional and environmental issues such as health inequalities. Lack of premorbid 
assessments and floor or ceiling effects in standard tests are also a consideration [10]. 
Rates of failure, on the part of family members and physicians, to recognize mild 
dementia have been estimated at 97 percent falling to 50 percent for moderate dementia 
[4]. Because of these issues, standardised criteria are commonly used in research and 
practise, the most frequent of these being the Diagnostic Statistical Manual IV [11]. 
This requires the development of multiple cognitive deficits representing a decline from 
previous function with memory impairment a necessary and a prominent early symptom 
with either an additional aphasia, apraxia, agnosia or disturbance in executive function 
[11]. 
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The two most common dementia types are Alzheimer's disease [AD] and 
Vascular Dementia [VaD]; or a combination of the two. Specific diagnostic criteria 
have also been formulated for these and other rarer dementia types. Specific criteria 
include the DSM IV and, in addition, for Alzheimer's disease, the National Institute of 
Neurological and Communicative Disorder and Stroke — Alzheimer's Disease and 
Related Disorders Association [NINCDS-ADRDA] and for Vascular Dementia the 
National Institute of Neurological and Communicative Disorders and Stroke-
Association Internationale pour la Recherche et l'Enseignement en Neurosciences 
[NINDS-AIREN]. Also used with regard to vascular dementia is the Hachinski 
Ischemic Score [HIS], a measure of vascular impact, or Modified Ischemic Score [MIS] 
[12,13] incorporating information from a CT scan (a recommended aspect of diagnosis) 
[4]. 
1.2. Epidemiology of dementia 
Dementia and cognitive decline are largely disorders of ageing and the world has an 
ageing population. In 1950 eight percent of the population were aged 60 or over. This 
rose to 10 percent in 2000 and is expected to reach 21 percent by 2050. The fastest 
growing group are those aged 80 and over, increasing at 3.8 percent per year [14]. The 
number of patients suffering from dementia is also increasing, for example, case 
numbers are projected to almost quadruple in Canada between 1991 and 2031 [15]. 
Similarly in the United States the prevalence of dementia was estimated at 4.5 million in 
2000 and is expected to rise to 13.5 million by 2050 at an estimated cost (1996 figures) 
of $83.9 billion per year [4]. An additional $18,386 per patient per year is also 
estimated as the cost for informal caring in the community [16]. Lost productivity 
increments to the total cost to society as does caregiver health burden, as the caregiver 
tends to neglect their own health and report for care only when their own diseases are 
advanced [16]. Patterns are similar in the European Union with around 1,018,931 men 
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and 2,269,063 women aged 65 and over and suffering from dementia in 2000 [17]. 
Across Europe, in the same year, age standardised prevalence of dementia was reported 
as 6.4 percent overall, broken down as 4.4 percent AD and 1.6 percent VaD. For men 
aged 80-84 years the prevalence rate was 11 percent rising to 22.1 percent in those aged 
90 and over. For women the rates were 12.6 and 30.8 percent respectively. In all 
studies, rates rise with age and tend to be higher in women. [17]. Alzheimer's disease is 
the main contributor at 60-70 percent of all cases [17,18]. As prevalence rates rise so 
does incidence with rates in women rising fastest in those over the age of 80 whilst 
those in men level off [18], particularly for Alzheimer's disease [19] although this has 
not been found in all studies [20]. Studies estimating incidence report a wide range of 
rates per 1000 patient years. From 80 to 84 years of age, rates range from 31 to 96 per 
1000 patient years and, from 84 to 89 years, 45 to 117 per 1000 patient years [18,20,21]. 
In a Sydney-based study an increase in incidence with age has been shown with some 
slowing in the rate for those over the age of 89 years of age and without a sex effect 
[21] and yet, a further study found that females had an increase in incident Alzheimer's 
disease in very old age whereas for males the increase was in vascular dementia and at 
younger ages [20]. 
The differences in incident rates between different studies are probably multi-factorial 
although most study populations are drawn from European and North American 
populations, however the studies agree that the rates increase with increasing age. With 
regard to non American, non European populations, Chinese patients' incidence rates 
have been calculated at 1.15 percent per year in patients aged 65 and over, during a five 
year follow up study. The rates were the same in the illiterate as in the literate subjects 
[22]. Vascular Dementia has been reported as the most frequent cause of dementia in 
Japan, China and Russia [23] although whether this remains the case given changing 
lifestyles and falling stroke rate [23,24] is unclear. Cognitive impairment shows a 
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commensurate increase with increasing age rising from 2.3 percent in 65-74 year olds to 
7.2 percent at 75-84 years and 21.9 percent in those aged 85 and over. [25]. 
The findings from individual studies have been further validated by pooled analyses 
from Eurodem studies including four population based prospective cohorts which also 
found an increase in dementia with increasing age [26]. 
The wealth of data in this area clearly points to an almost exponential increase in 
dementia with age, the majority of cases being of Alzheimer's disease and in females. A 
systematic review supports this but shows a slight slowing in those aged 85 and over 
although the authors also comment that some of the differences between studies with 
regard to the older age groups may be partially due to small numbers [27]. Recruitment 
and selection of patients may also have an impact in the very elderly, for example the 
frailest patients may be excluded from research or inaccessible in the community due to 
living in supported housing or care homes. 
Anything that could reduce dementia incidence would therefore be important 
particularly with a focus on Alzheimer's Disease because of the dominance of this 
condition. Cognitive decline itself should also be considered as affected people require 
more support [25] and may go on to suffer from dementia [28]. 
1.3. Potential risk factors for dementia or cognitive 
decline 
Many factors have been identified in the literature as increasing or decreasing risk of 
dementia or cognitive decline. Some are open to intervention and some not, relatively 
few of them have substantial or robust evidence to support their effects. 
In the Cardiovascular Risk Factors Aging and Dementia Study [CAIDE] study age, 
educational level, sex, systolic blood pressure, body mass index, total cholesterol, 
physical activity and presence of the ApoeE4 allele were identified as risk factors in 
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midlife and included in a 'risk score' calculated both with and without ApoeE4 [29]. 
CAIDE was a population based Finnish study and the authors point out that other 
factors may also have had an impact but data were not available for analysis. Such 
factors are listed as including family history of dementia, triglycerides, High Density 
Lipoprotein [HDL], Low Density Lipoprotein [LDL], waist hip ratio, diabetes and C 
reactive protein [29]. A further study calculating a cardiovascular risk score for 
dementia, based on a modified version of the Framingham cardiovascular risk score, 
identified hypertension, diabetes, high cholesterol and smoking as risk factors [30]. The 
analyses were adjusted for age at midlife, age at case ascertainment, race, educational 
level and sex; data were gathered using a retrospective cohort study from members of 
the Kaiser Permenante Medical Care Program in California and included voluntary 
participants in multiphasic health checks. This may have generated some bias since it 
may have attracted a subset of the population, those that participated in this particular 
medical care program and that were keen to receive higher levels of health care without 
additional financial outlay [30]. Many of the risk factors that have been severally 
identified were shown at midlife and an argument can be made for a life course 
approach to dementia in order to identify the nature and timing of environmental 
influence. Factors proposed for inclusion in such an analysis include ischaemic heart 
disease, obesity, hypertension, hyperlipidaemia, diabetes, childhood intelligence 
quotient [IQ], educational level, socioeconomic status, occupation, lifetime dietary 
history, foetal development and genetics [31]. It is also important to be aware of overlap 
between factors such as diet, socioeconomic status, educational level and health. [31]. 
Further studies have confirmed similar risk factors: diabetes, hypertension, heart 
disease, presence of ApoeE4, and current smoking, [28,32-34] with age, hypertension, 
previous stroke and alcohol as increasing risk of Vascular Dementia in a Japanese 
population [35]. Although the evidence for the effect of ApoeE4 was not universal [36]. 
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A systematic review assessing Alzheimer's disease and atherosclerosis concluded that 
both are susceptible to convergent disease processes including increased risk from 
ApoeE4, hypercholesterolemia, hypertension, hyperhomocystenaemia, diabetes, 
metabolic syndrome, smoking, systemic inflammation, high dietary fat intake and 
obesity [37]. 
Disentangling contributory factors presents a challenge in research including such 
issues as classification of dementia and severity, quantification of risk factor impact and 
exposure, and the need to generate clear hypotheses [38]. It has already been suggested 
that treatment factors could take this multiplicity of risk into account with multiple 
treatments [39] and focusing on the factors that allow intervention is likely to be most 
profitable in the very elderly high risk group who are already at highest risk. The 
following section examines the risk factors that have been linked with dementia in the 
form of a literature review. 
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2. Chapter 2: Literature review 
Chapter two focuses on each area of risk and evaluates the evidence available in the 
literature. The principal risk factors in the literature to date can be divided into two main 
categories. 1: those where intervention can occur and 2: those where it cannot. 
Fortunately the later category includes only age, gender, race and genetics although 
these may all be very strong determinants of outcome. Additional clustering may also 
take place for example lifestyle related factors like body mass index, obesity and waist 
hip ratio may have similar actions. 
Factors where intervention is possible are more numerous and include vascular factors 
(blood pressure both systolic and diastolic), stroke or transient ischaemic attack, 
cardiovascular disease and diabetes. Related to these are cholesterol (total cholesterol, 
low and high density lipoprotein [LDL] and [HDL] respectively) and triglycerides. 
Haemoglobin levels and/or anaemia may also be risk factors as may inflammatory 
processes. Finally lifestyle related factors include smoking, drinking alcohol, diet 
(including folic acid), obesity and to a certain extent education, occupation, 
socioeconomic status and leisure activity. 
The following section is divided into four parts. The first is focused on the risk factors 
where intervention is not possible and includes age, gender, genetics and race. The other 
three sections are based around risk factors where intervention is possible and include 
vascular factors; blood pressure and stroke, heart failure, diabetes and cholesterol level; 
lifestyle factors: smoking, alcohol consumption, diet and obesity, 
educational/occupational attainment and leisure and finally other factors: haemoglobin 
concentration, inflammatory response, depression and nootropic use. In the following 
sections of this thesis the literatures surrounding each area of risk and those relevant to 
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the very elderly, that is the population currently expanding and most at risk, have been 
reviewed. Articles were then selected for detailed examination from an appropriate 
retrospective period of time, a minimum of ten years, and in an appropriately chosen 
population. When the extant literature included relevant reviews these were examined 
and when these were not available full systematic review and meta-analysis techniques 
were used as much as possible to examine the data. A full meta-analysis was carried 
out for the subject areas of cholesterol, body mass index, smoking, alcohol and 
haemoglobin, with cognitive decline, dementia, vascular dementia and Alzheimer's 
disease, in those aged 65 and over. Details of the methodology, results and conclusions 
are contained below in the relevant sections of the literature review. 
Longitudinal data was prioritised as this gives the best indication of causality, cross 
sectional data were only included, to give any possible additional information, when the 
amount of longitudinal data were very small. This allowed the gathering of the most 
relevant and practical information and interpretation of this with regard to the already 
elderly population at risk. Risk factors where intervention is possible were examined in 
the most detail. 
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2.1. Risk factors where intervention is not possible 
2.1.1. Age 
As discussed above, dementia occurs largely in the elderly with prevalence rates 
estimated to double for every ten year increase in age, from around 11 to 12 percent in 
the early eighties rising to over 20 or 30 percent in the over nineties [17]. Incidence 
rates therefore show a commensurate rise with an up to 25 percent increase when 
comparing 80-84 year olds to the 85-90 year olds [18,20,21]. The ageing of the brain 
and vasculature may contribute to this but it is difficult to separate out the effects of 
lifestyle including diet, life events and education. In addition to this the normal ranges 
for brain atrophy and vascular changes are wider in this age group. Despite this, 
however, it is clear that increasing age confers increased risk of cognitive decline and 
dementia. 
2.1.2. Gender 
It has been observed that the prevalence of dementia is higher in females than males, 
even when the longer survival of females is taken into account. It must be recognized, 
however, that there may be many factors that could lead to reportedly different rates in 
addition to sex per se [18,40]. For example males currently aged over 79 are likely to 
have received more education than their female peers or be less likely to have the life 
skills to live alone and so may be more likely to be institutionalised and therefore 
possibly less likely to receive a diagnosis of cognitive decline [40]. 
There are, however, plausible reasons why sex itself may have an impact. Recent 
reviews suggest that the effects of oestrogen include: increased synaptic density in the 
hippocampus, stimulation of nerve cell growth, antioxidant action, increasing levels of 
compounds involved in the production of acetylcholine and positive effects on the 
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seratonergic and dopaminergic systems. It may be therefore that the loss of oestrogen 
post menopause contributes to the apparently higher rates of dementia in women 
[41,42]. Oestrogen may also help protect against coronary heart disease and this too 
may help with regard to the vascular factors in dementia, both vascular dementia and 
Alzheimer's disease [41]. In some studies, including these reviews, the authors have 
observed differential change in the ageing brain of males and females with females 
showing later expansion of the ventricles, greater loss in the hippocampus/parietal lobes 
or decline in glucose metabolism in the brain, although this is not universally agreed 
[41-50] . 
Based on these findings it was thought that oestrogen, or hormone replacement therapy 
may have a positive effect in the treatment or prevention of dementia and early studies 
gave limited support to this [40,42]. However, a Cochrane review published in 2006 
failed to find any evidence for a positive effect of conjugated equine oestrogens on 
cognitive function with the exception of young women injected post surgical 
menopause [51]. Additionally two large double blind placebo controlled trials have 
since been stopped early after one reported a negative effect of hormone replacement 
for cognition/incident dementia [40,52]. The two trials were the Women's International 
Study of Long Duration Oestrogen after Menopause (WISDOM) [52] and the Women's 
Health Initiative Memory Study [WHIMS] [53]. The latter concluded that 
oestrogen/oestrogen and progesterone therapy increased the risk for dementia and mild 
cognitive impairment and that 'hormone replacement therapy to prevent dementia or 
cognitive decline in women 65 years of age or older is not recommended' [53]. Given 
the mixed findings in the literature and the negative findings from a robustly designed 
trial we can conclude that more research on the effects of hormonal changes in women 
may need to be carried out [54]. Recent reports have suggested that it is not the 
23 
oestrogen, but increased levels of gonadtrophins, post menopause that increase the risk, 
at least of Alzheimer's disease [55]. 
2.1.3. Genetics and race 
It has been suggested that Chinese and Caucasian populations differ in terms of 
dementia type with the Chinese manifesting higher levels of vascular dementia and the 
others Alzheimer's disease [56]. People of African origin may also manifest different 
levels of Alzheimer's disease possibly independently of the genetic risk factors which 
act on Caucasian populations [57]. Whether this is due to genetic differences, 
physiological differences or lifestyle is not clear [56] and increased levels of dementia 
identified as vascular could easily be due to higher levels of stroke in certain 
populations. For example, stroke levels are high in the Chinese but have been falling in 
Europe over the last decade. Certainly there are genetic risk factors for dementia and a 
multiplicity of these have been identified for both Alzheimer's disease and vascular 
dementia [58-62]. The best known is the Apolipoprotein E4 allele [Apoe4] which 
confers an increased risk for Alzheimer's disease and cardiovascular disease although 
its presence does not make dementia a certainty and its absence is not a guarantee of 
escaping dementia [63]. 
2.2. Brief summary of risk factors where intervention is 
not possible 
There is good evidence that increasing age and female gender are related to increased 
risk of developing dementia. The evidence for genetics show an increased risk with 
presence of Apoe4 but the evidence for ethnicity is not yet clear. 
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2.3. Risk factors where intervention is possible (vascular 
factors) 
2.3.1. Blood pressure and stroke 
High blood pressure has been linked to an increased likelihood of both cerebrovascular 
accident [64] and white matter lesions (ischaemic lesions in the white matter) [64] both 
of which may impair cognitive functioning [65,66]. Pre-existing hypertension and 
stroke have been shown to be strong predictors of cognitive decline in females aged 65 
and over [67]. In a study of 10 European cohorts Van Dijk et al [68] reported that high 
systolic blood pressure and a high or low diastolic pressure were associated with more 
severe periventricular white matter lesions [68]. Poor control of hypertension was also 
associated with severe lesions; and data from the Cardiovascular Determinants of 
Dementia [CASCADE] study showed pooled relative risk values with a 15 percent 
increased risk (RR 1.15 (95 percent Confidence Interval (1.90-1.23)) for each five 
millimetre of mercury (mmHg) rise in diastolic pressure and a 13 percent increase (RR 
1.13 (95 percent CI 1.06-1.21) for each 10inmHg rise in systolic pressure. Both 
concurrent and previous blood pressure data from this study showed similar results even 
though blood pressure differed by country, with lower levels in France and Spain and 
higher levels in Poland. The German data did not fit clearly with the trends shown in the 
other countries and was not included in the pooled data; the difference being attributed 
to sample selection issues [68]. Pulse pressure and orthostatic change have also been 
associated with dementia [69,70]. The optimal level of blood pressure, though, is not 
known, particularly in the elderly and it has been commented that a blood pressure that 
is too low may lower cerebral perfusion and be dangerous in people with previous risk 
factors and established cerebrovascular disease [71]. 
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The dementia types seen most frequently in the elderly are Alzheimer's Disease (AD) 
accounting for around 40-70 percent of dementias, and Vascular Dementia (VaD) 15-30 
percent [17,18]. Vascular Dementia has traditionally been most closely linked with 
vascular factors but blood pressure has also been associated with the increased 
neurofibrilliary tangles characteristic of AD [72] and in recent years, it has seemed 
increasingly likely that there is an overlap between these two dementias [73]. There 
have been calls for AD to be reclassified as a vascular disorder [74] or for 'dementia' to 
become a multi-factorial disorder [75]. A post-mortem study found that 77 percent of 
the VaD cases (diagnosed pre-mortem) showed AD pathology post-mortem [76]. 
Multiple types of vascular pathology have also been associated with Alzheimer's 
disease including microvascular degeneration, disorders of the blood brain barrier, white 
matter lesions, microinfarctions and cerebral haemorrhages [77]. It has been suggested 
that vascular factors, e.g. atherosclerosis, increase the risk of AD [78] and may play a 
role in cerebral vessel amyloid deposition [79]. Post mortem AD patients do show 
significantly higher levels of cerebrovascular pathology when compared to controls [80] 
although this did not correlate with severity of cognitive decline. A similar finding, that 
small infarcts in AD do not affect the rate of cognitive decline [81], suggests that 
vascular factors may unmask or magnify underlying AD pathology [77, 82] or shorten 
the pre-clinical phase of AD [83]. Alternatively multiple risk factors may be acting 
together [28]. This has resulted in calls for combination therapy [39] and for changing 
several risk factors, although the evidence as yet is far from clear. 
Blood pressure has also impacted on brain atrophy with high diastolic pressure 
predicting increased hippocampal atrophy in a study of over 300 non-demented people 
aged 60-90 untreated for hypertension [84,85]. Similar results were found for Japanese 
American males studied in the Honolulu Asia Aging Study. People not treated with 
anti-hypertensives at midlife were at higher risk of hippocampal atrophy with an odds 
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ratio of 1.7 (95 percent CI, 1.12-2.65). The results were adjusted for age, educational 
level, presence of ApoeE4, smoking, alcohol consumption and dementia [86]. 
Hippocampal volume was greater in non demented participants. However, the same 
pattern of results occurred when the analyses were re-run excluding demented patients. 
Previous studies looking at the relationship between blood pressure and cognitive 
decline and blood pressure and dementia are many and varied. Different population 
groups, assessment techniques and intervals of follow up have combined to produce a 
mixture of findings. Added to this are variations in study design, age range, definition of 
age-related decline, length of exposure to hypertension, different measurements, 
variability at baseline, different data management and differences in determining the 
effects of sex, education, activity levels and health [87]. Cognitive domains affected by 
ageing include episodic memory, verbal fluency, visuoconstructive skills and 
psychomotor speed although cognitive reserve can be present even in the oldest old 
[87]. There are though, many studies in this area [86-120] and the majority of studies, 
particularly those with longitudinal data, support the idea that higher blood pressure is 
related to poorer cognitive function. A summary table of the main longitudinal 
epidemiological studies in the field of blood pressure and cognition, dementia can be 
found in appendix 1. Longitudinal studies will also be discussed below in order to aid 
the investigation of causality and the assessment of risk factors for incident dementia. 
In the Kungsholmen project [88] for subjects assessed after 3 — 6 years of follow up, a 
baseline SBP greater than 180mmllg was associated with a significant adjusted relative 
risk for incident Alzheimer's disease of 1.5 (95 percent CI 1.0-2.3) Low SBP 
(<140mmllg) was not related to incident dementia. Despite this there are confusing 
results for DBP. A DBP lower than 66 resulted in a significant increased relative risk 
for Alzheimer's disease (RR 1.7) and for unspecified dementia (RR 1.5). The 
longitudinal data from the Honolulu Aging study [89] also found an increased risk at 
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higher levels of blood pressure. For every l OmmHg increase in SBP they found a seven 
percent increased risk of what they classified as intermediate cognitive function (a score 
of 82-<92 on the Cognitive Abilities Screening Instrument) and a nine percent increased 
risk of poor cognition (a score of <82). Another study that has shown a relationship, in 
those aged 55-88, between high blood pressure and poor cognitive function is the 
Framingham Heart Study [90]. Systolic and diastolic blood pressure were both inversely 
related to cognitive function over eight years of follow up, for example, Elias et al 
found that for every one mmHg rise in DBP, composite neuropsychological score 
decreased by 0.068 of a standard score unit. Their analyses took accommodation, age, 
education, lifetime occupation and alcohol and/or smoking behaviours into account and 
they comment that earlier findings from this study which were negative were likely to 
have been due to their cross sectional nature. Similar findings were seen in the 
Epidemiology of Vascular Ageing study (EVA) [91]. In the EVA study a community 
based population was followed for five years. Higher blood pressure at baseline was 
related to higher rates of cognitive decline, defined as a drop in the Mini-Mental State 
Exam [MMSE] score of four points during the assessment period. 
Similar studies have found a relationship between blood pressure and cognitive function 
after intervals of time ranging from 4-20 years. A longitudinal population based study 
of 70 year olds in Goteborg [92] Sweden followed 382 men who were free from 
dementia at baseline. High SBP (mean 178mmHg) at 70 years was associated with 
incident dementia at 79-85 years. High DBP (mean 101mmHg) at 70 or 75 years was 
associated with incident dementia at 79-85 years. The authors also note that there was a 
drop in blood pressure in the years just preceding diagnosis as would be expected if low 
blood pressure follows onset of dementia. The Vascular Risk Factors and Alzheimer's 
Disease [93] study with participants aged 65-79 after a mean follow up of 21 years 
found that high systolic blood pressure in midlife was related to incident Alzheimer's 
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disease later (Odds Ratio 2.6 (CI 1.1-6.6)) and in the Uppsala study [94] that high DBP 
at 50 years was related to poor cognitive function at 70 years of age. 
Other studies have found more tenuous results. The Canadian Study on Health and 
Ageing [95] found that a history of arterial hypertension, but not current hypertension, 
in those aged over 65 was associated with increased risk of vascular dementia. The 
Hypertension Detection and Follow up Program [96] in people aged 62-102 years found 
no strong relationship between blood pressure and cognitive function although high 
SBP and DBP measured nine years prior to baseline was associated with lower 
cognitive function and an increased error rate on cognitive assessment. In the case of 
DBP the relationship was U shaped. Baseline SBP was also associated with an 
increased error rate in a U shaped relationship. Testing was with the Short Portable 
Mental Status Questionnaire and the East Boston Memory Test. 
In contrast to the studies reported above, the Washington Heights Inwood Columbia 
Ageing Project, [97] (study population mean age at baseline 75.7), found no association 
between high blood pressure and change in memory, language or general cognitive 
functioning. A history of hypertension was associated with a two fold increase in 
vascular dementia but the history of hypertension was derived from participant self 
report. 
Furthermore the Swedish 'Men born in 1914 study' [98] found that over a 13 year 
period (in subjects aged 68 at baseline, 81 at follow up) an SBP over 179, or DBP over 
109, were associated with less cognitive decline than lower pressures of 160-179 or 
100-109. Only 185 men were available at follow up, however. so the numbers are small 
and may indicate a survivor group with distinct characteristics. Finally the 
Atherosclerosis Risk In Communities [ARIC] [99] study found that, in older subjects, 
partially controlled or uncontrolled hypertension was associated with a significantly 
larger decline in cognitive scores although not in all cognitive tests [99]. Also important 
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is the project's definition of a hypertensive subject as one with an SBP greater than 139 
or DBP greater than 89, having been informed that they were hypertensive by a 
physician or whilst taking anti-hypertensive agents. The latter factor was assessed by 
patients bringing the medication packaging for drugs that they had taken during the two 
weeks prior to the study visit. It is unclear how accurate such an assessment would be 
and it does not take into account length of use or adherence to the drug regimen. It also 
does not help to partial out whether it is the medication or the blood pressure that may 
be having an effect on cognitive function. 
2.3.1.1. Studies that have looked at the effect of 
antihypertensive agents on cognition and dementia 
The Honolulu Asia Aging study [89] analysed subjects in three groups: never treated, 
treated during study visits one-three, and treated at least during study visit four. 
Treatment was assessed by questionnaire at visits 1-3 and by asking patients to bring the 
drug packaging to study visit four. Those that had never been treated and who had high 
blood pressure were found to be at increased risk of poor cognitive function although 
there may be other factors having an influence, for example, reasons why treatment had 
not been previously taken. The Framingham study [90] on the other hand had similar 
groups and assessments of treatment and found that the relationships between blood 
pressure and cognitive function appeared in both treated and untreated groups. Several 
other studies have found that treatment had a positive effect on cognitive function. 
The Uppsala study [94] found that the relationship between blood pressure and 
cognitive decline was strongest in the untreated participants as did the EVA [91,94] 
study with an OR for cognitive decline of 1.9 for the treated group and 4.3 in those 
without. Assessment was by self report and drug packaging availability and similar 
results were seen at two and four years after baseline. The Kungsholmen study [100] 
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assessed a subgroup for treatment use and checked prescription records. They found 
lower incidence and prevalence of dementia associated with treatment at the three year 
follow up visit. They also found that diuretic monotherapy resulted in a slightly lower 
relative risk than other medication types. The population based Rotterdam study [101] 
of 65 years and above with an average follow up of 2.2 years and assessments including 
the MMSE, neuropsychological testing and use of the DSMIV criteria, found that 
treatment at baseline was associated with reduced incidence of dementia. This was for 
both AD and VaD although only the values for VaD were significant (RR 0.30 (95% CI 
0.11-0.99). 
Conversely and in line with its findings for blood pressure and cognitive function the 
Washington Heights study [97] found no effect of treatment on risk estimation for VaD. 
One study [102] attempted to investigate the effect of blood pressure and patient 
adherence to treatment. Data were analyzed in four groups: controlled blood pressure 
and continuous medication usage, controlled blood pressure and intermittent usage, 
uncontrolled blood pressure and continuous usage etc: This study, a longitudinal 
analysis of a community based sample of African Americans, found that treatment 
reduced the odds of cognitive impairment although they found no significant difference 
for treatment type (listed as ACE inhibitors, antiadrenergic, beta adrenergic, calcium 
channel blockers, centrally acting, diuretics and reserpine). 
In summary, many population based studies point towards high blood pressure having a 
negative effect on cognitive function, either within 2-5 years or over a longer time scale, 
and, for SBP, DBP or both. Several studies also support the idea that blood pressure 
lowering treatment may be associated with preserved cognitive function. Unfortunately, 
these studies have heterogeneous populations and assessment tools: they have assessed 
subjects over differing time scales and are not rigorously controlled when 
antihypertensive use is considered. 
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There are, however, six published randomised placebo controlled trials also in this area. 
Five of these were double blind. Four found no particular effect of treatment group and 
two found that the treated group faired better than the placebo group with regard to 
cognitive function. Summary information for randomised controlled trials is given in 
table 1. Since each trial was reported slightly differently; only the most appropriate 
information is presented, the placebo controlled trials are discussed in detail below. A 
full listing of the studies discussed above and examining blood pressure and cognitive 
decline or dementia is given in appendix 1. 
There are also three small randomised trials comparing active treatments against each 
other but only one focused on the elderly. The Hypertensive Old People in Edinburgh 
(HOPE) study was a 24 week double blind trial comparing captopril and bendrofluazide 
in 81 community based residents aged 70-85 years. Patients had hypertension and 
cognitive scores between 20 and 28 on the Mini-Mental State Exam [103]. Despite the 
range of MMSE scores which were likely to include at least some patients with mild 
cognitive impairment or early dementia, practise effects were seen for most of the 
cognitive function tests with only two (paired associates learning test and anomalous 
sentences repetition test) showing a change sensitive to blood pressure change. The 
authors commented on the small sample size and the short length of follow up (24 
weeks) but concluded that it was likely to be the blood pressure change that had an 
affect on cognitive function rather than the drug type. A second trial including 690 men 
aged 60 and over found no treatment type effect using a battery of neuropsychological 
tests. They concluded that there was no adverse effect of treatment and that practice 
effects did not obscure true deterioration in function. There were, however, many 
assessments used (around 20) and comparisons were made by low or high dose 
hydrochlorthiazide use and addition of hydralazine, methyldopa, metoprolol or 
reserpine, all of which may have had different effects on cognitive function. [104]. A 
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third and smaller trial of 69 patients aged 30-70 years [105] comparing losartin with 
hydrochlorothiazide and found that the losartin treated group showed significant 
improvement in MMSE score over 26 weeks whereas the smaller hydrochlorothiazide 
group did not. None of these trials allow robust identification of specific drug effects 
and larger trials would be needed to extrapolate further. The most that can be concluded 
from this is that further research would need to be done in order to thoroughly compare 
different classes of antihypertensives. In addition to the three small trials briefly 
described above, and as mentioned above, there were six placebo controlled randomised 
trials (five were double blind) that looked at use of antihypertensive agents and 
cognitive function/dementia. Of these six, the first four discussed did not find an effect 
of anti-hypertensive treatment on cognition whilst the final two did. 
Systolic Hypertension in the Elderly Program (SHEP) (double blind) 
[106] 
SHEP recruited 4736 patients aged 60 or over, with a mean age 72 years. The inclusion 
criteria required isolated systolic hypertension and the mean BP at baseline was 170/77. 
Patients were followed for 4.5 years with six monthly assessments unless it was felt that 
they needed to be seen earlier than the next scheduled visit. Cognitive function was 
assessed with standardised screening questionnaires for depression and dementia (Short 
Comprehensive Referral Evaluation). Patients were referred on for full dementia 
diagnosis. Despite showing a reduction in stroke events SHEP found no effect of 
treatment group on incident dementia. Active treatment was a diuretic plus a beta 
blocker or a centrally acting antihypertensive. It may be that the beta blocker had a 
negative effect on cognitive function and helped to cancel out any differences between 
the two groups. A recent commentary by Di Bari et al [107] has suggested that the high 
dropout rate in the placebo group in SHEP and the fact that patients who drop out are 
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likely to have poorer cognitive function suggests that the lack of a significant difference 
between the treatment groups may have been due to differential participation. The 
placebo group may also be more likely to leave the trial. This is likely to be true also for 
other trials. 
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Table 1: Summary of randomised 
controlled trials of antihypertensives 
where cognitive decline or dementia 
were assessed 
Study name (first 
published) 
Study population 
Age at baseline 
Study 
duration 
Outcome Treatment (double 
blind unless 
specified) 
Perez-Stable et al 
(1999) [108] 
N=312 
Age range 22-59 years 
diastolic hypertensives 
only 
3 and 12 
months 
No significant differences by 
treatment for 11/13 parts of cognitive 
test battery. Propanolol patients made 












Mean age 69 years 
54 months No significant difference in 3 groups First line diuretic or 









Mean age 72 years 
4.5 years Non-significant effect of treatment, 3 
incidence cases in active group (1.6 
percent) versus 44 (1.9 percent) in 
placebo group 











Mean age 76 years 
(1053 _80 years) 
4.5 years No significant difference in cognitive 
decline between the two groups. Mean 
MMSE change in control group (28.5 
to 27.9) vs. active group (28.5 to 28) 
p=0.2 
Angiotensin Type 1 
(AT1)-receptor 
blocker or placebo 










Mean age 64 years 
3.9 years Incident dementia in actively treated 
group 6.3 percent vs. 7.1 percent in 
placebo group 
Cognitive decline 9.1 percent and 11.0 
per cent respectively 
Significant differences seen in 




diuretic or placebo 
Systolic 
Hypertension in 











Incident dementia 3.8/1000 patient 
years in actively treated group vs. 





diuretic or placebo 
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MRC treatment trial of hypertension in older adults (single blind) [109] 
The MRC hypertension trial followed 4396 patients aged 65-74 (mean age 69) in a 
single blind trial comparing a diuretic or beta blocker with a placebo. SBP at baseline 
was 160-209mmHg and DBP less than 115mmHg. Three hundred and eighty seven of 
these subjects were followed up 9-12 years later. Cognitive function was originally 
assessed in a subgroup of 2284 participants taken from the main trial. Instruments used 
were the paired associate learning test, the trail making test and the MMSE (added at the 
later follow up visits). The rate of change in cognitive function was initially assessed at 
visits one, eight, 21 and 54 months after baseline. There were no differences between 
the three groups at the initial analysis although in the follow up data 9-12 years later it 
was found that poorer cognitive function was associated with slower decline in SBP and 
abstinence from alcohol. This may provide some support for the idea that higher blood 
pressure may be related to cognitive decline although it must be remembered that only 
387 subjects were followed up at the later visits and that the trial was of a single blind 
design and therefore not as robust as double blind. 
A more recent study which was double blind and placebo controlled and which also 
found no effect of treatment group on change in cognitive function is the Study on 
Cognition and Prognosis in the Elderly (SCOPE) [110] 
Study on Cognition and Prognosis in the Elderly (SCOPE) (double 
blind) [110] 
SCOPE recruited 4964 patients aged 70-89 years with a mean age of 76, from 15 
participating countries. One thousand and fifty three of those were over 80. 
Cognitive decline was defined as a drop in MMSE score of four points or more over 
two consecutive visits. Suspected dementia cases were further evaluated by dementia 
experts. Follow up was for an average of 4.5 years and active treatment was an AT1 
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receptor blocker which was compared to placebo. Unfortunately only 16 percent of the 
placebo group remained only on placebo. The remainder received antihypertensive 
treatment and the difference in blood pressure between the two randomised groups at 
the end of the trial was 3.2/1.6 mmHg. It is perhaps not surprising that no difference in 
cognitive change was seen between the two groups since the blood pressure difference 
was small and the antihypertensive drugs used were varied. 
Propanolol versus Placebo trial [108] 
The remaining trial, propanolol versus placebo did not include elderly participants, 
included very short follow up and only those patients who had diastolic heart failure. 
The authors found no particular differences between the groups on cognitive testing 
after 3 and 12 months and did not assess dementia. 
The following two studies found a difference between the anti-hypertensive group and 
placebo group in favour of the treatment arms. 
Perindopril Protection against Recurrent Stroke Study (PROGRESS) 
(double blind) [111] 
In order to enter PROGRESS subjects had to have suffered from a previous stroke or 
Transient Ischemic Attack (TIA). Six thousand one hundred and five were recruited 
with a mean age of 64, 48 percent of whom were hypertensive, as defined by a systolic 
blood pressure of >160mmHg or diastolic pressure of > 90mmHg. Thirty nine percent 
of the trial population were recruited in China and Japan. The mean follow up was 3.9 
years and cognitive function was assessed by MMSE at baseline, 6 months, 12 months 
and annually thereafter. Cognitive decline was defined as a fall in MMSE score between 
two follow up visits of three points or more or, an MMSE below 26 at any follow up 
visit. Median MMSE at baseline was 29. If patients showed cognitive decline they were 
assessed for incident dementia. Treatment was with an ACE inhibitor with the addition 
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of a diuretic if necessary. The authors found a rate of dementia in the actively treated 
group of 6.6 percent compared to 7.1 percent in the placebo group. Similar patterns 
were shown for cognitive decline. However, when they investigated the effect of strokes 
occurring since study baseline they found no effect of treatment in the absence of 
concurrent stroke. It should be noted that a significant proportion of their study 
population were from China and Japan, traditionally countries where the rates of stroke 
and VaD are higher and AD less prevalent than in Europe. This may have resulted in a 
population more likely to show cognitive decline in the form of stroke events. 
Systolic Hypertension in Europe trial (SYST-EUR) (double blind) 
[112,113] 
Syst-Eur was a European based study which found a reduction in dementia incidence, 
both AD and VaD in the actively treated group. 
The Syst-Eur cognitive function side project studied 2902 individuals aged 60-92 years 
(median age 68) with an inclusion criteria of SBP 160-219mmHg. Cognitive function 
was assessed at baseline and annually using the MMSE. Subjects were free from 
clinical diagnoses of dementia at baseline. An MMSE falling from >24 to 23 or below at 
any point during the trial resulted in evaluation for incident dementia using the 
DSMIIIR criteria, Modified Hachinski Score and CT scan. If a CT scan was not 
available a full Hachinski score was used. Final diagnosis was confirmed by a panel of 
experts. Treatment was initially by a Calcium Channel Blocker with the addition of an 
ACE inhibitor or a diuretic if necessary. 
Because the trial reached its primary endpoint for strokes at an interim analysis the 
double blind phase of the study was stopped. At this point there was a significant 
difference between the two groups with regard to incident dementia (VaD and AD). The 
treatment actually showed a halving of incident dementia cases from 7.7 per 1000 
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patient years in the placebo group compared to 3.8/1000 patient years in the actively 
treated group. The study has been criticised for the small number of incident cases and 
was unable to continue due to a successful interim analysis for the trial primary 
endpoint, [114]. However, when the study followed the patients up in an open blind 
phase more cases were accrued and a similar result shown. When the double blind phase 
of the study stopped participants were invited to continue in open blind with the 
majority of the former placebo group starting to take antihypertensive medication. Rates 
of dementia remained similar and at the end of the study rates of incident dementia in 
the former placebo group were 7.4/1000 patient years compared to 3.3 in the former 
active group. It should be pointed out that the blood pressure difference between the 
groups was reduced but that despite this, the findings for incident dementia remained at 
study end [115]. 
Reviews have been carried out in this area and a recent systematic review concluded 
that there is some evidence for an effect of blood pressure in midlife linking to dementia 
incidence in late life although studies in late life are inconsistent if clearly different from 
the midlife picture. Late life studies are fewer in number, include few patients over the 
age of 80 and have differing lengths of follow up, some possibly falling within the 
prodromal phase of dementia [116]. It is not yet clear if low or high blood pressure is 
advantageous in late life and studies are further complicated by different rates and 
heterogeneity of so called normal ageing and the presence of lesions [116]. A meta-
analysis by Feigin et al [117] compared randomised controlled trials and concluded that 
there is some support for the reduction in blood pressure preventing dementia in high 
risk patients over the trial timescale, namely those with vascular disease. This finding 
was despite the fact that studies had been undermined by insufficient power, possible 
measurement errors in diagnosis of dementia, different treatment effects from different 
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agents and bias from missing data and/or variation in baseline factors. See below for a 
forest plot including trials where sufficient data were available. 
Figure 1: Forest plot combining all randomised placebo controlled trials of 
antihypertensive use where cognitive decline or dementia were assessed. 
As shown in the meta-analysis by Feigin et al [117]. 
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Added to this is a further meta-analysis assessing the change in specific cognitive tests 
with blood pressure lowering which concluded that 'anti-hypertensive treatment reduces 
decline in global cortical function and memory [e.g. performance on the MMSE] but 
may not have a similar effect on subcortical executive function and learning capacity 
[118]. 
Finally a Cochrane review assessing the use of blood pressure lowering in patients 
without prior cerebrovascular disease, for the prevention of cognitive impairment and 
dementia included SCOPE, SHEP and Syst-Eur. The authors concluded that there was 
no convincing evidence but that there were significant problems with analysing the data 
due to patients lost to follow up from serious adverse events and high drop out rates 
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plus the effect of patients initially randomised to placebo then taking active medication 
[119]. 
2.3.1.2. Effect of medication type 
There is some suggestion that the positive effect of treatment on incident cognitive 
decline or dementia may be attributed to the type of medication rather than the blood 
pressure change itself. For instance it has been suggested that the reduction in incident 
dementia in Syst-Eur [115] was due to the use of a Calcium Channel Blocker [CCB]. 
This is plausible since an intracellular neuronal surfeit of calcium forms with ageing and 
has been implicated in a series of neurotoxic precursors of degenerative and vascular 
dementias [120]. There has also been an opinion expressed that calcium antagonists 
have anti-platelet activity in vivo and that platelet hyperactivity may be involved in the 
pathogenesis of AD since platelets have been shown to be a main source of amyloid 
precursor protein and beta-amyloid peptide in the blood. [121]. Despite this the 
Canadian Study of Health and Ageing [122] found that the proportion of subjects whose 
cognitive function declined over the study period was significantly higher in the group 
using calcium channel blockers as compared to other blood pressure lowering agents. 
Positive effects of treatment type have been linked to other agents as well with similarly 
mixed results. The main results of the Heart Outcomes Prevention Evaluation (HOPE) 
study [123] reported that ACE-Inhibitors could reduce the risk of ischemic vascular 
events through mechanisms that were independent from their blood pressure lowering 
effects and O'Brien and Bulpitt [124] concluded that ACE-I do not have a deleterious 
effect on cognitive function. 
Diuretic monotherapy was found to have lower relative risk (RR 0.6 (95 percent CI 0.4-
0.9) for incident dementia than other agents in the Kungsholmen population [100]. Data 
on treatment use in this study should be interpreted with caution, however, since the 
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treated group had higher levels of heart disease and stroke than the untreated group and 
as such are not easily comparable. Finally beta-blockers have been implicated in having 
adverse effects on cognitive function [125]. 
Although the effect of different classes of antihypertensive drugs with regard to 
cognitive function are unclear there is substantial evidence that treating high blood 
pressure is beneficial at least in terms of cardiovascular risk and stroke reduction in 
patients under eighty, at least in younger elderly populations [126]. In very elderly 
populations, (over the age of eighty), the relative importance of high blood pressure per 
se and its drug treatment has yet to be determined [126]. There are few randomised 
controlled trials which include sufficient patients over eighty to allow separate analyses. 
The Hypertension in Elderly Patients trial [127] included no patients over the age of 
eighty, neither did the Medical Research Council treatment trial of hypertension in older 
adults study [128] The European Working Party for Hypertension in the Elderly [129] 
and Stop-Hypertension [129] recruited too few patients over that age to show any 
benefit. The Systolic Hypertension in the Elderly Program (SHEP) [106,131] and the 
Systolic Hypertension in Europe trial [132] both found that treatment reduced the 
incidence of non-fatal strokes but had no effect on fatal events in those aged eighty and 
over. A meta-analysis looking at the over eighties and published in 1999 [133] found a 
similar result for stroke events and reduction in major cardiovascular events and heart 
failure with active treatment compared to placebo. However they also found an increase 
in total mortality in the actively treated group with the relationship strongest in double 
blind studies. A pilot study [134] recruiting only patients aged 80 or over also found 
similar results in 1283 subjects randomised to three groups: diuretic, ACE inhibitor and 
no treatment groups. For every stroke that was prevented by anti-hypertensive treatment 
there was an extra non stroke death. Although, as a trial designed to pilot a study this 
trial was not of sufficient power to detect clear differences in stroke or mortality rate 
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and was not blinded [134]. Such a finding clearly has significant implications with 
regard to the treatment of this age group and this would impact on any further use of 
treatment and studies relating to this with cognitive function and or dementia as an 
outcome. In order to examine the question of whether or not the over eighties should 
receive treatment an international double blind placebo controlled trial is underway. The 
Hypertension in the Very Elderly Trial (HYVET) [135] compares a diuretic with the 
optional addition of an ACE inhibitor to matching placebos in 11 countries worldwide. 
As discussed above there are few previous studies examining this population. In 
addition, the majority of the studies investigating or reporting on hypertension and 
cognitive function are based on younger populations with the average age in most trials 
falling between 65 and 75 years although dementia incidence increases with age 
especially over the age of eighty. 
It seems then that there is a high chance that blood pressure has an impact on cognitive 
decline or dementia although the time scale within which it acts and whether blood 
pressure reduction or drug type has an influence is still unclear. 
2.3i. Heart failure 
Heart failure is a syndrome in which patients are typically breathless or have fatigue, 
either at rest or on exertion, or ankle swelling and objective cardiac dysfunction at rest 
[136]. Increased risk of developing heart failure comes with ageing and it occurs 
predominantly among elderly patients with a median age of 75 in community studies 
[136]. Heart failure is also frequently associated with other co-morbidities such as 
hypertension, diabetes and stroke among others [136]. Certainly heart failure is not a 
benign diagnosis and is associated with increased mortality [137]. In addition to this, 
anything that reduces cardiac output may be associated with an increased chance of 
developing ischemia, particularly in the cerebral periventricular white matter [138]. 
Heart failure and arrhythmias may therefore be risk factors for cognitive decline via this 
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or another route and/or an association with other factors that influence cognitive decline 
[139]. Not all studies support this view however and a cross sectional study using MRI 
scans and assessing 24 heart failure and 26 atrial fibrillation patients found no 
association between these disorders and white matter abnormalities as compared to 
controls [140]. Caution needs to be applied, however, as the cross sectional nature of 
this study means that causality cannot be assessed. Despite this, in patients with heart 
failure, cognitive dysfunction has been found and associated with functional disability 
[141] and with co-morbidities such as anaemia, lower systolic blood pressure, as well as 
with lower education, low serum albumin (<3.5 g/dl), high and low sodium (<135 and 
>145 mEq/1) and potassium (<3.6 and >5.0 mEq/1) [142]. Patients with severe 
congestive heart failure also show some limited gains in cognitive function whilst 
undergoing an exercise training program [143], something that is likely to improve 
cerebral perfusion. 
Many studies in this area are, however, cross sectional and in order to try to elucidate 
any causality longitudinal studies are needed. A review of the literature found that there 
are no large scale trials investigating the treatment of heart failure and subsequent 
cognitive change but at least four studies attempted some longitudinal follow up and an 
assessment of cognition. See table 2 for details. 
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term for heart failure 
and follow up survival 
status 
Heart failure is 
associated with an 
increased risk of 
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Alzheimer's disease 
Heart failure — risk of dementia — HR 1.84 (1.35- 
2.51) 
Heart failure — risk of Alzheimer's disease — HR 
1.80 (1.25-2.61) 
Also, 
Antihypertensives may reduce effect of heart 
failure HR 1.38 (0.99-1.94) 
Low diastolic pressure and heart failure additive 
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increased risk of poor 
cognition 
Study not designed to 
look at heart failure 
alone 
At 1 year follow up: 
RR for cognitive decline in patients with heart 
failure: 
1.6 (1.1-2.4) 
At 5 year follow up: 
RR for cognitive decline in patients with heart 
failure: 
1.83 (1.02-3.27) 
No longer significant at 10 year follow up RR not 
given 
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In the studies, outlined in table 2, that looked at heart failure and cognitive decline or 
dementia study populations varied. One study included 515 hospitalised patients 
assessed at entry and discharge although effect of length of stay or follow up time is not 
clear [144]. Patients admitted to hospital may also reasonably be likely to have an 
increased severity of disease which may impact on cognitive function. They may also be 
a selective population in other ways, for example be less able to self care. Nevertheless 
the non heart failure group had significantly better performance on the MMSE, 
attentional matrices, verbal fluency, Reys immediate recall and delayed recall. Just three 
neuropsychological tests showed no difference but these are not as relevant as those 
above when considering the cognitive areas usually involved in decline. Three further 
studies drew participants from the general population, the largest of which was the 
Kungsholmen project which included 1301 participants aged 75 or over with no 
dementia at baseline [145]. The authors assessed risk of developing 
dementia/Alzheimer's disease and classified these diseases according to standard 
criteria of the DSMIV. They also adjusted for several related variables that may affect 
cognitive function or dementia such as SBP, DBP, educational level, sex, stroke etc: 
Participants were followed for nine years and those with heart failure were found to 
have an 84 percent increased risk of developing dementia (HR 1.84, 95 percent (CI 
1.35-2.51) and an 80 percent increased risk of Alzheimer's disease. The authors 
comment on a possible additive risk of heart failure and low diastolic blood pressure. 
Heart failure was diagnosed according to results of clinical examination and according 
to European Society of Cardiology guidelines. 
Two smaller studies used 206 people, from a city registry, aged 70 years and over and 
followed up for four years [146], and 300 from a birth registry and born in 1904, 1909 
or 1914 [34]. Both assessed cognitive function, the first using a neuropsychological test 
battery and the second a clinical dementia rating scale and the MMSE. Heart failure was 
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diagnosed via medical examination and both adjusted for age with one adding baseline 
MMSE [34] and the other further variables such as socioeconomic status [146]. For the 
206 participants the summary intelligence score fell over four years in those with heart 
failure at baseline but it was difficult to partial out the effects in patients as due to heart 
failure alone. For the 300, the RR for cognitive decline at one year was an increase of 
60 percent (RR 1.60 (95 percent CI 1.1-2.4)) and at five years 83 percent (RR 1.83 (95 
percent CI 1.02-3.27)). Interestingly the data were not significant at the 10 year follow 
up although the details are not given and no information regarding decedents or 
participant characteristics versus non participants are presented to aid any explanation 
of this. 
None of the studies were designed primarily to assess heart failure and subsequent 
cognitive decline/dementia and study quality and aims varied. Many issues were not 
fully accounted for such as time of decline or time to dementia onset, loss to follow up 
or deaths during follow up and varied follow up periods. Added to this is the possibility 
of publication bias, i.e. those findings which report an association are more likely to be 
published. It may therefore be difficult to judge without further research but the balance 
of available findings suggests that heart failure may be a risk factor for later cognitive 
decline or dementia. 
2.3.3. Diabetes 
Diabetes is known to be a risk factor for stroke and associated with increased vascular 
events including silent cerebral infarcts and adverse changes to cerebral 
microvasculature [147,148]. Also linked to type two diabetes is increased cortical 
atrophy which is also linked to dementia [147, 148]. In a cross sectional study patients 
with diabetes and Alzheimer's disease (n=26) had more cortical atrophy and infarcts 
that those with Alzheimer's disease alone (n=47). It should be mentioned though, that 
the two groups had similar low MMSE scores of 20.8 and 21.6 respectively and the 
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patients with both disorders (diabetes and AD) had higher rates of vascular events and 
hypertension [148]. Infarcts, atrophy and other mechanisms have been proposed to 
explain any links between diabetes and dementia or cognitive impairment and these 
include glucose toxicity and change in insulin resistance although an interaction 
between such factors is the most likely outcome. 
Longitudinal studies suggest that a history of diabetes and lack of treatment may be 
associated with lower cognitive function at follow up [149-151] and two systematic 
reviews have been performed. The first, published in 2003, was a Cochrane review and 
focused on the effect of treatment of type II diabetes mellitus on the development of 
cognitive impairment and dementia [152]. The conclusion drawn from that review was 
that there were insufficient data available at the time. A later review published in 2006 
focused on the risk of dementia in diabetes mellitus and identified fourteen longitudinal 
studies of varying quality. The study populations included participants from white, 
Hispanic, black and Asian ethnicities and most included people both in and outside 
institutions. Only one study employed a Consort type diagram to detail participant flow 
through the study and very few gave detailed accounts of drop outs. Length of follow up 
also varied. Four studies assessed diabetes in midlife and had follow up visits in late 
life, the remainder included participants aged sixty five or over for both baseline and 
follow up data collection. Although the authors felt that a formal meta-analysis was not 
possible due to the wide variation in study methodology, quality or study, population 
size, age and follow up, they did conclude that there seems to be an increased risk of 
dementia in people with diabetes mellitus. It seems that this would apply both to 
Alzheimer's disease and to Vascular dementia but the data given were insufficient to 
reach a conclusion [148]. It should also be noted that the studies also varied widely in 
the factors for which they adjusted in their analysis and this could have influenced the 
49 
results if other cardiovascular factors were co-morbid with diabetes, e.g. hypertension, 
and masked the effect of diabetes itself. 
2.3.4. Cholesterol level 
As discussed above, there has been an increasing body of evidence pointing towards 
cardiovascular risk factors prompting an increased risk of dementia including dementia 
of the Alzheimer's type [37,112,113,115,153] In addition to this, the prevalence of such 
risk factors in the population is rising, not just in the United States and western Europe 
[154] but also in developing countries like China [155,156] possibly due to increasing 
prosperity, lowering of physical activity and adoption of some western dietary habits. 
Access and ability to consume high cholesterol foods, increasing body mass index and 
higher plasma cholesterol all contribute to cardiovascular risk and may have a 
relationship with dementia. 
Cholesterol levels may also affect cognitive function or incident Alzheimer's disease by 
influencing the production of the Amyloid Beta protein [An] a key part of the 
Alzheimer' s disease process [157]. High levels of High Density Lipoprotein cholesterol 
[HDL] in late and midlife have also been found to be associated with higher levels of 
the amyloid plaques and neurofibrilliary tangles (characteristic of AD). 
Lowering cholesterol, or reducing certain cholesterol types in the diet such as trans fatty 
acids may therefore reduce cognitive decline, and cross sectional studies support this 
[159,160]. Lipid lowering agents (both statins and fibrates) were associated with 
decreased prevalence of dementia and hyperlipidaemia with increased prevalence [161]. 
Statins maybe beneficial in addition to their cholesterol lowering effects. They have an 
antioxidant action [162] and may act on Ail metabolism promoting the non-
amyloidogenic pathway and therefore reducing creation of neuritic plaques [163] 
although the evidence does not wholly support this [164]. There are many cross 
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sectional studies in this area and some longitudinal but randomised controlled trials are 
rare although many authors have called for them to take place [165,166]. A recent meta-
analysis of seven observational studies supported a risk reduction for statins but not 
other lipid lowering agents [167]. There are two Cochrane reviews in this area, although 
neither assesses cholesterol, cholesterol lowering, and all cause dementia. The first 
review published in 2001, assessed statins for the prevention of Alzheimer's disease 
[168] and the second in 2006 assessing the use of Omega 3 fatty acids for the 
prevention of dementia [169]. The first concluded that there is no good evidence to 
recommend statins for reducing the risk of Alzheimer's disease despite a growing body 
of support [168] and the second, similarly, that there is a growing body of evidence in 
support of Omega 3 fatty acids but not enough good evidence to support its 
dietary/supplemental use [169]. Since the publication of the 2001 review there have 
been two randomised placebo controlled trials using statins and assessing cognitive 
function although neither have shown an effect on cognition [170,161]. 
The statistical power of both studies was, however, limited by low incident cognitive 
decline. New trials are ongoing, however, and are expected to report within the next few 
years [169,172,173]. 
In order to fully examine the current literature base with regard to the relationship 
between dietary cholesterol, plasma or serum cholesterol, statin use and incident 
cognitive decline or dementia and in the absence of an existing relevant review in the 
literature, a systematic review was carried out. 
2.3.5. Systematic review and meta-analysis: cholesterol 
The databases Medline, Embase and Psychinfo were searched for English language 
publications occurring between 1966 (Medline), 1980 (Embase), 1985 (Psychinfo) and 
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June 2006. When available, standard search categories were also used as matched the 
terms below. All searches were limited to subjects aged 65 and over. 
Dietary cholesterol: 
Search terms 'diet' or 'cholesterol' or `I-IDL cholesterol' or 'LDL cholesterol' or 
`VLDL cholesterol' and 'dementia' or 'vascular dementia' or 'multi infarct dementia' 
or 'Alzheimer's disease' or 'cognitive impairment' or 'cognitive decline' were used as 
keywords. 
Cholesterol: 
Search terms 'cholesterol' or `HDL cholesterol' or 'LDL cholesterol' or 'VLDL 
cholesterol' and 'dementia' or 'vascular dementia' or 'multi infarct dementia' or 
`Alzheimer's disease' or 'cognitive impairment' or 'cognitive decline' were used as 
keywords. 
Statins: 
Search terms `statins', 'hydroxymethylglutaryl coenzymeA reductase inhibitors' or 
statins that had been identified as standard search categories within the search engine 
(lovastatin, or simvastatin, or pravastatin) and 'dementia' or 'vascular dementia' or 
`multi infarct dementia' or 'Alzheimer's disease' or 'cognitive impairment' or 
`cognitive decline' were used as keywords. 
Studies were ranked on a methodological basis with randomised studies highest 
followed by case control and epidemiological population studies. Cross sectional 
studies, case studies, letters, consensus opinion from conferences and expert opinions or 
editorials were not included. In order to aid investigation of causality only longitudinal 
studies were assessed in detail. In order to ensure that appropriate systematic review 
methodology was retained an additional researcher participated in the double reading of 
all abstracts, consensus was obtained for inclusion and extraction tables checked by the 
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second reviewer . All papers were quality assessed using a scored check list including 
areas such as their study design, sample size, statistical analyses, presentation of results 
[173]. The results follow. 
Dietary cholesterol 
Searches identified three papers relating to two longitudinal studies, from a total of 15 
papers identified initially in Medline, four papers in Psychinfo and 28 papers in 
Embase. 
Cholesterol 
Searches identified 16 papers relating to 11 longitudinal studies, from a total of 399 
papers initially identified in Medline, 111 papers in Psychinfo and 396 papers in 
Embase. 
Statin use 
Searches identified 11 papers relating to nine longitudinal studies, from a total of 63 
papers identified initially in Medline, 19 papers in Psychinfo and 47 papers in Embase. 
There was some overlap with three studies appearing in both the serum cholesterol and 
statin categories. 
There were no randomised controlled trials assessing cognitive function/dementia as 
their primary endpoint but there were two trials that used statins versus placebo control 
and assessed cognitive function as a secondary outcome. The Heart Protection Study 
and the PROspective Study of Pravastatin in the Elderly at Risk [PROSPER] [170,171]. 
The vast majority of studies were observational and populations ranged from a few 
hundred to several thousand with follow up from 1 to 30 years. Populations were largely 
homogenous and drawn from Europe, particularly northern Europe, North America or 
Australia with one study including African Americans [173,175]. 
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Dietary cholesterol 
The two studies in this area found conflicting results. In the Chicago Health and Aging 
Project [CHAP] there was a linear relationship between increased intake of saturated 
and trans-saturated fat and reduced cognition, p values for trend were p=0.03 and 
p=0.06 respectively. There was also a significantly increased risk of Alzheimer's 
disease with increased intake of trans-unsaturated fat, [173,175] see table 3. Conversely, 
in the Rotterdam study increased intake of saturated and trans-unsaturated fat had a 
significantly reduced risk of Alzheimer's disease. There were no significant results for 
Vascular Dementia. The analyses were repeated excluding people with myocardial 
infarction, diabetes, lipid lowering agents, or with less than two years of follow up with 
similar results [176]. It was not possible to combine the two studies in a meta — analysis. 
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study — Chicago 
health and ageing 
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N=2560 >=65 at 
baseline. 
Follow up of 6 years 
attack, stroke or 
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Mean follow up 3.19 
years 
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Average of 4 tests 
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factors, antioxidant and 
other dietary fat intake 
sex, race, 
education, Apoe4 and 
other fats 
No OR/HR/RR 
Trend tests for saturated fat p=0.03 for transunsaturated fat 
p=0.06 (i.e. higher intake associated with greater decline) and 
for monounsaturated fat p=0.1 
5th quintile only reported below. (2nd and 3rd quintiles for 
transunsaturated fat are also significant — no other significant 
results for other fats or quintiles) 
Saturated fat: Median intake 25.1 grams/day RR 3.6 (0.7-18.6) 
Transunsaturated fat: Median intake 4.8 g/d RR 5.2 (1.5-18.5) 
Polyunsaturated fat: Median intake 14.5 g/d RR 0.3 (0.1-1.5) 
Monounsaturated fat: Median intake 27.7 g/d RR 0.2 (0.02-1.5) 








Mean age at 
baseline 68 (SD 8) 
Mean follow up 6 
years (SD 1.3) 
Participating 
subjects were 
younger, more likely 
to be male and to 
have higher levels of 
education than the 
general population. 
Dementia 
3 step procedure — 
screening with the 
MMSE and Geriatric 
mental state 
schedule. Poor 
performers were then 
assessed with the 
CAMDEX battery, 
saw a neurologist and 
neuropsychologist, 
had an MRI if possible 
and dementia 
diagnosed according 








over the past 
year. There 
was also an 
interview with 







Age, sex, total energy 
intake, education, 
vitamin E intake. For 
Alzheimer's disease 
adjustments were also 
made for smoking, 
alcohol, fruit and 
vegetable intake, dietary 
supplementation and 
BMI 
There were few cases of 
Vascular dementia n=29 
RR for standard deviation [SD] increase in intake in grams per 
day: 
Alzheimer's disease 
Saturated fat: SD increase 7.2 g/d RR 0.83 (0.70-0.98) 
Transunsaturated fat: increase 1.0 g/d RR 0.80 (0.65-0.97) 
Cholesterol: increase 0.062 g/d RR 0.86 (0.72-1.02) 
Vascular dementia 
Saturated fat: SD increase 7.2 g/d RR 1.03 (0.73-1.46) 
Transunsaturated fat: increase 1.0 g/d RR 1.01 (0.71-1.44) 
Cholesterol: increase 0.062 g/d RR 1.04 (0.72-1.5) 
Poly and mono unsaturated fats (MUFA, PUFA, N-6 PUFA & 
N-3 PUFA) were not significant 
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Methodological issues — dietary cholesterol 
Fat intake was assessed with a food frequency questionnaire [175] or diet checklist 
[176] indicating food consumed within the past year and a semi quantitative food 
frequency questionnaire plus interview with a dietician. Both studies used standard 
means of assessment for cognitive function and dementia. Study size and participant age 
was adequate with between 815 up to over 5000 participants included, aged over 65 or 
with a mean baseline age of 68 [173,175,176] The Northern European population 
included a younger population at baseline but followed subjects up for longer, a mean of 
6 years (SD 1.3) [176] as compared to the 3.16 years for Alzheimer's evaluation and 6 
years for evaluation of cognitive function in the Northern USA population. The 
Rotterdam study made multiple adjustments for potential confounders including 
smoking, alcohol, dietary factors, body mass, age, and education. The adjustments were 
only used for the analysis of Alzheimer's disease cases as they state that those of 
Vascular dementia were too few [176]. The Chicago study also adjusted for 
demographic information, plus age sex, race, education, ApoeE4 presence and other fat 
intake (for Alzheimer's disease) and cardiovascular risk factors, antioxidants and other 
fats (for cognitive function) [173,175]. The Rotterdam study also noted that participants 
were younger, more likely to be male and more educated than the general population 
[176]. 
Serum cholesterol 
The results were also mixed for serum/plasma cholesterol. 
There were six studies that assessed cognitive impairment: two that found no significant 
results [170,177,178], two who found that higher total cholesterol was associated with 
decreased risk of cognitive decline [179,180], one, that lower LDL was associated with 
less risk [181] and one that higher HDL was protective [180]. 
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Six studies also reported results for dementia. There was a suggestion that higher total 
cholesterol was associated with lower risk of dementia, [180,183-185] at least until the 
age of 79 [185]. Although three further studies found no such significant relationship 
[186-188]. High non-HDL was also associated with an increased risk of Vascular 
dementia [183]. It was not possible to combine the studies in a meta — analysis because 
the results were reported in too disparate a fashion with different levels of fat used for 
analyses. 
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MMSE was used — a 2 point 
drop over 3 years classified 





The group with Apoe4 had higher cholesterol values and more cognitive decline (defined as fall >2 
points on the MMSE) 
With ApoE4 & no cardiovascular risk factor cognitive decline high total cholesterol OR 2.5 (1.0-6.0) 
With ApoE4 & no cardiovascular risk factor cognitive decline high HDL cholesterol OR 3.7 (0.7- 
19.2) 
With ApoE4 & with cardiovascular risk factor cognitive decline high total cholesterol OR 4.0 (1.6- 
10.0) 
With ApoE4 & with cardiovascular risk factor cognitive decline high HDL cholesterol OR 6.2 (1.6- 
23.6) 
Reference value taken as 
<=6.5 total cholesterol 





N=1449 aged 65-79 at 
the last examination in 
1998. 
Average follow up 21 
years (range 11-26) 
Cognitive 




MCI classified using the 
Mayo clinic criteria 
(MCADRC) 
If MMSE was <=24 clinical 
exam and 
neuropsychological testing 
Dementia also diagnosed 
using DSMIV & NINCDS- 
ADRDA & MRI scan 
Age, body 
mass index 
• MCI OR 
Cholesterol >=6.5 	1.9 (1.2-3.0) 
Risk groups: 
One risk factor 2.2 (1.3-3.9) 
Two risk factors 2.3 (1.1-4.8) 
Dementia seems to show a similar pattern but no OR given Reference values cholesterol 
<6.5mmol/lor no risk factor group. 





1026 with no stroke or 
dementia to the 1988- 
1989 visit. 





MMSE and Clinical 
Dementia Rating scale 
(CDR) 
Diagnosis of dementia made 
using DSMIV, NINCDS 
ADRDA + symptoms had to 












Per 10mg/dlor 0.3mmol/l increase in cholesterol HR 0.95 (0.87-1.04) 
Alzheimer's disease 
Mean total cholesterol over all exams until before baseline 0.95 (0.87-1.04) 
Total cholesterol at baseline visit 0.97 (0.90-1.05) 
HDL cholesterol at baseline visit 1.10 (0.93-1.31) 








How information was 
gathered on cognitive 
function. 
What was 
adjusted for in 
the analyses 
Statistics if available. 
OR=Odds RatioRR=Relative RiskHR=Hazard Ratio 
(numbers in brackets are 95%. confidence intervals) 
Results used are those from the adjusted analyses unless otherwise stated. 




study n=1147 with 
follow up of 7 years 
Without dementia or 








ability and memory 
Classified subjects as ok, 
cognitively impaired, 









Nothing was significant after adjustments. No OR/HR available for cholesterol and all 
neuropsychological categories. 
baseline DSMIV) comparisons Lipid lowering agents were not associated with 
incident Vascular dementia HR 1.45 (0.65-3.28) 
Dementia 




and using 'standard 
OR incident Alzheimer's disease HR 0.88 (0.44-1.76) 
Risk of Vascular dementia increased with increasing quartile of non HDL — trend p=0.04 and 
LDL levels p=0.04 
Mean age 78.4 (SD Alzheimer's research criteria' Higher quartiles of total cholesterol were associated with lower risk of incident Alzheimer's 
Reitz et al 
6.2) years disease and 
Vascular 
Alzheimer's disease 
diagnosed using NINCDS 
Age, sex, 
education, race 
disease after adjustment for demographics and body mass, Apoe4, diabetes, heart disease 
and hypertension HR 0.48 (0.26-0.86) p=0.04 for trend — no other plasma lipid was associated 
(2004) 
[183] 
dementia ADRDA, Vascular dementia 
if history or evidence of a 
stroke 













How information was 
gathered on cognitive 
function. 
What was 
adjusted for in 
the analyses 
Statistics if available. 
OR=Odds RatioRR=Relative RiskHR=Hazard Ratio 
(numbers in brackets are 95% confidence intervals) 
Results used are those from the adjusted analyses unless otherwise stated. 
Mielke et al 
(2005) 
[185] 
From Goteborg study: 
Aged 70 at baseline 
and re-examined at 75, 
79, 81, 83, 85 & 88 
N=382 
Dementia 
At visits 70, 75, 79, 81 & 85 
dementia was diagnosed 
based on severe 
disorientation in time and 
place and long standing 
memory impairment plus 
collateral information from 
medical records 
At visits 85 & 88 the 
DSMIIIR was also used 
Subjects with dementia at 
70yrs visit were removed 







Only 4th quartile of cholesterol values reported below. 
Total cholesterol: mmo1/1 
Age 70 	8.03-11.44 HR 0.31 (0.11-0.85) 
Age 75 	7.03-9.29 HR 0.20 (0.05-0.75) 
Age 79 	6.82 -9.10 HR 0.45 (0.17-1.23) 
Triglycerides: mmo1/1 
Age 70 	1.44-2.54 HR 0.45 (0.18-1.11) 
Age 75 	1.79-3.90 HR 0.91 (0.37-2.24) 
Age 79 1.70-3.80 HR 0.77 (0.30-1.93) 
No other quartiles were significant 
Li et al 
(2005) 
[187] 




changes in thought 
study) >=65 at 
baseline seen 
biennially thereafter. 
Mean follow up 5.6 
(SD 1.8) years 
Free from cognitive 




Cognitive abilities screening 
instrument [CASI] — if 
performance was poor 
subject had 
neuropsychological testing, 
MRI/CT scan and dementia 
was diagnosed with DSMIV 
& NINCDS-ADRDA — a 
follow up visit to verify 
dementia symptoms 
continuing also took place 












those with a 




Only highest quartile of total cholesterol and lowest quartile of HDL cholesterol values reported 
below. 
Dementia: 
Total cholesterol: >254 mg/dl HR 1.16 (0.81-1.67) 
HDL cholesterol 43 mg/dl HR 1.04 (0.69-1.55) 
Alzheimer's disease: 
Total cholesterol: >254 mg/dl HR 1.00 (0.61-1.62) 
HDL cholesterol 43 mgldl HR 1.23 (0.71-2.15) 
No other quartiles were significant either 




Heart protection and 
estrogen/progestin 
replacement study 




Modified MMSE scores 
<84/>1.5 standard 
deviations below the mean 









A reduction in LDL cholesterol over the 4 years of follow up was associated with non 
significant decreased odds for cognitive impairment 0.61 (0.36-1.03) as compared to the 
women whose LDL cholesterol rose 









How information was 
gathered on cognitive 
function. 
What was 
adjusted for in 
the analyses 
Statistics if available. 
OR=Odds 	 brat et 	RiskHR=Hazard Ratio 
(numbers in brackets are 95% confidence intervals) 




Gaw et al 
(2005) 
[178] 
PROspective Study of 
Pravastatin in the 




N=2804 men, n=3000 
women 
70-82 years 
















Picture word learning test, 
letter digit substitution, 
stroop test (executive 
function) MMSE 
Baseline compared to last 




















Difference between groups, 
Letter digit substitution -0.01 (-0.24_0.23) p=0.95 
Picture word learning test 0.02 (-0.12_0.16) p=0.80 
Stroop test 0.8s (-0.4_2.0) p=0.19 
MMSE 0.06 (-0.04_0.16) p=0.26 
No association with cognitive function scores except marginally for delayed verbal learning 
p=0.028 
Moroney et al 
(1999) 
[186] 
N=1111 with a mean 
age of 75.0 (SD 
5.9) at baseline 
followed for a mean 
of 2.1 years (range 
1-7.8 years) 
Dementia 
Using the NINCDS-ADRDA 
NINCDS AIREN criteria 
and medical records with a 
case conference to 
determine diagnoses. 









Used time to 
event and age 
at onset of 
dementia so did 




Alzheimer's disease RR 
LDL mmo1/1 
<=2.47 — reference category 
>2.47<=3.04 RR 0.83 (0.56-1.23) 
>3.04<=3.70 RR 0.75 (0.51-1.10) 
>3.70 RR 0.77 (0.51-1.15) 
Dementia with stroke RR 
LDL mmol/lmodel A 
<=2.47 — reference category 
>2.47<=3.04 RR 1.2 (0.5-3.0) 
>3.04<=3.70 RR 1.8 (0.8-4.3) 
>3.70 RR 2.9 (1.3-6.7) 
LDL mmol/l model B 
<=2.47 — reference category 
>2.47<=3.04 RR 1.8 (0.7-4.7) 
>3.04<=3.70 RR 2.4 (1.0-5.8) 
>3.70 RR 4.1 (1.8-9.6) 
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Methodological issues — serum cholesterol 
The studies reporting on cholesterol were varied in their outcome but most used 
standard assessment criteria for cognitive disorders, e.g. DSMIIIR [185] and adjusted 
for age, sex and educational level. Follow up time also varied but the vast majority 
followed patients for at least two years, long enough to exclude undiagnosed dementia 
at baseline. The populations were mostly older than 70 years, (see table 4). 
Statin use 
There were two randomised placebo controlled trials of statin use, the PROspective 
Study of Pravastatin in the Elderly at Risk PROSPER trial and the Heart Protection 
Study [HPS] [171]. Neither found any effect of statins on cognition even assessing 
subtle differences in cognitive function (see table 5). In addition to the trials there were 
other studies in this area showing a trend for lower likelihood of cognitive impairment 
[181] and a slower fall in modified MMSE score after seven years of follow up with 
continual statin use [189]. 
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Table 5: Details of randomised placebo controlled trials where statin use and cognitive 
decline was assessed 
Author 
How information 
was gathered on 
cognitive 
function. 
What was adjusted for in 
the analyses 




(numbers in brackets are 95 percent 
confidence intervals) 
Results used are those from the adjusted 
analyses unless otherwise stated. 














compared to last 
on treatment 
score 




— as appropriate 
Age, education, sex, 
body mass index, 
systolic and diastolic 
blood pressure, 
smoking, history of 
diabetes, hypertension 
and country 
No differences and similar decline in 2 
randomised groups 
Letter digit substitution (change in score) 
-0.01 (-0.24_0.23) p=0.95 
Picture word learning test (change in score) 
0.02 (-0.12_0.16) p=0.80 
Stroop test (change in score) 0.8s (-0.4_2.0) 
p=0.19 
MMSE (change in score) 0.06 (-0.04_0.16) 
p=0.26 
No association with cognitive function scores 













Analysis by intention to 
treat 
Factors adjusted for not 
clear for cognitive 
function analyses 
No differences between the 2 randomised 
groups 
Still not significantly different when examined 
subgroups by age, previous cerebrovascular 
disease etc. 
In addition to the two randomised controlled trials with statins, one further study found 
no significant results for dementia or Alzheimer's disease and statins [190] and one no 
effect of lipid lowering agents [183]. Two others found a protective effect of statin use 
on all cause dementia (under 80 years) [191] or a decreased risk of Alzheimer's 
disease/mixed dementia [HR] 0.56 (95 percent CI 0.35-0.92) [192]. A further study 
found an Odds Ratio [OR] for dementia of 0.55 (95 percent CI 0.32-0.93) among statin 
users but only when looking at the data as a case control study with the case exposure 
until diagnosis and the control exposure until study end. The authors comment that 
when using a time dependant proportional hazards model they found no significant 
results [193]. 
Where results could be combined I entered them into a meta-analysis. The results were 
found to be sufficiently homogeneous, (Cochran Q=89.90) p=0.117, to allow the 
production of a forest plot and a combined risk ratio, see figure 2. The combined risk 
ratio was 0.84 using a random effects model (95 percent CI 0.64-1.09). Despite the non- 
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significant results from the randomised controlled trials, other studies suggest a 
protective effect for statins. 
Figure 2: Forest plot combining longitudinal studies where statin use and cognitive 
decline were assessed 
Summary meta-analysis plot [random effects] 
[194Nementia<80 OR 





















1.19 (0.82, 1.75) 
1.19 (0.35, 2.96) 
0.82 (0.46, 1.46) 
0.88 (0.44, 1.76) 
0.56 (0.35, 0.92) 
0.67 (0.42, 1.05) 
(0.64, 3.28) 1.45 
0.84 (0.64, 1.09) 
I 	 I 	I 	 I 
0.01 0.1 0.2 0.5 	• 
• ratio (95% confidence interval) 
I 	 I 
2 5 
Methodological issues - statins 
The mean follow up was 3.2 [170] and 5 years [171] for the two trials, PROSPER and 
HPS respectively, and although the HPS study had some younger participants both 
studies included the elderly. The cognitive testing was less robust for the HPS as they 
used a telephone testing system [171], although it was validated. PROSPER trained 
their cognitive testers and used alternative equivalent versions of cognitive tests to 
avoid practice effects [194]. The population studies were able to be combined but had 
different endpoints and so despite producing a positive result need to be interpreted 
carefully. 
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To summarise the findings for cholesterol, dietary, plasma and statin use, it is difficult 
to draw any conclusions either in favour of, or against high or low dietary or plasma 
cholesterol and statin use at least with regard to their impact on either cognitive function 
and/or dementia. Although most studies included participants of an appropriate age and 
used recognised assessment or diagnostic tools the other factors that were controlled for 
varied enormously. It may also be that different follow up times may produce different 
results and it may be that as people begin to suffer from early dementia their dietary 
intake changes. In the Rotterdam study the higher risk participants may already have left 
the study due in part to higher rates of cognitive decline and this may explain the 
different findings in the two dietary studies although it cannot be certain that this was 
the case. Food frequency questionnaires are also flawed and recall for reporting intake is 
affected by cognitive decline. 
It seems clear that further research is necessary before any conclusions can be drawn, 
particularly including more representative and wider ranging population groups. This 
may be particularly useful for dietary cholesterol as the two included studies were both 
based in northern areas with cold winters and high likelihood of habitual easy access to 
a high cholesterol diet, especially in winter. 
Although the meta-analysis showed a reduced risk ratio for statin use this must also be 
interpreted with caution since not all studies could be included due to the disparate ways 
in which results were presented. In addition, they include differing outcomes of 
dementia, Alzheimer's disease, Alzheimer's disease and mixed dementia combined and 
cognitive function fall. It is important to remember that there are many interacting 
factors that could be affecting the outcomes in these studies, for example worse 
cardiovascular health could link with statin use as well as more disadvantaged 
background, including intrauterine environment. Conversely people who can afford to 
use statins may come from a more privileged background and this too may vary by 
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country and population. For example treatment is free in the UK but not in the USA. 
Findings related to former users may also be subject to bias as people may stop taking 
their medication as their cognition starts to fall. Although there were two randomised 
controlled trials of statin use neither was powered to assess cognition and it may be that 
a greater effect could be seen with further data and more account of other contributory 
risk factors 
Publication bias may also exist such that the studies that could be found in the literature 
for dietary cholesterol, plasma/serum cholesterol and statin use were more likely to have 
significant and possibly positive results. It was not possible to examine this fully since 
not all studies could be incorporated into a meta-analysis, however, the selection of 
positive and negative outcomes would argue against a bias being likely. The 
cardiovascular risks associated with a high cholesterol diet and high plasma cholesterol 
are well known and the efficacy of statins in this area demonstrated. It is time to explore 
this area further specifically in order to establish whether statins or cholesterol level do 
have an impact on cognitive decline taking into account and controlling for other 
frequently existing conditions and medications. 
2.4. 	Brief summary of vascular risk factors where 
intervention is possible 
There is evidence that higher blood pressure increases risk although reduction in risk 
may be related to reduction in incident stroke and to type of antihypertensive treatment 
rather than pure blood pressure reduction. The evidence for heart failure suggests that its 
presence may have a negative effect on subsequent cognitive decline and dementia 
whereas although the impact of diabetes plausibly could impact negatively on cognition 
the outcome data are far from clear. Cholesterol itself does not seem to have an effect 
although statins may and the studies are heterogeneous and difficult to compare. 
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2.5. 	Risk factors where intervention is possible (lifestyle 
factors) 
2.5.1. Smoking behaviour 
That smoking has a negative impact on health is no longer at question. Apart from the 
well known risks of increased likelihood of lung and other cancers, smoking is also an 
independent predictor of cardiovascular morbidity, mortality and development of 
myocardial infarction [195]. Smoking may also accelerate cerebral atrophy, perfusional 
decline and white matter lesions [196]. Although Meyer et al, in this study, may have 
had selective entry as the participants, from the USA received free medical care. In 
contrast to the risk of smoking, nicotine itself has plausible mechanisms whereby it may 
enhance cognitive function. Throughout the cholinergic system there are nicotinic 
acetylcholine receptors which can bind to nicotine. Use of nicotine as an agonist is said 
to up regulate these receptors in a dose dependent fashion, possibly by several hundred 
percent, depending on brain region [197-198]. The use of nicotine has also been found 
to aid attention, reaction time and some learning and memory [198]. Although it is 
thought that this effect would be short lived if exposure was discontinued, potential 
benefits may be present. Such receptors are thought to decline with ageing, with 
Alzheimer's disease and with Lewy Body dementia [198]. A histopathological study in 
this area found mixed results with a possible protective effect of smoking against senile 
plaque formation in twenty eight matched pairs, and a positive correlation between the 
amount of smoking and neurofibrilliary changes, but in smokers only [199]. 
A Cochrane review attempted to investigate the use of nicotine in Alzheimer's disease, 
but found no suitable data [200]. Other authors have compared smokers and non 
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smokers in case control studies of Alzheimer's disease or cross sectional population 
studies and found mixed results. Studies have found no difference between smokers and 
non smokers in either white or African American populations [201]; significantly 
increased risk of current smoking (RR 2.33 (95% CI 1.37-3.97)) in a Chinese 
population [202] and a reduced risk in male smokers only, (but in an unmatched case 
control study) [203]. Still further studies found male and female differences [204], an 
association between current smoking and reduced psychomotor speed and cognitive 
flexibility [205] and no difference between smokers and non smokers aged over fifty 
years for memory, reasoning and simple choice reaction time [199,206]. It should be 
noted though that the smokers in this study, did die earlier. 
A systematic review published in 2001 and examining the relationship between 
Alzheimer's disease and smoking, pointed out that when combining twenty one case 
control studies the pooled odds ratio (using adjusted data) was 0.82 (95 percent CI 0.70-
0.97). This suggests a protective effect and the same result was observed when four 
matched studies were included albeit, with a loss of significance and an odds ratio of 
0.82 (95 percent 0.53-1.27). There were eight cohort studies with a relative risk from 
`ever smoking' of 1.10 (95 percent CI 0.94-1.29), but selecting only studies with 
smoking current at baseline and the later development of Alzheimer's disease (two 
only) resulted in a relative risk of 1.99 (95 percent CI1.33-2.98) [207]. 
One of the difficulties with research in this area is the potential overlapping of risk and 
protective factors as well as the undoubtedly negative constituents in cigarette smoke, 
despite smoking remaining the primary means by which people gain nicotine. Other 
issues are the clustering of risk or protective factors including, the possible cognitive 
protection from a healthy diet [208], the influence of drinking alcohol, and obesity. One 
study found that smoking was associated with reduced risk of Alzheimer's disease in 
drinkers only [209,210], and in seventy year olds both smoking and obesity were 
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associated with poorer cognition on a neuropsychological battery [211]. Smoking 
behaviour may also change over time and by sector or cohort within the population; for 
example, smoking rates may be markedly lower with increasing age, lower in women 
[212] and may be affected by ill health or change in circumstances. Studies also vary in 
quality with both matched and unmatched case control studies and much cross sectional 
data in the literature. In addition to this, subjects, either non smokers or smokers, may 
self select for studies [213] and survival biases may be present with smokers dying at a 
younger age [214]. 
Therefore, in order to attempt an evaluation of recently published literature relating to 
the effects of smoking as a risk or protective factor for dementia or cognitive decline, I 
carried out a systematic review and meta-analysis including only longitudinal studies. 
2.5.2. Systematic review and meta-analysis: smoking 
Search terms 'smoking' and 'dementia' or 'vascular dementia' or 'multi infarct 
dementia' or 'Alzheimer's disease' or 'cognitive impairment' or 'cognitive decline' 
were used as keywords. The databases Medline, Embase and Psychinfo were searched 
for English language publications relating to human populations and which occurred 
between 1996 and August 2006. When available, standard search categories were also 
used as matched to the above terms. All searches were limited to subjects aged 65 and 
over in accordance with the limits allowed by each search engine, see figure 3 for 
details. In order to follow appropriate systematic review methodology an additional 
researcher appraised all abstracts and selected manuscripts, any discrepancies in 
decisions were discussed to achieve a unanimous choice of articles. No hand searching 
was carried out. 
Studies were ranked on a methodological basis with randomised studies first followed 
by case control and epidemiological population studies. These were quality assessed 
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taking account of the guidelines presented by Stroup et al for the reporting of meta-
analyses of epidemiological studies [215]. There were no randomised controlled trials. 
Case studies, letters, consensus opinion from conferences and expert opinions or 
editorials were not included. In order to aid investigation of causality only longitudinal 
studies were assessed. Where possible, meta-analyses and funnel plots were created. 
Forty seven papers were found from the three search engines and 25 retained. The 25 
papers described 22 longitudinal studies. The studies found are summarised in table 6 
and those where data were reported as Odds Ratios (OR), Hazard Ratios (HR) or 
Relative Risks (RR) were combined into a meta-analysis. 
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Figure 3: Detailing studies identified in a systematic review process examining smoking 
and cognitive decline or dementia 
Medline number 
identified 327 






        
        
       
•  
        
Medline number 
possibly relevant to 
research question 39 




possibly relevant to 
research question 1 




possibly relevant to 
research question 35 
(judged on abstract 
alone) 
 
47 identified after overlap between search engines accounted for and full text 
examined. 
23 rejected (inappropriate content or insufficient methodological detail) 
25 papers retained 
22 (longitudinal studies — 25 papers) 
   
        
Five studies found a positive significant link between current smoking and incident 
dementia [32,216-220], and six with cognitive decline [221-225]. Nine found no 
significant link with dementia or cognitive decline and current smoking [226-235]. No 
studies found a significant link between former smoking and incident cognitive decline 
or dementia. Of the other two studies, one study found an association between daily 
dose of cigarettes and decline in a paired associate learning test but only in females of 
below median intelligence [236] and in the other an association was found between 
smoking and a diminished risk of decline for attention and visuospatial tasks [237]. 
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Table 6: Details of longitudinal studies assessing smoking and cognitive decline or dementia 
Author Population recruited from where 
Baseline numbers, 








Relationship with smoking 
Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard 
Ratio, (numbers in brackets are 95 percent confidence 
intervals) 
In order to assess the most conservative finding, 
results used are those from the adjusted analyses 
unless otherwise stated. 
Juan D et al 
(2004) 
[218] 
China 6 communities 
N=2820 >=60 years 
Prevalent cases excluded at 
baseline FU 2 years 
Cohort Dementia 
Current smoking significantly 
increased risk of all dementia types 
except 'other' Past smokers similar 
trend but not significant and higher 
smoking level increased risk — except 
for very heavy smokers 
Relative risk of dementia subtypes by baseline 
cigarette smoking: 
Compared to never smokers: 
Past smokers: 
RR AD 1.53* (0.65-1.42) *as written in the paper 
RR AD with CVD 1.61 (0.52-3.73) 
RR AD without CVD 1.44 (0.61-2.26) 
RR VaD 1.33 (0.51-3.02) 
RR Other 1.75 (0.49-3.33) 
Current smokers: 
RR AD 2.72 (1.63-5.42) 
RR AD with CVD 3.35 (1.33-4.71) 
RR AD without CVD 2.39 (1.99-2.70) 
RR VaD 1.98 (1.53-3.12) 
RR Other 2.22 (0.39-6.19) 
Wang et al 
(2006) 
[221] 
China — 9 randomly 
selected communities 
N=5437 enrolled >=55 years 
Mean FU 4.7 (SD 05) years Cohort Cognitive decline 
Current smoking may increase risk of 
later cognitive impairment 
Of those who developed cognitive impairment 22.9 
percent were current smokers at baseline, the 
corresponding value for those that remained 





Chicago Health and 
Aging Project 
(CHAP) 
1064 participants aged 65 
years and older (mean age 
73.8 years SD 9.6) Mean FU 4 
years 
Cohort Incident AD 
Risk of incident dementia 
significantly higher for current 
smokers compared to non smokers. 
Only current smokers with no Apoe4 
allele significantly at risk. No 
significant risk for former smokers. 
Smoking status and incident AD compared to never 
smokers. 
Current smokers OR 3.40 (1.44-8.01) 
Former smokers OR 0.90 (0.47-1.70) 










Association between daily dose of 
cigarettes and decline in Paired 
Associate Learning Test score only 




Author Population recruited from where 
Baseline numbers, 








Relationship with smoking 
Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard 
Ratio, (numbers in brackets are 95 percent confidence 
intervals) 
In order to assess the most conservative finding, 
results used are those from the adjusted analyses 
unless otherwise stated. 
Tyas et al 
(2003) 
[238] 
Galanis et al 
(1997) 
[223] done 
Honolulu Asia aging 
study 
N=3232, Age at baseline 58.6, 








Current smoking and former smoking 
not significant. In smokers amount of 
smoking correlated with incident 
dementia of all types except for very 
heavy smokers. 
Continuous smoking is associated 
with higher risk than quitting or never 
smoking. Former smokers have a non 
significant increased risk. 
Risk of Dementia by mid-life smoking status. 
Former smokers compared to never smokers 
OR AD 0.93 (0.58-1.50) OR AD fl- CVD 0.88(0.58- 
1.33) 
OR VaD 0.82 (0.43-1.52) 
OR all 0.80 (0.58-1,10) 
Current smokers compared to never smokers 
OR AD 1.17 (0.69-1.98) OR AD +/- CVD 1.31 
(0.85-2.01) 
OR VaD 1.14 (0.60-2.13) 
OR all 1.11 (0.79-1.55) 
Risk of cognitive impairment compared to never 
smokers. 
Ex smokers OR 0.86 (0.68-1.07) 
Quitters between exam 1 & 3 OR 1.30 (0.98-1.74) 
Continuous smokers OR 1.29 (1.03-1.62) 
N=3429 Age at baseline 58.6, 
SD 4.7. Cognitive assessment 
77.7 years, SD 4.6. FU 
20-30 years 
Quitting at least 6 years before exam 3 (baseline) was 





> 65 year olds 
recruited from the 
electoral ward of 
Gospel Oak, London 






Current smokers were significantly 
more likely to be cognitively impaired 
when adjusted for smoking and 
drinking after age 65. 
Controlling for smoking and drinking after age 65. 
Ex smokers — adjusted result not clear in paper 
Current smokers -RR 4.07 (1.01-16.3) 





N= 343, dementia free at 
baseline. Age >75 years FU 3 
years 
Cohort 
All 	• Dementia 
plus AD 
Non significant increased risk for 
smokers. 
Risk of smokers versus non smokers. 
OR AD 1.1 (0.5-2.4) 
OR Dementia 1.4 (0.8-2.7) 




function and aging 
study, England and 
Wales 
N=4075 aged 65. N=3505 at 





Past smokers (smoking in past two 
years) were significantly less likely to 
develop dementia. 
Those who developed dementia during follow up: 
Past smokers OR 0.7 (0.5-1.0) 
Current smokers 0.9 (0.5-1.5) 
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Author Population recruited from where 
Baseline numbers, descriptives. 








Relationship with smoking 
Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard 
Ratio, (numbers in brackets are 95 percent 
confidence intervals) 
In order to assess the most conservative finding, 
results used are those from the adjusted analyses 





from the community 
Washington Heights 
N=1062 baseline 
Mean age of those who went on 
to develop AD 77.2 (SD5.7) 
Those who did not go on to 
develop AD 75.1 (SD6.2) 





Current smoking significantly 
increased risk of AD 
RR of Alzheimer's disease, smokers compared to 
never smokers 
RR Past smokers: 0.7 (0.5-1.1) 
RR Current smokers 1.7 (1.1-2.8) 
Luchsinger 
[32] 
et al (2005) other 
Baseline >=65 years, at 	FU 
76.2 (5.9) years, 69.8 percent 
female. 
N=1138 (1012 with complete 
date) at baseline 





Smokers at significantly higher 
risk of probable & possible AD - 
higher risk when combined with 
risk factors (diabetes, 
hypertension and 
heart disease) 
(41 participants were smokers) 
Current smoking.... 
Probable and possible AD 
HR 2.2 (1.0-4.9) 
Probable AD 
HR 2.7 (1.2-6.3) 
Reitz et al 
(2005) 
[224] 
N=791 baseline Mean age 75.6 







<75 years - no significant 
association between cognition and 
smoking 
>75 years smokers perform more 
poorly in cognitive tests and 
memory declines faster in smokers 
without ApoeE4 as compared to 
never smokers or quitters 
Current smoking was associated with faster 
cognitive decline only in memory among subjects 
aged >75years without ApoeE4 allele p=0.0I6 
No OR/ 	R 




N=6870 baseline aged >= 55 








Current smokers with AD with and 
without CVD are significantly 
more likely to develop dementia. 
Former and current smokers were 
more likely to have dementia 
overall. Smoking had no effect 
with APOE e4 allele. 
Risk of dementia compared to never smokers. 
All subjects: Former smokers RR 1.4 (0.9-2.0) 
Current smokers RR 2.2 (1.3-3.6) 
AD without CVD: 	Former smokers RR 1.4 (0.8- 
2.3) 	Current smokers RR 2.1 (1.1-4.0) 
AD with CVD : 	Former smokers RR 1.2 (0.4-
4.2) Current smokers RR 3.9 (1.0-15.2) 
VaD : 	 Former smokers RR 1.4 (0.5-
4.4) Current smokers RR 2.2 (0.6-8.4) 
Other dementia: 	Former smokers RR 1.5 (0.5-
4.2) Current smokers RR 2.1 (0.6-6.8) 




of vacular aging) 
study. Based in 
France 
N=1389 aged 59-71. N=1094 at 
FU 4 years Cohort 
Cognitive 
decline 
No significant findings - tending 
to lower relative risks 
Compared to never smoker without APOE e4 
Never smoker with APOE e 4 RR 1.1 (0.7-1.9) 
Ex smoker without APOE e4 RR 1.1 (0.7-1.9) Ex 
smoker with APOE e4 RR 0.9 (0.4-2.0) 
Current smoker without APOE e4 RR 0.8 (0.4-1.7) 
Current smoker with APOE e4 RR 0.5 (0.1-2.6) 74 
Author Population recruited from where 
Baseline numbers, descriptives. 








Relationship with smoking 
Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard 
Ratio, (numbers in brackets are 95 percent 
confidence intervals) 
In order to assess the most conservative finding, 
results used are those from the adjusted analyses 
unless otherwise stated. 
Launer at al 
(1996) 
[230]  
Zutphen Elderly study 
— Dutch contribution 
Males 939 at baseline, 560 at FU 
after 5 years and 360 after 8 
years. Age at baseline 65-84 
years mean 71.6 (SD 5.4), after 5 
years 75.1 (4.7) after 8 years 





No significant findings with pure 
scores but mean change in MMSE 
was significantly greater for all 
categories with CVD/diabetes 








N=14348 aged 45-64 at baseline 
N=10963 at FU Re-examined 
every 3 years — 
6 year follow up (mean 6 — range 
3.6-8.8) 
Cohort Cognitive decline 
Possible that decline in some 
neuropsychological tests is greater in 
smokers/ exsmokers 
Change in digit symbol substitution, delayed 
word recall and word fluency seem greater in 
current than in former smokers — no detailed 
table with significance values available but 
authors comment that older black subjects who 
were current smokers showed greater decline of 







N=833 aged > 60 at baseline 




decline — a 
drop of ten 




Smokers had a lower risk of decline 
on attention tasks 
Smokers compared to non smokers: 
Diminished risk of decline for attention tasks OR 
0.54(0.3-0.97) and visuospatial tasks OR 
0.51(0.2-1.2) 
Diminished risk of decline in visuospatial task 
reaction time OR 0.28(0.07-1.2) 




N=647 at baseline, 529 in 
analysis for incident impairment. 
74 years and over 
excluded prevalent cognitive 
impairment. FU 4 years 
Cohort Cognitive impairment Not significant 







N=558, mean age 78 SD 8.1 
years FU 3 years Cohort 
Cognitive 
decline 
Current smoking was significantly 
associated with combined decline - 
cognitive decline alone not significant. 
Association between smoking and cognitive 
decline compared to never smoking: 
Former smokers OR 1.03 (0.43-2.46) 
Current smokers OR 1.38 (0.48-4.0) 
75 
Author Population recruited from where 
Baseline numbers, descriptives. 








Relationship with smoking 
Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard 
Ratio, (numbers in brackets are 95 percent 
confidence intervals) 
In order to assess the most conservative finding, 
results used are those from the adjusted analyses 
unless otherwise stated. 
Launer et al 
(1999) 
[217] 
European studies — 
Denmark, France, the 
Netherlands and UK. 
N=16334 >= 65 years. Mean FU 





Current smoking significantly 
associated with increased risk of AD, 
and all dementias. 
Risk of AD compared with never smokers 
Former smokers RR 1.19 (0.8-1.51) 
Current smokers RR 1.74 (1.21-2.5) 
Risk of all dementias compared with never 
smokers 
Former smokers RR 1.03 (0.79-1.34) 
Current smokers RR 1.39 (1.03-1.89) 
Ott et al 
(2004) 
[222] 




Smokers had significantly greater 
decline in MMSE score than those 
who never smoked. Significantly 
greater decline with higher cigarette 
pack year exposure. 
Yearly mean change in MMSE compared to 
never smokers 
Never smokers -0.03 
Former smokers OR -0.06(-0.12-0.01) 
Current smokers OR -0.16(-0.22-0.10) 




N=34439 males at baseline. 473 
cases and 4 matched controls for 




No significant relationship between 
dementia and smoking 
Probable or definitely due to AD compared to 
never smokers 
Continuing smokers RR 0.83 (0.60-1.16) 	Ex 
smokers RR 0.78 (0.56-1.10) 
Vascular or Lewy body compared to never 
smokers 
Continuing smokers RR 0.94 (0.49-1.82) 
Exsmokers RR 1.07 (0.57-2.02) 
Any dementia compared to never smokers 
Continuing smoker RR 0.85 (0.63-1.14) 	Ex 
smokers RR 0.84 (0.63-1.13) 
al (2002) 
[239] 
Canadian study of 
health and aging 
N=4615 participants >=65 years 
FU 5 years 
Lindsay etAssociation Case control 
Cohort Dementia 
Smoking not significantly associated 
with AD 
between smoking and risk of AD 
compared with controls 
Cases OR 0.82 (0.57-1.17) 
Piguet et al 
(2003) 
[233]  
Sydney Older Persons 
Study 
N=377 subjects >+ 75. (mean 








No significant association between 
smoking and dementia. 
No OR or RR just means for smoking (number 
of packets per day per year). 
Broe et al 
(1998) 
[234]  
=  N=327 participants > 75 years 






Smoking was not a significant 
predictor of incident dementia 
Partial correlations between smoking and 
cognitive test performance selected tests: 
Clock drawing Current smokers: 0.06 Ex 
smokers: -0.05 
MMSE 	Current smokers: 0.05 	Ex 
smokers: 0.04 
76 
Table 6: Details of longitudinal studies assessing smoking and cognitive decline or dementia 
Author Population recruited from where 
Baseline numbers, 








Relationship with smoking 
Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard 
Ratio, (numbers in brackets are 95 percent confidence 
intervals) 
In order to assess the most conservative finding, 
results used are those from the adjusted analyses 
unless otherwise stated. 
Juan D et al 
(2004) 
[218] 
China 6 communities 
N=2820 >=60 years 
Prevalent cases excluded at 
baseline FU 2 years 
Cohort Dementia 
Current smoking significantly 
increased risk of all dementia types 
except 'other' Past smokers similar 
trend but not significant and higher 
smoking level increased risk — except 
for very heavy smokers 
Relative risk of dementia subtypes by baseline 
cigarette smoking: 
Compared to never smokers: 
Past smokers: 
RR AD 1.53* (0.65-1.42) *as written in the paper 
RR AD with CVD 1.61 (0.52-3.73) 
RR AD without CVD 1.44 (0.61-2.26) 
RR VaD 1.33 (0.51-3.02) 
RR Other 1.75 (0.49-3.33) 
Current smokers: 
RR AD 2.72 (1.63-5.42) 
RR AD with CVD 3.35 (1.33-4.71) 
RR AD without CVD 2.39 (1.99-2.70) 
RR VaD 1.98 (1.53-3.12) 
RR Other 2.22 (0.39-6.19) 
Wang et al 
(2006) 
[221] 
China— 9 randomly 
selected communities 
N=5437 enrolled >=55 years 
Mean FU 4.7 (SD 05) years Cohort Cognitive decline 
Current smoking may increase risk of 
later cognitive impairment 
Of those who developed cognitive impairment 22.9 
percent were current smokers at baseline, the 
corresponding value for those that remained 





Chicago Health and 
Aging Project 
(CHAP) 
1064 participants aged 65 
years and older (mean age 
73.8 years SD 9.6) Mean FU 4 
years 
Cohort Incident AD 
Risk of incident dementia 
significantly higher for current 
smokers compared to non smokers. 
Only current smokers with no Apoe4 
allele significantly at risk. No 
significant risk for former smokers. 
Smoking status and incident AD compared to never 
smokers. 
Current smokers OR 3.40 (1.44-8.01) 
Former smokers OR 0.90 (0.47-1.70) 










Association between daily dose of 
cigarettes and decline in Paired 
Associate Learning Test score only 




Author Population recruited from where 
Baseline numbers, 








Relationship with smoking 
Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard 
Ratio, (numbers in brackets are 95 percent confidence 
intervals) 
In order to assess the most conservative finding, 
results used are those from the adjusted analyses 
unless otherwise stated. 
Tyas et al 
(2003) 
[238] 
Galanis et al 
(1997) 
[223] 
Honolulu Asia aging 
study 
N=3232, Age at baseline 58.6, 








Current smoking and former smoking 
not significant. In smokers amount of 
smoking correlated with incident 
dementia of all types except for very 
heavy smokers. 
Continuous smoking is associated 
with higher risk than quitting or never 
smoking. Former smokers have a non 
significant increased risk. 
Risk of Dementia by mid-life smoking status. 
Former smokers compared to never smokers 
OR AD 0.93 (0.58-1.50) OR AD+/- CVD 0.88(0.58- 
1.33) 
OR VaD 0.82 (0.43-1.52) 
OR all 0.80 (0.58-1.10) 
Current smokers compared to never smokers 
OR AD 1.17 (0.69-1.98) OR AD +/- CVD 1.31 
(0.85-2.01) 
OR VaD 1.14 (0.60-2.13) 
OR all 1.11 (0.79-1.55) 
Risk of cognitive impairment compared to never 
smokers. 
Ex smokers OR 0.86 (0.68-1.07) 
Quitters between exam 1 & 3 OR 1.30 (0.98-1.74) 
Continuous smokers OR 1.29 (1.03-1.62) 
N=3429 Age at baseline 58.6, 
SD 4.7. Cognitive assessment 
done 77.7 years, SD 4.6. FU 
20-30 years 
Quitting at least 6 years before exam 3 (baseline) was 





> 65 year olds 
recruited from the 
electoral ward of 
Gospel Oak, London 






Current smokers were significantly 
more likely to be cognitively impaired 
when adjusted for smoking and 
drinking after age 65. 
Controlling for smoking and drinking after age 65. 
Ex smokers — adjusted result not clear in paper 
Current smokers -RR 4.07 (1.01-16.3) 





N= 343, dementia free at 






Non significant increased risk for 
smokers. 
Risk of smokers versus non smokers. 
OR AD 1.1 (0.5-2.4) 
OR Dementia 1.4 (0.8-2.7) 
Yip et al 
[228]  
MRC cognitive 
function and aging 
study, England and 
Wales 





Past smokers (smoking in past two 
were significantly less likely to 
develop dementia. 
Those who developed dementia during follow up: 
Past smokers OR 0.7 (0.5-1.0) 
Current smokers 0.9 (0.5-1.5) 
73 
Author Population recruited from where 
Baseline numbers, descriptives. 








Relationship with smoking 
Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard 
Ratio, (numbers in brackets are 95 percent 
confidence intervals) 
In order to assess the most conservative finding, 
results used are those from the adjusted analyses 





from the community 
Washington Heights 
N=1062 baseline 
Mean age of those who went on 
to develop AD 77.2 (SD5.7) 
Those who did not go on to 
develop AD 75.1 (SD6.2) 





Current smoking significantly 
increased risk of AD 
RR of Alzheimer's disease, smokers compared to 
never smokers 
RR Past smokers: 0.7 (0.5-1.1) 
RR Current smokers 1.7 (1.1-2.8) 
Luchsinger 
et al (2005) 
[32] 
Baseline >=65 years, at 	FU 
76.2 (5.9) years, 69.8 percent 
female. 
N=1138 (1012 with complete 
date) at baseline 





Smokers at significantly higher 
risk of probable & possible AD - 
higher risk when combined with 
other risk factors (diabetes, 
hypertension and 
heart disease) 
(41 participants were smokers) 
Current smoking.... 
Probable and possible AD 
HR 2.2 (1.0-4.9) 
Probable AD 
HR 2.7 (1.2-6.3) 
Reitz et al 
(2005) 
[224] 
N=791 baseline Mean age 75.6 







<75 years - no significant 
association between cognition and 
smoking 
>75 years smokers perform more 
poorly in cognitive tests and 
memory declines faster in smokers 
without ApoeE4 as compared to 
never smokers or quitters 
Current smoking was associated with faster 
cognitive decline only in memory among subjects 
aged >75years without ApoeE4 allele p=0.016 
No OR/RR/HR 




N=6870 baseline aged >= 55 








Current smokers with AD with and 
without CVD are significantly 
more likely to develop dementia. 
Former and current smokers were 
more likely to have dementia 
overall. Smoking had no effect 
with APOE e4 allele. 
Risk of dementia compared to never smokers. 
All subjects: Former smokers RR 1.4 (0.9-2.0) 
Current smokers RR 2.2 (1.3-3.6) 
AD without CVD: 	Former smokers RR 1.4 (0.8- 
2.3) 	Current smokers RR 2.1 (1.1-4.0) 
AD with CVD : 	Former smokers RR 1.2 (0.4-
4.2) Current smokers RR 3.9 (1.0-15.2) 
VaD : 	 Former smokers RR 1.4 (0.5-
4.4) Current smokers RR 2.2 (0.6-8.4) 
Other dementia: 	Former smokers RR 1.5 (0.5-
4.2) Current smokers RR 2.1 (0.6-6.8) 




of vacular aging) 
study. Based in 
France 
N=1389 aged 59-71. N=1094 at 
FU 4 years Cohort 
Cognitive 
decline 
No significant findings - tending 
to lower relative risks 
Compared to never smoker without APOE e4 
Never smoker with APOE e 4 RR 1.1 (0.7-1.9) 
Ex smoker without APOE e4 RR 1.1 (0.7-1.9) Ex 
smoker with APOE e4 RR 0.9 (0.4-2.0) 
Current smoker without APOE e4 RR 0.8 (0.4-1.7) 
Current smoker with APOE e4 RR 0.5 (0.1-2.6) 74 
Author Population recruited from where 
Baseline numbers, descriptives. 








Relationship with smoking 
Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard 
Ratio, (numbers in brackets are 95 percent 
confidence intervals) 
In order to assess the most conservative finding, 
results used are those from the adjusted analyses 
unless otherwise stated. 
Launer at al 
(1996) 
[230]  
Zutphen Elderly study 
— Dutch contribution 
Males 939 at baseline, 560 at FU 
after 5 years and 360 after 8 
years. Age at baseline 65-84 
years mean 71.6 (SD 5.4), after 5 
years 75.1 (4.7) after 8 years 





No significant findings with pure 
scores but mean change in MMSE 
was significantly greater for all 
categories with CVD/diabetes 








N=14348 aged 45-64 at baseline 
N=10963 at FU Re-examined 
every 3 years — 
6 year follow up (mean 6 — range 
3.6-8.8) 
Cohort Cognitive. decline 
Possible that decline in some 
neuropsychological tests is greater in 
smokers/ exsmokers 
Change in digit symbol substitution, delayed 
word recall and word fluency seem greater in 
current than in former smokers — no detailed 
table with significance values available but 
authors comment that older black subjects who 
were current smokers showed greater decline of 







N=833 aged > 60 at baseline 




decline — a 
drop of ten 




Smokers had a lower risk of decline 
on attention tasks 
Smokers compared to non smokers: 
Diminished risk of decline for attention tasks OR 
0.54(0.3-0.97) and visuospatial tasks OR 
0.51(0.2-1.2) 
Diminished risk of decline in visuospatial task 
reaction time OR 0.28(0.07-1.2) 




N=647 at baseline, 529 in 
analysis for incident impairment. 
74 years and over 
excluded prevalent cognitive 
impairment. FU 4 years 
Cohort Cognitive impairment Not significant 







N=558, mean age 78 SD 8.1 
years FU 3 years Cohort 
Cognitive 
decline 
Current smoking was significantly 
associated with combined decline - 
cognitive decline alone not significant. 
Association between smoking and cognitive 
decline compared to never smoking: 
Former smokers OR 1.03 (0.43-2.46) 
Current smokers OR 1.38 (0.48-4.0) 
75 
Author Population recruited from where 
Baseline numbers, descriptives. 








Relationship with smoking 
Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard 
Ratio, (numbers in brackets are 95 percent 
confidence intervals) 
In order to assess the most conservative finding, 
results used are those from the adjusted analyses 
unless otherwise stated. 
Launer et al 
(1999) 
[217] 
European studies — 
Denmark, France, the 
Netherlands and UK. 
N=16334 >= 65 years. Mean FU 





Current smoking significantly 
associated with increased risk of AD, 
and all dementias. 
Risk of AD compared with never smokers 
Former smokers RR 1.19 (0.8-1.51) 
Current smokers RR 1.74 (1.21-2.5) 
Risk of all dementias compared with never 
smokers 
Former smokers RR 1.03 (0.79-1.34) 
Current smokers RR 1.39 (1.03-1.89) 
Ott et al 
(2004) 
[222] 




Smokers had significantly greater 
decline in MMSE score than those 
who never smoked. Significantly 
greater decline with higher cigarette 
pack year exposure. 
Yearly mean change in MMSE compared to 
never smokers 
Never smokers -0.03 
Former smokers OR -0.06(-0.12-0.01) 
Current smokers OR -0.16(-0.22-0.10) 




N=34439 males at baseline. 473 
cases and 4 matched controls for 




No significant relationship between 
dementia and smoking 
Probable or definitely due to AD compared to 
never smokers 
Continuing smokers RR 0.83 (0.60-1.16) 	Ex 
smokers RR 0.78 (0.56-1.10) 
Vascular or Lewy body compared to never 
smokers 
Continuing smokers RR 0.94 (0.49-1.82) 
Exsmokers RR 1.07 (0.57-2.02) 
Any dementia compared to never smokers 
Continuing smoker RR 0.85 (0.63-1.14) 	Ex 




Canadian study of 
health and aging 
N=4615 participants >=65 years 
FU 5 years 
Case control 
Cohort Dementia 
Smoking not significantly associated 
with AD 
Association between smoking and risk of AD 
compared with controls 
Cases OR 0.82 (0.57-1.17) 
Piguet et al 
(2003) 
[233]  
Sydney Older Persons 
Study 
N=377 subjects >-F 75. (mean 








No significant association between 
smoking and dementia. 
No OR or RR just means for smoking (number 
of packets per day per year). 
Broe et al 
(1998) 
[234]  
N=327 participants >=75 years 






Smoking was not a significant 
predictor of incident dementia 
Partial correlations between smoking and 
cognitive test performance selected tests: 
Clock drawing Current smokers: 0.06 Ex 
smokers: -0.05 
MMSE 	Current smokers: 0.05 	Ex 
smokers: 0.04 
76 
Two sets of meta-analyses were carried out: those of current smokers against never or 
non-smokers for the four outcomes of Alzheimer's disease (summary ratio, 1.59 (95 
percent CI 1.12-2.25)), vascular dementia (1.45 (0.96-2.20)), dementia unspecified 
(1.24 (0.88-1.75)) and cognitive decline (1.20 (0.90-1.59)); and those between 
exsmokers and never smokers for the same four outcomes. For exsmokers against never 
smokers, the summary values were as follows: Alzheimer's disease (1.02 (95 percent CI 
0.82-1.27)), Vascular dementia (1.05 (0.72-1.52)), dementia unspecified (0.95 (0.73-
1.22)) and cognitive decline (0.90 (0.74-1.10)). Measurements of heterogeneity were 
not significant with the exception of those for Alzheimer's disease with current smoking 
and dementia (unspecified) with current smoking. Publication bias did not seem evident 
from funnel plots. Forest plots are below (figures 4 to 11). 
Figure 4: Forest plot combining longitudinal studies where current smoking and 
Alzheimer's disease were assessed 
Summary meta-analysis plot [random effects] 
RR AD (216] 
RR AD (210] 
RR Prob AD (32] 
OR AD (2271 
RR AD without Cardiovascular disease(CVD) (2161 
RR AD with Cardiovascular disease (216] 
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RR AD (235] 
OR AD (2391 
OR AD (220] 
combined 
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to decreased risk to increased risk 
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Figure 5: Forest plot combining longitudinal studies where current smoking and 
vascular dementia were assessed 
Summary meta-analysis plot [random effects] 
RR VaD [218] 
RR VaD [210] 
RR VaD [216] 
RR VaD or Lewy body dementia [235] 
combined 
   
1.98 (1.53, 3.12) 
1.14 (0.60, 2.13) 
2.20 (0.60, 8.40) 
0.94 (0.49, 1.82) 
1.45 (0.96, 2.20) 
  
■ 
     
       
     
• 	 
 
      
  





* ratio (95% confidence interval) 
Smoking related 
to decreased risk 
Smoking related 
to increased risk 
Figure 6: Forest plot combining longitudinal studies where current smoking and 
dementia (unspecified) were assessed 
Summary meta-analysis plot [random effects] 
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Figure 7: Forest plot combining longitudinal studies where current smoking and 
cognitive decline were assessed 
Summary meta-analysis plot [random effects] 
OR Cognitive impairment [223] 
RR Cognitive impairment (225] 
RR Cognitive decline with APOEe4 (229] 
RR Cognitive decline without APOEe4 [229] 
OR cognitive decline (226] 
OR cognitive decline [232] 
combined 
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Figure 8: Forest plot combining longitudinal studies where former smoking and 
Alzheimer's disease were assessed 
Summary meta-analysis plot [random effects] 
	• RR AD [218] 
OR AD 1210] 
RR AD (219] 
RR AD without CVD (216] 
RR AD with CVD (216] 
RR AD (217] 
RR AD (235] 
OR AD (220] 
combined 
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Figure 9: Forest plot combining longitudinal studies where former smoking and 
vascular dementia were assessed 
 
Summary meta-analysis plot [random effects] 
 
RR VaD [218] 
OR VaD [210] 
RR VaD [216] 
RR VaD or Lewy body dementia [235] 
combined 
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Figure 10: Forest plot combining longitudinal studies where former smoking and 
dementia (unspecified) were assessed 
Summary meta-analysis plot [random effects] 
OR dementia [228] 
RR dementia [216] 
RR dementia [217] 
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Figure 11: Forest plot combining longitudinal studies where former smoking and 
cognitive decline were assessed 
Summary meta-analysis plot [random effects] 
OR Cognitive impairment [223] 
RR cognitive decline without APOEe4 [229] 
RR cognitive decline with APOEe4 [229] 
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The results have to be interpreted in the context of the small numbers of results 
available for meta-analysis for some outcomes and methodological issues such as the 
likelihood of increased mortality of smokers. Methodological issues are discussed 
further below. 
Methodological issues — smoking 
There were 25 papers identified reporting on 22 studies. Two of these reported on 
pooled cohort studies derived from combining the data from several smaller studies, 
none of the constituent studies were included in the analyses. One paper reported on 
dementia and the other on cognitive decline [216,217]. Three of the 22 studies were 
found to have generated several papers each, two from the Honolulu Asia Aging Study 
[223,238] and three from a Washington Heights Medicare population [32,219,224] each 
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paper reported on a different outcome. For the two papers reporting on the Sydney older 
persons study the same outcome was used but with differing follow up; one reported on 
three year follow up [234] and one on six year follow up [233]. There were therefore 18 
cohort studies in total [32,216-229-234,236-238]. One of the papers from the 
Washington Heights data set also reported using a case control analysis [219] and a 
further study used both cohort and case control methodology [239]. Two studies used a 
case control analysis only, [228,235] Doll et al was the only study to use individually 
matched case controls with four age matched controls to every case [235] 
The populations were drawn from different parts of the world. Most of the studies used 
populations from Northern Europe [216,217,222,225,227-230,235-237J and North 
America with one study including African Americans (Chicago health and aging 
project) [32,219,220,224,226,231,230,237] Two populations were from China 
[218,221] and one of the populations from the US was comprised solely of Japanese 
men [238,223]. There was also one population from Australia though these, given their 
age, were likely to be similar genetically to European populations [233,234]. The 
European countries represented were the UK, France, Sweden, Holland and Denmark. 
The studies varied in size at baseline although sample sizes were generally large. Seven 
studies had less than 1000 participants, [225-227,230,232-234,237] seven had more 
than 1000 but less than 5000 [218,220,223,228,229,236,238,239] and there was one 
population where the three papers reported different outcomes with different 
populations, one with a population of less than 1000 [224] and two with more than 1000 
[32,219]. There were also six studies with more than 5000 participants, with the largest 
population being Doll et al with 34439 participants [216,217,221,222,231,235]. 
Not all studies gave a clear indication of participant age at baseline with some reporting 
mean age, some minimum age and some age range. Despite this, when taking the 
available data regarding baseline age and follow up time into account mean age at 
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follow up seems likely to be 65 or over. Eight studies reported recruiting subjects aged 
65 and over [32,217,219,222,224,225,228,230,236,239] and two more with participants 
over 60 [218,237]. Several studies actually included younger populations although 
follow up length varied with the Epidemiology of Vascular Ageing [EVA] study 
following subjects of 59-71 for four years [229] and the Atherosclerosis Risk in the 
Community [ARIC] cohort aged 45-64 followed for a mean of six years (range 3.6-8.8) 
[231]. Two studies included participants aged 55 and over, one following them for a 
mean of 4.7 years (standard deviation [SD] 0.5) [221] and one for 2.1 years (range 1.5-
3.4) [216] and both publications from the Honolulu Asia Aging Study [HAAS] had a 
mean age of 58.6 at baseline [222,237] but followed their subjects for 20 to 30 years 
afterwards. The remaining six studies reported older baseline ages with mean ages 
between 73.8 [220] and 83.4 [234]. Finally, one study did not report baseline age but 
did follow their (adult medical professional) participants for 47 years and so can be 
assumed to have included some late life [235]. 
The period of follow up was less diverse with Doll et al the longest at 47 years, [235] 
and one of only two studies longer than 10 years [223,235,238]. Three papers reported 
on populations followed between 6 and 10 years [228,231,233] although two were from 
studies that also published papers with shorter follow up times [228,233]. The 
remaining data were from studies with at least one but less than six year follow up 
[32,216-222,224-230,232,234,236,237,239]. 
Several studies examined more than one outcome with ten reporting incident dementia 
[216-218,224,227,228,233,235,238,239] four Alzheimer's disease [32,216,219,220,227] 
twelve cognitive decline [221-226,229-232,236,237] and five, vascular dementia 
[216,218,233,235,238]. For the studies with multiple publications, these publications 
reported on different outcomes with the exception of those from the Sydney Older 
Persons study where both dementia and cognitive decline were reported after three 
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[234] and six [233] year follow up. The longer follow up was used in this analysis. For 
the publications from the Washington Heights data set, the cohort analysis reporting 
possible or probable Alzheimer's disease was used in preference to the unmatched case 
control analysis incorporating Alzheimer's disease. Most authors reported these 
analyses adjusted for age, gender and education, although a handful included wider 
factors such as ethnicity, income, social class, historical or current cardiovascular or 
respiratory diseases, blood pressure and alcohol use [32,216-220,222-
232,234,236,237,238,239]. 
The majority of the studies specified that prevalent dementia was excluded at baseline 
or that they had assessed incident dementia or cognitive decline [32,216-231,232-
234,236-239] or used study designs that made prevalent dementia at baseline highly 
unlikely, for example, recruiting practising medical doctors [235]. Standardised criteria 
for the assessment and diagnosis of dementia and cognitive decline were used in most 
studies with eight using the Diagnostic Statistical Manual edition three revised 
(DSMIIIR) [216,218,227,228,230,233,237-239] four using the National Institute of 
Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and 
Related Disorders Association [NINCDS-ADRDA] for the diagnosis of Alzheimer's 
disease and nine using the Mini-Mental State Exam (MMSE), 
[32,217,218,230,221,226,227,233,234,239]. Some studies used more than one 
instrument and some reported detailed neuropsychological testing [231,233,236]. Other 
instruments included the Portable Mental Status Questionnaire [232], the Clinical 
Dementia Rating scale [32,219] the Organic Brain syndrome scale [225] and the 
Cognitive Abilities Screening Instrument (CASI) [223,238]. One study used solely the 
information from death certificates [235]. 
The assessment of smoking was by self report and was also fairly standard with studies 
reporting on smokers versus non smokers and exsmokers [32,216-219,220,222- 
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230,234,238]. Some reported effects of smoking versus non smoking [231-233,236,239] 
with one specifying that smokers included those who had stopped during the past 10 
years [237]. One, combined ex and never-smokers since the majority of exsmokers had 
ceased to smoke several decades previously with data for current smokers based on 
smoking habits during the 15 years before death [235]. One study was able to assess 
those who quit between visits and included this information [223], one excluded 
intermittent smokers [218] and one divided exsmokers into those who quit before age 
40 or more than five years previously from those who did not [227]. Only cigarette use 
was reported in sufficient detail. Few studies reported the characteristics of smokers 
compared to non smokers but those who did found that never smokers were older, more 
highly educated, drank less alcohol and in some studies more likely to be female 
[218,221,223,227,238]. One study reported that former and current smokers showed 
younger age of dementia onset [216]. Unsurprisingly, mortality during study follow up 
was also greater with smoking [218,230,232,233,236,238] and three studies assessed 
causes of death from death certification data [216,227,235]. Non-participation or loss to 
follow up was associated with lower educational levels, higher levels of impairment, 
increased age, smoking, higher body mass index, cardiovascular risk (for example 
diabetes and hypertension) and membership of an ethic minority group 
[228,230,231,236,238]. One study reported that those who refused to continue were not 
significantly different in age or MMSE score at baseline [233], another reported that 
they were older but there were no differences in tobacco use [229]. A further paper 
reported that those who refused to continue had lower MMSE and included 
proportionally more smokers and absteiners from alcohol [230], and another that lower 
income was associated with refusal but that there were no differences in follow up for 
sex, age, smoking or drinking levels [225]. Although the latter study followed subjects 
only for one year [225]. 
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In summary, the data available in the published papers meant that only certain results 
could be included in the meta-analyses and resulted in relatively few studies within the 
meta-analyses for cognitive impairment, vascular dementia and dementia (unspecified). 
This may have resulted in a lower likelihood of significant result. There was, however, a 
larger number of eligible studies examining Alzheimer's disease and smoking with a 
significantly increased risk of incident Alzheimer's disease with current smoking. There 
were non statistically significant relationships between current smoking and vascular 
dementia, dementia (unspecified), and cognitive decline although all odds ratio point 
estimates were over one despite the lower limit of the 95 percent CI falling below 
one/unity. In contrast the odds ratio point estimates for exsmokers, although also non 
significant were much closer to or just under one/unity suggesting that any increased 
risk conferred by current smoking may be reduced after stopping. A note of caution 
should be sounded with regard to the interpretation of the data relating to exsmokers as 
the studies were not always consistent or clear with regard to the time since stopping 
smoking and the level of smoking that had previously been 'usual'. Similar issues relate 
to current smokers in terms of amount of tobacco used, however, this was not 
consistently reported in the studies and may be biased by the higher death rates in 
smokers, likely to be even higher in heavy smokers. Despite all of the methodological 
issues that inevitably apply to combining several studies and the flaws inherent in those 
studies themselves it seems clear that current smoking is a risk factor for the most 
common dementia, Alzheimer's disease. It may also be a risk factor for other dementias 
and cognitive decline. Given the well known health risks associated with smoking, and 
the evidence that ceasing to smoke can lower the impact of such risks, the evidence 
presented here adds another reason for ceasing to smoke or for preventing people from 
starting to smoke. The effects of nicotine itself may be different from smoking and at 
least one study found less decline in attentional processes with smoking which may be 
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as expected with increased nicotine consumption. Further studies are clearly required 
with regard to this and any possible benefits although provision of nicotine through 
smoking is clearly not an advantageous way to test this. 
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2.5.3. Alcohol consumption 
Despite chronic alcohol abuse producing progressive neurodegenerative disease [240] 
there have been several studies suggesting that alcohol consumption, within certain 
limits and/or of certain types, is associated with a decreased risk of dementia or 
cognitive decline. There are many mechanisms proposed in the literature to explain how 
alcohol may be acting in this way. It has been suggested that the anti-oxidant properties 
of the flavenoids in wine may help prevent the oxidative damage which has been 
implicated in dementia [241,242,243]. Alcohol also increases levels of HDL cholesterol 
and fibrinolytic factors leading to lower platelet aggregation and possibly lower risk of 
stroke/ischemia [244,245]. At least one study has found that light to moderate alcohol 
intake (one drink per week to four drinks per day) is associated with a lower prevalence 
of vascular brain findings on imaging and less atrophy of the hippocampus and 
amygdala in APOEe4 carriers as assessed by MRI [246]. 
The consumption of alcohol has also been associated with decreased cardiovascular risk 
via the mechanisms described above and possible enhancement of insulin sensitivity or 
reduction in inflammatory response [244,247,248]. Given the link between vascular 
dementia and vascular function, and the increasing body of evidence suggesting that 
Alzheimer's disease may be influenced by vascular factors [249-258] it may also be that 
this cardiovascular protection decreases incident dementia/cognitive decline. Counter to 
this are the effects of heavy alcohol consumption and alcoholism as detrimental to 
memory function [240]. 
Whilst most evidence is derived from studies of younger adults, the possible protective 
effects of alcohol may also apply to the elderly, that is those at greatest risk from 
dementia, although lower levels of alcohol intake have proportionally greater effects in 
the elderly, due to their decreased lean body mass and lower percentage of body weight 
made up of water [259]. Alcohol may also have negative impacts on other body systems 
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in this age group and may be the cause of increased falls with potentially more serious 
consequences than in younger people although the evidence for this is not clear cut 
[259,260]. 
Nevertheless it is not clear whether regular alcohol use protects against incident 
cognitive decline and/or dementia in the elderly and if so what level of intake would be 
preferred? There are issues related to the research question with regard to the 
practicalities of answering this question. As it would be neither ethical nor feasible to 
carry out a randomised controlled trial with alcohol as a dose controlled intervention 
and a study duration of several years in order to examine incident cognitive decline or 
dementia as an outcome, epidemiological methods are an alternative option although 
less robust. However, a systematic review of all the available appropriate evidence may 
provide a robust and pragmatic way of answering this research question. Three existing 
systematic reviews proved inappropriate and were excluded as their research questions 
were not closely aligned with the objectives of this thesis. They focused on 
psychotherapeutic approaches to Alzheimer's disease [241], health related effects of 
alcohol use in older people [259], and risk factors for functional status decline [261]. In 
order to evaluate the relationship between alcohol consumption and incident cognitive 
decline/dementia in the elderly I carried out a systematic review and meta-analysis, and 
evaluated the strength of the findings taking into account the methodological differences 
in constituent studies. Dementia of specific types can be hard to diagnose pre-mortem 
therefore the review included unspecified dementia in addition to Alzheimer's disease 
and vascular dementia (both prevalent in the elderly) [17]. 
2.5.4. Systematic review and meta-analysis: alcohol 
Search terms 'alcohol' or 'wine' or 'beer' and 'dementia' or vascular dementia' or 
`multi infarct dementia' or Alzheimer's disease' or 'cognitive impairment' or 'cognitive 
decline' were used as keywords and the databases Medline, Embase and Psychinfo were 
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searched for English language publications relating to human populations and occurring 
between 1995 and March 2006. When available, standard search categories were also 
used that matched the above terms. All searches were limited to subjects aged 65 and 
over. In order to fully comply with systematic review methodology an additional 
reviewer read all abstracts and selected papers and consensus opinion was obtained for 
inclusion and extraction tables. No hand searching was carried out. 
Studies were ranked on a methodological basis with any randomised studies first 
followed by case control and epidemiological population studies. Quality was assessed 
using standard criteria assessing key factors including appropriate design, recruitment, 
analysis and provision of suitable information relating to key aspects of the study [262]. 
Case studies, letters, consensus opinion from conferences and expert opinions or 
editorials were not included. Studies with inadequate definition of the outcomes of 
interest were also excluded. To be eligible for inclusion in the meta-analyses, studies 
had to compare alcohol intake (yes, or defined dose) versus no/none (or baseline 
amount) against an outcome of dementia or cognitive decline. A random effects model 
was used as this provides a more conservative approach and tests for heterogeneity of 
the data and funnel plots were carried out to examine suitability for meta-analysis and 
any publication bias. 
From the selected abstracts, 94 papers were obtained for further review, and of these, 26 
papers reporting on 23 studies were included in this systematic review (Figure 12). 
Studies were assessed according to their methodology as above although only 
epidemiological studies were found. There were no randomised controlled trials and no 
studies employed blinding, randomisation or controlled intervention. 
Nine reviews were identified although only three were systematic and not directly 
related to the research question. 
90 
Of the 26 identified papers describing longitudinal studies 22 were epidemiological 
population cohort studies [35,146,225,229,230,234,237,265-274,276-280] and four 
[263,264,239,275] retrospective matched case control based assessments nested in 
cohort samples. In at least one study [267] alcohol intake and dementia/cognition was 
not a primary focus. For one study two papers were published based on the same 
population and reporting similar results [35,280]. For two further studies different 
populations were described in each pair of publications, with different follow-up 
periods also in one pair of papers. Each such study was represented by two papers 










possibly relevant to 
research question 68 
(judged on abstract 
alone) 
Psychinfo number 
possibly relevant to 
research question 32 
(judged on abstract 
alone) 
Embase number 
possibly relevant to 
research question 64 
(judged on abstract 
alone) 
94 identified after overlap between search engines accounted for and full text 
examined. 
68 rejected (inappropriate content or insufficient methodological detail) 
• 
Longitudinal studies 23 (26 papers reporting on 23 studies) 
Figure 12: Studies identified in a systematic review examining alcohol consumption and 
cognitive decline or dementia 
This systematic review therefore included 26 papers, representing 23 studies, reporting 
on 25 different sets of results. Follow-up length varied from one to twenty five years 
with most studies having more than five years of follow-up. Mean follow-up times for 
two studies were less than two years [226,265] ten studies, two-five years 
[145,229,230,234,237,239,264,266-268], eight studies, six-ten years [35,225,263,269, 
271,273,274,280] and six more than ten years [270,275-279]. Since dementia incidence 
rises with increasing age, the age at follow-up is important and was found to range 
widely from participants in their sixties to those in their eighties or over. It was not 
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always possible to establish mean/median ages or age ranges as these were not reported 
consistently in all papers. The vast majority of the studies were in populations drawn 
from Europe, particularly northern Europe, or from North America/Canada. 
Five studies report assessing dementia [267,270,276,277,279]. Three studies examined 
Alzheimer's disease alone [239,278,274], three Alzheimer's disease and dementia 
[269,271,275], two vascular dementia [35,264], one Alzheimer's disease and vascular 
dementia [230] and two all dementia, Vascular Dementia and Alzheimer's disease 
[263,273]. Eleven studies assessed cognitive decline [145,225,229,230,234,265,267, 
271,272,278,279]. Those studies that assessed Alzheimer's disease and dementia 
together, or vascular dementia and Alzheimer's disease together, found similar patterns 
in both categories. 
Fifteen papers (14 studies) found one or more statistically significant association with 
alcohol intake: three studies found an increased risk for either vascular dementia [35], 
Alzheimer's disease (when place of residence only was controlled for) [237], dementia 
as a whole, or of poorer performance on a visual reproduction test [234]. The remaining 
eleven studies were positive, with one finding that reduced cognitive function was 
associated with abstinence before age sixty [272]. These 15 papers are summarised in 
table 7. A detailed table of all studies is available in appendix 2. 
The reported results from all included studies as relative risks, odds ratios or hazard 
ratios were collated for meta-analyses in accordance with their outcome: dementia, 
Alzheimer's disease, vascular dementia and cognitive decline respectively. Two studies 
reported results as mean change scores [234,230] and were not included in the meta-
analysis. Tests for heterogeneity proved to be significant for each of the four meta-
analyses with the values of (Cochran Q=43.98) p=0.017, (Cochran Q=22.23) p=0.035, 
(Cochran Q=9.98) p=0.041 and (Cochran Q=79.83) p<0.0001 respectively. Although 
this indicates caution for the interpretation of meta analysis results, forest plots were 
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generated using a random effects model in order to allow graphical representation of the 
findings. Using a fixed effects model produced similar results. Where two papers from 
one study reported different lengths of follow up with dementia as an outcome, the 
results from the shorter follow up were removed and the meta-analysis re-run. This 
ensured that the same population had not been double counted but in fact had no effect 
on the results. Figure 13 shows the studies with dementia as an outcome, figure 14, 
those that specified Alzheimer's disease, figure 15, vascular dementia and figure 16, 
cognitive decline. Some studies provided data for multiple subgroups and this 
information is also included as far as possible. Some studies also looked at more than 
one outcome and so appear in more than one graph. In order to take the most 
conservative view, where available, the values used in the meta-analyses were from 
modelled data, adjusted by the individual authors for confounding. To summarise, 
alcohol consumption appears to be protective for dementia and Alzheimer's Disease, 
but there is no evidence of a protective effect against vascular dementia or impaired 
cognitive function. The combined risk ratios for each of the four outcomes were; 
dementia 0.62 (95 percent CI 0.52-0.74), Alzheimer's disease 0.57 (95 percent CI 0.44-
0.74), vascular dementia 0.82 (95 percent CI 0.50-1.35) and cognitive decline 0.88 (95 
percent CI 0.67-1.16), respectively with some alcohol intake. 
It was not practical to examine every numerically reported risk as full data were not 
always available However risk by alcohol consumption and type, and gender and 
APOEe4 status of drinker were examined and are reported below. 
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Table 7: Details of longitudinal studies assessing alcohol consumption and cognitive decline dementia and with significant results (all studies are 
available in appendix 2) 










Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard Ratio, 
(numbers in brackets are 95 percent confidence intervals) 
In order to assess the most conservative finding, results used 




From MoVIES study 
community living 
people on voter lists 









Age at FU 72.6 






<1 drink/month vs abstainers: 	OR 0.05 (0.01-0.26) 
>=1/month vs abstainers: 	OR 0.27 (0.09-0.84) 
Adjusted for 'true abstainers' and change in alcohol 
consumption. 
Launer et al 
(1996) 
[230] 
From the Zutphen 
Elderly study, 
randomly selected 
sample living in 
Zutphen 
N=333, men only 
Age 65-84 years, 
mean 71.6 yrs (SD 
5 4) . 
1985, 1990, 1993. 
Age at first FU 
mean 75.1 (SD 









Mean change in MMSE score between 1990 and 1993 adjusted 
for baseline MMSE score, education, alcohol intake (a negative 
value indicates a fall in MMSE/decline in cognition) 
No alcohol: 	-0.2 (-0.7-0.4) 
< 1drink/day: -0.4 (-0.8- -0.01) 
1-2 drinks/day: 	-0.3 (-0.8-0.3) 
>= 3 drinks/day: 	0.3 (-0.9-1.6) 
Participants with CVD/diabetes 
Mean change in MMSE score between 1990 and 1993 
No alcohol: 	-0.1 (-1.1-0.8) 
<1 drink/day: 	-1.4 (-2.1- -0.6) 
1-2 drinks/day 	-0.8 (-1.8-0.1) 
>= 3 drinks/day 	-0.7 (-3.8-2.3) 
No difference in amount of change in MMSE score by number of 

















<=1 drink/day vs none: 	HR 0.76 (0.41-1.40) 
>1 drink/day vs none: 	HR 0.28 (0.08-0.99) 
3MSE drop of 8 points 
<1 drink/day vs none: 	OR 0.69 (0.49-0.97) 
>1 drink/day vs none: 	OR 0.53 (0.28-0.99 
Significance lost when adjusted for baseline cognition — but this 
adjustment did not include all other covariates. 
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Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard Ratio, (numbers 
in brackets are 95 percent confidence intervals) 
In order to assess the most conservative finding, results used 
are those from the adjusted analyses unless otherwise stated. 
Broe et al 
(1998) 
[234] 
From the Sydney 
older persons study 
community dwelling at 
baseline 
N=630 
N=327 (with FU data, 
47 with dementia) 
Age mean 80.6 (range 
75-96) years 
At 3 year FU 50.5 
percent male 
age at FU mean 






Visual reproduction cognitive test and alcohol intake 
P<0.05 change in test values to poorer Performance 






study - nested case 
selected from 
Medicare lists, 373 
incident cases of 
dementia and 373 
controls matched on 
age, death pre 1999, 
attendance at 1998-
1999 clinic 
N=373 incident cases 
and 373matched 
controls 
Age >=65 years 
control study subjects Adjusted 1992-1994 and 
1997-1999 median 
follow up 6.1 years 












<1 drink/week vs abstainers: 	 OR 0.65 (0.41-1.02) 
1-6 drinks/week vs abstainers: OR 0.46 (0.27-0.77) 
7-13 drinks/week vs abstainers: 	OR 0.69 (0.37-1.31) 
>=14 drinks/week vs abstainers: OR 1.22 (0.60-2.49) 
for 'true abstainers' and change in alcohol 
consumption 
Selected results by sex: 
Dementia 
Women - 7-13 drinks/week vs abstainers: 	OR 0.23 (0.09-0.61) 
Men - 1-6 drinks/week vs abstainers: 	OR 0.36 (0.17-0.77) 
Alzheimer's disease 
Women 7-13 drinks/week vs abstainers: 	OR 0.27 (0.10-0.72) 




Recruited via GP N=225 network >=60 years 
without dementia. 
(with complete 







3-4 glasses wine/day vs nondrinkers: OR 0.13 (0.04-1.2) p=0.08 
(adjusted for age & education) 
3-4 glasses wine/day vs nondrinkers: OR 10.7 (2-56) p=0.005 




From Canadian study 




N=4615 (with FU) 










Alzheimer's disease, for weekly consumption; 
Weekly wine consumption vs none: 	OR 0.49 (0.28-0.88) 
Weekly beer consumption vs none: 	OR 0.84 (0.51-1.41) 
Weekly spirit consumption vs none: 	OR 0.78 (0.52-1.19) 
Weekly alcohol consumption vs none: OR 0.68 (0.47-1.00) 
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Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard Ratio, (numbers 
in brackets are 95 percent confidence intervals) 
In order to assess the most conservative finding, results used are 
those from the adjusted analyses unless otherwise stated. 




et al (1997) 
[266] 
From the PAQUID 
study, community 
living residents 2 
areas south west 
France 
N=2950 with at least 1 
FU visit and without 
dementia 








<250 ml wine /day vs none: 	RR 0.89 (0.70-1.15) 
250-500m1wine /day vs none: RR 56 (0.36-0.92) 
Alzheimer's disease 
<250 ml wine /day vs none: RR 0.88 (0.66-1.18) 
250-500 ml wine /day vs none: RR 0.53 0.30-0.95 
Huang et al 
(2002) [274] 
Kungsholmen project 
community living and 
dementia free at 
baseline 
N=402 (with FU) 
Age >=75years 
the  
FU at 4-6 years 







For 1-21 units/week males and 1-14 units/week females vs none: 
RR 0.5 ( 	-.7) 
Alzheimer'sdisease 
For 1-21 units/week males and 1-14 units/week females vs none: 







(58.6 percent of 
survivors from the 
original study) 
9-12 years Cognitive function 
Alcohol 
reduces risk 
Cognitive function and alcohol intake 
P=0.034 consumption before 60 
Higher values of cognition with higher values alcohol consumption. 
Orgogozo 
et al (1997) 
[266] 
From the PAQUID 
study, community 
living residents 2 
areas south west 
France 
N=2273 (with 3 year 
FU & not demented at 
baseline) 
Age >=65 years 
3 years (99 with 
dementia, 66 with 
Alzheimer's 








Dementia as a whole 
Mild (>=2 drinks/week <= 250m1 wine /day) vs none 
OR 0.81 (0.5-1.3) 
Moderate (250-500 ml wine /day) vs none: 
OR 0.19 (0.05-0.66) 
Heavy (>=500m1 wine /day) vs none: 
OR 0.31 (0.04-2.42) 
Alzheimer's disease 
Mild (>=2 drinks/week/<=250ml wine /day) vs none: 
OR 0.55 (0.31-0.99) 
Moderate (250-500ml wine /day) vs none: 
OR 0.28 (0.08-0.99) 
Heavy (>=500m1 wine /day) vs none: 
OR 0.48 (0.06-3.92) 
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Statistics if available. 
OR=Odds Ratio, RR=Relative Risk, HR=Hazard Ratio, (numbers in 
brackets are 95 percent confidence intervals) 
In order to assess the most conservative finding, results used are 
those from the adjusted analyses unless otherwise stated. 
Ruitenberg  
et al (2002) 
[273] 
From the Rotterdam 
study population 
study 
N=5395 with data on 
alcohol at baseline 
and without dementia 
Age >=55 years. 








1-3 drinks/day vs none: Men - 	HR 0.39 (0.21-0.74) 
Women — HR 0.80 (0.47-1.57) 
Both sexes — HR 0.58 (0.38-0.90) 
Vascular dementia 
1-3 drinks/day vs none: both sexes- HR 0.30 (0.10-0.92) 
All other categories of alcohol consumption vs none were non 
significant for: all subjects and males and female separately for all 





city heart study 
N=83 developed 
dementia and 1626 
controls 











Dementia as a whole 
All alcohol types (adjusted model), both sexes 
<1 unit/week vs 1-7 units/week: 	OR 0.87 (0.46-1.64) 
8-14 units/week vs 1-7 units/week: 	OR 0.81 (0.39-1.72) 
15-21 units/week vs 1-7 units/week: OR 1.74 (0.74-4.07) 
Wine intake only 
Monthly wine intake vs never: 	OR 0.43 (0.23-0.82) 
Weekly wine intake vs never: 	OR 0.33 (0.13-0.86) 
Daily wine intake vs never: 	OR 0.57 (0.15-2.11) 
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Figure 13: Forest plot combining longitudinal studies where alcohol consumption and 
dementia (unspecified) were assessed 
Summary meta-analysis plot [random effects] 
HR (1-7 standard drinks/week)1270] 0.70 (0.52, 0.93) 
HR (8-14 standard drinks/week)[270] 0.65 (0.45, 0.96) 
HR (15-28 standard drinks/week)[270] 0.40 (0.18, 0.79) 
OR (frequent drinkers vs infrequent drinkers)(279) 1.44 (0.66, 3.15) 
RR (women 1-14/men 1-21 units/week)12741 0.50 (0.30, 0.70) 
RR (250-500mI/day)1269] -111- 0.56 (0.36, 0.92) 
HR (1-3 drinks/day)[273) -111- 0.58 (0.38, 0.90) 
RR (<=250mUday)1266] 0.81 (0.50, 1.30) 
RR (250-500ml/day)[266] 0.19 (0.05, 0.66) 
RR 0.31 (0.04, 2.42) (>=500m1/day)(266] 
RR (Wine monthly consumption)1275) 0.43 (0.23, 0.82) 
RR (Wine weekly consumption)(275) ■ 0.33 (0.13, 0.86) 
RR (Wine daily consumption)(2751 ■ 0.33 (0.13, 0.86) 
HR (<1 drink/day)1267] ■ 0.28 (0.08, 0.99) 
HR (>1 drink/day)(2671 (0.41, 1.40) 0.76 
OR(Women <lchink/week)[263] 0.52 (0.30, 0.90) 
OR (Women 1-6 drinksAveek)(263] • 0.57 (0.28, 1.17) 
OR (Women 7-13 drinks/week)[263] ■ 0.23 (0.09, 0.61) 
OR (Women >=14drinks/week)[263] ■ (0.14, 1.10) 0.39 
OR(Men <1drink/week)12631 0.82 (0.38, 1.78) 
OR (Men 1-6 drinks/week)1263] • 0.36 (0.17, 0.77) 
OR (Men 7-13 drinks/week)(263) 1.42 (0.58, 3.48) 
OR (Men >=14drinks/week)[263] (0.86, 6.64) 2.40 
OR (Light <=3 drinks/week)[277) 1.00 (0.50, 2.00) 
OR (Moderate women 3-7/men 3-14 drinks/week)(277) 0.80 (0.30, 2.30) 
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Figure 14: Forest plot combining longitudinal studies where alcohol consumption and 
Alzheimer's disease were assessed 
Summary meta-analysis plot [random effects] 
OR (3-4 glasses/day) AD[237] ■ 10.70 (2.00, 56.00) 
OR (Wine-weekly) AD[239] 0.49 (0.28, 0.88) 
OR (Beer-weekly) AD [239] 0.84 (0.51, 1.41) 
OR (Spirits-weekly) AD(2391 0.78 (0.22, 1.19) 
RR (1-21units/wk(m)1-14u/wk(f)AD[274] 0.40 (0.20, 0.60) 
RR (250-500m1/day) AD(269] 0.53 (0.30, 0.95) 
RR (<=250m1/day) AD[266] 0.55 (0.31, 0.99) 
RR (250-500m1/day) AD[266] 0.28 (0.08, 0.99) ■ 
RR (>=500m1/day) AD[266] 0.48 (0.06, 3.92) ■ 
OR (Women 7-13 drinks/week) AD[263] ■ 0.27 (0.10, 0.72) 
OR (Men 1-6 drinks/week) AD[263] 0.36 (0.17, 0.80) 
RR (Wine 1-21 drinks/week) AD[268] 0.69 (0.45, 1.09) 
OR (Alcohol consumed) AD[276] 0.63 (0.35, 1.14) 
combined 0.57 (0.44, 0.74) 
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Figure 15: Forest plot combining longitudinal studies where alcohol consumption and 
vascular dementia were assessed 
Summary meta-analysis plot [random effects] 
HR (1-3 drinks/day) VaD[273J 
OR (Wine - once/week) VaLV2641 
OR (Beer - once/week) VaD12641 
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Figure 16: Forest plot combining longitudinal studies where alcohol consumption and 
cognitive decline were assessed 
Summary meta-analysis plot [random effects] 
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Alcohol consumption: optimal consumption and alcohol type 
With regard to cognitive function, results for optimal consumption were mixed, either 
above/below or equal to one drink a month or day [267 271] and in those subjects with 
cardiovascular disease or diabetes, one-two drinks per week [230]. For Alzheimer's 
disease optimal amounts were a weekly consumption of wine [239], either classified as 
one to six or, more than two drinks per week [263,266], or more than three drinks/250-
500m1 per day (usually wine) [263], or where examined by sex, one-three per day in 
males [266,269,273]. For dementia, benefit was shown for more than one drink per day, 
weekly or monthly wine consumption, 250-500m1 (usually wine) or more than three 
drinks per day [266,267,269,275] and from one-twenty eight units per week [270]. For 
vascular dementia from one-three drinks per day in males [273] was beneficial. In 
summary, there was no close agreement between studies as to the optimal level of 
consumption and although most studies reported that light to moderate consumption 
was best with regard to incident decline or dementia the classification of light to 
moderate drinking varied very widely between studies. 
Several studies did not identify a specific amount of consumed alcohol as favourable. 
One study reported that there was a positive effect although not linked to a specific 
amount of alcohol [230], and one that social/habitual drinking was associated with a 
better outcome [278]. 
With regard to alcohol type, 12 studies looked at beers and wines and spirits separately 
[234,237,239,263,265,266,267,268,273,274,275,277] although for two, only wine was 
consumed in any quantity by the study population [266,237]. One study reported 
examining red and white wine separately in their questions but did not report in detail 
regarding this [263]. In four papers (two from the same population but with different 
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follow up [266,269], wine intake was found to significantly reduce risk 
[266,269,239,275]. 
Gender and APOEe4 status if drinker 
Two studies included only female participants, [265,267], and one study only males 
[230]. Of the studies that reported analysing their results by gender 
[263,268,273,277,278,279] only three found any differences. In one, females showed a 
slightly stronger relationship with alcohol [278], in one it was weaker but a similar 
pattern [273], and in the third, for females higher levels of drinking (seven-thirteen 
drinks/week) were associated with a reduction in risk of Alzheimer's disease/all 
dementia whereas for males it was one-six drinks/week [263]. 
Five studies considered the effect of the APOEe4 allele. For two studies people with the 
APOEe4 allele had a reduced risk of dementia/cognitive decline only for low (less than 
two drinks per week) or no drinking categories [229,273], one study found this for both 
Alzheimer's disease and vascular dementia [273]. A further study found that the 
protective association seen with alcohol disappeared when APOEe4 was factored in 
[268] and in a further two, one found that those with APOEe4 retained the protective 
pattern of association [279] and one suggested this but without achieving statistical 
significance [263]. 
Methodological considerations - alcohol 
There are a number of methodological issues with the individual studies that may 
impact on the findings in this systematic review. These include the methods used to 
gather data on alcohol consumption and losses to follow-up, measures of quantity and 
type of alcohol consumed, lack of account for true abstainers or those who had reduced 
their consumption, or for defaulters and characteristics of drinkers as compared to non 
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drinkers. The outcomes and definitions of cognitive decline and dementia also varied 
between papers. 
1. Effects of non participation due to death during follow up or other causes 
Three studies that found either a positive relationship between alcohol and cognition or 
no negative relationship also took some account of the effect that deaths have on 
outcome [239,263,266,]. Survivors may be less cognitively impaired and constitute 
higher functioning participants. 
Six studies compared participants with non participants with four finding no significant 
differences [230,266,272,277] and two finding that non participants were slightly older 
[275] and to have lower levels of education and higher levels of cardiovascular risk 
factors [279]. 
2. Quantity and type of alcohol intake and changes in intake over time 
Only one study reported analysing alcohol intake as a continuous variable in addition to 
using categories although this did not change their findings [273]. All other studies used 
categories though these could be as basic as use/not use of alcohol. Wine was the most 
widely reported alcohol type in five studies [237,239,266,269,275] although in two of 
these studies the only alcohol that was consumed in any quantity and assessed was 
wine. The numbers of beer and spirit drinkers tended to be much smaller and therefore 
possibly underpowered to detect any impact on outcome. 
The reference category used was '0' i.e. non drinkers in the vast majority of studies and 
although several stated that they asked participants if they had drunk 'ever/never' only a 
few accounted for reported abstainers/quitters in more detail [263,265,271,277,278]. In 
three studies the reference category included low level drinkers, less than or equal to 
one drink a week [266], less than one drink per week [274], or infrequent/less than one 
drink per month [279]. The time over which alcohol intake was assessed also varied. 
Participants were asked to consider their alcohol intake over the last five years [273], 
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one year [265,271] three months [267], one month [230,278], at the time of 
questionnaire completion [263], their usual weekly or monthly consumption 
[225,268,274,275,277] and the most alcohol they would have consumed in an average 
week before age 60 or after age 60, and during the week before the interview [225]. Not 
all studies gave full details of the questions that participants answered with regard to 
their alcohol consumption and strength/intake of alcohol in grams was reported as used 
in three studies [234,265,275]. All studies relied on some form of self report. 
Binge drinking was accounted for in three studies [273,277,278] with one classifying a 
binge as drinking one bottle of wine, 1/4 bottle of spirits or equivalent on one occasion at 
least once/month. A diagnosis of alcoholism was accounted for in one study [278]. 
Ten studies reported collecting information related to whether subjects had changed 
their alcohol consumption over time [230,237,263,265,267,271,272,273,277,278] with 
five studies accounting for this and also defining 'true abstainers' 
[263,265,271,277,278]. All five found a positive relationship between better cognition 
or reduced risk of Alzheimer's disease and alcohol consumption to varying degrees 
from less than one drink a month (OR 0.05 (0.01-0.26)) [270] to 7-13 drinks/week for 
women (0.23 (0.09-0.61)) [263] and 1-6 drinks/week for men (0.36 (0.17-0.77))[263]. 
Of these five, in two the findings were statistically significant [263, 2701], a further two 
showed a similar pattern but non-significant results [277,278] and one did not give 
enough detail to be fully evaluated [265]. It would appear that abstainers and those that 
have reduced their alcohol consumption over time do not necessarily consist of 
abstainers that were not drinkers or who have stopped drinking for health reasons. 
3. 	Characteristics of drinkers 
Ten studies reported other differences between drinkers and non drinkers, with drinkers 
more likely to be current or ex smokers [267,271,273,274,279], have a higher family 
income, educational or occupational attainment [229,237,266,273,274,279], to be more 
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likely to live with others and to be male [229,230,237,266,273,275,279]. Drinkers were 
also found to be less likely to have a history of cardiovascular disease, diabetes, 
hypertension and depression [229,230,266,267,273], to be Caucasian [267] (in studies 
with multiethnic populations), younger, [279], have lower [267] or higher body mass 
index [266], to use `psychotropic drugs' [229,266], and for women, to have used 
hormone replacement treatment in the past [267], and to have better subjective health 
scores (men and women) [266]. 
There was also a wide variation in the reporting of factors adjusted for in analyses. 
Factors in one or more papers included demographic (such as age, age at menopause, 
sex, race, educational level, income, marital status), lifestyle (such as physical activity, 
smoking status), biochemical (such as cholesterol, fibrinogen, use of hormone 
replacement therapy, vitamin E supplementation, non-steroidal anti-inflammatories, 
APOEe4), clinical (such as hypertension, diabetes, heart disease, atrial fibrillation, 
stroke, transient ischemic attack, heart failure, depression, mental health) and when 
beverage type was considered separately alternative beverage types were controlled for. 
Five studies stated that they controlled for baseline cognitive function in their analyses 
[225,229,266,271,272] but detailed information was not available for all studies and it is 
possible that additional confounders were present and uncontrolled for. 
4. Definition of outcomes 
Individual studies used variable definitions of cognitive decline and dementia as their 
outcome measure. The most common was a fall in the Mini-Mental State Exam 
[MMSE] (cognitive function), the diagnostic criteria from the Diagnostic and Statistical 
Manual of mental disorders fourth edition IV [DSMIV] (dementia, Alzheimer's disease 
and vascular dementia), the National Institute of Neurological and Communicative 
Diseases and Stroke/Alzheimer's Disease and Related Disorders Association [NINCDS-
ADRDA] (Alzheimer's disease), and the National Institute of Neurological 
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Communicative Disorders and Stroke—Association Internationale pour la Recherché et 
l'Enseignement en Neurosciences [NINCDS-AIREN] (vascular dementia). 
In summary, an examination of all research published within the last ten years suggests 
that, at least in epidemiological studies, low to moderate alcohol use is associated with a 
38 per cent reduced risk of unspecified incident dementia. For Alzheimer's disease also 
low to moderate alcohol was associated with a significantly reduced risk of 32 per cent. 
Although the point estimates are also in a similar direction for vascular dementia and 
cognitive decline (0.82 and 0.88 respectively), the results were not statistically 
significant. However, all of these results should be interpreted with caution given the 
significant heterogeneity of the available studies and the long time scale and insidious 
onset of dementing illnesses. A possibility of publication bias may have resulted in 
negative studies not being published, although this was not indicated by funnel plots 
and bias indicators were non significant. The differences seen between the significant 
results in unspecified dementia and Alzheimer's disease as compared to vascular 
dementia and cognitive decline may be due to the small number of studies, five only, 
reporting vascular dementia as an outcome and to the difficulties in the classification of 
pure vascular dementia and cognitive decline. It could be argued that unspecified 
dementia is the stronger endpoint. On the other hand the protective effects of alcohol are 
thought to have cardiovascular mechanisms at least in part and it may be expected to 
have an even greater effect on vascular dementia. Further confounding comes from the 
different ways that Alzheimer's disease and vascular dementia are classified with 
studies often including cases with vascular factors in the Alzheimer's disease category. 
The difficulty lies in trying to clarify this issue further. The different studies vary in 
population, assessment, follow up, and classification of alcohol use with some studies 
not specifying the amount of alcohol in a 'standard drink', a value that can vary by 
country [281]. Also related to this is the repeated finding that it is the low to moderate 
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levels of alcohol that are protective despite the amounts included in this category 
varying widely between studies. It may be that the part of the population studied who 
drink what are moderate levels of alcohol for their societies also practise moderation in 
other areas and may be healthier generally that those who do not. With respect to 
alcohol intake the amount of detail reported regarding the collection of these data also 
varies widely with some studies collecting data on recent consumption through to some 
assessing consumption further back in time or lifetime abstinence/change in 
consumption and with the 'non-drinker' reference category, at least for three studies, 
allowing for some consumption. This may be particularly pertinent in the elderly as 
people may reduce consumption as they age [281] although not all studies agree with 
this [259,273,277]. It may be that the prevalence of binge drinking has only increased 
recently, especially for women, but it is surprising that so few studies assessed this in 
their participants. It must be remembered also that the participants in these studies will 
suffer from cohort effects with exhaustion of susceptibles and that traditionally men 
drank far more than women. Gender was adjusted for in many of the studies as were a 
variety of other factors although these too ranged widely. 
The attempts made in some studies to examine the topic in more detail, looking at 
specific dementia type, alcohol type, gender or APOEe4 status seemed to suggest that 
the protective effects are more likely with wine consumption and the absence of an 
APOEe4 allele, although many studies suffered from small numbers of cases in their 
subgroups. The T shaped curve was seen in the majority of the studies although with 
wide confidence intervals and lack of significance. Given the possibility that red wine 
rather than white may provide most protection although the evidence is slight [282], it 
is unfortunate that no studies reported specifically in this area although this may be due 
to small numbers and changing trends in alcohol type preference. 
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The results of a recent meta-analysis looking at mortality and alcohol suggest that the 
protective effects have been over estimated due to the diversity of the studies involved 
and the lack of accounting for loss in follow up. This allowed for past drinking in the 
non drinker comparator group. There was also a lack of standardisation regarding 
alcoholic amount consumed [281]. It is not clear whether this would also apply to 
cognitive function but it is clear that there are at least two studies that are not subject to 
the pitfalls described in the above meta-analysis and which did show positive beneficial 
findings for alcohol [263,271]. 
Although alcohol may be associated with less incident dementia we are far from being 
able to infer causality and it could still be that participants who drink alcohol sensibly 
also moderate themselves to live healthier lives both in physical, dietary and mental 
perspectives. Certainly in the studies that reported the characteristics of the drinkers 
they appear to do so. 
As it is highly unlikely that it would ever be possible to carry out a randomised placebo 
controlled trial in this area, it may never be feasible to answer with certainty the 
question of whether alcohol consumption may be protective in certain quantities against 
either cognitive decline or dementia. Judging from the publications of robust 
longitudinal studies over the last ten years it would seem that mild to moderate alcohol 
intake is protective and certainly not strongly detrimental with regard to incident 
dementia, at least in Western populations. 
2.5.5. Diet and obesity 
The thought that diet may have a role to play in the development of dementia has been 
raised by studies showing that increased consumption of fish and seafood even just once 
a month may be protective and reduce stroke [269,283,284,285]. It is thought that the 
protective action stemming from fish may be via the consumption of omega 3 fatty 
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acids. However, a Cochrane review from 2005 assessed the use of omega 3 fatty acid 
supplementation and concluded that there was no firm evidence. The authors did state, 
however, that it did seem that omega 3 fatty acids may be protective and randomised 
controlled trials were called for [168]. Antioxidant intake either by supplements [284], 
or in the diet [242,269,286] may also be protective with one study finding a 76 percent 
reduction in risk of developing Alzheimer's disease in those who drank at least three 
glasses of fruit/vegetable juice a week compared to those who drank less than one [286]. 
A deficiency in folic acid intake and a diet low in antioxidants may be risk factors 
although these may be reversible and a recently published double blind placebo 
controlled trial of folic acid supplementation found that serum folate increased, plasma 
homocysteine decreased and cognition was better in the folic acid group [287,288]. This 
may also be related to findings that raised homocysteine is associated with increased 
risk of silent brain infarct in the elderly [289] although other authors have suggested that 
there are insufficient data available for conclusions to be drawn [290]. Studies looking 
at the effect of vitamins including vitamin B, E and folate found conflicting results 
[269,285,286]. Calorie intake may also have an impact with studies showing that a diet 
higher in calories and lower in antioxidants is a risk factor [291] alongside studies 
showing that calorific restriction may prolong life [292,293], reduce oxidative damage 
[293] and may ameliorate cognitive decline or protect against it [292,293,295]. Obesity 
resulting from excess calorific intake brings with it a series of health problems and 
several studies have employed body mass index as a means to examine this with regard 
to cognition and dementia. 
There has also been some suggestion that a high waist hip ratio is associated with 
reduced hippocampal volume and increased levels of white matter lesions [296] both 
factors which have been linked to less good cognitive functioning [297,298]. Waist size 
or abdominal obesity is also one of the indicators of metabolic syndrome alongside 
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hypertriglyceridemia, low HDL levels, hypertension and hyperglycaemia with 
metabolic syndrome usually defined as certain levels of three or more of these factors. 
As yet the literature surrounding incident cognitive decline or incident dementia and 
metabolic syndrome is sparse although there are plausible mechanisms to explain why 
each of these factors may impact upon the development of cognitive decline or 
dementia. A case control study examining 50 patients with Alzheimer's disease and 75 
controls found that those with the dementia had higher levels of the components of 
metabolic syndrome, larger waists, higher triglycerides, higher glucose and lower HDL 
cholesterol although not higher blood pressure. Presence of metabolic syndrome was 
associated with an OR for Alzheimer's disease of 3.2 (95% CI 1.2-8.4), a relationship 
that became even stronger when blood pressure was not included [299]. Longitudinal 
studies in elderly participants have found similar results with one showing significant 
associations between metabolic syndrome and falling 3MS scores and another an 
increased risk of a five point fall in 3MS of 1.95 (95%CI 1.25-3.00) when levels of 
inflammation were also taken into account [300]. The finding was attenuated and 
became non-significant when inflammation was not included. Despite this at least two 
studies have reported no effect of metabolic syndrome. One followed those aged 65 and 
over for an average of 4.4 years and finding no association between metabolic syndrome 
and either prevalent or incident dementia [301] and the other, the opposite relationship 
in those aged 85 and over, that metabolic syndrome was significantly associated with 
slower decline on the MMSE p=0.01 [302]. Metabolic syndrome is a relatively recent 
concept and is becoming more prevalent, it is highly likely that the literature in this area 
will grow over the next few years. At the moment, it seems possible that the syndrome 
could impact on cognitive decline and dementia but further research is required, 
particularly in the very elderly. Another risk factor relating to obesity is the Body Mass 
Index and this literature in this area is more extensive although there are no thorough or 
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systematic reviews. Therefore, to examine the literature a systematic review was carried 
out to investigate the effect of BMI on the development of dementia and/or cognitive 
decline including dementia of the Alzheimer's type. 
2.5.6. Systematic review and meta-analysis: body mass index 
The search terms used were 'body mass index' or `BMI' and 'dementia' or vascular 
dementia' or 'multi infarct dementia' or Alzheimer's disease' or 'cognitive impairment' 
or 'cognitive decline'. The databases Medline, Embase and Psychinfo were searched for 
English language publications occurring from 1966 (Medline), 1980 (Embase), 1985 
(Psychinfo) to May 2006. When available, standard search categories were also used if 
they matched the search terms detailed above. All searches were limited to subjects 
aged 65 and over. 
From the literature search 210 records were identified in Medline, 82 in Psychinfo and 
213 in Embase. Of these, 10 papers reporting longitudinal studies were identified. Two 
studies, the Framingham study [303,304] and the Personnes Agees QUID [PAQUID] 
[305,308] study, had published two papers each and so the total number of reported 
projects was eight. See table 8 below detailing these eight studies below. 
When the studies were examined, overweight and obese women were found to be at 
increased risk of dementia, (BMI categories 25-29.9 usually taken as indicating 
overweight status and that of BMI >=30 as obese). BMI values of 25-29.9 and >=30 had 
Hazard Ratios of 1.5 (1.22-1.97) and 2.07 (1.49-2.89) respectively [307]. Unfortunately 
there were too few men in the higher BMI categories to evaluate the effect of 
obesity/overweight status and dementia in men but another study of men only, found 
decreased cognitive performance with BMI values >30 [298,299]. For both sexes an 
increased risk of Alzheimer's disease, Vascular Dementia or 'all dementia' was found at 
age 75 for each one point increase in BMI [308]. Four further studies found that 
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baseline BMI had no significant effect on subsequent dementia [180,305,306,309,310]. 
One of these studies excluded dementia diagnoses made 1-4 years after baseline 
[305,306] in an attempt to rule out any sub clinical dementia at baseline. Another study 
also employed this technique but found that a lower BMI was associated with increased 
risk such that every unit loss in BMI was associated with a 25 percent increased risk 
[311]. 
There are two ways in which the studies identified assessed the impact of body mass 
index on cognition, either by examining effect of unit change in BMI [308,309-311] or 
by comparing categories of BMI [180,305-307]. It is difficult to fully evaluate the 
literature due to these two different approaches, and the unit change in BMI method 
does not fully account for baseline BMI. It may be that a larger percentage change may 
have a greater effect that a smaller one and ethnicity may impact on this. This is likely 
to be, particularly important in Chinese or Japanese populations where average body 
mass index may be lower. These populations could also be affected by the choice of 
categories as different cut offs may be more appropriate. The measurement of body 
mass index is also flawed to the extent that it takes no account of muscle mass or central 
adiposity. 
Of the two studies reporting comparative categories and odds ratios, an increased risk is 
seen with a BMI over 30 [180,307] although it was only significant in one study [307]. 
Low BMI was also reported as a risk factor [305,306,311] although this should be 
interpreted with caution as studies relied on self report, and data from inpatient and 
outpatient records and had short follow up times which may have meant that subjects 
with early dementia or cognitive impairment were included [311]. It should also be 
remembered that any relationship between BMI and subsequent cognitive decline may 
be bi-directional such that lower BMI like lower blood pressure and lower total 
cholesterol may be indicative of an ongoing but undetected disease process [312]. 
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At the moment the published data are too diverse to draw clear conclusions as to the 
effects of BMI as a risk factor for subsequent dementia or cognitive decline although it 
may certainly have an effect and it seems highly likely that maintaining a healthy 
weight and diet would reduce cardiovascular risk and may confer protection against 
cognitive decline or dementia. 
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Table 8: Details of longitudinal studies assessing body mass index and cognitive decline or dementia. 
Author 




How information was 
gathered on cognitive 
function. 
What was adjusted for in the 
analyses 
RR=Relative Risk 
HR=Hazard Ratio  
Statistics if available. 
OR=Odds Ratio 
(numbers in brackets are 95 percent 
confidence intervals) 
Results used are those from the adjusted 
analyses unless otherwise stated. 
Whitmer 
et al (2005) 
[307]  
Recruited from health plan 
membership — 
Baseline 1964-1973 aged 40-45 
years. Follow up n=10,276 
people who were still members 
Members were representative of 
the community 
Dementia 
of the health plan in 1994. found 
Inpatient and outpatient 
records searched. hypertension, 
smoking, alcohol use, marital  
ischemic heart disease 
HR 1.35 (1.14-1.60)  
Age, sex, race, education, 
status, diabetes, 
hyperlipidaemia, stroke and 
BMI 18.6-24.9 reference category 
BMI 25-29.9 
BMI >=30 
HR 1.74 (1.43-2.26) 
Skin folds (sub-scapular and triceps) 
a similar relationship — bigger skin 
fold greater risk dementia. 
Sex specific models: not many obese 
men. 
For women BMI >=30 HR 2.07 (1.49-2.89) 
25-29.9 HR 1.55 0.22-1.97 
Gustafson 
et al (2003) 
[308]  
392 non demented Swedish on 
adults 70-88 years follow up at 







Severe disorientation in 
time/place. Long standing 
severe memory impairment 
rating scales at ages 70, 
75, 79, 81, 83 — 
DSMIIIR at ages 85 & 88 
Type of dementia identified 
between 79 & 88 using 
NINCDS ADRDA/NINCDS 
AIREN 





For each 1 point increase in BMI in 
women... (male data not shown in paper) 
BMI at age 70 
HR All dementia 1.13 (1.04-1.241 
HR Alzheimer's disease 1.36 (1.16-1.59) 
HR Vascular dementia 1.01 (0.88-1.15) 
BMI at age 75 
HR all dementia 1.13 (1.04-1.24) 
HR Alzheimer's disease 1.35 (1.19-1.53) 
HR Vascular dementia 1.07 (1.02-1.12) 
BMI at age 79 
HR all dementia 1.15 (1.05-1.26) 
HR Alzheimer's disease 1.23 (1.23-1.37) 
HR Vascular dementia 1.00 (0.89-1.13) 
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Author 




How information was 
gathered on cognitive 
function. 
What was adjusted for in 
the analyses 
HR=Hazard Ratio  
Statistics if available. 
OR=Odds Ratio 
RR=Relative Risk 
(numbers in brackets are 95 percent 
confidence intervals) 
Results used are those from the adjusted 
analyses unless otherwise stated. 
Nourhashe 




et al (2002) 
[306] 
From the PAQUID study, 
community living residents 2 
areas south west France 
Aged >=68 
8 year follow up with subjects 
included with normal cognition 
at baseline. 





dementia diagnosis DSMIIIR 
& NINCDS-ADRDA & 
si score; incident demon is  
dementia assessed at each 
follow up visit 
MMSE 
Age, agexsex interaction, 
sex, education, alcohol and 
tobacco consumption 
Age, sex, education 
At 5 year follow up 
BMI >=23 OR cognitive decline 0.28 (0.09-0.9) 
At 8 year follow up — BMI 23-26 as a reference 
category 
No significant results for BMI categories 21-22 
or >=27. 
For BMI <21 RR 1.48 (1.08-2.04) 
But — when patients who were diagnosed early 
in follow up (years 1-4) were excluded no 
significant relationships remained. 
BMI <21 RR 1.19 (0.72-1.96) 
BMI 21-22 RR 0.71 (0.40-1.25) 
BMI >=27 RR 0.72 (0.43-1.20) 
Brubacher 
et al (2004) 
[310]  
Basel study cohort n=531 
BMI assessed in 1990 & 2000 
Cognitive function assessed in 
2000 





Boston naming test 
MMSE 
Word list learning 
Figure copying & delayed 
recall 
Word list delayed recall 
Word list recognition 
Poor cognitive function if >=2 
variables were <1.5 SD below 
mean 
For the OR this is unclear 
An OR of 1.5 is associated with an annual 
change in BMI of -0.5 or +0.3 kg/m2 
No confidence intervals supplied —'j' shaped 
graph in paper 
Buchman 
et al (2005) 
[311]  
Religious orders study without 
dementia at baseline. Mean 
follow up 5.5 years. N=832 
BMI mean 27.4 at baseline 




NINCDS ADRDA, MMSE 19 
neuropsychological tests 
including episodic memory, 
semantic memory, working 
memory, perceptual speed 
Age, sex, education 
For 1 unit/year loss in BMI associated with 
increased risk of 35 percent for global cognitive 
decline as compared to no change in BMI 
Similar results when controlling for chronic 
disease/ MI hypertension, stroke, diabetes, 
thyroid disease, head injury, cancer, smoking, 
depression, hormone replacement therapy, 
physical activity. 
Similar results also when excluding people who 
developed Alzheimer's during the first 4 years. 
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Author 




How information was gathered 
on cognitive function. 
What was adjusted for in 
the analyses 




(numbers in brackets are 95 percent 
confidence intervals) 
Results used are those from the adjusted 





CAIDE study cardiovascular risk 
factor ageing and dementia. N=1449 
65-79 years at follow up after an 
average 21 years (SD 4.9) follow up. 
900 females, 549 males 
mean age 50.6 (SD 6) years 
baseline, 71.6 (SD 4.1) at follow up 






3 step procedure — screening 
clinical and differential diagnosis 
phase. 
NINCDS ADRDA & DSMIV 
Also re ran analyses using 
diagnoses from medical records 
and including non participants 
Age,& a 	sex, education, follow 
up time, sociodemographic 
variables, midlife blood 
pressure, total cholesterol, 
smoking, Apoe4, history of 
vascular disorders (stroke, 
MI, diabetes) 
Reference value for BMI <=25 
All dementia 
BMI 25-30 OR 0.99 (0.47-2.15) 
BMI >30 OR 1.88 (0.76-4.63) 
Alzheimer's disease — similar pattern 





Adult Health Study 
Baseline n=1774 born before 1932 
Assessed from1958 onwards 






DSMIIIR — diagnosed in visits 
between 1992 & 1997 Age, sex, education 
Per unit increase in BMI, 
Associated with 
OR Vascular dementia 1.074 p=0.0134 




Framingham Heart Study 
Participants with no dementia, stroke 
or cardiovascular disease up until the 
time of cognitive testing 
551 men & 872 women (both papers) Cognitive 
function 
Risk surveillance period 1954- 
1970 
Preceded cognitive testing. 
Neuropsychological testing in 
1974-1978 
Sub tests of the Wechsler Adult 
Intelligence Scale and 
multilingual aphasia exam 
Learning, memory, executive 




disease risk, obesity and 
diabetes 
Neuropsychological test results - for males: 
visual reproduction p<0.05 
digit span p<0.05 





Mean age of reported study 67 
(range 55-88) 
4-6 year follow up 
As above plus cigarettes, 
alcohol, total cholesterol, 
normo/hypertensive status 
Same pattern as above — obese men worse at: 
Visual reproduction p=0.00004 
Digit span backward p=0.00002 
Similarities p=0.07 
Word fluency p=0.03 
Logical memory — delayed recall p=0.03 
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2.5.7. Education, occupation and leisure activity 
There have been many studies demonstrating that ageing brings cognitive change, as 
assessed by performance on cognitive testing, and brain activation, using imaging 
techniques [313,314,315]. Not all elderly persons show cognitive impairment or 
dementia, however, and decline may not be inevitable [316,317]. The elderly may use 
different strategies to compensate for decline and/or may have a cognitive reserve [318]. 
Education and learning seem to contribute to a cognitive reserve and have either a 
protective or masking effect against a deleterious change [319,320]. In a study of 258 
people with a mean age of 73.1 years and 61.6 percent female, higher educational level 
was associated with a slower decline in MMSE, despite earlier symptom onset [321]. A 
further study found that females with low levels of education had an increased risk of 
Alzheimer's disease of RR4.3 (95 percent CI 1.5-11.9) whereas for those with medium 
educational level it was RR2.6 (95 percent CI 1.0-7.1) [322]. For males the risks 
remained close to 1.0 [322]. Occupational attainment and leisure activities may also be 
protective against cognitive deterioration [319] and a systematic review published in 
2004 [323] found that social, mental and physical stimulation seem to act in convergent 
pathways to reduce the incidence of dementia. 
Animal studies have shown that enriched environments and training increase dendritic 
branching and synaptogenisis and long term potentiation has been put forward as a 
plausible mechanism to explain such findings in humans [324]. 'Long term potentiation 
is an activity dependent increase in synaptic efficiency and is recognized as a cellular 
correlate of learning and memory induced by frequent afferent stimulus lasting more 
than an hour' i.e. learning new skills or information [324]. A review of human studies 
has found that both cross sectional and longitudinal studies support the concept that 
education provides protection although not all studies were in total agreement [319]. 
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The apparent protective effects of education and activity need to be interpreted with 
caution as causality is far from clear. For example, childhood IQ shows links with both 
social class and deprivation category of residence in adulthood [325] and it may be that 
those with higher ability are more likely to devote time to education or leisure activities. 
There are, however, three plausible mechanisms presented to explain the effect of 
education/activity [323]. The cognitive reserve hypothesis, such that enriched 
environments promote brain plasticity, the vascular hypothesis, such that increased 
fitness reduces vascular disease and stroke, and the stress hypothesis such that stress 
may make Alzheimer's disease more likely and those with leisure activities and social 
interaction may be less affected by stress [323]. Alternatively another independent 
factor may both increase childhood IQ and length of education and resistance to 
dementia with no causal relationship between the two. 
2.6. 	Brief summary of risk factors where intervention is 
possible (lifestyle factors) 
Current smoking increases risk of dementia and possibly cognitive decline although 
exsmokers do not seem to show the same pattern. Lower educational level increases risk 
and moderate alcohol use seems to reduce risk. A healthy diet may offer protection but 
is difficult to assess. 
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2.7. 	Risk factors where intervention is possible (other 
factors) 
2.7.1. Haemoglobin level 
Anaemia, defined by the World Health Organisation [WHO] as <12 gm/di women and 
<13grn/d1 men, is a common condition especially in children and women of child 
bearing age and affects two billion people worldwide [326]. The elderly may also suffer 
from anaemia and it may indicate poor health status or adversely affect health status. 
Anaemia prevalence rates are reported around 25 percent [327], or 29.6 percent in men 
and 16.5 percent in women over the age of 85 when defined according to the WHO 
criteria [328]. The latter study was confined to a Norwegian population but the literature 
generally agrees that a fall in haemoglobin levels in the eighth decade of life occurs 
with additional evidence from a Japanese population [329] and in Americans [330]. The 
American based National Health and Nutrition Examination Survey [NHANES] 
reported a prevalence rate of 20 percent in those aged over 85 and that one third of this 
anaemia stemmed from nutritional inadequacies, one third from chronic illness and one 
third was unexplained [330]. The authors speculate therefore that ageing itself may be 
playing a part and this has been echoed by other authors [327]. 
Low levels of haemoglobin and presence of anaemia have been found to be risk factors 
for poor mobility, increased frailty and decreased executive function in women with 
moderate to severe disability participating in the Women's Health and Aging Study 
[WHAS] [331-333]. Adding to this, is a relationship with poorer outcome after sub 
arachnid haemorrhage [334] and decreased motor performance, although only in a 
univariate analysis [335]. Mortality risk also seems to have a relationship with 
haemoglobin level, in patients with coronary artery disease lower haemoglobin 
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increased risk of death [336]. Furthermore, in 5797 participants in the American based 
cardiovascular health study, participants aged 65 or over were followed up for eleven 
and a half years and showed a 'reverse J' shaped curve relationship between mortality 
and haemoglobin [337]. Both lower (<13.7gm/d1 for women and <12.6gm/d1 for men) 
and higher (>14.1gm/d1 for women and >15.6gm/d1 for men) haemoglobin levels 
conferred significantly increased risk of death. In the higher category this was a 
significant 17 percent increase in risk, with significance remaining even after multiple 
adjustments [337]. 
This finding is similar to that from the WHAS study when mortality was examined 
[331,332]. The WHAS, again in those aged 65 or over but restricted to women with 
moderate or severe disability, found that in 686 participants haemoglobin below 12 
conferred significantly increased risk of mortality. The reference value that the 
researchers used was >12 to <15 and when values of 15 or over were examined the 
reverse J shape was seen although the higher category was not statistically significant. 
Again this relationship remained when adjusting for a wide variety of factors including 
age, race, educational level, smoking, drinking alcohol, co-morbidities, cognitive 
function and several biochemical and physical variables. Certainly higher haemoglobin 
levels have been associated with increased risk of stroke [338] and polycythemia is 
associated with circulatory disturbances, although treatment with aspirin may ameliorate 
the risks of cardiovascular events and mortality [339]. 
The report from the WHAS study questioned the thresholds for anaemia as defined by 
the World Health Organisation [WHO] [326]. The WHAS query was based on their 
own findings of increased risk at levels that differed from those of the WHO. 
The elderly, particularly the very elderly, aged eighty and over, are the fastest growing 
sector of the population worldwide [14], are at high risk of mortality and other illnesses 
such as dementia and related cognitive decline. These health issues may be contributed 
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to by stroke, high levels of cardiovascular risk factors and poor cerebral circulation or 
low levels of circulating oxygen due to low haemoglobin levels. The optimal 
haemoglobin level in the elderly is unclear. A systematic review relating to prevalence 
and outcome of anaemia or low haemoglobin in geriatrics was published in 2004. It 
reported that few studies in this area had actually systematically examined the 
functional, clinical and economic outcomes [340] although highlighted by the review 
are the increased risk of mortality and also dementia or cognitive decline. Dementia and 
cognitive decline are more likely to occur with increasing age and the review raises an 
interesting issue. If haemoglobin levels are related to either incident or prevalent 
dementia or cognitive decline, there may be a possibility of intervention and whilst 
prevention of mortality would be of benefit, prevention or amelioration of dementia 
symptoms and cognitive decline may be even more important both for potential 
sufferers and carers and in economic terms [4]. Given that, since the 2004 review, the 
literature has grown and the very elderly become even more of an important group in 
society a further systematic review, focused on dementia and cognitive decline, would 
contribute to the literature in this area. 
2.7.2. Systematic review and meta-analysis: haemoglobin 
I therefore carried out a systematic review to examine the evidence for a relationship 
between haemoglobin level, anaemia and cognitive decline/dementia in the elderly. 
Given the possibility that high as well as low haemoglobin may have an impact on 
cognitive decline or dementia but that available data is sparse, cross sectional and 
longitudinal studies were included but analysed separately. Hypotheses were therefore 
formulated as detailed below: 
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Haemoglobin as a risk factor: 
1: That anaemia (labelled as such in the literature) or as defined by the WHO as low 
levels of haemoglobin (<12 gm/di women and <13gm/d1 men) would be predictive of 
lower cognitive function and or dementia. 
2: That high haemoglobin (>14.1 gm/di women and >15.6 gm/di men) would be 
predictive of lower cognitive function and or dementia. 
Haemoglobin associated with concurrent cognitive impairment or dementia: 
3: That anaemia (labelled as such in the literature) or as defined by the WHO as low 
levels of haemoglobin (<12 gin/di women and <13gm/d1 men) would be associated with 
concurrent cognitive impairment and or dementia. 
4: That high haemoglobin (>14.1 gm/di women and >15.6 gm/di men) would be 
associated with concurrent cognitive impairment and or dementia. 
The search terms used for the review were 'anaemia' or 'anemia' or 'haemoglobin' or 
`hemoglobin' and 'dementia' or vascular dementia' or 'multi infarct dementia' or 
Alzheimer's disease' or 'cognitive impairment' or 'cognitive decline' were used as 
keywords and the databases Medline, Embase and Psychinfo were searched for English 
language publications relating to human populations and occurring between 1996 and 
March 2006. When available, standard search categories were also used as matched the 
above terms. All searches were limited to subjects aged 65 and over. See figure 17 for 
details. In order to fully comply with systematic review methodology an additional 
reviewer read all abstracts and selected papers, consensus opinion was obtained for 
inclusion and extraction tables. No hand searching was carried out. 
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Figure 17: Detailing studies identified in a systematic review process examining 










             
             
 
Medline number 
possibly relevant to 
research question 14 
(judged on abstract 
alone) 
   
Psychinfo number 
possibly relevant to 
research question 2 




possibly relevant to 
research question 12 
(judged on abstract 
alone) 
       
  
             
 
7 papers reporting on 8 studies identified after overlap between search 
engines accounted for and full text examined. 
 
15 rejected (inappropriate content or insufficient methodological detail) 
           
            
 
Longitudinal studies 3 
        
Cross sectional studies 4 
             
Studies were ranked on a methodological basis with any randomised studies first 
followed by case control and epidemiological population studies and quality assessed 
using key factors including appropriate design, recruitment, analysis and provision of 
suitable information relating to key aspects of the study. Case studies, letters, consensus 
opinion from conferences and expert opinions or editorials were not included. In order 
to aid investigation of causality longitudinal studies and cross sectional studies were 
assessed separately. All studies were assessed in detail. Studies reporting results that 
could be used in a meta-analysis were analysed accordingly and tests for heterogeneity 
also carried out. 
From an initial 22 papers identified as relevant based on abstract alone only seven 
papers (reporting on eight studies) remained so after full evaluation. There were four 
longitudinal studies and four cross sectional studies reporting primarily on anaemia and 
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dementia. Study quality varied and there were no randomised controlled trials or 
intervention studies of any sort. Methodological details and meta-analytical results are 
discussed below. Tables 9 and 10 detail all of the studies and study type included. 
In order to examine hypotheses 1 and 2 relating to haemoglobin levels as risk factors for 
later cognitive change, longitudinal studies are discussed first below. Cross sectional 
studies follow in order to evaluate the data with regard to hypotheses 3 and 4. 
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Table 9: Details of longitudinal studies assessing haemoglobin level or anaemia and cognitive decline or dementia 
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1435 people without 
dementia at baseline 
Aged 75-95 years 





review by specialist 
dementia 
information on 




using DSM-III-R — of 
those who died in i 
WHO criteria 130g/L 
men, 120g/L women 
Plus: 
Lowest 25th percentile 
135d/L men & 129 g/L 
women and lowest 5  
percentile 117g/L & 
116 g/L women 
In those with MMSE>=26: 
Age, sex, education, history 
hypertension, diabetes, 
cerebrovascular disease,>=26 .  heart failure, chronic coronary 
disease, COPD, 
hypothyroidism, chronic renal 
failure, high white blood cells, 
high blood sedimentation 
rate,. Low albumin, low BMI. 
Anaemia increases 
risk of dementia in 
those with MMSE 
Low Hb - below 
130g/L men & 
120g/L women 
increases risk of 
dementia 
In addition in subjects with MMSE 
>=26.... 
With Hb<25th percentile HR 1.2 
(0.7-2.01 
With Hb WHO criteria HR 2.0 (1.0- 
3.8) 









Women's health & 
ageing study 1, USA 
558 women with MMSE 
>24 and walking speed 
>0.4m/s. 
Mean age of whole 
study = 78 yrs (SD 8.1) 




in MMSE to 
<24) 
MMSE Hb (g/dl) 
Age, race, smoking, 
education, no diseases, 
pulmonary disease, Hb, 
baseline walking speed, 
baseline MMSE, baseline 
IADL, baseline ADL 




OR 0.86 (0.60-1.21) 
Combined physical and cognitive 
decline 






1. 302 incident cases of 
Alzheimer's Disease 
[AD] with matched 
controls. (255 pairs 
analysed) 
fu: Hb from year 















1. AD identified 
from lists of 
diagnostic terms 
thought to include 
dementia — 
diagnostic criteria 
similar to DSM. 
controls matched 
by age and gender. 
WHO criteria 130g/L 
men, 120g/L women. 
1. Lowest 
measurement 
recorded in 2 yr 
window (onset + 




1. age, gender 
1. anaemia 
increases risk of 
AD (not significant 
in men) 
1. OR 188 (1.17-3.03) 
Men OR 1.81 (0.75-4.39) 
Women OR 1.96 (1.11-3.47) 
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Longitudinal studies — haemoglobin, anaemia, results of included studies and meta-
analysis 
For the hypothesis that anaemia or low haemoglobin was predictive for dementia or 
cognitive decline; two studies using the WHO criteria for anaemia found significant 
results. 
The population study the Kungsholmen project found a Hazard Ratio [HR] of 2.0 (95 
percent CI 1.0-3.8) for incident dementia with anaemia [341]. The retrospective case 
control study from Beard et al [343] found a similar result for Alzheimer's disease 
which was significant only in women (OR 1.96 (95 percent CI 1.11-3.47)) although 
men showed a similar but non-significant effect((OR 1.81 (95 percent CI 0.75-4.39). An 
additional analysis from the Kungsholmen population found an even stronger 
relationship with haemoglobin values below 11.7 g/dl for men and 11.6 g/dl for women 
respectively (The fifth percentile of their population (males and females). HR 2.2 (95 
percent CI 1.0-4.9) [341]. No other evidence relating to low haemoglobin levels other 
than those defined above was available. There was also no evidence relating to 
cognitive decline. 
For the hypothesis that high haemoglobin may predict incident dementia or cognitive 
decline, there was no clear evidence in the published literature. 
The relationship between low haemoglobin levels and dementia was ameliorated when 
all cases below the 25th percentile of the Kungsholmen project were included as would 
be expected [341]. Higher haemoglobin gave rise to an odds ratio of less than one (0.86) 
for incident cognitive decline in the WHAS study but this was non significant and 
neither supports nor undermines the hypothesis, (95 percent CI 0.60-1.21)[231] 
It was only possible to combine two longitudinal papers in a meta-analytic way to 
examine anaemia and dementia and the forest plot demonstrating this is shown in figure 
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18. The analysis of heterogeneity was non significant (Cochran Q=0.03; p=0.98) 
suggesting that the studies were able to be combined. The summary ratio was 
significant at 1.94 (95 percent CI 1.32-2.87). It was not feasible to include the cohort 
study from Beard et al [343] in the analysis, as it reported only standardised incidence 
rates (a ratio of the incidence rate in the study population to that expected in a 'standard' 
population). and the source of the standard population data were unclear. No analyses 
regarding haemoglobin level or cognitive decline were possible. 
Figure 18: Forest plot combining longitudinal studies where anaemia and dementia 
(unspecified) where assessed 
Summary meta-analysis plot [random effects] 
HR (Dementia) [341] 
Case control OR (AD) Men [341] 
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Methodological considerations longitudinal studies 
1. Study design 
Two of the longitudinal studies were population based cohort designs [341,230] with 
prevalent cases of dementia plus those with baseline MMSE below 20 and below 24 
excluded respectively. The remaining longitudinal study reported on both a 
retrospective case control, (where haemoglobin values taken up to two years before 
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incident dementia were used), and a cohort, (where all participants had newly 
recognized anaemia and were subsequently followed up) [343]. 
2. Study population 
Longitudinal study populations were fairly homogeneous and drawn from northern 
Europe [341] and the United States [343.230] with age ranges or mean ages between 65 
and 95 and therefore old enough to manifest dementia cases. Studies were relatively 
large with patient numbers ranging from 255 case control pairs [343] to 1435 followed 
for a mean of 3.4 years (Standard Deviation [SD] 0.5) [341]. Follow up was less clear 
with one paper including a cohort follow up and a case control sub study of incident 
cases with retrospective haemoglobin measurements from the year of, and the year 
preceding, onset of dementia [343]. Cohort follow up was wide ranging from one day 
to 7.9 years. This follow up included patients who had poorer cognition and who were 
not included in the analysis, there were 2417 person-years of follow up for the group 
that were analysed but the range was not clear [343]. Follow up for the only study 
recruiting women only was three years [230]. 
3. Outcome 
There was some heterogeneity in the cognitive assessment outcome of the identified 
studies and standardised criteria were not always applied. Of the three studies that were 
longitudinal in nature, two assessed dementia and one cognitive decline. Only one, the 
Kungsholmen project, used the standardised Diagnostic and Statistical Manual of 
mental disorders [DSM] criteria, and this was the DSM third edition revised [DSM-III-
R] supplemented with information from clinical examination, death certificates and 
medical records [341]. Beard et al [343] reported on Alzheimer's disease but used an 
adapted form of diagnostic criteria, similar to the DSM and the Women's Health and 
Aging Study [230] defined cognitive decline as a fall in MMSE to less than 24. 
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When measurement of haemoglobin or anaemia was considered two of the longitudinal 
studies [341,343] used the World Health Organisation [WHO] criteria for anaemia of 
less that 13 g/dl for men and less than 12 g/dl for women [326]. Atkinson et al reported 
using haemoglobin measures but no specific cut off values for anaemia. There was some 
discussion in the literature with regard to the utility of the WHO cut-off values and the 
Kungsholmen project also analysed their data using cut off values from the 25th and 5th 
percentiles (13.5 g/dl men, 12.9 g/dl women and 11.7 g/dl men, 11.6 g/dl women 
respectively). 
4. Variables adjusted for, and data from subjects not included or lost to follow up. 
Comprehensive adjustments for confounding variables were made in two studies only: 
the Kungsholmen study (age, sex, education, history of hypertension, diabetes, 
cerebrovascular disease, heart failure, chronic coronary disease, COPD, 
hypothyroidism, chronic renal failure, high white blood cells, high blood sedimentation 
rate, low albumin, low BMI.)[341] and in the WHAS study (age, race, smoking, 
education, no diseases, pulmonary disease, haemoglobin, baseline walking speed, 
baseline MMSE, baseline IADL, baseline ADL) [230]. 
Of the longitudinal studies only one took into account the effect of patients who died or 
left the study [341]. Death certificates were assessed to identify cases of dementia. 
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Cross sectional studies — haemoglobin, anaemia, results of included studies and meta-
analysis 
For the hypothesis that there is an association between anaemia or low haemoglobin and 
prevalence of dementia or cognitive decline, three studies found an association. 
The association for Alzheimer's disease for Pandav et al [344] was non significant 
OR1.8 (95 percent CI 0.8-4.1) and there was a non significant association for all 
dementias OR1.5 (95 percent CI 0.7-3.2) also in this study. The association with 
Alzheimer's disease and anaemia was significant for a further study OR1.7 (95 percent 
CI 1.02-2.09) [345]. The third study [346] reported an increased prevalence in 
Alzheimer's disease and vascular dementia with anaemia p=0.012 (no further 
information was provided). One study found significant differences between 
haemoglobin levels for subjects with dementia, cognitive impairment and normal 
subjects, such that the normal subjects had the highest haemoglobin (p=0.004) and the 
least abnormal values (p<0.001) with the dementia sufferers showing the opposite 
pattern [347]. No other cross sectional studies commented on cognitive decline. 
It was only possible to combine two of the cross sectional studies [344,345]; however, 
one of these studies did provide two overlapping outcomes (AD and all dementias) 
[344]. If Alzheimer's disease only was included, the analysis of heterogeneity was non 
significant (p=0.90) suggesting that the studies were able to be combined. The summary 
ratio was significant (1.72(95 percent 1.24-2.38)). If a definition of all dementia was 
used, for heterogeneity p=0.77 and the summary ratio was 1.66 (95 percent CI 1.20-
2.30). The forest plot for all dementia is shown in figure 19. No analyses regarding 
either haemoglobin or cognitive decline were possible. 
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Figure 19: Forest plot for cross sectional studies; association between anaemia and 
dementia 
Summary meta-analysis plot [random effects] 
1.50 (0.70, 3.20) OR (all dementia) (344] 
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Table 10: Details of cross sectional studies assessing haemoglobin level or anaemia and cognitive decline or dementia 
Author Population 



















Statistics if available. 
SD=Standard Deviation, OR=Odds Ratio, 
RR=Relative Risk, HR=Hazard Ratio, 
(numbers in brackets are 95 percent 
confidence intervals) 
In order to assess the most conservative 
finding, results used are those from the 
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seems to be a OR (abnormal values) 
Anaemia 1.7 (1.02-2.09) 
Reported as true only for Men. 








people from Sydney, 
Australia 
Mean age 84.9 ± 3.7 
years (men 84.2 ± 3.2 
years, women 85.5 ± 
4.0 years) 









NINCDS-ADRDA & DSM-IV 
criteria 
WHO criteria 130g/L 
men, 120g/L women 
Unadjust 




> 50 percent 
of all subjects 
with both VAD 
& AD were 
anaemic. 20 
percent of all 
subjects with 




Alzheimer's disease + vascular dementia 
p=0.012 
Pure Alzheimer's disease p=0.401 
Pure vascular dementia p=0.087 
All dementia with a vascular aspect p=0.005 
Men: 	Alzheimer's disease + vascular 
dementia p=0.808 
Pure Alzheimer's disease p=0.440 
Pure vascular dementia p=0.208 
All dementia with a vascular aspect p=0.266 
Women: Alzheimer's disease + vascular 
dementia p=0.005 
Pure Alzheimer's disease p=0.207 
Pure vascular dementia p=0.243 























Statistics if available. 
SD=Standard Deviation, OR=Odds Ratio, 
RR=Relative Risk, HR=Hazard Ratio, (numbers 
in brackets are 95 percent confidence intervals) 
In order to assess the most conservative finding, 
results used are those from the adjusted 
analyses unless otherwise stated. 
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groups  
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values seen in 
the impaired 
Mean Hb in Dementia 12.9 (SD 1.8) 
Mean Hb in Cognitive impairment 13.2 (SD 1.7) 
Mean Hb in Normal 13.4 (SD 1.6) 
Percentage of abnormal values 
Dementia 27.9 percent ,cognitive impairment 
26.5 percent , Normal 13.1 percent 
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Methodological considerations cross sectional studies 
1. Study design 
Two of the cross sectional studies were unmatched case control studies [344,346]. Two 
were observational [345,347]. 
2. Study population 
The populations from the four cross sectional studies varied widely with populations 
from rural India [344], Australia [346], Thailand [347] and Northern Greece [345]. In 
the latter the researchers recruited from an elderly people's home, from those who 
visited an open centre for elderly people, and those elderly who visited a health centre 
for medical care. The subjects recruited for all three cross sectional studies were over 
the age of 55 [344,345,347] the Australians being the oldest, with a mean of 84.9 years 
(SD 3.7) [346]. All of the cross sectional study populations were mixed gender. The 
largest population sample was Indian, 605 [344] and the smallest Australian 316 [346]. 
3. Outcome 
Two of the three cross sectional studies reported on cognitive impairment, defining this 
as an MMSE of less than 24 [345] or an MMSE less than 24 but without diagnosis of 
dementia [347]. One study reported on dementia in addition to cognitive impairment, 
diagnosing dementia with the DSM fourth edition [347]. The other two projects had 
Alzheimer's disease or all dementia classified by the DSM-III-R, CDR and the National 
Institute of Neurological and Communicative Diseases and Stroke/Alzheimer' s Disease 
and Related Disorders Association [NINCDS-ADRDA] [344] or Alzheimer's disease 
and Vascular dementia classified with NINCDS-ADRDA and DSMIV [346]. 
For the measurement of anaemia two studies used the WHO criteria [344,346] with two 
also reporting on haemoglobin level without use of a cut off value [344,347]. One study 
reported the percentage of subjects with abnormal levels of haemoglobin, defined as 
less than 12 or more than 18 g/dl [347] The final study presented information on the 
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numbers of participants with anaemia but reported only vitamin B12, folate and 
heamatocrit levels with no clear definition for anaemia [345]. 
4. Variables adjusted for, and data from subjects not included or lost to follow up. 
Adjustments were made only for age and gender [343], age gender and male literacy 
[344] or no clear adjustments were mentioned [345-347]. 
Only one of the cross sectional studies commented with regard to characteristics of 
subjects who didn't participate [344]. Those who did not provide haemoglobin samples 
were significantly older but had similar levels of literacy and gender distribution. 
Summary— haemoglobin, anaemia 
Three longitudinal studies were identified and considered in this review, the most robust 
one of which was the large population study, the Kungsholmen project [341]. The 
WHAS [230] was also of reasonable quality and both studies found an increased risk of 
dementia or cognitive decline with anaemia at baseline after follow up of around three 
years. The third paper reported on two studies and was weaker in that the length of 
follow up varied within the cohort and was unclear for the case control study [343], the 
latter was significant only and supported the relationship between anaemia and 
dementia. It was only possible to combine the case control study from Beard et al and 
the Kungsholmen data in a meta-analytic way and the result was unsurprisingly 
significant given its constituent parts. For the cross sectional data two studies showed a 
significantly decreased risk with higher haemoglobin levels [344,347] but the 
participants of one study were from Rural India and the other Thailand, so it is difficult 
to evaluate whether they may have dietary factors that impact on their haemoglobin 
levels to a greater or lesser extent than other populations. The study based in Greece 
found a significant association between anaemia and cognitive impairment but the 
definition of anaemia and the account of any confounding factors was unclear [345]. 
Similarly, the Australian study found that women were significantly more likely to 
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suffer from prevalent dementia with a vascular aspect to it if they were anaemic but 
information on confounding factors is unclear [347]. 
In reference to our hypotheses, the literature suggests that low haemoglobin or anaemia 
increases the risk of incident dementia or cognitive decline, although the available 
studies are few. More tentative are the data from the cross sectional studies and an 
association between prevalent dementia and anaemia or low haemoglobin. 
There were no data available that allowed examination of the hypothesis relating to high 
levels of haemoglobin or to that relating prevalent cognitive decline to anaemia/low 
haemoglobin. 
It can be imagined that low haemoglobin or diagnosed anaemia could impact on future 
cognitive impairment, either directly by reducing blood oxygen levels in the brain over 
a sustained period of time or possibly by lowering a threshold or reserve capacity such 
that an otherwise silent cerebrovascular accident, such as a small stroke or transient 
ischemic attack, has a greater impact on subsequent cognition. It is also feasible that 
anaemia or low haemoglobin would be associated with prevalent decline or dementia 
although the results here were not conclusive. This could occur as the sufferer declines 
and is less able to maintain a healthy diet and/or may also reflect any anaemia possibly 
reducing blood oxygen available to the brain. Finally all such relationships may also be 
related to other co-morbidities which could prompt both anaemia and cognitive 
impairment. 
Although the data here are reflective of the literature there are many limitations to this 
investigation. The studies considered here were heterogeneous in that they looked at 
different populations; one study looked at women only; and the age range was large, 
including ages at which dementia and cognitive decline are not common. Only one of 
the studies looked at different levels of haemoglobin in detail and took into account the 
possibility that the elderly may have different normal levels. Studies adjusted for 
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confounders to different levels of detail. Definitions of dementia and cognitive decline 
varied between the studies. 
Despite many limitations, the strength of these studies is the frequent use of the standard 
definition of anaemia from the WHO. The wide range of populations may also be 
considered as a strength in that the findings can be more widely applicable. 
All of the above leads us to conclude that further studies to examine the effect of 
anaemia and haemoglobin on dementia and cognitive decline are needed. Such studies 
would need to be of large size and longitudinal in design with clear definition of the 
condition and robust cognitive assessment in the very elderly. This would allow the 
evaluation of possible risks and benefits in treatment or prevention of dementia or 
amelioration of cognitive symptoms. 
2.7.3. Inflammatory response 
It has been suggested that non-aspirin Non-steroidal anti inflammatory drugs [NSAID] 
may have a protective effect with regard to Alzheimer's disease via anti-inflammatory 
and anti-amyloid actions [348]. There is also some evidence that reduction of hyper 
platelet aggregability results in a reduction of leukoariosis [349] which in turn may have 
protective effects with regard to reduction in cognitive function. Aspirin itself reduces 
platelet aggregation and may therefore serve as a prophylactic for both cardio and 
cerebrovascular disease [350]. Cochrane reviews assessing the effects of indomethacin 
and ibuprofen (Alzheimer's disease), and aspirin (Vascular Dementia) have called for 
more research and concluded that there is insufficient evidence currently to recommend 
usage for treatment [351,352]. In addition to this a recently published randomised 
double blind placebo controlled trial of low dose aspirin found no benefit in cognition 
for women aged 65 and over [353]. There has been some suggestion that ApoeE4 
carriers suffering from Alzheimer's disease may show an increased benefit from 
139 
NSAIDs [354] with ApoeE4 negative participants being at increased risk of 
Alzheimer's disease with use of aspirin [350]. One meta analysis showed NSAIDs 
offering some protection from development of Alzheimer's disease [355] Whilst 
another meta-analysis showed a 20 percent benefit from NSAID use and incident 
dementia (0.79 95 percent CI 0.68-0.92) but no effect for cognitive impairment (1.23 95 
percent CI 0.70-2.31). When the authors re-ran the analyses and included baseline 
dementia the effect and direction of the effect was greater. The authors concluded 
therefore that a substantial number of studies are affected by recall bias (accurate recall 
being less likely if dementia already progressing), prescription bias (people with 
dementia may be less likely to receive prescriptions for NSAIDs) and publication bias 
towards positive studies [356]. Specifically assessing the prophylactic effects of 
NSAIDs in AD, a rigorous systematic review and meta-analysis found risk estimates of 
0.74 (95 percent CI 0.62-0.89) for prospective studies reporting lifetime use (four 
studies). With studies reporting exposure durations of two or more years, the risk 
estimate became 0.42 (95 percent CI 0.26-0.66) (3 studies) [357]. The authors comment 
that their conclusions are by necessity based on the studies available and as such may be 
affected by issues such as recall bias from participants. There are as yet no randomised 
blinded trials although one began in 2001 and will probably report within the next few 
years [357]. 
2.7.4. Depression 
A review of the literature in 2001 aiming to discover whether a history of depression is 
a risk factor for dementia concluded that both case control studies (estimated relative 
risk 2.01, 95 percent CI 1.16-3.50) and prospective studies (estimated relative risk 
1.87, 95 percent CI 1.09-3.20) showed an increased risk. Depression at baseline is also a 
risk factor for Mild Cognitive Impairment [MCI] [358] and patients with late onset 
depression have been found to have increased levels of cognitive impairment and white 
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matter lesions [359]. Three review articles [359-362] two systematic, have concurred 
and put forward several possible explanations for this finding; 
• depression as a prodromal stage of dementia via noradrenergic changes or via 
white matter lesions post stroke; 
• depression stemming from insight into impairment at early stages of decline; 
• depression highlighting underlying deficits i.e. by reducing motivation and 
bringing its own cognitive deficits; 
• depression having a direct, negative affect on the cardiovascular system via 
hormonal influences and thus raising risk of dementia. 
2.7.5. Nootropics 
Nootropics are compounds purported to aid memory/learning or ameliorate the effects 
of cognitive decline/dementia but which are usually available without prescription and 
are not usually licensed as medicines. The most frequently used nootropics for memory 
are piracetam and Ginkgo Biloba, the first acting as an acetyl choline agonist. There 
have been no systematic reviews looking specifically at the use of nootropics for the 
prevention of dementia but there is some evidence for use of piracetam on the global 
impression of change for the treatment of dementia or cognitive impairment. However, 
no benefit was shown on more specific cognitive function measures and the authors 
conclude that currently available published evidence does not support the use of 
piracetam in the treatment of people with dementia or cognitive impairment [363]. Most 
research to date focuses on the treatment of people with dementia or cognitive 
impairment and a comprehensive review from [364] based mostly on findings from 
double blind placebo controlled trials, concluded that the research was generally 
suggestive of small beneficial effects and called for more research [364]. A similar 
conclusion was voiced by [365] and although authors differ [366,367] there are few 
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randomised controlled trials. Those trials that do exist tend to be of short duration and 
include relatively few participants [368-371]. A Cochrane review looking at the use of 
Gingko Biloba for the treatment of cognitive impairment/dementia concluded that there 
is not yet enough evidence to recommend usage to ameliorate the condition [372]. A 
protocol for a Cochrane review assessing the evidence for the effect of Gingko Biloba in 
healthy elderly individuals has been published and the conclusions are awaited [373] 
Further research has been called for [374] and further caution needs to be taken when 
considering whether patients who take or who receive nootropics such as Ginkgo Biloba 
and piracetam are a particular subgroup of the population. 
	
2.8. 	Brief summary of risk factors where intervention is 
possible (other factors) 
Low haemoglobin and higher depression levels are likely to confer increased risk and 
use of anti-inflammatories or the nootropics (piracetam or Ginkgo) may reduce risk 
although evidence is unclear. 
2.9. 	Summary - main risk factors for dementia, as 
described in the literature 
Having reviewed the possible risk factors it is clear that whilst some are well 
established such as age and blood pressure others may have a more tenuous relationship 
with cognition if indeed there is such a relationship at all. It also seems clear that 
although midlife risk factors are becoming increasingly clear, those factors that predict 
decline in an already elderly population have been less studied. It is acknowledged that 
dementia has a prodromal phase that may last for some time without detection of any 
decline and that a proportion of those who are already elderly may have embarked on 
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this prodromal phase. However, our world population is ageing and although 
intervening in midlife is ideal it may already be too late for the fastest growing sector of 
the population, the elderly. In addition to this, treatment for some of the risk factors 
mentioned above may be started in elderly patients and may have an impact even after a 
short period of time; for example in the Syst-Eur trial blood pressure reduction in a 
young elderly group reduced incident dementia [112,113,115], at least for the years of 
the study follow up. Any delay or prevention of incident dementia or cognitive decline 
would be beneficial especially if it can be applied in the groups most at risk and in the 
elderly. One difficulty with regard to evaluating the literature reporting on risk factors 
for dementia in the elderly is that the vast majority of studies focus on the younger 
rather than the very elderly, those aged 80 and over. Of the literature reviewed above 
very few studies reported a clear mean age over 80 [224,346] although this is the fastest 
growing area of the population. However most studies did recruit within this age range 
and it could therefore be argued that they provide useful information to incorporate in 
an assessment of the evidence base. Because of the differing information given in 
published papers with regard to study population composition it can be difficult to 
compile a complete picture with regard the age of the participants and although few 
studies have focused upon the very elderly, maybe due to a previous lack of population 
to study or difficulty in recruiting, they are an important area to consider. 
Given all of the above, it would therefore be useful to examine the impact of possible 
risk factors for cognitive decline and dementia in an international population already at 
high risk due to age and followed up for a time period congruent with their age and life 
expectancy. The Hypertension in the Very Elderly Trial is an ongoing trial assessing the 
risks and benefits associated with the treatment of high blood pressure in the very 
elderly (see methods section for full details). Briefly, at trial baseline participants must 
be hypertensive, aged 80 or over and have completed a two month placebo run in phase 
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such that they have taken only placebo and have not taken any anti-hypertensive drugs 
for the two preceding months. The HYVET trial aims to follow patients for several 
years and is international, including both Europe (Western and Eastern), Tunisia, New 
Zealand and China. As such this trial is perfectly placed to allow the examination of 
baseline risk factors and subsequent cognitive decline in this high risk group. However, 
related to this is the difficulty of assessing cognition in such a population, with differing 
levels of education and different languages. This thesis aims to identify and discuss the 
risk factors associated with incident cognitive decline and of cognitive decline of a level 
likely to indicate dementia in the HYVET population. Validated dementia outcomes are 
not available to this analysis. It is expected that they may be available in 2010. 
In the following section I will outline the tests available for the identification of 
cognitive decline and describe those used in the HYVET study. 
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3. Chapter 3: Literature review, assessment of cognitive 
function 
Following on from the consideration of the literature surrounding risk factors, the next 
area to be focused upon is the means of assessing cognitive decline and incident 
dementia. The subsequent two sections cover the background to assessments, the 
different screening and diagnostic tests. 
3.1.1. Background 
The means by which cognitive decline can be assessed or incident dementia identified 
are many, and the vast majority of research studies and trials in this area have used at 
least a two step procedure. This has usually involved a screening instrument with a 
previously recognized cut off in terms of the identification of cognitive decline, 
followed by a diagnostic tool to allow gathering of additional information and a clinical 
examination or use of a committee of experts who examine all of the evidence, clinical 
and cognitive [88,93,95,100,101,110,111]. 
There are batteries of tests and multi-question instruments for assessing cognition, 
cognitive decline and dementia. Some of these are well known and widely used and 
some developed and used in small local areas. In addition to these there are individual 
neuropsychological tests designed to assess specific domains [375]. 
The characteristic deficits seen in cognitive decline are similar to those identified as 
present in Mild Cognitive Impairment [MCI] and early dementia, with some authors 
suggesting that MCI may be an early indication of dementia itself [5,6]. It should be 
noted though that this is not universally agreed [5,6] and follow up times in studies 
assessing transfer from mild impairment to dementia differ. The characteristics of mild 
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cognitive impairment focus on memory impairment or encompass broader deficits in 
other cognitive domains, usually in addition to memory impairment [376]. Early 
dementia has also been shown by memory impairment, particularly for episodic 
memory (memory for events in time) in Alzheimer's disease [377]. The instruments 
used to assess cognition and cognitive decline in everyday practice primarily include 
multi-question screening tests whereas dementia should be diagnosed additionally using 
diagnostic tools. The most common screening tests are discussed first. There are no tests 
(screening or diagnostic) that have been validated specifically for use in the very elderly 
hypertensive. 
3.1.2. Screening tests 
One of the shortest instruments available is the Abbreviated Mental Test Score [AMTS] 
[378] consisting of 10 questions including culturally specific ones such as 'name of 
present monarch'. It takes a short time to administer and so may be less likely to cause 
tiredness and poor performance due to loss of concentration. However, it could be 
argued that it is insufficiently broad, subject to bias, (one must be familiar with cultural 
and historic information for the society where the test is being administered) and 
therefore a poor assessment of cognitive function. 
The test used most frequently in general research and practice is probably the Mini-
Mental State Exam [MMSE] [379]. This is a brief screening test of cognitive function 
with 30 points spread over 11 sections including delayed recall. It should not be used in 
isolation but can be an indicator of cognitive impairment, takes around 10-20 minutes to 
complete and has widely accepted cut off points although it, like many other tests, can 
be influenced by educational level, patient affect and has ceiling and floor effects. 
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Other common tests include; 
• the Orientation Memory Concentration test [OMC] a shortened version of the 
Blessed Memory test, [380] 
• the CAMCOG, part B of the CAMDEX Schedule, the Cambridge examination 
for mental disorders in the elderly [381] including items from the MMSE and 
the AMTS with additional questions assessing abstract thought and perception, 
• the ADAS-COG from the Manual for Alzheimer's Disease Assessment Scale 
[382] 
• the Rivermead Behavioural Memory Test an assessment of everyday memory, 
[383] including multiple sets of questions but which takes a significant amount 
of time to administer. 
3.1.3. Diagnostic tests 
For dementia a number of instruments are also available although a definite diagnosis of 
Alzheimer's disease can only be made post mortem and definitive biomarkers are 
promising but not yet widely available [384]. The Diagnostic Statistical Manual for 
mental disorders edition four [DSMIV] is widely used for the diagnosis of Alzheimer's 
disease, Vascular dementia and other dementia as are the more detailed National 
Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease 
and Related Disorders Association [NINCDS-ADRDA] (Alzheimer's disease), and the 
National Institute of Neurological Communicative Disorders and Stroke—Association 
Internationale pour la Recherché et l'Enseignement en Neurosciences [NINDS-AIREN] 
(vascular dementia) although the latter two are much longer and more complex than the 
former. Also used to support a diagnosis of dementia with vascular aspects is imaging, 
computed tomography or magnetic resonance imaging and the Hachinski scale or 
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modified Hachinski scale assessing the impact of vascular damage. 
In terms of assessment of cognition and incident dementia the HYVET subjects are a 
high risk group and despite the wide range of possible screening instruments detailed 
above it was considered that the MMSE was the best available screening tool. Although 
other less well known instruments may be more applicable [385] such as the Rivermead 
Behavioural Memory Test [383], these are too time consuming to administer in a clinic 
setting, and alongside blood pressure measurements, blood tests and other questions 
may put too great a constraint on the concentration of elderly patients. More complex 
tests require prohibitive levels of training on the part of the average general practitioner, 
geriatrician or study investigator, are not validated in multiple languages and would not 
reflect everyday clinical practise. For any study results to be practically applicable in the 
clinic the MMSE appeared the most appropriate choice particularly if supporting 
evidence could be provided that attested to the affect of the patient and compensated 
somewhat for the reliance of the MMSE on level of literacy. Similarly for the diagnostic 
data the DSMIV and CT scan would be considered to be the most practical choices 
although the NINCDS criteria and MRI scan would be helpful to those with expertise. 
Detailed examination of the utility of the tests that fit the above criteria is below. 
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4. Chapter 4: Method 
Following on from discussion of the assessment tools for cognitive decline and incident 
dementia the first part of the method section describes those used in the HYVET trial. 
This is followed by a description of the study objective, hypotheses and detailed 
methods including details of the study population, data collection, data processing, 
quality control and administration of cognitive assessments in this study and the 
HYVET trial. Details of the statistical methods also follow. 
4.1. 	Instruments employed in the HYVET trial to assess 
cognitive decline and incident dementia 
4.1.1. Mini-Mental State Exam (MMSE). 
The Mini Mental State Examination of Folstein (M.M.S.E.) [379] is a widespread and 
well known screening tool for the assessment of cognitive function. It requires 
approximately 10-20 minutes to administer making it applicable and practical to use in a 
variety of clinical settings as a first line screening tool [386,387]. It is appropriate cross 
culturally [112,388,389] and has been used successfully in the elderly [112,390]. The 
MMSE consists of a series of subtests and assesses orientation to time and space, 
immediate and delayed recall, comprehension, constructional capacities and the use of 
language. 
It has been suggested that performance on some subtests of the MMSE may be 
differentially impaired by different disorders [391]. In Alzheimer's disease such tests 
are language based, for memory and orientation in time and place [386]. For vascular 
dementia, memory, recognition, following instructions, writing a sentence and copying 
are impaired [386]. However, these differences are far from definite since Almkmist 
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[392] and Fahlander [393] writing about the Kungsholmen population found similar 
episodic memory deficits in AD and VaD. Although the numbers of participants used in 
the latter paper were small, the finding that it is primarily memory impaired in both 
disorders is supported by other work. [394-396]. 
It has been suggested that the MMSE is potentially insensitive to cognitive change [194] 
and for this reason the authors of the PROSPER trial employed both the MMSE, the 
picture word learning test, digit symbol substitution test and a Stroop test although in 
fact none of these assessments demonstrated a significant difference between the 
randomised groups [170]. The differences between their findings with regard to the 
MMSE and the other tests were not great. When the difference between the baseline and 
last on treatment value for the placebo group was subtracted from that of the Pravastatin 
group the MMSE demonstrated change in the same direction and significance levels 
that were similar to those of the other tests. (MMSE p=0.26, Stroop test p=0.19, Picture 
word learning test p=0.80, letter digit coding test p=0.95) [170]. This suggests that the 
MMSE was at least as good or bad as the more specific neuropsychological tests at 
assessing cognitive decline in this instance. In addition the MMSE has been used 
successfully in at least two models of cognitive decline [397,398]. 
It has also been suggested that that the MMSE demonstrates floor, ceiling and learning 
effects, focuses on crystalline rather than fluid intelligence and does not assess the 
appropriate neuropsychological functions implicated in dementia [194]. 
The MMSE does demonstrate floor and ceiling effects and maybe less sensitive to Mild 
Cognitive Impairment [399] but this should not have an impact on the assessment of 
cognitive function in the very elderly. The mean MMSE score demonstrated by the 
cognitively intact over eighties is around 27. The mean MMSE in a European 
population over eighty was 27.66; SD 1.57 [400] whilst the mean for all 80-84 year olds 
in a US, Baltimore population was 25 [400]. The maximum MMSE score is 30, 
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suggesting that ceiling effects are not often a problem in the very elderly. Floor effects 
would be expected to be seen after a diagnosis of dementia had been made. It is not 
thought that learning effects are likely given the mean levels of cognitive function in 
very elderly populations. 
It has also been suggested that the MMSE measures crystalline rather than fluid abilities 
and assesses semantic memory (memory for factual information) and that this may not 
be appropriate in assessment of cognitive decline, however, the relative loss of 
crystalline versus fluid functions in dementia is far from clear [194,401]. In addition 
fluid abilities defined as 'the basic reasoning ability of an individual' are hard to 
separate out from crystalline abilities defined as 'this ability as it is evinced in the skills 
valued by the culture in which the individual lives' [402]. As such crystalline 
intelligence is culturally specific and therefore biased by societal background, 
processing written language tasks rather than, for example, animal tracking. It has been 
suggested that it may be nearly impossible to devise questions that assess only fluid 
ability [402]. 
With regard to the neuropsychological aspects of the MMSE, the questions included in 
the MMSE do not assess pure aspects of neuropsychological functioning. However, the 
majority of the items contained in the MMSE do require at least one of the 
neuropsychological areas affected by dementia. Memory problems cause difficulties in 
immediate and delayed recall. Alzheimer's disease with its characteristic loss of 
episodic memory affects orientation in time questions. Executive function difficulties 
impact on the serial 7s/world backwards or three part task as the working memory 
central executive suffers. Aphasic or language difficulties manifest in naming or 
sentence production whilst agnosia may also impact on the naming question. Apraxias 
show up on the three part task or the copying of the pentagons. 
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4.1.2. Diagnostic Statistical Manual IV (DSMIV) 
The DSMIV criteria [11] are standard international diagnostic criteria for dementia and 
have been shown to have good inter-rater reliability [403]. 
4.1.3. Modified Hachinski infarct scale (MIS) 
The MIS is a validated series of questions about symptoms and is designed to assess any 
vascular contribution to the dementia [13]. The MIS requires a CT scan to have been 
completed. If this is not possible the original Hachinski Infarct Scale (HIS) is used in 
HYVET [12]. This contains 13 areas which indicate the possible involvement of 
vascular factors and which have scores weighted accordingly. There are two cut off 
values, > 7 indicating vascular dementia and < 4 indicating Alzheimer's disease. The 
use of the MIS is preferred since there is less opportunity for ambiguous interpretation 
of the questions, something that has been found with the HIS and which may have a 
negative impact on scoring and therefore classification of dementia. 
4.1.4. Computed Tomography scan (CT) 
The CT scan is the most wide spread type of scanner. Computed Tomography is 
sufficient to allow the examination of vascular damage and is a most pragmatic option 
available in an international clinical trial involving a wide range of health care systems. 
The abnormalities that can be detected include infarcts, cortical and sub cortical, lacunes 
and white matter changes, size, number and location of lesions [404,405] and lobe 
atrophy. Of particular interest is the Medial Temporal Lobe [MTL] since it has been 
suggested that atrophy in this area is indicative of AD [406]. This information could be 
particularly used to divide dementia cases into those that have a vascular component 
and those that do not and to rank those with a vascular component by severity of 
vascular damage. 
152 
4.1.5. Geriatric Depression scale (GDS) 
The assessment of depression is particularly important since depression can sometimes 
result in cognitive deficits that may appear to indicate dementia, so called 'pseudo-
dementia' [407]. Co-morbid depressive symptoms are common in mild dementia and 
may lead to lower scores on cognitive function tests [408]. The 15 item Geriatric 
Depression Scale is a good screening instrument for depression [409-412], was 
designed for use in elderly patients [400] and has also been used successfully in this 
population [413-416]. GDS is able to measure longitudinal change [417]. It has been 
successfully administered in a written self report format and this format results in more 
openness on the part of the patient than an orally administered version [418]. 
The original GDS contained 30 items; however, the shortened 15 item GDS takes less 
time to complete and is adequate with sensitivity demonstrated as 92.7 or 88 percent 
and specificities of 65.2 and 76 percent [410, 415, 417]. The patients are asked to 
answer 'yes' or 'no' to 15 questions, according to which answer best applies to how 
they have been feeling in the last week, and this results in a score of between zero and 
15. Multiple cut off points have been used with varying levels of sensitivity and 
specificity the most frequently used cut off is 5/6 with higher scores indicating more 
severe depression [400]. 
4.1.6. Clock Drawing Test (CDT) 
The CDT has been used successfully in the elderly [419,420], is likely to be suitable 
cross culturally since its completion does not rely on language skills and is thought to be 
unaffected by level of education [421]. It is also thought to be unaffected by depression 
[422]. The CDT is a good initial tool for the identification of dementia [423-426] and 'is 
particularly suited for the purpose of assessing global cognitive function reflecting 
subtle changes in overall brain functioning' [427] It has been used successfully in 
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longitudinal assessments [427] and in the assessment of severity [428] although it 
should be noted that the latter study only included 26 patients. It has also been 
suggested that performance on the CDT may help to demonstrate different 
neuropsychological profiles of impairment in VaD compared to AD [429]. The CDT 
also correlates with the MMSE [430] and may indicate early cognitive decline 
particularly pre-clinically before the MMSE score falls below 23 [419,427,431] The 
CDT may therefore identify people at risk of cognitive decline, adding prognostic 
information that supplements the standard MMSE [419]. The CDT therefore can 
provide supplementary information on cognitive function. The CDT is easy to 
administer, patient friendly and quick to complete. It is also less susceptible to 
difficulties arising from translation than language based tests and as such admirably 
suited to an international population. However it does require the patients to make the 
drawing attempt by themselves so patients who cannot see or hold a pencil well enough 
may be able to answer cognitively based questions but not to draw a clock. 
4.2. 	Identification of participants at risk of dementia and 
cognitive decline 
It seems that there are suitable instruments available for use in an elderly international 
population with differing educational levels and resources. The next issue that arises 
relates to the employment of such instruments. The MMSE is suitably placed to act as a 
screening instrument and the cut off value of 24/23 has been previously used to identify 
people who may be suffering from definite cognitive decline and possibly mild 
dementia [112]. However, people with an initial high or low MMSE score (below 24) 
may miss evaluation even if their cognitive function declines rapidly. Recent studies 
[110,111] have also used a fall in MMSE score of more than two, or more than three, 
points to prompt investigation of cognitive decline and dementia and this could be of 
particular importance in the elderly where mean MMSE scores can be as low as 20 for 
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those with less than five years of education [4001. The pragmatic approach has been 
therefore to include both a fall below the traditionally used threshold and a fall of more 
than three points in a year in order to be sure to identify those with cognitive decline. 
Based on all of the above a study was proposed with the following objective. 
4.3. 	Objective of cohort study: 
To identify and examine the impact of possible risk factors for cognitive decline and 
dementia on a population of very elderly hypertensives followed up for two years and to 
establish predictors for such cognitive decline and dementia that can be used in this 
population. 
Each baseline risk factor was examined in relation to three outcomes: 
1: Incident cognitive decline (a fall in MMSE of more than three points in one year or a 
fall to a score below 24, 
2: Change in MMSE over two years of follow up 
3: Diagnosed dementia (data not available until 2010) 
Cross sectional relationships between cognitive function (as assessed by the MMSE 
score) will also be examined in order to fully describe the patient group at baseline. 
The information relating to risk factors was taken from that collected during the 
HYVET trial baseline visit and includes collection and collation of the specific data as 
discussed under the method section below. 
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4.4. 	Hypotheses for baseline risk factors 
4.4.1. Vascular: 
• Stroke is known to be likely to have an impact on cognitive function and to 
increase risk of future stroke. It is therefore hypothesized that a previous stroke 
reported at baseline will be associated with a larger fall in MMSE over two 
years, higher likelihood of incident cognitive decline and dementia. 
• Heart failure may have an impact on cognitive function and may reduce cerebral 
perfusion. It is therefore hypothesized that heart failure reported at baseline 
will be associated with a larger fall in MMSE over two years, higher likelihood 
of incident cognitive decline and dementia. 
• There is evidence that diabetes may adversely affect cognitive function and it is 
therefore hypothesized that diabetes reported at baseline will be associated with 
a larger fall in MMSE over two years, higher likelihood of incident cognitive 
decline and dementia. 
• There is substantial evidence that higher blood pressure provides increased risk 
of cognitive decline. It is therefore hypothesized that higher Sitting SBP, Sitting 
DBP, at entry will be associated with a larger fall in MMSE over two years, 
higher likelihood of incident cognitive decline and dementia. 
• Higher pulse pressure and lower diastolic pressure may be associated with 
subsequent cognitive decline and it is hypothesized that lower Standing SBP, 
and lower Standing DBP at entry will be associated with a larger fall in MMSE 
over two years, higher likelihood of incident cognitive decline and dementia. 
• Orthostatic hypotension may be associated with fluctuating cerebral perfusion 
and may be associated with cognitive decline. It is therefore hypothesized that 
patients suffering from orthostatic hypotension (a fall of >=20mmllg in SBP or 
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of >=10mmHg in DBP on standing) at entry will be associated with a larger fall 
in MMSE over two years, higher likelihood of incident cognitive decline and 
dementia. 
4.4.2. Drug treatment: 
• There is evidence from the Syst-Eur trial that anti-hypertensive treatment 
reduced risk of subsequent cognitive decline. It is therefore hypothesized that no 
previous use of antihypertensive treatment in patients diagnosed with 
hypertension before baseline will be associated with a larger fall in MMSE over 
two years, higher likelihood of incident cognitive decline and dementia. 
• There is epidemiological evidence to suggest that statin use reduces incident 
cognitive decline and it is hypothesized that patients not using statins at baseline 
will be more likely to show a larger fall in MMSE over two years, higher 
likelihood of incident cognitive decline and dementia. 
• Piracetam may aid cerebral perfusion and it is hypothesized that patients not 
using Piracetam at baseline will be more likely to show a larger fall in MMSE 
over two years, higher likelihood of incident cognitive decline and dementia. 
• Gingko Biloba may aid cognitive function and it is therefore hypothesized that 
patients not using Gingko at baseline will be more likely to show a larger fall in 
MMSE over two years, higher likelihood of incident cognitive decline and 
dementia. 
• There is some evidence that NSAIDs are associated with less cognitive decline 
and it is hypothesized that patients not using NSAIDs at baseline will be more 
likely to show a larger fall in MMSE over two years, higher likelihood of 
incident cognitive decline and dementia. 
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• Similarly, it is hypothesized that patients not using Aspirin as an antiplatelet at 
baseline will be more likely to show a larger fall in MMSE over two years, 
higher likelihood of incident cognitive decline and dementia. 
4.4.3. Sociodemographic & lifestyle: 
• Education has been shown to be protective against identification of cognitive 
decline, therefore it is hypothesised that lower levels of education will be 
associated with a larger fall in MMSE over two years, higher likelihood of 
incident cognitive decline and dementia. 
• The literature and a meta-analysis show a protective effect of alcohol 
consumption, therefore it is hypothesised that non-drinkers will be more likely 
to show a larger fall in MMSE over two years, higher likelihood of incident 
cognitive decline and dementia. 
• That heavy drinkers (>14 units/week for women and >21 units/week for men) 
will be more likely to show a larger fall in MMSE over two years, higher 
likelihood of incident cognitive decline and dementia. 
• The literature and a meta-analysis show a detrimental effect of smoking, it is 
hypothesised therefore, that smokers will be more likely to show a larger fall in 
MMSE over two years, higher likelihood of incident cognitive decline and 
dementia. 
• Females have been widely observed to be more likely to suffer from cognitive 
decline. It is hypothesised that female sex will be associated with a larger fall in 
MMSE over two years, higher likelihood of incident cognitive decline and 
dementia. 
• Prevalence and incidence of dementia rise with age, it is hypothesised that older 
age will be associated with a larger fall in MMSE over two years, higher 
likelihood of incident cognitive decline and dementia. 
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4.4.4. Clinical: 
• There is some evidence that higher BMI is a risk factor for cognitive decline. It 
is hypothesized that higher BMI will be associated with a larger fall in MMSE 
over two years, higher likelihood of incident cognitive decline and dementia. 
• Lower haemoglobin/anaemia, (defined by the World Health Organisation 
[WHO] as <12 gm/di women and <13gm/d1 men), may plausibly be associated 
with cognitive decline and it is hypothesized that lower haemoglobin/anaemia 
will be associated with a larger fall in MMSE over two years, higher likelihood 
of incident cognitive decline and dementia. 
• Higher haemoglobin may also confer increased risk and it is hypothesized that 
higher haemoglobin, (>14.1 gm/di women and >15.6 gm/di men), will be 
associated with a larger fall in MMSE over two years, higher likelihood of 
incident cognitive decline and dementia. 
• There is some evidence that higher cholesterol is associated with cognitive 
decline and it is hypothesized that higher total cholesterol will be associated 
with a larger fall in MMSE over two years, higher likelihood of incident 
cognitive decline and dementia. 
• Similarly it is hypothesized that lower HDL cholesterol will be associated with 
a larger fall in MMSE over two years, higher likelihood of incident cognitive 
decline and dementia. 
• Given the findings from papers by Whitmer et al [30] and Kivipelto et al [29] it 
is likely that multiple co-morbidities may associate with cognitive decline. It is 
hypothesized therefore that a greater number of co-morbidities at baseline will 
be associated with a larger fall in MMSE over two years, higher likelihood of 
incident cognitive decline and dementia. 
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• There is evidence that depressive symptoms and depression are risk factors for 
cognitive decline. It is hypothesized that a higher depression score at baseline 
will be associated with a larger fall in MMSE over two years, higher likelihood 
of incident cognitive decline and dementia. 
• Given the impact that a serious adverse event could have in this age group it is 
also hypothesized that patients suffering from a Serious Adverse Event during 
the two years of follow up will be more likely to show a larger fall in MMSE 
over two years, higher likelihood of incident cognitive decline and dementia. 
Serious adverse events are defined, in accordance with the UK law, as any event 
that is life threatening, requires or prolongs hospitalisation, results in permanent 
disability. 
4.4.5. Hypothesis for predictor risk factors when adjusted for 
all confounding factors 
That higher blood pressure, higher total cholesterol, increased age and higher body mass 
index will remain significantly associated with falling MMSE over two years, higher 
likelihood of incident cognitive decline and dementia, in accordance with similar 
findings in midlife [29]. Due to the age of the population under consideration, and 
unlike the population studied by Kivipelto it is expected that female rather than male 
sex will be associated with a larger fall in MMSE and higher likelihood of incident 
cognitive decline and dementia. 
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4.5. 	Detailed methods 
Figure 20: Shows the procedures involved in data collection and dementia diagnosis. 
4.5.1. Study population, settings and data collection 
Data were collected as part of an international randomised double blind placebo 
controlled trial investigating whether to treat hypertension in those aged eighty and 
over. There is clear evidence to support the treatment of blood pressure until this age 
[106,131] but a meta-analysis focusing on the very elderly [132] and the HYVET pilot 
trial suggest that treatment may bring increased risk of mortality despite a decreased 
risk of stroke in this very elderly group [132,133]. The trial began in 2001 and is due to 
end in 2009. The trial protocol papers for both the main trial and the cognitive function 
part of it have been published [134,432]. Details of both are given below. The HYVET 
trial has a primary endpoint of stroke and secondary endpoints of all cause mortality, 
cardiovascular mortality, myocardial infarction, new retinal lesions, aortic aneurysm, 
skeletal fracture, overt heart failure and doubling of baseline creatinine. The trial has an 
independent endpoint committee who validate the endpoints listed above and 
independent ethics, dementia, steering and data monitoring committees, the latter of 
which reviews the data regularly and is called upon to carry out a priori defined interim 
analyses for which there are stopping rules defined in the protocol with regard to stroke 
and death. Once randomised, patients take either indapamide 1.5 mg Slow Release or 
matching placebo with the option of additional 2 or 4 mg of perindopril or matching 
placebo. Patients are seen every three months during their first year and every six 
months thereafter until they leave the study. 
Several protocol amendments were found to be necessary after the trial started and 
included within these were those that allowed participation in the cognitive function 
aspect of the trial including consent for CT scan and the inclusion of patients with 
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isolated systolic hypertension. The initial protocol required both systolic and diastolic 
hypertension, full inclusion and exclusion criteria are given below. The different 
countries participating in the trial were able to begin recruiting at different times due to 
logistic and regulatory factors and this, combined with the protocol amendment meant 
that the majority of subjects first recruited were from Bulgaria and had both systolic and 
diastolic hypertension. Patients recruited into HYVET remain in the study unless they 
suffer from a fatal event or they refuse to continue their participation. In all other events 
patients may remain in trial open follow up. Data presented here were taken from the 
cohort of patients who had completed two years of follow up by October 2006 and are 
therefore dominated by Bulgarian patients. As only 18 patients within this two year 
cohort had isolated systolic hypertension, these were excluded to prevent their differing 
diastolic blood pressure from influencing the results. The trial randomisation code was 
not broken for the analyses presented as part of this thesis, as the trial is ongoing and 
must remain blinded. Baseline data were collected before trial medication was started 
and only cognitive decline and incident dementia assessed over the two year follow up. 
Data pertaining to risk factors for cognitive decline and dementia were collected at 
baseline only, in order to ensure that the analyses for this project did not prejudge the 
results from the main trial. For example assessing fall in blood pressure which may 
indicate active treatment. All of the baseline data presented here were taken before 
subjects were randomised to trial treatment group and it has been assumed that the risk 
factors would be evenly distributed between groups, such that any effect of group 
membership would not impact more or less in any one area. 
Data presented here come from patients recruited from 48 Centres located in the UK, 
France, China, Belgium, Australia, New Zealand, Bulgaria, Finland, Romania, Ireland, 
Tunisia and Russia. Centres were based in either general practice or hospital settings. 
Local and national ethical and regulatory approvals have been granted for the main trial 
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protocol and all subsequent amendments for all trial centres. Standard case report forms 
were used in each centre to collect all data and were submitted to and approved by all 
ethics committees. 
Inclusion criteria. 
In order to enter the HYVET trial patients had to be aged 80 or over at the time of 
randomisation and to remain on placebo during a two month run-in phase with no other 
antihypertensive medication. Blood pressure was measured at entry to this phase (month 
minus two), after one month on placebo (month minus one) and at baseline (month 
zero). Inclusion criteria required systolic hypertension with pressures of >=160mmHg 
and <200mmHg sitting and >=140mmHg standing and a sitting diastolic pressure of 
<110mmHg. The inclusion blood pressures were an average from two visits whilst on 
placebo (month minus one and month zero). Biochemistry was also checked at month 
zero particularly potassium and creatinine. Full exclusion criteria are listed below. 
4.5.2. Exclusion criteria: 
• Known accelerated hypertension (retinal haemorrhages, exudates or papilloedema). 
• Overt clinical congestive heart failure requiring treatment with a diuretic or 
angiotensin converting enzyme inhibitor. Patients were accepted if they were treated 
with digoxin only. 
• Renal failure (serum creatinine of more than 150 pmo1/1). 
• Previously documented cerebral or subarachnoid haemorrhage in the six months 
before the baseline trial visit. (Ischaemic cerebral and cardiac events do not exclude, 
although the patient must be neurologically and cardiologically stable). 
• Condition expected to severely limit survival, e.g. terminal illness. 
• Known secondary hypertension (e.g. renal artery stenosis, chronic renal 
insufficiency, and endocrine cause). 
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• Gout, in the opinion of the investigator. 
• Clinical diagnosis of dementia. 
• Resident in a Nursing Home i.e. where the dependency and care requirements of the 
patients are such that they require the regular input of qualified nurses and therefore 
the majority of staff in the home are nurses (other forms of residential care 
acceptable). 
• Contra-indication to trial medication. (e.g. serum potassium less than 3.5mmo1/1 
(indapamide) or more than 5.5 mmo1/1 (perindopril)). 
• Unable to stand up or walk. 
Both the criteria of age and hypertension put patients at increased risk of cognitive 
decline allowing greater chance of examining this in sufficient numbers of patients. 
Patients signed informed consent prior to entering the two month placebo run-in phase. 
During this two month period patients continued to take all usual medication with the 
exception of any antihypertensives and trial placebo tablets provided. Illiterate patients 
agreed to consent in the presence of a witness in addition to the local investigator as 
required by Good Clinical Practice [GCP]. At baseline, data were collected on past 
medical history including specific questions on history of hypertension, previous stroke, 
Myocardial Infarction [MI], heart failure, atrial fibrillation and diabetes. Data on current 
diseases, symptoms and treatments were also collected as were blood pressures and 
standard blood test results including total cholesterol, HDL cholesterol and sex and 
haemoglobin. Data were also collected on height, weight, educational level, age and 
ECG used by the Sponsor's staff to verify presence of atrial fibrillation. 
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Figure 20: Procedure and scope of cognitive function data collection in HYVET. 
---... 1: Patient consent and two month placebo run in phase culminated in baseline visit 
(month 0). 
Data was collected on: 







Clock drawing test* 
*(patient completion voluntary and may 
be administered by investigator or relativ 
Patient eligibility for main trial assessed —
age required was 80 years or over with no 
clinical diagnosis of dementia at baseline 




2: Annual assessment of cognition (MMSE) 
3: If a patient had a fall in MMSE score from 24 or above to 23 or below, or a >3 point 
drop during a 12 month period the patient was classified as having cognitive decline 
and further assessments were requested: 
CT scan and Modified Hachinski Score 
If patient did not consent to CT scan — full Hachinski score 
Information on whether the patient met the DSMIV criteria for dementia (AD/VaD) 
MMSE score at the time of assessment/CT scan 
The CT scan was seen by two independent neuroradiologists (Dr A.Waldman and Dr 
M.Patel) and a report generated 
4:All of the above information and details and timing of any serious adverse events that 
have occurred to the patient were presented to an expert committee (Prof J. Tuomihleto, 
Dr I. Walton, Dr R.Clarke, Dr A.Waldman, Dr C.Ritchie) who made a diagnosis of 
dementia (specifying type of dementia if they were able to do so) 
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4.5.3. Quality control and data entry 
Centres were asked to use mercury sphygmomanometers or automated machines as 
validated by the British Hypertension Society and these were viewed during onsite 
visits and extensive central checking carried out in assessing with and between patient 
patterns for any evidence of careless measurement. All patient identity documents were 
checked to confirm identity and to ensure that patients were over 80 years of age. Data 
were collected in accordance with GCP and local monitoring took place checking a 
minimum of patient consent, identity, age, ten percent of data and 100 percent of serious 
adverse events and endpoints. In addition to this, at least ten percent of the data 
collected were compared to patient files and source documents at the centres and this 
included, for example, comparing blood test results with the printout from the local 
laboratory. This was carried out by the co-ordinating centre in conjunction with the 
local monitor who provided translation help and viewed the source documents with 
patient details such that the co-ordinating office staff remained unable to identify 
patients. Data were exported into statistical software packages and cleaned every three 
months. Any unexpected values resulted in queries being sent to the investigators on-
site to check. Co-ordinating centre staff also carried out regular data quality control 
assessments centrally looking at changes in the data or patterns that would suggest that 
the data may need further investigation. Interviews between the co-ordinating centre and 
each investigator site were also carried out annually and any data related issued 
discussed. 
An independent Data Monitoring Committee was also in place as is appropriate in 
Clinical trials [433] to regularly review data and to assure data quality. The data were 
cleaned using SAS and SPSS statistical software and programs used to identify patients 
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who had MMSE scores that changed dramatically or those with large numbers of 
missing values. The same software was used to carry out the analyses. 
Investigators received training in trial methodology and Case Report Form [CRF] 
completion at country specific start up meetings with presentations by the co-ordinating 
office and specific interviews with each centre's staff (principal and co-investigators). A 
document providing guidelines regarding the correct completion of trial forms was also 
distributed to all investigators and translated into the local language (appendix 3). The 
CRFs were also translated for Russian and Chinese investigators. 
All of the data collected for the trial is processed by the co-ordinating office. The data 
were coded using the International Classification of Disease [ICD10] for co-morbid 
diseases and symptoms and unique eight and four digit codes for concomitant 
medication and operations respectively. The data were entered using electronic data 
capture software which results in higher levels of accuracy than manual data entry (error 
rate for electronically captured data is < 0.2/1000 compared to 10/1000 for manual data 
entry) [434]. One record in every 10 was completely checked manually. Once entered 
the data underwent stringent central quality control checks. If the co-ordinating centre 
was unsure about any values or if important information was missing the local 
investigator was contacted and asked to provide their help. SAS programs were used to 
collate data pertaining to risk factors from the raw data, ICD codes and drug 
information from the HYVET baseline data form. (The SAS programs are too large to 
be included in the appendices. I authored the majority of these programs and can 
therefore provide copies on request.) 
There were three stages involved in the detection of cognitive decline and incident 
dementia.  
Stage 1:  The MMSE was administered to all trial participants at baseline and annually. 
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Stage 2:  Patients who had an MMSE score which fell to below 24 or by more than three 
points in a 12 month period were identified. 
Stage3: Diagnostic information was collected including CT scan, ischemic score, 
DSMIV criteria and new MMSE. This was sent, complete with all supporting 
documentation including details of co morbidities, depression scores and clock drawing 
test if available, to an expert committee to make a diagnosis of dementia. (Available by 
2010). 
4.5.4. Cognitive testing. 
Training for the administration of the MMSE and a quality of life questionnaire 
including the Geriatric Depression Scale [GDS] and Clock Drawing test [CDT] was 
provided during the country specific start up and annual meetings and during annual 
interviews between investigators and the co-ordinating centre. Information sheets 
detailing how to administer the MMSE were also distributed in the local language. The 
MMSE was administered in the local language and used the translations developed for 
the Syst-Eur trial. Investigators were asked to mark whether the patient had answered 
the question correctly or incorrectly and the score was completed by the co-coordinating 
centre. The pentagons and the sentence question were usually completed on the CRF by 
the patient and the scoring checked by the co-ordinating centre. The sentences were 
translated in order to allow their assessment and as a measure of quality control. 
Investigators were asked to use both the subtraction and backwards spelling tasks in 
order to ensure a time delay between registration and recall of the three item memory 
test. If subtraction was present this was used in all scoring. If only the backwards 
spelling task was present this was used, however, investigators were reminded to use the 
same task each year in order to consistently assess cognition. 
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If all of the MMSE values were missing the MMSE was considered to have been 
omitted. 
In all other cases the number of such, unanswered, questions were collated in order to 
examine the levels of missing items and with regard to whether missing items were 
responsible for any falls in MMSE score which put patients into the at risk group. Items 
which are optional, i.e. where it may be that the patient has not been able to complete 
the sequence of tasks (backwards spelling, subtraction or recall) are not included in the 
total amount of missing values. The MMSEs and change in MMSE were scored using 
SAS programs, taking account of missing values (These SAS programs are also too 
large to be included in the appendices. I authored these programs and can therefore 
provide copies on request.) 
The Quality of Life questionnaire was completed only by patients who were willing to 
participate in this. Patients were asked to complete the questionnaire themselves if they 
could. If not, all aspects of the questionnaire except the CDT were presented verbally by 
the investigator. This help was detailed in two ways: On the questionnaire itself; and in 
an additional, investigator completed, questionnaire asking about reasons for patient 
non completion. This means that patients with poor sight who had trouble reading the 
questions or who find holding and using a pencil difficult could still be assessed. This 
has had demonstrable success previously in a postal format [430] and worked in 
HYVET. 
The quality of life questionnaire was provided in large text and in the local language 
after being translated, checked, and back translated where validated language versions 
were not previously available. 
When completing the Clock Drawing Test patients were asked, following written 
instructions, to draw a clock face and to set the hands to read a time of 10 past 11. The 
resulting clock face was scored at the co-ordinating centre by two independent assessors 
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using the scoring system with numerical scores ranging from 1-10 and adapted from 
Sunderland et al [436] with additional questions derived from Freedman et al [431]. On 
occasions where the two scorers differed by two or more points a third scorer scored the 
clocks. If the third scorer agreed with one of the initial scorers the score that both agreed 
on was used. If all three scorers differed the clock was examined by all scorers and by a 
fourth person. The score was discussed and an agreement reached. Additional 
information regarding the quality of the drawing, for example integrity of the outline 
and hands, was also collected by the scorers and a similarity judgement made in order to 
help identify any tests where an investigator or research nurse may have helped the 
patients. Consistency of CDT scoring both within and between raters was also examined 
for quality control purposes. 
The CDT scores were used to aid the decisions made by the expert committee for the 
final diagnosis of dementia. The CDT has been successfully used in a written form self 
administered by a section of participants in a large study of UK based elderly subjects 
aged 75 and over [420]. 
For those patients who fell into the criteria for cognitive decline and possible incident 
dementia, investigators were contacted and asked to organise a CT scan and to complete 
a questionnaire which detailed the Modified Ischaemic Score and the DSMIV criteria 
for Alzheimer's disease and Vascular dementia. Investigators were also asked to obtain 
a new MMSE score. If the patient did not consent to the CT scan the investigators were 
asked to complete an additional questionnaire detailing the full Hachinski Ischaemic 
Score. The completed questionnaires and the CT scan image were returned to the co-
ordinating centre. Detailed guidelines for the completion of the these questionnaires and 
the questionnaires themselves were provided in the local language and training given at 
annual investigator meetings. 
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Quality control measures were also employed with regard to the CT. Copies of the 
scans/films were examined by two independent neuroradiologists who provided a report 
describing the location and size of infarcts and lacunae, details of white matter changes 
and comments on the implications the scan had with regard to the presence of dementia. 
4.5.5. Dementia Diagnosis committee  
This committee included representatives with expertise in epidemiology, psychiatry of 
old age, statistics, trials and neuroradiology. The committee operated in accordance with 
the following standard operating procedures. 
• As was felt likely that around 95 percent of cases would have some vascular 
changes: several levels of classification were detailed in the 'decision form' with 
the NINCDS criteria (as collected on the form completed by the neuroradiologist 
during CT scan assessment) the most robust. 
• History of stroke and transient ischemic attack (TIA) and stroke or TIA suffered 
during the study with the date of the event if it occurred during the study were 
presented to the committee and taken into account when making a diagnosis. 
• Questions relating to clinical evidence for vascular changes were also completed 
if there was a history/event (e.g. stroke) during the study as this may differ from 
CT findings or there may be no CT available. 
• Further information on serial MMSEs, were presented to the committee. For 
example a patient's MMSE could fall during the first year making them a 
candidate for dementia assessment. However, by the time that this had been 
carried out and the data presented to the committee the patient may have 
completed at least one more annual MMSE. The committee felt that this was 
useful in allowing them a greater understanding of the process happening to the 
patient. However, as this would not be available for all patients (for example if 
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a patient declined to continue in the study after the first year), it should be 
considered separately. 
• It was therefore stated on the 'decision form' as to whether or not the original 
diagnosis was confirmed by additional information. 
• Further additional information was provided by the co-ordinating office, 
including, concomitant medication, co-morbid disease, information on any 
serious adverse events occurring to the patient during the study, blood test 
information as collected by the study, original radiology reports collected by the 
centres (if available and in addition to the independent report collated by the 
neuroradiologists for HYVET), age of patient, sex of patient, educational level 
(as collected in the main trial) translated sentences from the MMSEs, copies of 
the MMSEs (including pentagons) and if available from the Quality of life 
questionnaires (voluntary patient completion) serial Short Form 36 (quality of 
life) scores, Geriatric Depression Scale scores and clock drawing tests. Further 
information, was supplied as required for example annual body mass index and 
annual smoking and drinking status. 
• On a practical basis the co-ordinating office returned to the committee at a later 
date with cases that had been unclassifiable/not demented based on the initial 
information assuming that additional information had been collected. It was 
agreed that the committee would classify cases without additional information 
(e.g. closed centres) as best they could. 
• The use of the DSMIV information: the investigators completing this 
information may not be familiar with diagnosing dementia and it may be 
difficult for local investigators to quantify any change that interfered with the 
usual life of the patients as many of them live with their families and so any 
additional deficits may have been absorbed into the usual care of the patient. In 
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this context, whilst the DSMIV information collected by the investigators 
informs the committee, if the committee felt that a patient had clearly indicated 
dementia they could classify this even if all of the DSMIV criteria were not 
strictly met. 
• Finally it was decided that the committee would record a diagnosis of dementia, 
and if possible one of AD (based on trajectory of decline, medial temporal lobe 
atrophy, DSMIV information and lack of vascular factors on CT/clinical 
history), VaD (based on trajectory of decline, CT scan & MIS/HIS score and 
history of vascular events before/during the study) or both. 
• A minimum of three committee members were required to agree on diagnosis 
and the input of at least one member with a day to day experience of diagnosing 
dementia is needed for each case. 
4.6. 	Statistical considerations: 
The characteristics of the cohort of patients, followed up for two years, were examined 
and compared to those of study participants who were entered into the study at least two 
years prior to the analyses but who had left the study for a variety of reasons including 
refusal to continue and death. These two groups were compared using chi squared and t-
tests for categorical and continuous variables respectively in order to examine levels of 
risk factors and cognitive performance in both groups as it has been suggested 
previously that patients who leave such studies may be at higher risk for cognitive 
decline and their loss lead to an underestimation of the effect of risk factors on cognitive 
function [110]. As attrition is likely to be focused in the frailer and higher risk 
participants a comparison allowed a measure of validation and quality control. 
Other studies have shown age and sex to be strong predictors of cognitive decline 
[17,18,20,21,25,26]. This study included the very elderly, and, as at a this age a greater 
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proportion of the population is female, baseline risk factors were also examined by 
stratified categories of age and sex. Comparisons were carried out using chi squared and 
analysis of variance [ANOVA] for categorical and continuous variables respectively. 
Country and centre differences at baseline were also considered using chi squared and 
ANOVAs, although variation in range of patient numbers per centre meant that 
analysing data per centre was not feasible. In addition, socioeconomic and societal 
differences impacting on cognition are likely to differ more widely by country area 
(Western Europe, Eastern Europe and China) than by centre within a country. As 
country was not considered to be a risk factor for cognitive decline itself, it was only 
entered into the multiple regression models, (i.e. no univariate analyses assessing the 
impact of country were carried out). Country was considered as both a categorical 
variable with each area (Bulgaria, Russia, Romania, China and Western Europe 
representing a category) and as a series of 'dummy' variables, with each country 
defined as separate from all of the others. For the multiple regression the analyses were 
run twice, once with country as a categorical variable and once with country as a series 
of dummy variables. 
Other variables that were coded included orthostatic hypotension (a fall of 20mmHg 
SBP and/or 1 OmmHg DBP) as 'yes/no', heart failure as 'present/absent', atrial 
fibrillation as 'present/absent', previous stroke as `present/absent', type of previous 
treatment centrally acting anti-hypertensives as 'yes/no', ACE-I as 'yes/no', diuretics as 
`yes/no, beta-blockers as 'yes/no', CCB as yes/no, other type of antihypertensive 
treatment as 'yes/no', current consumer of alcohol as 'yes/no', heavy drinker (over 14 
units per week for women or over 21 units per week for men) as 'yes/no', current 
smoker as 'yes/no', piracetam use as 'yes/no', educational level as 'illiterate, primary, 
secondary, tertiary, higher education', diabetes as `present/absent', aspirin taken as an 
antiplatelet as 'yes/no', NSAIDs as 'yes/no', hospitalisation occurring during two year 
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follow up as 'yes/no', stroke occurring during two year follow up as 'yes/no', MI 
occurring during two year follow up as 'yes/no'. 
For the main HYVET trial the study assesses whether there is risk or benefit (in terms 
of stroke and mortality) from antihypertensive treatment in this very elderly 
hypertensive group and appropriate power calculations exist. For the assessment of 
incident dementia, the number of dementia cases in the active and placebo groups at the 
end of the trial will be compared. For the power calculation relating to incident 
dementia, it was calculated that over the course of the trial 15 percent will develop 
dementia, and 840 patients in each treatment group followed for a median of 5 years 
will detect a 33 percent difference in incidence between the treatment groups at the 5 
percent level of significance and 85 percent power (a=0.05, p=0.15).. The respective 
rates are 36/1000 patient years (placebo group) and 24/1000 (active group) with an 
expected total accrual of 252 incident cases in a follow up of 8400 patient years. The 
main trial protocol also makes provision for interim analyses which may stop the trial 
earlier than planned with predefined stopping points based on main trial endpoints such 
as stroke [134]. 
4.6.1. Association of individual risk factors and cognition 
Each baseline risk factor variable was considered separately with two different 
longitudinal dependent variables, (final dementia diagnosis (outcome 3) could not be 
examined as dementia diagnosis data are to be available in 2010). 
Each baseline risk factor was therefore examined in relation to two outcomes: 
1: Incident cognitive decline (a fall in MMSE of more than three points in one year or a 
fall to a score below 24. (Logistic regression). 
2: Change in MMSE over two years of follow up. (Linear regression). 
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Each baseline factor was also examined with baseline MMSE in a cross sectional (linear 
regression) analysis to identify any differences between cross sectional and longitudinal 
relationships. 
Participants were excluded from HYVET if they had a clinical diagnosis of dementia, 
however, this did not preclude the inclusion of patients with low MMSE scores. 
Because the MMSE is scored using correct responses and has no facility to record 
whether a patient attempted a question, it is difficult to know whether the low scores 
represent undiagnosed dementia or a lack of willingness to complete the question. The 
data were therefore examined using all scores, and with the analyses repeated using only 
those patients who scored over 23 (acknowledged as the screening threshold for 
possible mild dementia). Large changes in MMSE score may also result from such 
situations and so no limits were imposed on the level of change in score over the time 
under consideration. Because of the difficulties in assessing completion level, 
unanswered MMSE questions were also counted, see above. This was done taking 
account of the way that the MMSE is administered, i.e. if registration is unsuccessful 
administration of recall is not required. This means that the patient has no possibility of 
completing this question and so the questions are un-administered rather than missing. 
If the three item registration was all missing or all incorrect, then missing answers for 
the recall section were not counted towards the total number of missing values. 
Similarly if part of the subtraction or backwards spelling tasks was attempted but not 
finished the remaining parts were not counted as missing since the question had been 
attempted. 
Generalised linear models were used to examine the relationship between each risk 
factor variable and the MMSE score. Logistic regression was used for the binary 
dependant variables of cognitive decline/possible dementia cases. 
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4.6.2. Association of multiple risk factors and cognition 
In order to gain an overall pattern of statistical significance and impact of multiple risk 
factors the above analyses were repeated with the same dependent variables but with 
1: risk factors shown to be significant in the univariate analyses plus the variable for 
country were entered simultaneously into multiple linear and logistic regressions, 
2: in order to act as a comparator and to reveal any risk factor variables that were not 
significant during univariate analyses but became so in multivariate analyses, all risk 
factor variables plus the variable for country entered simultaneously into a multiple 
linear regression. 
Therefore three main multivariate analyses were carried out: 
• 1: change in MMSE over two years as the dependent variable — all patients 
• 2: change in MMSE over two years as the dependent variable — patients with 
baseline MMSE scores over 23 
• 3: identification of cognitive decline (according to the HYVET protocol) as the 
dependent variable 
• Plus a final multivariate analysis which included all variables (regardless of 
significance in univariate analysis) and all patients. 
All multivariate analyses were run twice, once with country defined as a categorical 
variable and once with country defined as a series of binary variables one for each 
country/region). 
Finally a summary of risk factors was established and their relationship to cognitive 
decline and incident dementia established. 
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5. Chapter 5: Results 
There were 3696 participants who had been randomised to the HYVET trial by the 
autumn of 2006. All of these patients therefore had the potential to have baseline and 
follow up cognition scores. As a result of extensive data cleaning and monitoring both 
at investigator sites and centrally data were of good quality. Significant results are 
presented in bold in tabular format. The results section is divided into descriptions of 
patients lost to follow up, compared to the cohort of those who remained in the study for 
two years. This cohort is then examined by country and age and sex. Cognitive function 
data are presented and cross sectional analyses of risk factors are described briefly. 
These are followed by longitudinal analyses of individual risk factors with three 
dependent variables: change in MMSE over two years, change in MMSE for those 
patients with a baseline MMSE over 23, and possible incident dementia/cognitive 
decline (as defined by the HYVET protocol as a drop of three MMSE points over one 
year or a fall to an MMSE score below 24). Multiple risk factors are then examined via 
multiple longitudinal regression analyses using the same three dependent variables. 
5.1. 	Patients lost to follow up 
Some of these patients had either, not yet reached two year follow up or been lost to 
follow up, either because their centres were closed for quality control reasons (n=444), 
or due to death (n=149), or patient refusal to continue in the trial (n=187). Centre 
closure is not uncommon in linical trials and in this case was due to, a lack of regulatory 
approval for patient recruitment in one centre, an lack of appropriate delivery system for 
trial medication in another centre, an inability to produce validated equipment as 
required and a lack of source documents to support blood test results in a final centre. It 
is emphasized that although these centres were closed for regulatory and quality control 
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reasons no evidence of fraud was found and no legal proceedings occurred. Seventy 
further patients had not completed their two year follow up despite having been 
randomised more that two years previously. Data are being collected with regard to this 
group and they are included with the patient deaths and refusals as it is likely that their 
visit has not taken place for a reason. According to the HYVET protocol all patients 
randomised should be followed up until death or patient refusal with basic data 
collected as a minimum. The participation of the patient, however, is obviously 
important for cognitive function testing. Another important aspect of the trial protocol 
was amendment number one, allowing the randomisation of subjects with isolated 
systolic hypertension [ISH]. The majority of subjects randomised initially, i.e. before 
the protocol amendment was in place, had both systolic and diastolic hypertension (only 
18 subjects had ISH and two year cognition follow up by autumn 2006). These 18 
patients were therefore excluded from these analyses as their presence would alter the 
analyses of the risk factors, at minimum, that of diastolic pressure. 
5.2. 	Patients followed up for two years 
This resulted in 909 patients with both systolic and diastolic hypertension and who had 
two year follow up for cognition alongside baseline risk factor data. See figure 20. 
These patients were compared, using chi-squared and 't' tests, to the 406 that were 
randomised more than two years previously but have not completed two year follow up. 
See table 11. Further comparisons were undertaken to examine the baseline risk factor 
data by country and with regard to age and sex using analysis of variance and chi-
squared tests. Significant results for all comparisons are discussed below. Each risk 
factor variable is reported where data were available. There were no statin or ginkgo 
biloba users in the patient group followed for two years and so these variables are 
omitted. In addition to this, only 45 percent of those in the two year follow up group 
agreed to complete the quality of life questionnaire and this resulted in fewer scores for 
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the geriatric depression scale. Details of the number completing the geriatric depression 
scale are included in the tables below. The values in the tables are given to two decimal 
places with the exception of percentages which are given to one decimal place. All 
statistical values including significance levels are given to three decimal places or as 
convention p<0.0001. 
Figure 21: Flow diagram detailing patients recruited and used in the analyses 
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3696 Participants randomised 
into the HYVET trial by 
Autumn 2006 
444 from centres closed for data 
quality reasons 
1231 participants with Isolated 
Systolic Hypertension not included in 
current analysis (Only 18 had two 
year follow up) 
2021 participants with 
systolic and diastolic 
hypertension 
706 with less than two years elapsed 
since randomisation 
• 
1315 with two or more years 
elapsed since randomisation 




- 70 without two year follow 
up data at the time of 
analysis 
909 with two year follow up 
data for cognitive function 
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Table 11: Comparison of baseline characteristics between the group reaching two year follow up and those who did not 
Name Group with 2 year follow-up (n=909) 
Group without 2 year 
follow-up (n=406) Comparison 
Age in years - mean(SD) 83.72 (3.34) 84.19 (3.42) p=0.018 
Gender female % 
Vascular factors 
559 61.5 253 62.3 ..0.760 
Average sitting systolic blood pressure mmHg - mean(SD) 174.40 (7.84) 173.63 (8.37) p=0.107 
Average sitting diastolic blood pressure mmHg- mean(SD) 96.18 (3.47) 95.80 (4.012) p=0.080 
Average standing systolic blood pressure mmHg - mean(SD) 169.23 (9.41) 168.49 (9.68) p=0.191 
Average standing diastolic blood pressure mmHg- mean(SD) 94.200 (5.03) 93.606 (5.30) p=0.052 
Orthostatic hypotension - number (%) 46 (5.1) 21 (5.2) p=1.000 
Total cholesterol mmo1/1- mean(SD) 
5.63 (1.04) (range 
2.90 to 11.0) n=908 
5.46 (1.09) 
(range 3.0 to 10.10) n=405 p=0.008 
HDL cholesterol mmo1/1- mean(SD) 
1.32 (0.42) (range 
0.60 to 3.30) n=895 
1.35 (0.44) (range 0.60 to 
3.40) n=395 p=0.336 
Heart failure present (%) 5 (0.6) 4 (1.0) numbers too small 
Atrial fibrillation (reported by investigators) (%) 32 (3.5) 26 (6.4) p=0.027 
Previous stroke (`Yo ) 28 (3.1) 21 (5.2) p=0.090 
Type of previous treatment: centrally acting (%) 95 (10.5) 48 (11.8) p=0.521 
Type of previous treatment: ACE inhibitors (%) 286 (31.5) 120 (29.6) p=0.531 
Type of previous treatment: diuretics (cY0 ) 210 (23.1) 84 (20.7) p=0.369 
Type of previous treatment: beta blockers (%) 44 (4.8) 21 (5.2) p=0.905 
Type of previous treatment: Calcium channel blockers (%) 209 (23.0) 76 (18.7) p=0.096 
T • e of • revious treatment: other % 
Lifestyle factors 
26 2.9 36 8.9 • <0.0001 
Current consumer of alcohol (%) 243 (26.7) 90 (22.2) p=0.091 
Heavy drinker (>21units/week for males or >14/week females)(% ) 4 (0.4) 0 (0) numbers too small 
Units of alcohol per week in drinkers - mean(SD) 6.40 (5.40) 6.23 (5.63) p=0.810 
Current smoker (%) 37 (4.1) 23 (5.7) p=0.255 
Exsmoker (%) 133 (14.6) 57 (14.0) p=0.844 
Number of cigarettes per day - mean(SD) 12.88 (4.99) 11.25 (4.79) p=0.565 
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Name Group with 2 year follow-up (n=909) 
Group without 2 year 
follow-up (n=406) Comparison 
Body Mass Index - mean(SD) 25.54 (3.39) n=908 24.97 (3.55) p=0.006 
Ginkgo use reported (%) 0 (0) 0 (0) numbers too small 
Piracetam use reported (%) 29 (3.2) 11 (2.7) p=0.768 
Education (%) n=901 n=391 
0 (illiterate) 29 (3.2%) 59 (15.1% ) 
p<0.0001 1 (primary education only) 276 (30.6%) 124 (31.7%) 
2 (secondary education) 392 (43.5%) 125 (32.0% ) 
3 (tertiary education) 167 (18.5%) 70 (17.9% ) 
4 hi. her education 
Other 
37 4.1% 13 3.3% 
Haemoglobin g/d1- mean(SD) 
13.19 (1.75) (range 
7.80 to 19.30) 
12.95 (1.69) (range 7.40 to 
17.70) p=0.021 
Diabetes present (%) 62 (6.8) 41 (10.1) p=0.053 
Aspirin taken as an antiplatelet (%) 136 (15.0) 55 (13.5) 13=0.557 
NSAIDs use reported (%) 134 (14.7) 29 (7.1) p<0.0001 
Statin use reported (%) 0 (0) 1 (0.2) numbers too small 
Number of co-morbidities - mean(SD) 1.936 (1.42) 2.010 (1.38) p=0.381 
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Name 
Group with 2 
year follow-up 
(n=909) 




Geriatric Depression Scale score - (%) n=408 • n=209 
Mean(SD) 6.43 (3.71) 6.92 (3.38) 
1 0 (0) 0 (0) 
2 54 (13.2) 20 (4.9) 
3 56 (13.7) 13 (3.2) 
4 46 (11.3) 24 (5.9) 
5 50 (12.3) 30 (7.4) 
6 40 (9.8) 23 (5.7) 
7 29 (7.1) 15 (3.7) 
8 23 (5.6) 15 (3.7) p=0.049 
9 16 (3.9) 19 (4.7) 
10 14 (3.4) 13 (3.2) 
11 25 (6.1) 11 (2.7) 
12 16 (3.9) 9 (2.2) 
13 15 (3.7) 11 (2.7) 
14 18 (4.4) 5 (1.2) 
15 6 (1.5) 1 (0.2) 
MMSE score baseline(M0) - mean(SD) 26.28 (3.47) 24.93 (4.03) p<0.0001 
MMSE score one year(M12) - mean(SD) 25.70 (3.82) 23.46 (4.92) n=222 p<0.0001 
MMSE score two ears M24 - mean SD 25.40 4.07 
Characteristics of patients who went onto have a serious 
adverse event during their 2 years of follow up n=39 
MMSE score baseline (MO) - mean(SD) 26.15 (3.73) 
Age in years - mean(SD) 84.27(3.54) 
Gender female(% ) 25 (61.0) 
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5.3. 	Comparison between participants who were in the 
two year follow up group and those who were 
randomised more than two years previously but who did 
not complete two years in the trial. 
The two groups were largely similar with regard to baseline characteristics. The 
differences that do exist indicate that the non follow up group had lower reported health. 
They differed significantly for age, those without follow up were older, 84.19 years 
compared to 83.72 (v0.018). The former group also had lower total cholesterol 
5.47mmo1/1 versus 5.63mmo1/1 (p=0.008), a higher likelihood of reported atrial 
fibrillation, 6.4 percent versus 3.5 percent (p=0.027), and were more likely to have been 
previously treated with an antihypertensive that fell into the category 'other', i.e. neither 
a centrally acting antihypertensive, nor an ACE inhibitor, diuretic, beta blocker or 
calcium channel blocker; 8.9 percent versus 2.9 percent (p=<0.0001). Those who did 
not complete follow up were also more likely to have a lower body mass index; 24.97 
versus 25.54 (p=0.006); lower educational level, p<0.0001, higher depression scores 
(p=0.049) indicating higher levels of depression, although the depression scores were 
only completed by around half of either group. Finally, the group who were not 
followed up had lower haemoglobin values 12.85 versus 13.19 (p=0.021), lower levels 
of NSAID use, 7.1 percent versus 14.7 percent. They also had significantly lower 
baseline (24.93 versus 26.28, p<0.0001) and one year MMSE scores (23.46 versus 
25.70, p<0.0001) although there were only 222 participants from the non follow up 
group who reached one year. 
In the group with two year follow up 39 had suffered at least one serious adverse event 
during their two years of follow up (according to the legal definition of this) and these 
patients were slightly older (84.27 years) than the remainder of the follow up group. 
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The baseline characteristics for the follow up group were also examined by country and 
with regard to age and gender. 
Gender, sitting and standing systolic and diastolic blood pressure levels, orthostatic 
hypotension, HDL cholesterol, presence of heart failure, previous stroke and previous 
treatment with centrally acting, ACE-I, diuretics, beta-blockers and CCB were not 
significantly different between the two groups. Consumption of alcohol, heavy drinking, 
amount of alcohol consumed, smoking (current or ex), number of cigarettes per day, use 
of nootropics Ginkgo Biloba or piracetam, diabetes, aspirin taken as an anti-platelet, 
statin use and number of co-morbidities did not significantly differ between the group 
who remained in the study for two years compared to those who did not. 
5.4. 	Comparison of baseline characteristics by country 
The numbers recruited in each country differed partly because of the time that the 
different countries/areas gained entry/regulatory approval to enter the study, with lowest 
recruiters to this cohort being in Western Europe. For this reason the cohort from 
Western Europe (n=29) were compared to the largest contributor, Bulgaria (n=708) and 
to Romania (n=81), Russia (n=47) and China (n=44). See table 12 for details. There 
were no significant differences for age or gender although the Russian population had a 
higher percentage of female participants, 76.6 percent , with all other countries lower at 
less that 70 percent. 
Despite the minimum blood pressure requirements for trial entry there were significant 
differences for blood pressure variables, both sitting and standing, systolic and diastolic 
measures although no clear patterns emerged. The Chinese had the highest sitting 
systolic pressures at 178.62 mmHg and were close to the highest for standing systolic 
also at 172.20 mmHg with Western Europe the highest for this measure at 
173.89mmHg. Sitting systolic pressures for the other countries were lowest in Russia 
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(170.24) rising through Western Europe (172.48), Bulgaria (174.27) and Romania 
(176.34). Standing systolic had a similar pattern with the exception of Western Europe 
which was the highest. Sitting diastolic pressure was highest in Romania (96.79) and 
Bulgaria (96.25) with Russia lowest at 94.92 mmHg. Standing diastolic pressure was 
highest in Western Europe (98.05), China (94.89) and Romania (94.84) with Russia 
again lowest at 93.86 mmHg. There were no patients with orthostatic hypotension in 
Western Europe and only one in Russia, thus, the numbers with orthostatic hypotension 
were too small to allow a statistical comparison by country. Numbers were also too few 
to allow comparison of presence of heart failure, atrial fibrillation, and previous stroke. 
Cholesterol level, both total and HDL cholesterol differed significantly with the highest 
values for total cholesterol found in Western Europe (5.72mmo1/1) and lowest in 
Romania (5.12mmo1/1) where the standard deviation was also lowest (0.84mmoU1). 
HDL cholesterol was high in Western Europe (1.87mmo1/1), China (1.58mmo1/1) and 
Romania (1.58mmo1/1) and lowest in Bulgaria (1.26mmo1/1). Russians, Romanians and 
Bulgarians were significantly more likely to have been treated with ACE inhibitors in 
the past, prior to study entry, with diuretics used most in Western Europe and Romania. 
Calcium Channel Blockers were also favoured in Romania and Bulgaria. The numbers 
were too small to allow statistical testing for centrally acting antihypertensives, beta 
blockers or 'other' treatment. However, the use of centrally acting antihypertensives 
was highest in Bulgaria and absent in Western Europe, beta blockers were used most in 
Western Europe and Russia with 'other' treatment used in 36.4 percent of the Chinese. 
When comparing the countries with regard to lifestyle factors only consumption of 
alcohol was significantly different. 34.5 percent of the Western Europeans drank 
alcohol and 29.1 percent of the Bulgarians with Romanians at 17.3 percent, the 
Russians 14.9 percent and the Chinese 13.6 percent respectively. Numbers were too 
small to compare heavy drinking, current smoking, piracetam use or educational level, 
187 
however, more of the Chinese were illiterate (61.4 percent). The most common level of 
education was primary (category 1) for Western Europe (55.2 percent) and Romania 
(46.9 percent). The Bulgarians had most participants in category 2, secondary education 
(48.3 percent) and the Russians were most highly educated with 55.3 percent of their 
patients having reached tertiary education. 
Finally, significant differences were also found for haemoglobin, aspirin use (as an anti-
platelet), number of co-morbidities reported at baseline and MMSE score. Numbers 
were too small to allow comparisons of serious adverse events occurring within the two 
year follow up or numbers of participants with diabetes. 
For haemoglobin, the Chinese had the highest haemoglobin levels (14.58gm/d1) but 
with the largest standard deviation (2.00). The Romanians and Russians presented with 
the lowest levels at 12.77 and 12.85 respectively. Aspirin was favoured in Bulgaria with 
18.4 percent taking it, 10.3 percent of the Western Europeans also took aspirin but only 
2.5 percent and 2.3 percent of the Romanians and Chinese and none of the Russians 
used aspirin at all. The Russians, however, did report co-morbidities with a mean of 
2.75 per patient second only after Western Europeans at 3.21. The Chinese reported 
least with 1.23 per patient with the Bulgarians at 1.82 and the Romanians at 2.48 
respectively. 
MMSE scores were highest in Western Europe, Russia and Bulgaria, slightly lower in 
Romania and lower still in China. Despite this the difference between mean MMSE 
score for China and Western Europe was, at its largest (two year visit) 3.52 MMSE 
points. 
There were no significant differences for age, gender, sitting, standing or orthostatic 
blood pressure. Also none for presence of heart failure, atrial fibrillation, previous 
stroke, previous use of centrally acting, beta-blocker or 'other' type of anti-hypertensive 
treatment. Heavy drinking, smoking, exsmokers, body mass index, nootropic - 
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piracetam use (there were no participants using Gingko Biloba), educational level, 
presence of diabetes, NSAID use, GDS score, occurrence of serious adverse event were 
also not significantly different. 
5.5. 	Comparison of baseline characteristics by age and 
gender 
Study participants were divided into four groups, males aged 80-89 (n=335), males aged 
90 and over (n=15), females aged 80-89 (n=522) and females aged 90 and over (n=37), 
see table 13. There were significant differences in sitting systolic blood pressure with 
the older ages reporting higher pressures and the females higher than the males; 
173.37mmHg for males aged 80-89, 175mmHg for older males and 174.84mmHg for 
females aged 80-89, and 177.28mmHg for females aged 90 and over. Standard 
deviations were similar in all four groups. None of the other blood pressure 
measurements differed significantly and there were too few cases in the more elderly 
groups to allow a comparison of orthostatic hypertension. For baseline factors other 
than blood pressure, total cholesterol was significantly different with the highest values 
in older males (6.20mmo1/1) followed by younger females (5.68), younger males (5.54) 
and older females (5.54). HDL cholesterol and previous treatment were not significant 
although the numbers were too small to allow comparisons for previous use of centrally 
acting antihypertensives, beta blockers or 'other' types of treatment. Presence of heart 
failure, atrial fibrillation and previous stroke were also too few to allow comparison. 
With regard to lifestyle factors, alcohol use and former smoking were significant. Males 
were more likely to consume alcohol with 50.4 percent of younger males drinking 
alongside 60 percent of older males and 12.3 percent and 2.7 percent for younger and 
older females respectively. Males were also more likely to be current smokers (non 
significant) or ex-smokers (significant p<0.0001). Thirty point one (30.1) percent of 
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younger males and 60 percent of older males had smoked previously compared to four 
percent and 2.7 percent of females respectively. Comparisons for heavy drinking of 
alcohol and current smoking were not possible as numbers were too few. This was true 
also of piracetam use, education category, presence of diabetes and those who had 
suffered from serious adverse events at follow up. Haemoglobin level, geriatric 
depression score and MMSE did differ significantly with women showing lower 
haemoglobin as in younger age groups but with similar standard deviations. The older 
men and women also had lower haemoglobin than their younger counterparts with older 
men at a mean of 13.73g/di compared to younger men at 13.91. Values were 12.68g/di 
and 12.75 for women respectively. Women scored more highly than men on the 
geriatric depression scale thus indicating higher levels of depressive feelings, older men 
and older women also scored more highly than younger. Care must be taken when 
interpreting these results, however, as the numbers of patients completing these 
questions is lower than for the other categories and when stratified by age and sex 
results in just three older males and 21 older females provided data. 
Finally, cognitive function scores (MMSE) were highest in younger men (at all visits) 
and lowest in older women (for baseline and two years). At 12 months older men 
showed a fall in mean MMSE to 23.73 which rose again at their two year follow up 
(25.73), however, there were only 15 patients in this (older male two year cohort) group 
and the standard deviation for their 12 month data was larger than those recorded for all 
other groups at other visits. 
Age, standing systolic, standing and sitting diastolic blood pressure, orthostatic 
hypotension, HDL cholesterol, presence of heart failure, previous stroke, centrally 
acting antihypertensives, ACE-I, diuretic, beta blocker, CCB or other previous anti-
hypertensive treatment were not significantly different. Heavy drinking, current 
smoking, body mass index, piracetam use, educational level, presence of diabetes, use 
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of aspirin as an antiplatelet, use of NSAIDs, number of co-morbidities or occurrence of 
serious adverse event also did not differ between groups when examined by age and sex 
strata. 
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Table 12: Comparison of baseline characteristics between countries 



















(3.30) F=1.176 p=0.320 
Gender female - % 
Vascular factors 
421 	59.5 36. 76.6 54 66.7 28 63.6 20 69.0 chi=7.444 6=0.114 
Average sitting systolic blood pressure mmHg - 








(10.16) F=8.490 p<0.0001 
Average sitting diastolic blood pressure mmHg - 








(3.93) F=2.769 p=0.026 
Average standing systolic blood pressure mmHg - 








(15.71) F=5.583 p<0.0001 
Average standing diastolic blood pressure mmHg - 








(6.74) F=5.364 p<0.0001 
small Orthostatic hypotension - (%) 28 (4.0) 1 (2.1) 10 (12.3) 7 (15.9) 0 (0.0) numbers too 
Total cholesterol mmo1/1- mean (SD) 
5.70 (1.04) 




(1.13) 5.72 (1.07) F=5.871 p<0.0001 
p<0.0001 HDL cholesterol mmo1/1- mean (SD) 
1.26 (0.36) 




(0.35) 1.87 (0.58) F=30.462 
Heart failure present - (c/o ) 3 (0.4) 2 (4.3) 0 (0.0) 0 (0.0) 0 (0.0) numbers too small 
Atrial fibrillation (reported by investigators) - (Y° ) 29 (4.1) 2 (4.3) 0 (0.0) 0 (0.0) 1 (3.4) numbers too small 
Previous stroke - (%) 11 (1.6) 1 (2.1) 7 (8.6) 9 (20.5) 0 (0.0) numbers too small 
Type of previous treatment: centrally acting - (%) 90 (12.7) 2 (4.3) 1 (1.2) 2 (4.5) 0 (0.0) numbers too small 
Type of previous treatment: ACE inhibitors - (Vo ) 215 (30.4) 25 (53.2) 40 (49.4) 4 (9.1) 2 (6.9) chi=41.076 p<0.0001 
p<0.0001 Type of previous treatment: diuretics - (Vo ) 159 (22.5) 7 (14.9) 31 (38.3) 2 (4.5) 10 (34,5) chi=23.154 
Type of previous treatment: beta blockers - (%) 25 (3.5) 7 (14.9) 7 (8.6) 1 (2.3) 4 (13.8) numbers too small 
Type of previous treatment: Calcium channel 
blockers - (%) 168 (23.7) 8 (17.0) 24 (29.6) 7 (15.9) 1 (3.4) chi=10.711 p=0.030 
















Current consumer of alcohol - (%) 206 (29.1) 7 (14.9) 14 (17.3) 6 (13.6) 10 (34.5) chi=13.817 p=0.008 
Heavy drinker - (%) 3 (0.4) 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0) numbers too small 
Current smoker - (%) 33 (4.7) 0 (0.0) 2 (2.5) 1 (2.3) 1 (3.4) numbers too small 
Exsmoker - (%) 93 (13.1) 8 (17.0) 18 (22.2) 7 (15.9) 7 (24.1) chi=7.376 p=0.117 








(3.45) 26.37 (3.62) F=1.456 p=0.214 
Piracetam use reported - (%) 25 (3.5) 1 (2.1) 2 (2.5) 0 (0.0) 1 (3.4) numbers too small 






6 (0.6%) 0 (0.0%) 3 (3.7%) 27 (61.4%) 1 (3.4% ) 
numbers too small 
210 (29.7%) 1 (2.1% ) 38 (46.9%) 11 (25.0%) 16 (55.2% ) 
342 (48.3%) 13 (27.7%) 25 (30.9%) 2 (4.5%) 10 (34.5%) 
121 (17.1%) 26 (55.3% ) 15 (18.5% ) 4 (9.1% ) 1 (3.4%) 
29 4.1% 7 (14.9%) 0 (0.0%) 0 (0.0%) 1 3.4% 






(2.00) 13.61 (1.25) F=9.431 p<0.0001 
Diabetes present - (%) 52 (7.3) 0 (0.0) 7 (8.6) 2 (4.5%) 1 (3.4) numbers too small 
Aspirin taken as an antiplatelet - (%) 130 (18.4) 0 (0.0) 2 (2.5) 1 (2.3%) 3 (10.3) chi=30.691 p<0.0001 
p=0.127 
p<0.0001 
NSAIDs use reported - (%) 115 (16.2) 4 (8.5) 	. 10 (12.3) 2 (4.5%) 3 (10.3) chi=7.177 
Number of co-morbidities - mean (SD) 1.82 (1.25) 2.75 (1.34) 2.48 (2.15) 1.23 (0.91) 3.21 (1.8) F=17.935 










n=7 F=1.686 p=0.152 
Serious Adverse Event occurring during 2 year follow up n=28 n=4 n=3 n=1 n=3 numbers too small 
Hospitalisation occurring during 2 year follow up n=16 n=4 n=2 n=1 n=3 numbers too small 
Stroke occurring during 2 year follow up n=28 n=0 n=0 n=0 n=0 numbers too small 
Myocardial Infarction occurring during 2 year follow up n=0 n=0 n=1 n=0 n=0 numbers too small 
MMSE score M(0) - mean (SD) 26.45 (3.29) 26.60(2.47) 25.84(3.75) 24.36(5.48) 26.31 (2.83) F=4.313 p=0.002 
MMSE score M(12) - mean (SD) 25.86 (3.66) 26.06(3.12) 25.54(3.80) 23.16(5.88) 26.10 (3.13) F=5.534 p<0.0001 
MMSE score M(24) - mean (SD) 25.49 (3.69) 25.92(3.26) 25.46(4.39) 23.00(7.08) 26.52 (2.94) F=4.954 p=0.001 
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Table 13: Comparison of baseline characteristics by age and gender 
Name Male aged 80 
- 89 (n=335) 
Male aged 90 
and over 
(n=15) 
Female aged 80 - 
89 (n=522) 
Female aged 
90 and over 
(n=37) Comparison 
A.e in ears - mean SD 83.23 2.57 93.12 2.38 83.17 2.61 92.08 	1.75 
Vascular factors 
Average sitting systolic blood pressure mmHg - mean 
(SD) 173.37 (7.64) 175.00 (7.48) 174.84 (7.87) 177.28 (8.32) F=4.220 p=0.006 
p=0.680 Average sitting diastolic blood pressure mmHg - mean (SD) 96.01 (3.25) 95.85 (3.98) 96.30 (3.60) 96.25 (3.98) F=0.503 
Average standing systolic blood pressure mmHg - mean (SD) 168.71 (9.01) 166.53 (7.53) 169.53 (9.73) 170.53 (9.05) F=1.164 p=0.322 
Average standing diastolic blood pressure mmHg - mean (SD) 94.22 (4.67) 92.27 (4.06) 94.28 (5.19) 93.82 (6.14) F=0.850 p=0.467 
Orthostatic hypotension - (%) 9 (2.7) 1 (6.7) 33 (6.3) 3 (8.1) numbers too small 
Total cholesterol mmol/l - mean (SD) 5.54 (0.97) 6.20 (1.42) 5.68 (1.08) n=521 5.54 (0.87) F=2.861 p=0.036 
HDL cholesterol mmol/l - mean (SD) 
1.31 (0.42) 
n=331 1.19 (0.35) 1.33 (0.44) n=512 1.35 (0.42) F=0.686 p=0.561 
Heart failure present - (%) 1 (0.3) 0 (0.0) 3 (0.6) 1 (2.7) numbers too small 
Atrial fibrillation (reported by investigators) - (%) 12 (3.6) 1 (6.7) 16 (3.1) 3 (8.1) numbers too small 
Previous stroke - (%) 10 (3.0) 0 (0.0) 17 (3.3) 1 (2.7) numbers too small 
Type of previous treatment: centrally acting - (%) 25 (7.5) 4 (26.7) 61 (11.7) 5 (13.5) numbers too small 
Type of previous treatment: ACE inhibitors - (%) 101 (30.1) 3 (20.0) 169 (32.4) 13 (35.1) chi=1.615 p=0.656 
Type of previous treatment: diuretics - (%) 72 (21.5) 4 (26.7) 121 (23.2) 2 (32.4) chi=2.413 p=0.491 
Type of previous treatment: beta blockers - (%) 13 (3.9) 1 (6.7) 29 (5.6) 1 (2.7) numbers too small 
Type of previous treatment: Calcium channel blockers - (%) 84 (25.1) 1 (6.7) 116 (22.2) 7 (18.9) chi=3.606 	1 p=0.307 
T •e of •revious treatment: other - % 9 2.7 0 0.0 17 3.3 0 0.0 numbers too small 
Lifestyle factors 
Current consumer of alcohol - (%) 169 (50.4) 9 (60.0) 64 (12.3) 1 (2.7) chi=171.386 p<0.0001 
Heavy drinker - (%) 0 (0.0) 0 (0.0) 4 (0.8) 0 (0.0) numbers too small 
Current smoker - (%) 31 (9.3) 1 (6.7) 5 (1.0) 0 (0.0) numbers too small 
Exsmoker - (%) 102 (30.1) 9 (60.0) 21 (4.0) 1 (2.7) chi=143.057 p<0.0001 
p=0.523 Body Mass Index - mean (SD) 25.45 (2.83) 25.51 (2.79) 25.65(3.72)n=521 24.86 (3.34) F=0.749 
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Name Male aged 80 - 89 
(n=335) 




80 - 89 (n=522) 
Female aged 
90 and over 
(n=37) 
Comparison 
Piracetam use reported - (%) 13 (3.9) 0 (0.0) 13 (2.5) 3 (8.1) numbers too small 
Education n=330 n=15 n=520 n=36 
numbers too small 
0 5 (1.5% ) 0 (0.0% ) 22 (4.2% ) 2 (5.4% ) 
1 90 (26.9%) 3 (20.0%) 168 (32.2%) 15 (40.5%) 
2 138 (41.2%) 2 (13.3%) 236 (45.2%) 16 (43.2% ) 
3 77 (23.0%) 7 (46.7%) 81 (15.5%) 2 (5.4% ) 
4 
Other 
20(6.0%) 3(20.0%)13(2.5%)1 (2.7%)  
Haemoglobin unit g/dl - mean (SD) 13.90 (1.74) 13.73 (1.42) 12.75 (1.61) 12.68 (1.64) F=34.813 p<0.0001 
Diabetes present - (%) 22 (6.6) 1 (6.7%) 36 (6.9) 3 (8.1) numbers too small 
Aspirin taken as an antiplatelet - (Y° ) 60 (17.9) 4 (26.7) 65 (12.5) 7 (18.9) chi=6.944 p=0.074 
NSAIDs use reported - (%) 54 (16.1) 1 (6.7) 74 (14.2) 5 (13.5) chi=1.461 p=0.691 
Number of co-morbidities - mean (SD) 1.88 (1.35) 2.40 (1.35) 1.97 (1.47) 1.81 (1.35) F=0.880 p=0.451 






n=21 F=3.305 p=0.020 
Serious Adverse Event occurring during 2 year follow up n=14 n=1 n=22 n=2 numbers too small 
Hospitalisation occurring during 2 year follow up n=11 n=0 n=14 n=1 numbers too small 
Stroke occurring during 2 year follow up n=0 n=0 n=22 n=0 numbers too small 
Myocardial Infarction occurring during 2 year follow up n=1 n=0 n=0 n=0 numbers too small 
MMSE score M(0) - mean (SD) 27.20 (2.89) 25.40 (3.64) 25.90 (3.53) 24.03 (4.53) F=16.427 p<0.0001 
MMSE score M(12) - mean (SD) 26.54 (3.58) 
23.733 
(6.400) 25.36 (3.61) 24.03 (5.33) F=10.837 p<0.0001 
MMSE score M(24) - mean (SD) 26.09 (3.73) 25.73 (4.08) 25.15 (3.94) 23.11 (5.26) F=8.384 p<0.0001 
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5.6. 	Cognitive function 
The mean MMSE score was as expected for the age group [400] and showed a slight 
decline in the cohort over the two year period with a slight increase in standard 
deviation. See table 14. The median and mode followed the same pattern with all years 
showing significantly skewed data. Participants were excluded from HYVET if they 
had a clinical diagnosis of dementia. However, this did not preclude the inclusion of 
patients with low MMSE scores and, despite the data being skewed towards the 
maximum value and cognitive intact scores, there were low scores at each year of 
follow up, from values of eight at baseline down to six at two years. The investigators 
were trained before they began their baseline trial visits and annually thereafter. In some 
cases this is likely to have resulted in better completion of MMSE data after one or two 
year follow up. Although the level of variation within the MMSE was one, two or zero 
points different at follow up for the vast majority of patients, some few patients showed 
striking increases as well as decreases in values and those that entered the trial with low 
values did not manifest the same values at follow up. The MMSE was well completed 
with mean levels of missing data low at less than one MMSE point and median and 
mode values at zero. See table 15. Maximum missing values ranged from nine at 
baseline to 11 at one and two year follow up. These values indicate questions where no 
answer was provided on the case report form, i.e. not a negative answer. Around 40 
percent of patients had a falling MMSE over the study period with around 35 percent 
with a rising score. Over the first year 44.8 percent fell and 34.7 percent rose; over the 
second year 41.6 percent fell with 37.2 percent rising. 
196 
Table 14: Mini-Mental State Exam score, descriptive information 
MMSE baseline MMSE one year MMSE two years 
Mean(SD) 26.30 (3.44) 25.72 (3.80) 25.43 (3.98) 
Median 27 27 26 
Mode 28 29 28 
Skewness -1.43 -1.468 -1.59 
Shapiro-Wilks w=0.870, p<0.0001 w=0.873, p<0.0001 w=0.866, p<0.0001 
Interquartile range 4 5 4 
Minimum 8 7 6 
Maximum 30 30 30 
Table 15: Mini-Mental State Exam, missing values, descriptive information 
MMSE baseline MMSE one year MMSE two years 
Mean(SD) 0.42 (1.09) 0.57 (1.29) 0.55 (1.23) 
Median 0 0 0 
Mode 0 0 0 
Minimum 0 0 0 
Maximum 9 11 11 
The MMSE is not normally distributed, either in the normal population or in this data 
set, and this could not be remedied by using the square root, the log, the inverse or a 
normalisation equation (Stata command lnskew [437]). The original MMSE score 
values were therefore used in the regression analyses, and as is common in the 
literature, the results of which are presented in tables 17 — 23. Figures 22 and 23 show 
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Figure 22: Mini-Mental State Exam scores distribution (baseline) 
Baseline MMSE score 




Two year MMSE score 
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5.7. 	Serious adverse events occurring during the two 
year follow up, effect on cognition 
In addition to the above several patients suffered from 'Serious Adverse Events' during 
their two years of follow up and the number of these, categorised by type of event, are 
listed in table 16. These factors were included in the regression analyses as they may 
have affected MMSE scores when assessments were calculated after the event. 







Serious Adverse Event (Legal definition includes 
hospitalisation) 39 4.3 
Hospitalised 26 2.9 
None fatal stroke 2 0.2 
Myocardial infarction 1 0.1 
5.8. 	Analysis of individual risk factors, linear and logistic 
univariate regression. 
Each risk factor was entered into three regression analyses; 
• a linear regression with all patients and with change in MMSE score as the 
dependent variable, 
• a linear regression score with only those patients who scored over 23 at baseline 
MMSE and with change in MMSE as the dependent variable, 
• a logistic regression with all patients and with identification of cognitive decline, 
possible incident dementia, as defined in the HYVET protocol, as the dependent 
variable. 
• Finally, significant results risk factors (defined as p<0.05) were entered into a 
series multiple regression models. 
The results are presented with significance values, R squared values, slope for the linear 
regression and odds ratios with 95 percent confidence intervals for the logistic 
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regression models. Despite several values attaining significance none of the R square 
values are high, suggesting that the fit of the models was not good. Full details are 
presented below. 
5.8.1. Cross-sectional analyses — baseline data MMSE all 
subjects 
Cross sectional analyses for all patients with two year follow up and with baseline 
MMSE as the dependent variable found significant results for age, gender, sitting and 
standing systolic blood pressure, standing diastolic blood pressure, orthostatic 
hypotension, HDL cholesterol, educational level and alcohol consumption and amount, 
see table 17. Older age was associated with a lower MMSE (p=0.0006), as was female 
gender (p<0.0001). The relationship between age and baseline MMSE is illustrated 
graphically in figure 24. Sitting systolic and standing diastolic blood pressure showed 
similar levels of significance with higher sitting systolic associated with lower MMSE 
(p<0.0001) and lower standing diastolic associated with lower MMSE (p<0.0001). 
Higher standing systolic pressure was also associated with lower MMSE but was less 
strongly significant (p=0.039). Presence of orthostatic hypotension was associated with 
lower MMSE (p0.005) as was higher HDL cholesterol (p=0.002). Those who reported 
drinking alcohol at baseline were less likely to have lower baseline MMSE (p=0.024) 
and higher amounts of alcohol (numbers of units) were associated with higher MMSE 
(p=0.036), although this analysis obviously was restricted to the drinkers (n=243). 
Finally higher educational level was associated with higher MMSE at a significance 
level of p<0.0001. 
Sitting diastolic blood pressure, total cholesterol, presence of heart failure, presence of 
atrial fibrillation, previous stroke, previous treatment with centrally acting, ACE-I, 
diuretics, beta-blockers, CCB, or 'other' anti-hypertensives were not significantly 
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associated with baseline MMSE. Heavy drinking, current or exsmoking, number of 
cigarettes a day, body mass index, piracetam use, haemoglobin level, presence of 
diabetes, use of aspirin as an anti-platelet, use of NSAIDs, number of co-morbidities, 
GDS score were also not significant. 
5.8.2. Cross-sectional analyses — baseline data restricted to 
subjects with baseline MMSE over 23 
When the cross sectional analysis was restricted to those patients who had an MMSE 
over 23 at baseline, see table 18, the significant variables changed to include sitting and 
standing diastolic pressure, HDL cholesterol, alcohol consumption, educational level 
and haemoglobin only. Higher sitting and standing diastolic pressure were associated 
with a higher MMSE score (p=0.001 and <0.0001 respectively). Systolic blood pressure 
and orthostatic hypotension lost their significance. Higher HDL was associated with 
lower MMSE but was less significant (p=0.037), education remained associated with 
better cognition but was also less significant (p=0.024). Alcohol use (p=0.016) also 
remained associated with higher MMSE but the amount of alcohol lost significance. 
Finally haemoglobin level became significant such that a higher haemoglobin was 
associated with a higher MMSE (p=0.01). 
Sitting SBP, standing SBP, orthostatic hypotension, total cholesterol, presence of heart 
failure atrial fibrillation and previous stroke were not significantly associated with 
baseline MMSE. Previous treatment of any type, heavy drinking, current smoking, ex-
smoker status, number of cigarettes per day, body mass index, piracetam use, presence 
of diabetes, use of aspirin as an anti-platelet, use of NSAIDs, number of co-morbidities 
and GDS score also had no significant relationship with baseline MMSE 
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5.8.3. Longitudinal analyses — baseline data, MMSE all 
subjects 
Longitudinal analyses using a generalised linear regression model examined each 
baseline variable with the change in MMSE over two years (as the dependent variable). 
When all patients were included (table 17) only age, previous use of calcium channel 
blockers, piracetam use, education and haemoglobin were significant. Younger age was 
protective (p=0.030) as was higher education (p=0.028). The relationship between age 
and change in MMSE is illustrated graphically in figure 25 and that for education and 
MMSE in figure 26. Patients using piracetam or having previously used calcium 
channel blockers were at increased risk of a larger fall in MMSE (p=0.045 and p=0.007 
respectively). Higher levels of haemoglobin were also associated with increased risk of 
a larger fall in MMSE (p=0.002). 
Neither gender, nor SBP, DBP, sitting, standing blood pressure or orthostatic 
hypotension were statistically significantly related to MMSE change over two year 
follow up. Total cholesterol, HDL cholesterol, presence of heart failure, atrial 
fibrillation, previous stroke, any type of previous anti-hypertensive treatment, alcohol 
consumption, heavy drinking, units of alcohol, current or exsmoker status, number of 
cigarettes per day, body mass index, presence of diabetes, use of aspirin as an 
antiplatelet, NSAID use, number of co-morbidities, GDS score and serious adverse 
events were also not statistically related to MMSE change over two years. 
5.8.4. Longitudinal analyses —restricted to subjects with 
baseline MMSE over 23 
When the analyses were restricted to patients with MMSE scores over 23 at baseline 
(table 18) again using a generalised linear regression model the significant variables 
changed again to include orthostatic hypotension, previous use of ACE inhibitors, 
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piracetam use, educational level and haemoglobin level. Presence of orthostatic 
hypotension, use of piracetam, higher haemoglobin level and previous use of ACE 
inhibitors were associated with increased risk (p=0.018, p=0.047, p=0.001, p=0.016 
respectively). Education remained protective (p=0.002). 
Occurrence of a serious adverse event during the two year follow up had no significant 
impact on change in MMSE score, either for all patients or those with baseline MMSE 
over 23. 
Neither age, gender, nor SBP, DBP, sitting, standing blood pressure or total or HDL 
cholesterol were statistically significantly related to MMSE change over two year 
follow up. Presence of heart failure, atrial fibrillation, previous stroke, any type of 
previous anti-hypertensive treatment except ACE-I, alcohol consumption, heavy 
drinking, units of alcohol, current or exsmoker status, number of cigarettes per day, 
body mass index, presence of diabetes, use of aspirin as an antiplatelet, NSAID use, 
number of co-morbidities, GDS score and serious adverse events were also not 
statistically related to MMSE change over two years. 
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Table 17 Linear regression analyses showing the relationship between baseline risk factor variable and baseline MMSE score (cross-sectional) and 
change in MMSE score over two years (all patients followed for two years) 
Name 
Cross sectional analysis (MMSE at 
MO) Baseline N=909 
Longitudinal analysis (change in MMSE) 
Two year follow up N=909 
Age in years (slope) (R-square) p=0.0006 (-0.117) 	(0.013) p=0.030 (-0.075) (0.005) 
Gender sloe 	R-s•uare 	1=male/2=female 
Vascular factors 
'<0.0001 -1.375 	0.038 •=0.235 0.280 	0.002 
Average sitting systolic blood pressure mmHg (slope) (R-square) p<0.0001 (-0.068) (0.024) p=0.387 (-0.013) (0.001) 
Average sitting diastolic blood pressure mmHg (slope) (R-square) p=0.421 (0.027) (0.001) p=0.361 (-0.030) (0.001) 
Average standing systolic blood pressure mmHg (slope) (R-square) p=0.039 (-0.025) (0.005) p=0.135 (-0.018) (0.002) 
Average standing diastolic blood pressure mmHg (slope) (R-square) p<0.0001 (0.104) (0.023) p=0.394 (-0.019) (0.001) 
Orthostatic hypotension p=0.005 (-1.478) (0.009) p=0.162 (-0.732) (0.002) 
Total cholesterol mmo1/1(slope) (R-square) n=908 p=0.795 (0.028) (0.000) p=0.137 (0.164) (0.002) 
HDL cholesterol mmo1/1(slope) (R-square) n=895 p=0.002 (-0.882) (0.011) p=0.620 (0.137) (0.000) 
Heart failure present (slope) (R-square) p=0.651 (-0.699) (0.000) p=0.279 (1.679) (0.001) 
Atrial fibrillation (reported by investigators) (slope) (R-square) p=0.359 (0.569) (0.001) p=0.911 (-0.070) (0.000) 
Previous stroke (slope) (R-square) p=0.460 (-0.488) (0.001) p=0.632 (-0.318) (0.000) 
Type of previous treatment: centrally acting (slope) (R-square) p=0.378 (-0.329) (0.001) p=0.867 (-0.063) (0.000) 
Type of previous treatment: ACE inhibitors (slope) (R-square) p=0.863 (-0.042) (0.000) p=0.193 (-0.322) (0.002) 
Type of previous treatment: diuretics (slope) (R-square) p=0.402 (-0.228) (0.001) p=0.166 (0.378) (0.002) 
Type of previous treatment: beta blockers (slope) (R-square) p=0.892 (0.072) (0.000) p=0.115 (0.843) (0.003) 
Type of previous treatment: Calcium channel blockers (slope) (R-
square) p=0.132 (0.409) (0.003) p=0.045 (-0.549) (0.004) 
T se of •revious treatment: other sloe 	R-s•uare 
Lifestyle factors 
•=0.317 0.686 	0.001 •=0.971 	0.025 	0.000 
Current consumer of alcohol (slope) (R-square) p=0.024 (0.581) (0.006) p=0.804 (0.064) (0.000) 
Heavy drinker (slope) (R-square) p=0.578 (0.959) (0.000) p=0.513 (-1.135) (0.000) 
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Name 
Cross sectional analysis (MMSE at 
MO) Longitudinal analysis (change in MMSE) 
Units of alcohol per week in drinkers (slope) (R-square) n=243 p=0.036 (0.083) (0.018) p=0.610 (-0.020) (0.001) 
Current smoker (slope) (R-square) p=0.070 (1.045) (0.004) p=0.587 (0.315) (0.000) 
Exsmoker (slope) (R-square) p=0.402 (0.271) (0.001) p=0.719 (-0.117) (0.000) 
Number of cigarettes per day (slope) (R-square) n=16 p=0.702 (-0.035) (0.011) p=0.668 (0.064) (0.014) 
Body Mass Index (slope) (R-square) n=908 p=0.534 (0.021) (0.000) p=0.444 (-0.026) (0.001) 
Piracetam use reported (slope) (R-square) p=0.724 (0.230) (0.000) p=0.007 (-1.773) (0.008) 
Education cate• o 	slo se 	R-s. uare n=901 
Other 
o<0.0001 0.816 	0.043 •=0.028 0.288 	0.005 
Haemoglobin g/dl (slope) (R-square) p=0.448 (0.050) (0.001) p=0.002 (-0.204) (0.011) 
Diabetes present (slope) (R-square) p=0.695 (-0.178) (0.000) p=0.341 (-0.434) (0.001) 
Aspirin taken as an antiplatelet (slope) (R-square) p=0.052 (0.622) (0.004) p=0.395 (-0.274) (0.001) 
NSAIDs use reported (slope) (R-square) p=0.188 (0.424) (0.002) p=0.287 (-0.345) (0.001) 
Number of co-morbidities (slope) (R-square) p=0.566 (0.047) (0.000) p=0.980 (-0.002) (0.000) 
Geriatric Depression Scale score (slope) (R-square) n=408 p=0.087 (-0.080) (0.007) p=0.315 (0.046) (0.002) 
Serious Adverse Event occurring during 2 year follow up p=0.404 (-0.586) (0.001) 
Hospitalisation occurring during 2 year follow up p=0.590 (-0.371) (0.000) 
Stroke occurring during 2 year follow up p=0.200 (-3.137) (0.002) 
Myocardial Infarction occurring during 2 year follow up p=0.801 (0.871) (0.000) 
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Table 18 Linear regression analyses showing the relationship between baseline risk factor variable and baseline MMSE score (cross-sectional) and 
change in MMSE score over two years (patients with an MMSE score over 23 at baseline) 
Name 
Cross sectional analysis (MMSE at 
MO) n=745 
Longitudinal analysis (change in MMSE) 
n=745 
Age in years (slope) (R-square) p=0.038 (-0.044) (0.006) p=0.092 (-0.059) (0.004) 
Gender sloe 	R-s• uare 1=male/2=female 
Vascular factors 
•<0.0001 -0.662 	0.030 •=0.723 -0.081 	0.000 
Average sitting systolic blood pressure mmHg (slope) (R-square) p=0.060 (-0.017) (0.005) p=0.762 (-0.005) (0.000) 
Average sitting diastolic blood pressure mmHg (slope) (R-square) p=0.001 (0.064) (0.014) p=0.528 (-0.021) (0.001) 
Average standing systolic blood pressure mmHg (slope) (R-square) p=0.381 (-0.007) (0.001) p=0.349 (-0.012) (0.001) 
Average standing diastolic blood pressure mmHg (slope) (R-square) p<0.0001 (0.080) (0.041) p=0.612 (0.012) (0.000) 
Orthostatic hypotension p=0.348 (-0.327) (0.001) p=0.018 (-1.358) (0.007) 
Total cholesterol mmol/l (slope) (R-square) p=0.367 (0.060) (0.001) p=0.090 (0.187) (0.004) 
HDL cholesterol mmol/l (slope) (R-square) n=742 p=0.037 (-0.353) (0.006) p=0.560 (-0.161) (0.000) 
Heart failure present (slope) (R-square) p=0.750 (-0.299) (0.000) p=0.325 (1.521) (0.001) 
Atrial fibrillation (reported by investigators) (slope) (R-square) p=0.850 (-0.067) (0.000) p=0.438 (0.453) (0.001) 
Previous stroke (slope) (R-square) p=0.249 (0.466) (0.002) p=0.663 (-0.291) (0.000) 
Type of previous treatment: centrally acting (slope) (R-square) p=0.979 (0.006) (0.000) p=0.504 (-0.249) (0.001) 
Type of previous treatment: ACE inhibitors (slope) (R-square) p=0.339 (0.141) (0.001) p=0.047 (-0.482) (0.005) 
Type of previous treatment: diuretics (slope) (R-square) p=0.147 (0.242) (0.003) p=0.883 (0.040) (0.000) 
Type of previous treatment: beta blockers (slope) (R-square) p=0.978 (0.009) (0.000) p=0.391 (0.451) (0.001) 
Type of previous treatment: Calcium channel blockers (slope) (R-
square) p=0.450 (0.121) (0.001) p=0.259 (-0.296) (0.002) 
T •e of •revious treatment: other sloe 	R-s•uare 
Lifestyle factors 
•=0.086 -0.711 	0.004 •=0.916 -0.072 	0.000 
Current consumer of alcohol (slope) (R-square) p=0.016 (0.367) (0.008) p=0.901 (0.031) (0.000) 
Heavy drinker (slope) (R-square) p=0.750 (-0.299) (0.000) p=0.632 (-0.741) (0.000) 
Units of alcohol per week in drinkers (slope) (R-square) n=208 p=0.194 (0.032) (0.008) p=0.366 (0.037) (0.004) 
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Name 
Cross sectional analysis (MMSE at 
MO) Longitudinal analysis (change in MMSE) 
Current smoker (slope) (R-square) p=0.148 (0.474) (0.003) p=0.571 (0.306) (0.000) 
Exsmoker (slope) (R-square) p=0.096 (0.320) (0.004) p=0.371 (-0.283) (0.001) 
Number of cigarettes per day (slope) (R-square) n=16 p=0.702 (-0.035) (0.011) p=0.668 (0.062) (0.014) 
Body Mass Index (slope) (R-square) p=0.183 (0.027) (0.002) p=0.229 (-0.040) (0.002) 
Piracetam use reported (slope) (R-square) p=0.611 (-0.194) (0.000) p=0.016 (-1.507) (0.008) 
Education cate• o 	slo se 	R-s. uare n=746 
Other 
.=0.024 0.177 	0.007 •=0.002 0.406 	0.013 
Haemoglobin g/dI (slope) (R-square) p=0.010 (0.097) (0.009) p=0.001 (-0.203) (0.014) 
Diabetes present (slope) (R-square) p=0.490 (-0.187) (0.001) p=0.522 (-0.286) (0.001) 
Aspirin taken as an antiplatelet (slope) (R-square) p=0.485 (0.131) (0.001) p=0.954 (0.018) (0.000) 
NSAIDs use reported (slope) (R-square) p=0.548 (0.114) (0.000) p=0.787 (0.085) (0.000) 
Number of co-morbidities (slope) (R-square) p=0.435 (-0.037) (0.001) p=0.842 (-0.016) (0.000) 
Geriatric Depression Scale score (slope) (R-square) n=333 p=0.779 (-0.007) (0.000) p=0.099 (0.073) (0.008) 
Serious Adverse Event occurring during 2 year follow up p=0.276 (-0.607) (0.002) 
Hospitalisation occurring during 2 year follow up p=0.653 (-0.288) (0.000) 
Stroke occurring during 2 year follow up p=0.208 (-2.744) (0.002) 
Myocardial Infarction occurring during 2 year follow up p=0.682 (1.265) (0.000) 
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5.8.5. Logistic regression with the identification of cognitive 
decline and possible incident dementia as the dependent 
variable 
During the HYVET trial patients are monitored for cognitive decline and possible 
incident dementia. The MMSE as a screening test is used to identify those patients who 
have scores that fall to below 24, or a fall of more than three points in any 12 month 
period. These patients are then subject to more detailed assessment and diagnosis of 
dementia. The diagnostic information will not be available until 2010. However, the 
category of cognitive decline (an MMSE fall to <24 or >3 points in one year) has been 
used in these analyses as described below, (logistic regression) as the dependent 
variable and examined against these baseline risk factors. As patients may be included if 
their scores fall more than three points regardless of their baseline values all patients 
with two year follow up are included in this analysis. 
The number of people identified with cognitive decline over the two year period, and as 
categorised above, was 321, 35.3 percent. 
The results for each variable are shown in table 19 as an OR with 95 percent CI. 
Cognitive decline was significantly (P<=0.05) associated with age, HDL cholesterol, 
piracetam use, education, haemoglobin and use of Non-Steroidal Anti-Inflammatory 
[NSAID] medication. There was no effect of serious adverse event occurrence during 
the two years. Increased age conferred increased risk of cognitive decline with an Odds 
Ratio[OR] of 1.082 (p=0.0001). Similarly higher HDL cholesterol (OR 1.396; p=0.044), 
higher haemoglobin (OR 1.122; p=0.026) and use of piracetam (OR 2.320; p=0.027) or 
NSAID medication (OR 1.540; p=0.023) all conferred increased risk. Educational level 
was protective with each additional level of education reducing risk by 16 percent (OR 
0.836; p----0.026). There were no statistically significant relationships between identified 
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cognitive decline and gender, sitting or standing SBP and DBP, orthostatic hypotension, 
total cholesterol, presence of heart failure, atrial fibrillation, previous stroke, type of 
previous antihypertensive treatment, alcohol or cigarette consumption, heavy 
consumption or amount of consumption, diabetes, aspirin as an anti-platelet, number of 
co-morbidities, GDS, serious adverse event occurring during two year follow up. 
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Table 19: Logistic regression with the identification of cognitive decline and possible 
dementia as the dependent variable 
Name 
Logistic regression with 
identification of cognitive 
decline and possible dementia 
as the dependent variable. 
P values (OR, 95 percent CI 
given) 
Age in years p=0.0001 (1.082, 1.039 - 1.127) 
Gender female 
Vascular factors 
6=0.400 1.128, 0.852 - 1.495 
Average sitting systolic blood pressure mmHg p=0.190 (1.012, 0.994 - 1.029) 
Average sitting diastolic blood pressure mmHg p=0.753 (0.994, 0.955 - 1.034) 
Average standing systolic blood pressure mmHg p=0.302 (1.008, 0.993 - 1.022) 
Average standing diastolic blood pressure mmHg p=0.430 (0.989, 0.963 - 1.016) 
Orthostatic hypotension p=0.384 (1.307, 0.715 - 2.390) 
Total cholesterol mmol/l p=0.056 (0.878, 0.769 - 1.003) 
HDL cholesterol mmo1/1 n=895 p=0.044 (1.396, 1.009 - 1.932) 
Heart failure present p=0.826 (1.223, 0.203 - 7.355) 
Atrial fibrillation (reported by investigators) p=0.625 (0.827, 0.387 - 1.769) 
Previous stroke p=0.398 (1.388, 0.649 - 2.972) 
Type of previous treatment: centrally acting p=0.578 (1.133, 0.730 - 1.756) 
Type of previous treatment: ACE inhibitors p=0.766 (0.956, 0.713 - 1.283) 
Type of previous treatment: diuretics p=0.974 (1.005, 0.728 - 1.389) 
Type of previous treatment: beta blockers p=0.619 (0.848, 0.443 - 1.624) 
Type of previous treatment: Calcium channel blockers p=0.158 (1.258, 0.914 - 1.731) 
•e of •revious treatment: other 
Lifestyle factors 
•=0.091 0.427, 0.160 - 1.144 
Current consumer of alcohol p=0.168 (0.802, 0.587 - 1.097) 
Heavy drinker p=0.139 (5.536, 0.574 - 53.433) 
Units of alcohol per week in drinkers n=243 p=0.784 (0.993, 0.944 - 1.045) 
Current smoker p=0.982 (0.993, 0.498 - 1.976) 
Exsmoker p=0.690 (1.081, 0.738 - 1.584) 
Number of cigarettes per day n=16 p=0.990 (0.999, 0.814 - 1.225) 
Body Mass Index n=908 p=0.332 (1.020, 0.980 - 1.062) 
Piracetam use reported p=0.027 (2.320, 1.101 - 4.886) 
Education n=901 cate. o 
Other 
•=0.026 0.836, 0.714 - 0.979 
Haemoglobin unit g/dl p=0.005 (1.122, 1.036 - 1.215) 
Diabetes present p=0.162 (1.452, 0.861 - 2.445) 
Aspirin taken as an antiplatelet p=0.329 (0.823, 0.557 - 1.216) 
NSAIDs use reported p=0.023 (1.540, 1.062 - 2.235) 
Number of co-morbidities p=0.798 (0.988, 0.897 - 1.087) 
Geriatric Depression Scale score n=408 p=0.731 (0.991, 0.938 - 1.046) 
Serious Adverse Event occurring during 2 year follow up p=0.089 (0.519, 0.244 - 1.105) 
Hospitalisation occurring during 2 year follow up p=0.091 (0.428, 0.160 - 1.146) 
Stroke occurring during 2 year follow up p=0.667 (1.837, 0.115 - 29.475) 
Myocardial Infarction occurring during 2 year follow up numbers too small 
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5.8.6. Effect of educational level 
Higher educational level appeared as a significantly protective factor in both the linear 
and logistic regressions and was therefore examined further using box and whisker 
plots, both for the whole data set with two year follow up, and for those who had an 
MMSE over 23 at baseline. Figures 26 and 27 show the spread of MMSE scores after 
two year follow up and per category of education for all patients and those with baseline 
scores over 23. It can be seen that the illiterate patents had a lower mean and wider 
range of scores and that these patients were also more likely to have had baseline 
MMSE scores below 23 since the spread is much smaller in figure 27. The relationship 
between higher educational level and MMSE can be clearly seen and in both figures the 
confidence intervals show a tendency to become narrower as educational level 
increases. A similar but less striking pattern is seen when change in MMSE is examined 
by educational category, figures 28 and 29. 
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Figure 26: Box and whisker plot showing education category with MMSE score at two 
years (all patients) 
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Figure 28: Box and whisker plot showing education category with change in MMSE 
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Figure 29: Box and whisker plot showing education category with change in MMSE 
score over two years (patients with baseline MMSE over 23) 
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5.9. 	Multiple regression 
Having established which of the baseline risk factor variables were associated with a 
change in MMSE or cognitive decline, possible incident dementia, as defined by the 
HYVET protocol, the significant variables were entered simultaneously into multiple 
regression models. Since there were significant differences between the different 
countries at baseline 'country' was added into the regression models both as a series of 
dummy variables and as a categorical variable. The different methods of adjusting for 
country had no impact on the outcome. Depression variables were not entered into any 
multiple regression models as the numbers completing the depression scores were so 
low. Three main multivariate analyses were carried out: 
1: change in MMSE over two years as the dependent variable — all patients 
2: change in MMSE over two years as the dependent variable — patients with baseline 
MMSE scores over 23 
3: identification of cognitive decline (according to the HYVET protocol) as the 
dependent variable 
A final multivariate analysis included all variables (regardless of significance in 
univariate analysis) and all patients. 
5.9.1. Change in MMSE score after two years of follow up as 
the dependent variable, all patients 
Linear regression using change in MMSE score over two years as the dependent 
variable and including variables that were shown to be statistically significant when the 
whole data set was examined in the series of univariate analyses included age, previous 
CCB use, piracetam use, education and haemoglobin, see table 20. The multivariate 
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analysis resulted in a loss of significance for previous calcium channel blocker use. 
Age, piracetam use, haemoglobin and education retained significance. As previously 
only higher education was protective (p=0.004) with increasing age, (each education 
category conferring a lesser fall in MMSE over two years of 0.109 of an MMSE point). 
Higher haemoglobin, (each gm/di increase was associated with a larger fall in MMSE of 
0.111 of an MMSE point), and use of piracetam both conferring increased risk. Results 
in the table below occurred with country as dummy variables. Country used as a 
categorical variable produced similar results (not shown). 
Table 20: Multiple linear regression with change in MMSE score after two years of 
follow up as the dependent variable, all patients. 
Including significant risk factors remaining after all cohort and all 
risk factor variables (except depression score) plus country entered 
into the model (P value and slope) 
N=900, R-square = 0.030 
Age p=0.031 (-0.071) 
Previous Calcium channel blockers p=0.122 (-0.052) 
Piracetam use p=0.015 (-0.080) 
Education category p=0.004 (0.109) 
Haemoglobin gm/dl p=0.002 (-0.111) 
5.9.2. Change in MMSE score after two years of follow up as 
the dependent variable, patients with baseline MMSE 
scores over 23 
A further multivariate linear regression was carried out using change in MMSE score as 
the dependent variable and including only those patients that had MMSE scores >23 at 
baseline and those variables that were significant in the univariate analyses, see table 
21. The variables that were included were previous ACE-I use, orthostatic hypotension, 
piracetam use, education and haemoglobin. The multivariate analysis found that 
previous ACE inhibitor use and piracetam use lost their significance. Orthostatic 
hypotension and higher haemoglobin were associated with increased risk and education 
with decreased risk. Results in the table below occurred with country as dummy 
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variables. Country included as a categorical variable produced the same results (not 
shown). 
Table 21: Multiple linear regression with change in MMSE score after two years of 
follow up as the dependent variable, patients with baseline MMSE scores over 23 
Including significant risk factors remaining after all cohort with 
baseline MMSE>23 and all risk factor variables (except depression 
score) plus country entered into the model (P value and slope) 
N=745, R-square = 0.043 
Previous ACE inhibitors p=0.060 (-0.071) 
Orthostatic hypotension p=0.017 (-0.088) 
Piracetam use p=0.077 (-0.064) 
Education category p<0.0001 (0.187) 
Haemoglobin gm/dl p<0.0001 (-0.152) 
5.9.3. Multiple logistic regression with identification of 
cognitive decline, according to HYVET trial protocol as the 
dependent variable 
A multiple logistic regression with the identification of cognitive decline, possible 
incident dementia as the dependent variable was run and included age, HDL cholesterol, 
education, haemoglobin, NSAID use and country as above. See table 22. This analysis 
found that older age remained as a significant risk factor conferring 8.1 percent 
increased chance of falling into the cognitive decline group for each additional year of 
age. Higher HDL cholesterol, and higher haemoglobin level also conferred increased 
risk at 3.6 percent and 13.8 percent respectively. NSAID use reduced risk by 43.2 
percent. Education lost its significance but the odds ratios for the lower levels are 
clearly higher than those for the highest level, despite the lack of significance. One 
country became significant in this analysis, patients in China were at over three times 
the risk compared to those in other countries (p=0.047). 
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Table 22: Multiple logistic regression with identification of cognitive decline, according 
to HYVET trial protocol as the dependent variable 
Including significant risk factors remaining after all cohort and all 
risk factor variables (except depression score) plus country entered 
into the model (OR, 95 percent CI) 
N=888 
Age p<0.0001 (1.081, 1.037-1.127) 
HDL cholesterol p=0.036 (1.472, 1.026-2.112) 
Education 
(Illiterate) 0 p=0.011 
(Primary) 1 p=0.060 (4.225, 0.940-18.998) 
(Secondary) 2 p=0.527 (1.282, 0.594-2.764) 
(Tertiary) 3 p=0.731 (1.139, 0.542-2.393) 
(Higher education) 4 p=0.271 (0.642, 0.292-1.412) 
China P=0.047 (3.283, 1.015-10.622) 
Haemoglobin gm/dl p=0.001 (1.138, 1.060-1.264) 
NSAID use p=0.042 (0.668, 0.453-0.986) 
In order to examine whether a different result would have been obtained had all baseline 
risk factor variables been entered into the multiple regression, a linear regression was 
carried out for all patients and using all variables except depression score due to the 
lower numbers of patients completing the depression questions. Older age, higher 
standing systolic blood pressure, presence of orthostatic hypotension, piracetam use and 
higher haemoglobin all conferred increased risk with education showing a trend 
although not significant as a protective factor. None of the other variables used in these 
analyses approached significance. 
Table 23: Multiple linear regression with change in MMSE score after two years of 
follow up as the dependent variable, all patients and all variables. 
Including all risk factor variables (except depression score) plus 
country entered into the model (P value and slope) (only 
significant variables reported) 
N=884 R-square=0.033 
Age p=0.050 (-0.067) 
Average standing systolic blood 
pressure p=0.017 (-0.147) 
Orthostatic hypotension p=0.008 (-0.112) 
Piracetam use p=0.014 (-0.084 
Education category p=0.009 
p=0.004 
(0.104) 
(-0.112) Haemoglobin gm/dl 
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5.10. Summary 
Only one risk factor appeared consistently in each longitudinal multivariate analysis and 
that was haemoglobin with higher haemoglobin levels conferring increased risk in all 
analyses. 
Older age conferred increased risk in all except the group of patients with MMSE scores 
over 23 at baseline; these were selected out as more cognitively intact and also included 
fewer patients. Piracetam use was a risk factor when all patients were included and 
higher education protective in all except the logistic regression with the identification of 
cognitive decline as the dependent variable. However, in this latter analysis higher 
education showed a similar protective pattern and Chinese nationality became 
significant. The Chinese patients in the data set analysed here are more likely to be 
illiterate than those in the other countries (see table 12). Previous anti-hypertensive use 
lost its significance in the multivariate analyses, regardless of drug type. NSAID use 
appeared as protective in the multivariate logistic regression only and orthostatic 
hypotension as a risk factor in patients with a baseline MMSE over 23 and all patients 
with all variables included. Finally, the only risk factor to appear in the analysis 
including all risk factor variables, regardless of their significance in univariate analyses, 
was standing systolic blood pressure where each millimetre of mercury higher in 
pressure was associated with a greater fall in MMSE over two years of 0.147 of an 
MMSE point. 
Despite a large number of statistical tests the majority remained significant when 
reviewing these with a higher threshold for significance (p<0.01) and although each set 
of univariate analyses and multivariate analyses produced a slightly differing list of 
associated factors or risk/protective factors there were also high levels of overlap. Age, 
educational level, haemoglobin level, HDL cholesterol level, piracetam use appear 
several times. 
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6. Chapter 6: Discussion 
The discussion is divided into a discussion of the sample, an analysis of each 
statistically significant finding followed by a general discussion of the results, possible 
explanations, an analysis of the risk factors useful to take account of in the very 
elderly, and finally a discussion of limitations and strengths and consideration of wider 
and further implications. 
6.1. 	Representativeness of the sample 
When comparing the patients who remained in the study for the two year follow up 
period with those that did not, there were some significant differences. Leaving the 
study was predominantly due to patient refusal to continue or patient mortality. Due to 
the Data Protection Act it was not possible to collect further data with regard to the 
outcome for the patients who refused to continue and it may be that they went on to 
suffer from higher levels of morbidity and mortality. Certainly they were older and 
frailer with higher levels of diabetes and atrial fibrillation. Patients without follow up 
also had lower cognitive function scores at baseline and although this may have been 
due to higher levels of illiteracy it may also indicate failing cognition. It has been 
suggested that the lack of significant findings in similar studies with regard to blood 
pressure and cognition may be due to patients with early falling cognition leaving 
follow up prior to further or confirmatory assessment [107]. This may well have 
happened in this data set as the patients who left the study had a lower mean body 
mass index, lower total cholesterol and lower haemoglobin values, all of which may 
have been associated with existing early dementia, despite no diagnosis, rather than as 
risk factors for the development of dementia. Patients who left also scored more highly 
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on depression scores which could indicate early dementia or cause the lower cognition 
scores via apathy. Higher depression scores may also reflect higher levels of co-
morbidity. Patients remaining in the study were more likely to be taking NSAID 
medication and less likely to have taken anti-hypertensives in the category 'other' prior 
to study entry. Different levels of NSAID use may reflect the cognitive ability of the 
patients remaining in the study as previous work has suggested that it is the cognitively 
intact patients who are more likely to take and to be prescribed NSAIDS [351]. It may 
also be that patients with lower educational levels have less available income and are 
less likely to access such medication [438-440]. 
Level of income may also explain the high levels of 'other' medication. 'Other' 
medication may include traditional herbal or local remedies which may be cheaper and 
more likely to be accessed by patients with lower levels of education. This may be 
particularly true in rural Chinese patients. Finally standing diastolic blood pressure 
was slightly and almost significantly (p=0.052) lower in the group without follow up 
possibly also pointing to falling cognition since blood pressure is thought to fall just 
prior to dementia [88], however, the difference was only seen in standing diastolic 
values and despite almost reaching significance was only one millimetre of mercury. 
This has also to be viewed in the context of accuracy of blood pressure measurement, 
the majority of centres used mercury sphygmomanometers which are only accurate to 
two mmHg as well as the low clinical relevance of one millimetre of mercury. 
When comparing the different countries represented in the patient group with two year 
follow up data there were also some significant differences. It should be remembered, 
though, that the majority of the patients in the two year follow up were Bulgarian and 
relatively few Western Europeans were represented. This was due to differential 
recruitment and the timing of country entry into the study. Bulgaria was one of the first 
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countries to gain regulatory approvals and to enter patients. Patient recruitment was 
also easier in Eastern European countries where populations were less likely to already 
be receiving treatment for their hypertension [441] and where healthcare resources 
may be scarce and expensive to the patient group [438-440]. The significant 
differences may also reflect sociocultural differences in patient doctor relationships 
and willingness to discuss ailments, for example the Western Europeans and the 
Russians reported the most co-morbidities whilst the Chinese reported least. The 
Western Europeans also contained the highest proportion of alcohol consumers whilst 
China had least. It was surprising that the Russians did not report high levels of 
drinkers but it may be that heavier consumption at a younger age or access to poor 
quality alcohol has meant that fewer drinkers are present in the very elderly population 
[442]. Western Europeans may also have higher levels of income allowing them to 
access better quality alcohol. Interestingly the Bulgarians were most likely to take 
aspirin followed by Western Europe, there is no obvious reason why this would be the 
case unless it indicates a prescribing preference in Bulgaria in patients felt to be a risk 
of thrombosis. Also interesting were the haemoglobin levels which were surprisingly 
highest in the Chinese although only by 0.97gm/d1 but they also showed the highest 
standard deviation and it may be that there were undiagnosed cases of polycythemia 
included in this population. The Chinese also had the lowest MMSE values, followed 
by the Romanians and this is likely to reflect their relatively lower levels of education 
[319-322]. All countries showed a fall in mean MMSE over the two years. 
When comparing the participants in accordance with age and gender it was found that 
the older groups were less well represented and in line with national and international 
demographics [443] for the elderly population more women were recruited than men. 
This resulted in few older men and would therefore indicate caution in interpreting 
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results from this group. However, as would be expected, the older participants had 
higher systolic blood pressure [444] worse depression scores [414] and were less likely 
to consume alcohol. The latter may reflect the relatively greater affect that alcohol has 
with increasing age [259], increasing frailty decreasing the desire to consume alcohol 
or indicate survival in non-drinkers. Drinkers were also more likely to be male in these 
age groups possibly reflecting cultural and cohort effects. Total cholesterol was highest 
in the older men and lowest in the older women although it is not clear why this would 
be so, unless it indicates dietary factors and greater life skills present in the elderly 
women such that they can maintain healthier diets. Although the numbers were too 
small to test statistically, educational level was highest in men with more women 
illiterate. This was as expected and reflects the higher priority previously given to 
educating males and therefore now appearing in these age groups. Also as expected 
and as reported widely in the literature, depression scores were higher in women and 
people with older age [414,445] and the MMSE scores higher in males and those of 
younger age. This is likely to reflect the higher educational levels of the males, 
possibly also their higher occupational attainment through working life and any fall in 
cognitive function with ageing. Finally haemoglobin levels were highest in the 
younger men indicating that the sex difference in haemoglobin level is maintained into 
old age [446]. 
With regard to the applicability of the cognitive function testing, the mean and median 
MMSE scores are as would be expected from a population of this age [400] and also fit 
with the educational level of the participants. The country with the lowest mean 
MMSE also had the lowest educational levels and the mean MMSE in very elderly 
populations with education less than five years. has been shown to be 20 for those aged 
80-84 and 19 for those of 85 years and above [400]. Although population studies may 
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include participants with cognitive decline and dementia and therefore err on the low 
side when reporting mean values it could be argued that the Hyvet patients could show 
lower MMSEs due to their hypertensive status [111] despite excluding patients with 
clinically diagnosed dementia at baseline. It may also be that patients have been 
entered into HYVET without diagnosed dementia but with the beginnings of cognitive 
decline and that this had not yet been noticed. The majority of the HYVET patients 
live with their relatives and living in a familiar environment with regular carers to help 
may disguise failing cognition to both the patient, the family and the investigator. This 
may help to explain some of the low scores that were seen in the HYVET population. 
It may also be culturally important to maintain the elderly relative in the home [447] 
something which may also make diagnosis harder. Another possibility is that patients 
may become irritated with the MMSE coming as it did at the end of the consultation 
and after blood pressure measurement blood tests, weight measurement, discussion of 
co-morbidities, events since the last trial visit and concomitant medication and 
possibly an ECG. Patients who were not feeling well or who were tired and fed up may 
have been disinclined to answer questions or to try to get the answers correct. 
Although there were relatively few missing values there were MMSEs where the 
patient answered many of the questions incorrectly resulting in a low score. This may 
also help to explain the size of changes in cognitive function over time, both falls and 
rises, as a patient may be interested and alert one year on the day of the test, tired and 
ill a year later and better the year after that. A serious adverse event occurring prior to 
cognition assessment may have had a negative effect on performance on cognitive 
testing. Although serious adverse events did not have an impact on cognition overall in 
the two year follow up group this may be due to the low rate and would not preclude 
an effect on the cognition of the individual patient concerned. Certainly studies 
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assessing MMSE trajectories have shown that the MMSE can rise as well as fall even 
where the overall trend is a falling MMSE [397,448]. Other factors that could have 
influenced the score include the administration and although instructions and training 
were provided to the investigators it is possible that administration was not consistent, 
that another member of the site study team administered that MMSE on occasion or 
even that patients were entered into the study with early dementia. The latter is 
worrying, however, all patient consent forms were checked by study monitors and 
investigators repeatedly trained and reminded of good clinical practice guidelines and 
the need to follow the protocol. This is the most robust method that would be 
employed to ensure consistency, accuracy and to reduce bias and systematic error. 
Despite the unavoidable nature of research requiring selection of a sample from the 
population, the data set used here would seem to be a representative sample of the very 
elderly hypertensives that would be seen in clinics and at risk from dementia and 
cognitive decline. Any conclusions drawn here, then are likely to be credible and 
applicable, at the least, to a large proportion of the very elderly global population. 
6.2. 	Risk factors 
6.2.1. Baseline data (Cross sectional analysis) 
Although there were differences in the findings for the relationships between baseline 
MMSE and risk factors for (i) the whole group and (ii) those with MMSE over 23, 
both analyses found age, gender and education to be significant. As shown in the 
literature older age [17,18,20,21], less education [314,315] and female sex [18,40] 
were related to lower MMSE scores in cross sectional analyses. Interestingly vascular 
factors differed with lower diastolic pressure in the group with MMSE over 23 and 
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higher systolic pressure plus lower standing diastolic pressure in all patients both 
related to lower MMSE. Higher pulse pressure may therefore be associated with lower 
MMSE, but there is no clear reason why higher systolic pressure would be associated 
with lower cognition in all patients as it would be expected that the lower MMSE 
scores indicate failing cognition and therefore lower pressures may be expected to be 
seen [93]. However, if the lower MMSE scores merely reflect normal values for an 
uneducated elderly group and do not indicate a cognitive decline then it may just be 
that the patients with lower MMSE values are older and therefore have the higher 
systolic pressures allowing this finding to show. Orthostatic hypotension was also 
associated with lower MMSE in the 'all patient' group and this too rises with age and 
was not present in the group with MMSE over 23. It could also be that orthostatic 
hypotension indicates a failing ability to maintain homeostasis and that this too could 
indicate early cognitive decline and in itself impact on cognitive function via 
fluctuating cerebral perfusion. 
HDL cholesterol was significant in both analyses such that higher HDL was associated 
with lower MMSE scores. It is not clear why this would be the case, however, several 
studies have been published showing that high HDL and low total cholesterol may be 
related to incipient cognitive decline [177,183,187]. Consumption of alcohol was 
associated with higher MMSE in both analyses and this probably reflects the ability of 
the healthy and cognitively intact to access alcohol and to be able to cope with its 
effects. Also reflecting this, for 'all patients' the amount was also significant with 
more alcohol better than less although not above the weekly limits recommended in 
the UK. 
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Finally, in patients with MMSE over 23 higher haemoglobin was associated with 
higher baseline MMSE possibly indicating better health and good diet. 
6.2.2. Risk factors for fall in MMSE and identification of 
cognitive decline (univariate analyses) (Longitudinal 
analysis) 
There were risk factors identified in common between the linear analyses including all 
patients compared to those with a baseline MMSE over 23. 
When considering the change in MMSE scores over two years, for all patients the risk 
factors for greater cognitive decline, (larger fall in MMSE) were; increasing age, lower 
educational level, higher haemoglobin level, use of piracetam and previous treatment 
with calcium channel blockers. 
The relationship between increasing age, lower educational level and cognitive 
function assessment were as expected given the weight of evidence already present in 
the literature. More interesting were the findings for higher haemoglobin level and 
piracetam use. It may be that the former results in less effective cerebral perfusion and 
higher levels of microemboli that impact on cognition without other symptoms, 
although there is no clear data in the literature regarding higher haemoglobin and 
increased risk of cognitive decline. With regard to piracetam use, it seems likely that 
this indicates subjective memory problems and an expression of this in purchasing 
piracetam or expressing concern to a medical practitioner resulting in a prescription. 
Subjective memory impairments have been shown to relate to later objective decline 
[449]. Piracetam use itself has not been shown to have a robust positive effect on 
cognitive function although it has been used in this context [374]. Calcium channel 
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blocker use may reflect a longer history or higher level of previous hypertension which 
in turn may have conferred increased previous risk. It may also be that the Syst-Eur 
trial resulted in a preference for calcium channel blockers to treat hypertension in those 
with incipient memory problems [112]. 
When the analysis was restricted to those patients with baseline MMSE over 23 age 
lost its significance although lower education, higher haemoglobin and piracetam use 
remained. Previous use of ACE inhibitors increased risk as did presence of orthostatic 
hypotension. The restriction to those with higher MMSE may have acted to reduce the 
age range and thus removed the significance in the univariate analysis. It is not clear 
why previous use of ACE inhibitors emerged as significant with the significance for 
calcium channel blocker use disappearing, it may reflect prescribing changes in a 
population group with different characteristics. 
When the data were analysed using logistic regression and relating each risk factor 
with later 'cognitive decline' (as defined by the HYVET protocol) as the dependent 
variable this regression also found that older age, lower education, higher 
haemoglobin, higher HDL cholesterol and piracetam use were all significantly related 
to increased risk. Use of NSAIDs were also associated with an decreased likelihood of 
falling into the protocol defined category of cognitive decline and higher total 
cholesterol almost reached significance as a protective factor. The use of NSAIDs as 
protective may reflect the intimation from epidemiological studies, i.e. that patients 
receiving prescriptions for NSAIDs are more likely to be cognitively intact [357] but 
may also indicate that the patients with MMSEs falling below 24 or more than three 
points may have been less well and less likely to have been prescribed NSAIDs at 
baseline [415]. A maintenance of homeostasis and usual diet may result in higher total 
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cholesterol and lower HDL cholesterol associating with less cognitive decline at 
follow up. 
6.2.3. Key risk factors adjusted for confounding (multivariate 
analyses) and hypotheses 
After adjusting for potential confounders in a multivariate linear model the risk factors 
that emerged differed from those found at midlife. The most ubiquitous risk factors 
proved to be high haemoglobin levels and lower education. appearing in all three 
analyses although education was no longer significant when analysed in the multiple 
logistic regression. Age and piracetam use were risk factors when all patients were 
entered into the analysis suggesting that they are related to the lower baseline MMSE. 
Older age is known to be associated with decline in MMSE, possibly without incipient 
dementia and it could be that the older patients are more likely to have lower baseline 
MMSE, more likely to take medication for memory problems and more likely to 
deteriorate over two years. Although estimates vary a large majority of patients with 
mild cognitive impairment do progress to dementia [449] and this would suggest that 
the older patients with lower MMSEs were at higher risk. In the group with baseline 
MMSE scores over 23, orthostatic hypotension was shown to be significant and whilst 
it is clear that this could indicate failing homeostasis and inconsistent cerebral 
perfusion it is not clear why this should be restricted to the group with the higher 
MMSEs unless they were more active and able to stand more quickly thus prompting 
an orthostatic fall that was not present in the frailer slower patients with the lower 
MMSE. 
The multiple logistic regression analysis highlighted age, education and haemoglobin 
but also found higher HDL and country status 'China' to be a significant risk factors. 
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This was the only significant effect of country and the significance was borderline. 
This is despite the fact that all analyses, logistic and linear, were adjusted for country 
and the analysis run with country as a categorical variable and as a series of binary 
`dummy' variables. The Chinese were more likely to be illiterate and have lower levels 
of education, since an MMSE of 20 could be considered within the normal population 
range for a poorly educated group [400] it is likely that proportionally more of the 
Chinese patients began HYVET close to the score of 24 and were thus more likely to 
fall into the category for possible incident dementia and cognitive decline. This would 
apply to this dependent variable particularly and may explain why country status did 
not occur in the other analyses with change in MMSE as the dependent variable. High 
HDL remained significant and may reflect dietary changes, the literature is varied with 
regard to the different cholesterols and their effects on cognition and whilst younger 
age groups show increased risk from high total cholesterol older populations may 
differ. NSAID use was protective in the multivariate analysis and as in the univariate, 
is likely to reflect the cognitive capacity of those that are receiving prescriptions for 
this rather than any effect of the medication upon cognition directly. 
Finally when, all patients and all risk factors were entered into a multiple regression 
model one additional risk factor emerged as significant, that of standing systolic blood 
pressure with higher pressure conferring increased risk. That high blood pressure is a 
significant risk factor is of no surprise but that it should only show in this analysis 
suggests that it is not playing a large part in the risk factors, or is masked by other risk 
factors, in any case, as it is treatable, it should be borne in mind when considering the 
wider and further implications of this finding when depending on the results of the 
HYVET main trial, will indicate whether hypertension should be treated in this study 
population at all. Another factor that should be taken into account is the risk of 
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significant findings with multiple testing although strongly significant values may still 
represent true relationships. 
6.2.4. Hypotheses 
Sociodemographic & lifestyle:  
Lower levels of education, older age and female sex were associated with a larger fall 
in MMSE over two years and higher likelihood of incident cognitive decline and 
possible dementia. Other sociodemographic factors were not as expected. Non-
drinkers were not significantly different to drinkers in any longitudinal analyses and 
heavy alcohol consumption had no significant relationships with longitudinal cognition 
scores. Smoking status also had no significant relationships with longitudinal cognition 
scores. It is possible that this very elderly group were survivors and less likely to 
smoke and drink, possibly also more likely to have given up or reduced consumption 
with ageing. 
Clinical:  
Only higher haemoglobin was associated with a larger fall in MMSE over two years, 
higher likelihood of incident cognitive decline and possible dementia. BMI, lower 
haemoglobin, total cholesterol, HDL cholesterol, number of co-morbidities, depression 
scores and serious adverse events had no significant relationships with longitudinal 
cognition scores. It may be that the participants who enter and remain in a clinical trial 
are better able to maintain their diet and less likely to suffer from co-morbidities and 
depression than the general elderly population and that described in epidemiological 
studies. The number of participants providing depression scores was also lower than 




Orthostatic hypotension was associated with a larger fall in MMSE over two years 
only when the analysis was restricted to patients with baseline MMSE scores over 23. 
Previous stroke, heart failure, diabetes and blood pressure variables had no 
longitudinal relationship with cognitive function Again, possibly due to the likelihood 
that trial participants are healthier than the general population, there were low numbers 
of patients with previous stroke, heart failure and diabetes and the range of blood 
pressures was by necessity limited by the HYVET trial inclusion criteria. These factors 
may have made significant findings less likely although as trial follow up continues 
further relationships may emerge. 
Drug treatment:  
Lack of previous antihypertensive use was not associated with longitudinal cognition 
scores although previous use of calcium channel blockers (in the analysis of all 
patients) and ACE inhibitors (patients with baseline MMSE score over 23) were 
associated with larger fall in MMSE over two years. Patients using piracetam at 
baseline were more likely to show a larger fall in MMSE over two years, higher 
likelihood of incident cognitive decline and possible dementia, and patients not using 
NSAIDs at baseline were more likely to have higher likelihood of incident cognitive 
decline and possible dementia. Statin, aspirin use and use of Ginkgo Biloba had no 
significant relationships with any longitudinal cognition scores. The numbers of 
patients taking different drugs and different classes of anti-hypertensives were small, 
despite this, significant relationships were seen for the noteworthy exceptions of 
calcium channel blockers, ACE-I, NSAIDs and piracetam. 
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Hypothesis for predictor risk factors when adjusted for all confounding factors 
The risk factors that were associated with cognitive decline and MMSE fall in the very 
elderly were education and higher haemoglobin followed by piracetam use, orthostatic 
hypotension, older age, higher standing systolic blood pressure, higher HDL 
cholesterol, lack of NSAID use and Chinese status all identified variously as additional 
risk factors. 
6.3. 	Risk factors for cognitive decline in the very elderly 
Older age put individuals at risk from greater fall in MMSE over the subsequent two 
year period and conferred an increased risk of identification of possible incident 
dementia, cognitive decline, at least as detailed within the HYVET protocol. The 
HYVET protocol was designed to take a pragmatic approach to this identification and 
to mirror the usual care settings where possible. It seems likely therefore that this 
HYVET approach can be used as a proxy for the detection of patients for further 
assessment in real world situations. Lower educational level continues to increase risk 
even in the very elderly group and this is likely to be a larger issue in the developing 
world. Neither age nor, realistically, education can be amended in the very elderly 
population. Vascular factors though invite intervention since, higher blood pressure (at 
least standing systolic pressure) and orthostatic hypotension were seen to increase risk, 
the former only in those with baseline MMSE scores over 23 and the later only in one 
multiple analysis where all risk factor variables were entered, thus a large number of 
tests took place and the risk of a chance significant finding increased. 
More robust were the findings that piracetam use was associated with fall in MMSE, 
although it was not significant when only patients with baseline MMSE over 23 were 
considered or when possible incident dementia, cognitive decline was used as the 
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dependent variable. This suggests that, at the least, subjective or early objective 
memory problems prompting patients to seek piracetam do predict change in MMSE 
and although this would be useful to take account of, it is insufficient to use as a robust 
risk factor for the identification of patients at risk from incident dementia, at least over 
a two year period. In contrast, higher HDL cholesterol and lack of NSAID use did 
predict risk of falling into the category for possible incident dementia and cognitive 
decline although neither predicted MMSE fall over two years. For this reason it is 
suggested that they too are taken into account but not used as robust risk factors in the 
identification of at risk patients. The presence of China as a risk factor for 
identification of possible incident dementia, cognitive decline has been discussed 
already and is thought likely to reflect the relatively lower baseline MMSE scores of 
the Chinese and their proximity to the cut-off value or 24/23. The single most robust 
risk factor, where intervention may be possible, appearing in all analyses was the 
presence of higher levels of haemoglobin, such that for every gram per decilitre 
increase the risk of falling into the category for possible incident dementia, cognitive 
decline rose by 16 percent. This was a surprising outcome as, although the literature 
shows an increased risk of mortality with raised haemoglobin there is little evidence 
with regard to cognitive decline. It is plausible, however, that this could occur and 
there is literature suggesting that 'normal' haemoglobin levels are not necessarily 
normal within the elderly [331,332]. Although this focused on anaemia, it is possible 
that regulation of haemoglobin becomes less certain with aging and that this results in 
higher as well as lower values placing the elderly at risk from poorer cerebral 
perfusion and generation of microemboli. 
When assessing an elderly patient over the age of 80, therefore, high haemoglobin, 
older age and low education are key factors that confer increased risk. Additional 
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factors, if present may strengthen the assessment of risk and these include piracetam 
use, higher HDL cholesterol and lack of NSAID use. If patients present with an 
MMSE over 23 then presence of orthostatic hypotension and educational level should 
be considered 
6.4. 	Limitations and strengths 
The study has recruited the very elderly in many sites and from a global population 
thus hopefully presenting results pertinent to the globally ageing population and 
applicable to many countries despite differing healthcare systems. The study used 
pragmatic approaches to the assessment of cognitive change and the identification of 
possible incident dementia, cognitive decline. Such approaches worked well in the 
countries involved in HYVET and the data are being gathered for the final diagnoses 
of dementia. This implies that a similar method could feasibly be used internationally 
even without membership of a research project in order to highlight patients at risk in 
usual clinical practice. Although this is a benefit, it can also act as a limitation. 
Because of the many dispersed study sites based within different cultures and 
healthcare systems it was difficult to be sure of standard administration and data 
collection. All study sites were monitored both by local monitors based in country and 
by trial co-ordinating staff. Regular training and follow up training materials were also 
provided by co-ordinating centre staff, however, as in any multi-site project ensuring 
that each patient was examined in the same way and across the time of the study was 
difficult. Different healthcare systems may also introduce bias, for example healthcare 
systems where acetylycholinesterase inhibitors are available may be more geared up to 
identifying or have a greater awareness of dementia. In countries where the majority of 
elderly patients live with family it may be harder to notice cognitive failings since the 
environment will be familiar to the patient and the carers will absorb the deficits. In 
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countries where life expectancy has not regularly reached 80 before or where resources 
are scarce there may also be a lack of awareness of, or interest in, dementia and 
cognitive decline, particularly as the patients are elderly and no robust treatments 
available. All of this may result in study site personnel being less efficacious or less 
interested in the administration of the MMSE and any subsequent assessments. In 
addition to this, using the same instrument across all patients was a necessity but could 
have caused bias in the different populations. 
The MMSE is the most frequently chosen tool for this kind of research and translated 
versions were made available to us by a previous study, thus allowing a direct 
comparison, however, as a full neuropsychological assessment of cognition the MMSE 
is lacking. The MMSE is a brief global assessment of function and cannot hope to 
collect the data of a full neuropsychological examination or even a more 
comprehensive screening test, however, there were no internationally validated 
neuropsychological test batteries available in the languages that were required still less 
ones that required minimal training at the time of study start. Even if such tools had 
been available the staff equipped to carry out such exam would have been few and far 
between in some of the rural areas where the study was running if indeed they existed 
at all at the beginning of the study in 2000. That the study encompassed rural as well 
as urban centres is a positive point, but this too may have had an impact on the MMSE. 
There is some evidence that rurality of participants and/or, education and appropriate 
translation may have impact on results [318,319]. Illiteracy is more common in 
developing countries and may mean that a patient has not held a pen resulting in 
difficulty completing the reading, writing and drawing subtests of the MMSE and 
giving a true score from 27 rather than 30. Patients in this category who had falling 
cognition would still have been identified with the protocol requirement of a fall of 
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more than three points in one year, however, this would have affected their baseline 
scores. There is currently no consensus in the literature with regard to the use of the 
MMSE in such patients, however, at least in this study, decline should have been 
highlighted via change in score. The very elderly nature of the group may have 
prevented the practise effects often seen in younger populations tested with the MMSE 
although many of the participants showed rising scores. A further issue in the very 
elderly may be fluctuating concentration and feelings of ill health. Since the MMSE 
was only collected annually a relatively short period of ill health could have an effect 
on one year of cognitive function assessment. It could also be argued that there were 
some ceiling effects in this study, however, it would not have been possible to find a 
test sensitive to higher functioning individuals who had falling cognition but remained 
with a score above 30, and the median and mode values for the baseline MMSE were 
not 30 but 27 and 28 respectively suggesting that ceiling effects were not a large 
problem. In addition to this the assessment of change in MMSE and the use of the 
three point annual fall to identify those at high risk of possible incident dementia, 
cognitive decline should have helped to ameliorate ceiling effects seen with the 
MMSE. The low MMSE scores have been discussed above and could easily indicate a 
cognitively intact but poorly educated and ill patient having a bad day, despite this it 
could be that patients entered the study with early but undiagnosed dementia. Having 
said that, a minimum MMSE criteria would not prevent that happening and the training 
and checking of informed consent and the running of the study to good clinical practise 
standards should have prevented any clear dementia cases entering the study. 
The patients who participate in research also raise the issue of applicability of findings 
as they are likely to differ from the normal population. Usually people who participate 
in research are a more selective group than the general population and are in better 
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health as they have to fit within study inclusion criteria. Research study exclusion 
criteria are likely to reject those who are unwell unless it is with the condition under 
investigation. This can often mean that the research subjects are also from higher 
socioeconomic backgrounds which may well influence their own health awareness, 
dietary and leisure choices and living arrangements all of which may have a 
relationship with health. Whether this still applies in the very elderly population is 
unclear, particularly as those having reached this age will be to a greater or lesser 
degree survivors and carry with them the particular characteristics that have made this 
the case. This may well be a feature of the population investigated here and it could be 
argued that the very elderly Chinese will have had to manifest the greatest survivor 
characteristics having had to overcome the most historical adversity to reach eighty. 
The former eastern European countries may well be next with the western Europeans 
possibly standing a higher chance of reaching eighty even without strong survivor 
characteristics. This seems to borne out in so far as it can be assessed from the data 
available. In the UK the trial participants are few but have fairly low levels of 
education, the Finns also have the majority of trial participants with primary education 
only as do the French and this would suggest that trial participants in Western Europe 
are surviving despite being likely to fall within low socioeconomic groups, 
traditionally the groups least likely to survive [450]. The Russian population in the trial 
have the most participants who received tertiary (equivalent to university) education at 
35.3 percent with the Bulgarians and Romanians next at 17.2 percent and 17 percent 
respectively. The eastern European populations participating in the trial are more 
highly educated and likely to have higher socioeconomic status within their population 
limits and be those more likely to reach advanced age. The Chinese are the only 
country that go against this trend with very low levels of education, however, it must 
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be remembered that they had an additional upheaval in the cultural revolution and it 
may be that as a result education is not as closely linked to socioeconomic status in 
China. Following on from this is the interaction of multiple factors, cultural, education, 
dietary, behavioural and socioeconomic factors and the likely impact that they may 
have on assessment of cognition, participation and cohort within the population. The 
ageing population will itself change as successive generations with different life 
experiences progress through to old age [212]. However, these differences too are 
unlikely to change dramatically in the near future and the study findings should remain 
applicable to the very elderly populations at least in the participating countries. 
Once patients are recruited into the trial, those who remain and are followed up for 
longest also tend to be distinct from those who leave. Those who leave studies tend to 
be older and in poorer health than those who remain [107] and this can have an impact 
on study results. This is particularly pertinent here since those that leave studies tend to 
have lower cognitive functioning and may well go on to develop dementia but are not 
assessed and counted as they have declined to continue. This has been recognised and 
an attempt made at assessing the impact of this in a double blind trial, particularly as it 
is the placebo group in such a trial who may be most likely to leave [107]. The authors 
found that had all patients been available for follow up, and had similar numbers gone 
on to suffer from dementia as in the placebo and active follow up groups it was likely 
that a significant result may have been obtained and the statistical power of the trial 
increased. 
Finally the study also depends on the trial investigators to report information with 
regard to the risk factors considered. The information presented is as would be 
expected from a very elderly population but may be influenced by the frequency of the 
study visits (annually for cognitive function and every six months for the main trial). 
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Patients suffering from events between visits are required to remember these and 
report them to the site investigator. It could be that some of these events were resolved 
or forgotten prior to the next visit and that serious adverse events played a greater part 
than would be concluded from these results. Again, the trial investigators are subject to 
regular training and monitoring with regard to the reporting of events and so it seems 
unlikely that many would be lost. 
The study follow up is, however, another issue that could be considered a limitation. 
Although a two year follow up is relatively long in terms of the average life 
expectancy of an 80 year old it may be that cases of decline were missed because the 
follow up was too short to fully evaluate the change in MMSE. It has also been 
suggested that longer treatment, at least with antihypertensives, could further reduce 
risk [451]. Given that the aim here was to identify the risk factors that were associated 
with cognitive decline, possible incident dementia and fall in MMSE over two years 
this was acceptable. Assessment of patients to identify decline for the forthcoming two 
years would be useful in clinical practice, raising as it does, different risk factors to 
those found in midlife. As the HYVET trial is ongoing further evaluation of risk 
factors can be carried out related to longer time intervals and indeed to incident 
dementia cases as the data for these are gathered and processed. This also means that 
the number of patients included in future analyses should be greater. 
It is possible that the number of patients and follow up time reported here resulted in 
too little statistical power to assess some risk factors. Despite this though there was 
clearly sufficient power for statistical significance to be reached for some factors and 
the study was not designed to achieve power for all comparisons, rather to provide 
epidemiological data and to support future practice. The fact that the data are drawn 
from a clinical double blind placebo controlled trial may also be considered a 
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limitation, however, randomisation occurred after the collection of baseline risk factor 
data and there is nothing to suggest that the risk factor data would not have been 
randomly distributed by trial group. It may be that the trial active treatment changed 
the progression of cognitive change in patients who were taking it although given 
previous work on blood pressure reduction, this would be likely to reduce decline 
rather than enhance it. This then would mean that the results found here may have been 
even stronger without trial treatment although this must remain speculation until the 
trial double blind code is broken. Finally, it should be remembered that carrying out 
multiple analyses also raises the risk of a significant finding occurring by chance. 
7. Chapter 7: Conclusion 
7.1. 	Literature review 
Risk factors for cognitive decline/dementia as identified in the literature were 
evaluated. There are risk factors where intervention in not feasible, increasing age, 
female gender and presence of ApoeE4; risks associated with racial factors are 
possible but the evidence is unclear to date. Where risk factors are modifiable they can 
be divided into vascular, lifestyle and other. For vascular risk factors; the evidence in 
the literature would suggest that previous stroke and hypertensive status increase rise 
although, whether lowering blood pressure reduces risk is unclear and there is a 
suggestion that it may be related to the class of drug. Calcium channel blockers may 
provide additional protection. Heart failure and diabetes may also increase risk 
although the evidence is far from clear cut. Cholesterol levels may be important 
although after carrying out a systematic review it was clear that there was insufficient 
evidence available, to decide whether plasma cholesterol, dietary cholesterol or statin 
use had an effect on cognition although it is possible. Lifestyle factors may also have 
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an effect and current smoking increases risk whereas moderate alcohol use seems to 
decrease risk according to systematic review and meta-analysis. Higher body mass 
index may increase risk according to systematic review although studies are limited 
and attempts to amalgamate data require the caveats associated with limitations related 
to different methods of data collection, analysis etc: Lower education is likely to 
increase risk although the complex interactions between education, opportunity and 
intelligence are not fully clear. In addition to the above, the literature review suggests 
that lower haemoglobin (or anaemia) may increase risk but there is no evidence 
pertaining to higher haemoglobin and dementia risk despite the fact that mortality risk 
is increased. The evidence for use of anti-inflammatories and nootropics, (specifically 
the two most common in the population under discussion, piracetam and ginkgo 
biloba), is limited and mixed. The evidence for depression playing a part is stronger 
with the suggestion that higher levels of depression are associated with increased risk 
and that the aetiology behind this could be complex and multifactorial. 
71. 	Cohort study 
A hypothesis was identified for each risk factor and tested using the data available 
from the baseline visit of the HYVET trial. These risk factors were then re-examined 
in relation to change in MMSE over two years and identification of cognitive decline, 
possible incident dementia. The main factors that were identified as increasing risk of 
decline were low education and high haemoglobin. Several other factors also reached 
significance in some analyses but only haemoglobin and education remained 
significant in all analyses. 
The following conclusions are based mainly on the results of the multivariate analyse 
Sociodemographic & lifestyle: 
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• Lower levels of education were associated with a larger fall in MMSE over two 
years, and a higher likelihood of incident cognitive decline and dementia 
• Non-drinkers were not significantly different to drinkers in any longitudinal 
analyses 
• Heavy alcohol consumption had no significant relationship to longitudinal 
cognition scores 
• Smoking status had no significant relationship to longitudinal cognition scores 
• Female sex was associated with a larger fall in MMSE over two years, and 
higher likelihood of incident cognitive decline and dementia 
• Older age was associated with a larger fall in MMSE over two years, and a 
higher likelihood of incident cognitive decline and dementia 
Clinical: 
• BMI had no significant relationship to longitudinal cognition scores 
• A lower haemoglobin had no significant relationship to longitudinal cognition 
scores 
• A higher haemoglobin was associated with a larger fall in MMSE over two 
years, and a higher likelihood of incident cognitive decline and dementia 
• A higher total cholesterol was not significantly associated with a larger fall in 
MMSE over two years, or with a higher likelihood of incident cognitive decline 
and dementia 
• HDL cholesterol had no significant relationship to change in MMSE over two 
years but a higher HDL cholesterol was related to increased risk of incident 
cognitive scores. 
• The number of co-morbidities had no significant relationship to longitudinal 
cognition scores 
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• Depression scales were not related to longitudinal cognition scores 
• Serious adverse events occurring in two year follow up had no significant 
relationship to longitudinal cognition scores 
Vascular: 
• Previous stroke had no significant relationship to longitudinal cognition scores 
• Heart failure had no significant relationship to longitudinal cognition scores 
• Diabetes had no significant relationship to longitudinal cognition scores 
• There was no significant relationship between any systolic or diastolic blood 
pressure measure and longitudinal cognitive function 
• Orthostatic hypotension was associated with a larger fall in MMSE over two 
years. 
Drug treatment: 
• Lack of previous antihypertensive use was not associated with longitudinal 
cognition scores although previous use of calcium channel blockers and ACE 
inhibitors were associated with larger fall in MMSE over two years 
• Statin use had no significant relationship to longitudinal cognition scores 
• Patients using piracetam at baseline were more likely to show a larger fall in 
MMSE over two years, and a higher likelihood of incident cognitive decline 
and dementia. 
• Patients using NSAIDs at baseline were less likely to show a fall in MMSE 
over two years, but had a higher likelihood of incident cognitive decline and 
dementia 
• Aspirin use had no significant relationship to longitudinal cognition scores 
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The aim of the study, to identify the risk factors that predicted fall in MMSE over two 
years or identification of cognitive decline, in very elderly hypertensives, was realised 
successfully. 
7.3. 	Wider and further implications 
This is the first time that such a population has been examined so comprehensively and 
the findings presented here clearly point to a means of easily assessing very elderly 
patients, particularly hypertensive patients, for likelihood of cognitive decline and 
falling MMSE over two years. 
Educational level is not easy to change and although there is some evidence suggesting 
that people who continue to use their cognitive skills more assiduously are less likely 
to suffer from dementia [314,323] this is likely to be confounded by a number of 
factors and recommending cognitive exercises to this population may not have a strong 
effect. High haemoglobin should be investigated. The patients may have underlying 
respiratory problems, particularly in countries with high smoking rates and high levels 
of pollution such as China. 
Account should also be taken of, older age, higher HDL cholesterol, lack of NSAID 
use, piracetam use, orthostatic hypotension and high standing systolic blood pressure. 
Future analyses from the HYVET database will allow the examination of these risk 
factors with a longer follow up and answer the primary question of whether to treat the 
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pattern of results) 
40% drank infrequently, 30% 
frequently. 
Drinking levels in midlife were 
similar to old age. 
Infrequent drinkers taken as 
the reference group (non-
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2.14), frequent drinkers 1.44 
(0.66-3.15). 
Compared to infrequent drinkers 
Cognitive impairment similar 
pattern. 
non-drinkers OR 2.15 (1.01- 
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marked difference for 
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Cognitive 
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Adjusted for 'true abstainers' 
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Alcohol found to be a risk 
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alcohol than women (6.9%) 
Vascular 
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RR vascular dementia 2.18 
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MMSE, (BMI, self 
perceived health, use 
of psychotropic drugs, 
family 
status, diabetes not 
used in final model) 
250-500m1 protective for 
dementia and Alzheimer's 
disease 
Alzheimer' 
s disease + 
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For dementia as a whole, 
none=reference category 
mild use 0.81 (0.5-1.3); 
moderate 0.19 (0.05-0.66):. 
heavy 0.31 (0.04-2.42). 
Alzheimer's disease 
mild 0.55(0.31-0.99)(p<0.05), 
moderate 0.28 (0.08- 
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of stroke. Beers wines 
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individually 
Men were more likely to 
drink. 
No significant results but less 
than one drink per week of 
wine reduced risk compared 
to reference category of 
never. 
Pattern similar when adjusted 
and analysesed separately 
for men/women. 
No others showed similar 
pattern. 
Also did analysis including 
those who refused - no 
difference. 
Alzheimer' 
s disease + 
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All alcohol types, both sexes, 
risk of dementia,reference 1-7 
units/week 
<1 drink OR 0.87(0.46-1.64) 
15-21 units/week 2.26 (1.09-
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8-14 units/week 0.81 (0.39-1.72) 
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Type of alcohol analysesed 
separately with never as the 
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Wine: monthly OR 0.43 (0.23- 
0.82)J, weekly 1.65(0.74-3.69), 
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daily 0.57 (0.15-2.11) 

















accounted for Finding 
Main 
outcome 




(numbers in brackets are 95% 
confidence intervals) 
Results used are those from the 




























the last three 
months. Also 
asked 'in you 
whole life 
have you had 












if the 3MSE 
fell from 
baseline. 












statin & aspirin use. 
56% drank. 56.4% of non 
drinkers had consumed at 
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score but not other covariates? 
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outcome 
Statistics if available. 
OR=Odds Ratio 
HR=Hazard Ratio 
(numbers in brackets are 95% 
confidence intervals) 
Results used am those from the 








r health study 

































Self report on 
usual 
frequency at 
















































race, sex, Hormone 
Replacement Therapy 
use, total cholesterol, 
Atrial Fibrillation, HDL 
cholesterol, 
fibrinogen, former 
smoker status, current 
smoker status, history 
of heart failure, stroke 
and Transient 
lschemic Attack, plus 
when beverage type 
was considered 
separately the other 2 
beverage types were 
controlled for. 
Adjusted for 'true 
abstainers' and 
change in alcohol 
consumption. 
OR for dementia 
Similar for Alzheimer's and 
Vascular dementia. Dementia 
rates higher in males and 
with APOE4 the pattern was 
similar although those with 
APOE4 were at higher risk. 
Similar findings when 
excluded people who had 
changed consumption level. 
Pattern of results was similar 
when only those with an 
MMSE >27 were analysesed 
or when results were 
adjusted for baseline MMSE. 
Incident rates were higher in 
blacks. When beers wines 
and spirits were examined 
separately the confidence 
intervals were wide and wine 
showed an essentially linear 
relationship although with a 
reduction in risk, beer a U 








Adj OR for dementia vs no 
drinks , all subjects
<1 drink/week 0.65 (0.41-1.02), 
1-6 drinks/week 0.46 (0.27- 
0.77), 
7-13 drinks/week 0.69 (0.37-
1.31), 
>=14 drinks/week 1.22 (0.60- 
2.49) 
women (n=363) 
<1 drink/week 0.52(0.30-0.90) 
1-6 drinks/wk 0.57(0.28-1.17) 7- 
7-13 drinks/wk 0.23 (0.09-0.61), 
>=14 drinks/wkk 0.39(0.14-1.10) 
men (n=241) 
< ldrinldwkk 0.82(0.38-1.78) 
1-6 drinks/week 0.36 (0.17-0.77) 
7-13 drinks/wk 1.42(0.58-3.48) 
>=14 drinks/wkk 2.40(0.86-6.64) 
OR for Alzheimer's disease - 
women 7-13 drinks/week 0.27 
(0.10-0.72); men 1-6 
drinks/week 0.36 (0.17-0.80) rst 
as 
adjusted for age, sex, race, 
APOE4, diabetes, and vital and 

















accounted for Finding 
Main 
outcome 




(numbers in brackets are 95% 
confidence intervals) 
Results used are those from the 















































































bottle of wine, 



















participants were not 
different to 
nonparticipants at 
follow up. Also that 
they adjusted for the 
potential confounders 
arising from the fact 
that the majority of the 
study were twin pairs. 
Using abstainers as the 
reference category and 
including alcohol answers 
without binge drinking...=eek Moderate 
Binge drinking - compared 
those who answered 
positively either in 1975 or 
1981 or both. No binge 
drinking on either occasion 
used as reference category. 
Increased OR for 
dementia/cognitive decline 
regardless of date with binge 
drinking. Similar for 'passing 
out'. For both though 95% 
confidence intervals very 
wide. 
When binge drinking and 
level of drinking were looked 
at together OR lower for 
moderate/heavy drinking at 
least for dementia but 
confidence intervals wide. 
No effect of alcohol type. 
Dementia 
Light drinking at baseline vs 
none 
OR 1.0 (0.5-2.0) Dementia, 
1.8 (1.0-3.5) cognitive decline 
OR 0.8 (0.3-2.3) Dementia, 
2.1 (0.9-4.9) cognitive decline 
Heavy 
OR 2.4 (0.7-8.7) Dementia, 
2.5 (0.8-8.1) cognitive decline 
Similar results for drinking at 
baseline and FU included 
Binge drinking at baseline 
OR 3.9(1.6-9.5) dementia 
OR 2.4 (1.1-5.2) cognitive define 
Binge drinking at baseline + 
alcohol intake 
OR 5.6(2.0-16) dementia 
increased the odds ratio for 
dementia/cognitive decline 
Adjusted for 'true abstainers' 


















accounted for Finding 
Main 
outcome 




(numbers in brackets are 95% 
confidence intervals) 
Results used are those from the 
adjusted analyses unless 
otherwise stated. 
Luchsing 

























up 4.1 (1.5) 
years. 980 















1 per week, 2- 
4, 5-6 per 
week, 1 per 
day, 2-3, 4-5, 














due to low 
numbers -
new category 


























diagnosed by alcohol 
- 
For Alzheimer's 
disease : age, sex, 
APOE4, education. 
For dementia and 
dementia assoicaued 
with stroke: as above 
= heart disease 
No significant association of 
intake with dementia 
after adjustement for 
covariates with exception of 
light to moderate intake of 
wine. There was no effect 
when grams of alcohol were 
used instead of categories. 
Where Apoe4 was positive 








Alzheimer's disease — 
Light to moderate intake vs 
 none 
Wine: HR 0.69 (0.45-1.09) 
Beer: HR 1.39(0.95-2.06)  
Dementia associated with stroke 
Light to moderate intake vs 
none 
Wine: HR 0.47(0.18-1.20) 
Beer: HR 0.59(0.23-1.53) 
Liquor: HR 1.14(0.53-2.47) 
— 
Non-significant similar trend. 
Using dummy variables for each 
alcohol type, 
Light to moderate intake vs 
none 
Demetia 
Wine: HR 0.52(0.34-0.80) 
Alzheimer's disease 
Wine: HR 0.55(0.34-0.89) 
NS for beer and liquor — values 
not given 
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9.2. 	Appendix 3: HYVET main trial and cognitive function 
protocol papers 
307 
9.3. 	Appendix 4: Copies of the guidelines for form 
completion as provided to the investigators. Translated 
copies are available on request from the author. 
308 
Hyvet Trial  
Guidelines for form completion 
The Case Report Forms for the Hyvet Trial are designed to be entered using an 
electronic reader and constructed with carbon paper to allow three copies to be 
produced simultaneously. Because of this we wish to pass on some information 
regarding the completion of the forms that will allow electronic data entry. 
Contents:  
Form appearance 	 2 
Page appearance 	 3 
Form completion 	Numbers & letters 	 4 
Tickboxes 	 5 
Diseases, operations & fractures 	5 
Drugs 	 5 
Form completion information:  
Entry Form 	 .[E] 	 6 
Interim Report Form 	  [1]  11 
Annual Report Form . [A] 	  13 
Cardiovascular Event Form 	. [CE]  18 
Hyvet Serious Adverse Event Form 	[AE] 	  19 
Terminating Event Form 	 [T] 22 
Open Follow up Interim Report Form. ....[FIJ 	  24 
Open Follow up Annual Report Form.....[FA]  26 
LOG BOOK FORM 	  31 
LABELS FORM 30 
When to send forms 	 34 
Sample forms:  
Entry Form 
Interim Report Form 
Annual Report Form 
Cardiovascular Event Form 
Hyvet Serious Adverse Event Form 
Terminating Event Form 
Open Follow Up Interim Report Form 
Open Follow Up Annual Report Form 




All of the Case Report Forms are provided with two carbon paper copies of each page. 
NB: Because of this the cardboard sheet provided must be placed behind each 
yellow?' page to prevent marking the subsequent pages. 
1: 'white' -page is the original and must be returned completed writing firmly 
with 
a ballpoint pen. 
-The white pages must remain together in the booklet and be 
returned to us for electronic entry. 
2: 'pink' -page is a carbon copy and as such will be completed automatically 
when the white page is written on. 
-The pink page should be detached and placed in the patient's file. 
3: 'yellow' -page is a carbon copy and will be completed automatically when 
the white page is written on. 
-The yellow page should be detached and placed in patient's file for 
possible collection by the Monitor. 
** If you wish to fax the white pages to the co-ordinating centre, for speed 
randomisation or because there is a problem with postage please remove the 
staples to fax the form then reassemble the white pages and post to the co-
ordinating centre.  
NB Even if forms are faxed initially we still need to receive the original white copy by 
post. 
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Nave any of the following occurred since last visit? 
D D 
	
Y Y Y Y 
0 0 
MALE FEMALE 
O 0 LI 
	
Y Y Y Y 
3,6,9,18,30,42,54 
Date of birth 
Sex 
Date of visit 
VISIT M. 	 
PAGE APPEARANCE 
■ 
Locator blocks: These are the black printed 
rectangles at each corner of each page. They 
allow the computer to work out where to 'look' 
on the page. They are vital to successful data 




Type of actor 
Lives on own: 
Lives with spot 
Lives with relat 
Sheltered: 




These are vital for data entry 
and must not be removed or 
written over. There are three 
barcodes at the bottom of 





Aortic dissecting aneurysm 





❑  ❑..Please complete Fonn T 
(requiring anthypertensive 
treatment other than trial medication for more than 3 months) 
Yes Na 
...Please c 	  
...Please complete Form T 
„Please complete Form T 
..Please complete Form T 
...Please complete Form T 








❑ ❑  
Survey barcode: 
This tells the computer which 
type of form it is reading for 
this reason pages from one 
form cannot be used in place 
of another. For example pages 
from an interim report form [I] 
cannot be used in lieu of an 
annual report form [A]. 
1 	 
fractures or operations specify site) 
Office use only 
M 
sue: sue, 	 Page , 
IIIIIIIIIIIIII 
age barcode: 
This tells the computer 
which page it is 
currently reading and 
therefore where to find 
the information. 
Serialisation barcode: 
This barcode is unique to each form - 
this is to ensure that data cannot be 
lost or mixed up. Because of this the 
investigator must complete an 
entire form for each patient and 
must not use parts of different 







   
Please DO NOT draw lines across boxes 
  
x 
     
     
If the question is not applicable leave the box blank 	 
For example: 
Previous cardiovascular disease:  
	
Yes 	No Year of last occurrence 
Subarachnoid haemorrhage n 	 
Year of last occurrence is none applicable and should be left blank. 
Numbers and letters. 
Number and letter boxes should be completed as shown below. 
7 9 4 
 
• Numbers and letters have to be clear and must not overlap the edges of the boxes 
provided. 
• Only one number digit or letter may be written in each box. 
Text should be written in English capital letters. A B C D E F G H I etc: 
1 a 3i.5L4.890 
Numbers should be written like the following; 	 ✓  
(Please cross sevens) 
Please do not write numbers differently for example: 0  
Please fill in the numbers according to the boxes provided, i.e. with the appropriate 
number of digits - we cannot accept different numbers of decimal places or extra 
numbers written outside the boxes shown as we cannot process them. 
VI 





     
Letters also: For example, Patient initials for 'Mary Ann Smith' 
FORM COMPLETION 
Tickboxes 
Tickboxes should be completed as shown below. (With a diagonal line across 
the box.) 
M3le Female Single n  
Married 
Widowed 
• Diagonal lines have to be clear and must not overlap the edges of the boxes 
provided. 
For completion of questions asking about Diseases, operations and 
fractures  
• Please write the name of the disease, operation, event, site of fracture in the space 
provided. 
• Please do not write in the boxes marked 'office use only' 
• For example: page 2 Entry Form. 
Drugs 
• If known please write the generic name for the drug in the space provided. 
* Randomisation may be delayed if the generic name is not given 
• Please do not write in the boxes marked 'office use only' 
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Patient initials:  
• Please write the initial of patient's 
• Given name first 
• Additional name 
• Family name last 
For example: Dr Nigel Stanley Becket 
N S B 
Entry Form  [El 
• 8 page form 
• survey number 20 
• to be completed at M=0 
• required for randomisation 
Page  
Patient number:  
• complete only the country code and centre code, 
• We will complete the last 4 digits after randomisation. 
Inclusion & Exclusion criteria:  
• Please complete the 'yes/no' questions for all inclusion and exclusion criteria. 
• For a patient to be randomised all inclusion criteria must be answered yes and all 
exclusion criteria must be answered no. 
Page 2 
• Please complete all questions that are applicable. See p4 - Form Completion. 
Page 3 
Current drugs 
• If known please give the generic name for each drug. 
Page 4 
Living arrangement 
• Please choose only one option - mark only one box. 
Marital status  




The ECG will be recorded as follows: 
• A calibration mark should be recorded, in each channel. This calibration mark 
has to be adjusted to exactly 10mm. Leads recorded with a reduced calibration 
should be preceded by a calibration mark of exactly 5nun. 
• The tracings will be recorded at a paper speed of 25mm per second and for each 
lead, I, II, III, aVR, aVL, aVF, VI to V6 , a strip of at least 5 seconds should be 
obtained. 
• Baseline drift and noise should be avoided. 
• Each ECG should be identified as follows: 
• Patient number 
• Date of birth 
• Initials 
• Date of recording 
The calibration signal is measured from the top margin of the baseline to the top 
of the square wave. (See figure 1) 
Figure 1: Calibration wave 
R-waves are measured to the nearest whole millimetre in the next to last 
complete normal beat in the appropriate leads. The R-wave amplitude is the 
vertical distance between the upper margin of the P-R baseline at the onset of 
the QRS complex and the peak of the R-wave, even if the R-wave is preceded 
by a Q-wave (See figures 2 and 3). 
The maximum S-wave is measured in the same way as the maximum R-wave. 
Figures 2&3 Below 
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Figure.2 Measure vertically from the onset of the ORS 
to the peak of the R 
R 
• 
Figure.3 Measure vertically from the onset 








• Record blood test results in accordance with the units given and the number of 
decimal places provided. 
(See page 4 of guidelines) 
• See below for conversion table. 
Table: Conversion of SI units to conventional units. 
Haemoglobin: 	(g/dl) x 0.62 = (mmo1/1) 
Uric acid: 	(mg/dl) x 59 = (Amo1/1) 
Creatinine (mg/dl) x 88.4 = ("Imola) 
Sodium 	 (meq/1) x 1 = (mmo1/1) 
Potassium (meq/1) x 1 = (mmo1/1) 
Urea 	 (mg/100m1) x 0.17 = (mmo1/1) 
Glucose (mg/dl) x 0.056 = (mmo1/1) 
Total cholesterol 	(mg/dl) x 0.026 = (mmo1/1) 
HDL Cholesterol 	(mg/dl) x 0.026 = (mmo1/1) 
Ref: see Bold A., Wilding P. 1976 Clinical Chemistry. Conversion scales for SI units 
with normal adult reference values. Blackwell Scientific Publications (Oxford). 
Page 6 
Orientation Memory Concentration test (OMC)  
• Please mark whether patient correctly names the year and month 
• Do not mark in the box marked 'office use only' 
• Memory phrase, 
➢ when asking the patient to remember a name and address please 
choose an appropriate name and address according to your country. 
D There are two fields to be remembered for the name 
- in english  'Forename & Surname' 
➢ There are three fields to be remembered for the address 
- 'Number, Street/Road & Town/City' 
Nikes 7&8 
Mini Mental State Exam (MMSE)  
Please use templates provided to administer the MMSE in the appropriate language. 
The MMSE has several sections, 
➢ Orientation, 
D Registration, 
➢ Attention & Calculation 
ONLY ATTEMPT PART B IF PATIENT UNABLE TO COMPLETE PART A 
➢ Recall 
D Language, Naming and Repeating, 
D Reading, 
➢ Writing, 
➢ Three stage command, 
317 
Use a separate sheet of paper, not the questionnaire, this is because if the 
questionnaire is folded it will be difficult to scan electronically. 
➢ Construction. 
➢ Extra question. 
We would like to know if patient was unable to do some parts of the MMSE 
because they have a physical problem rather than because they have a memory 
problem. 
** PLEASE SIGN THE TOP RIGHT CORNER OF PAGE 1 AFTER FORM IS 
COMPLETE. 
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Interim Report Form  [I] 
• 2 page form 
• Survey number 21 
• To be completed at M3, M6, M9, M18, M30, M42 & M54 
• If patient leaves the double blind part of the trial complete the Follow-up Interim 
Report Form instead. 
Puke I  
Patient number:  
• Complete full patient number, 
Living arrangement:  
• Choose one box only 
Visit M= 
• Please complete current visit number, 03, 06 etc: 
Have any of the following occurred since last visit?  




Stroke - site not known 
Aortic dissecting aneurysm 
Retinal haemorrhages exudates and papilloedema 
Or - other events requiring antihypertensive treatment other than trial medication 
for more than three months. 
The patient cannot remain in the double blind trial and a Terminating Event Form 
.rja must be completed. If alive, the patient should be followed in the open follow 
up. 
If the patient has had an event but not required antihypertensive treatment other 
than trial medication for more than three months the patient may remain in the 
trial but a Cardiovascular Event Form 10E1 must be completed. 
Other diseases/events since last visit includirm any fractures or operations & current 
symptoms.  
• Please do not write in the boxes 'office use only'. 
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Page 2 
Study medication at moment of visit 
• Please mark only one box 
• If treatment changed since last visit choose box next to current treatment, 
and tick yes under 'Dose change since last visit' and specify date dose changed. 
• If treatment interrupted please specify number of days missed 
• Please complete blood test results if Indapamide or Perindopril started at previous 
visit 
Other current drugs including aspirin other analgesics and laxatives etc:  
• Please give GENERIC drug name and dose, if known. 
Blood pressure  
• Please record blood pressure results 
Number of Indapamide/Perindopril tablets remaining,  
State how many tablets remaining - NB not applicable for visits M3 & M9 
** PLEASE SIGN THE TOP RIGHT CORNER OF PAGE 1 AFTER FORM IS 
COMPLETE. 
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Annual Report Form  [A] 
• 7 page form 
• Survey number 22 
• To be completed at M12, M24, M36, M48 & M60 
• If patient leaves the double blind part of the trial complete the Follow-up Annual 
Report Form instead. 
P 
Patient number:  
• Complete full patient number, 
Living arrangement:  
• Choose one box only 
Visit M=,  
• Please complete current visit number, 03, 06 etc: 
Have any of the following occurred since last visit 




Stroke - site not known 
Aortic dissecting aneurysm 
Retinal haemorrhages exudates and papilloedema 
Or - other events requiring antihypertensive treatment other than trial medication 
for more than three months. 
The patient cannot remain in the double blind trial and a Terminating Event Form 
Lil must be completed. If alive, the patient should be followed in the open follow 
up 
If the patient has had an event but not required antihypertensive treatment other 
than trial medication for more than three months the patient may remain in the 
trial but a Cardiovascular Event Form ICE] must be completed. 
Other diseases/events since last visit including any fractures or operations.  
• Please do not write in the boxes 'office use only'. 
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Page 2 
Study medication at moment of visit 
• Please mark only one box 
• If treatment changed since last visit choose box next to current treatment, 
and tick yes under 'Dose change since last visit' and specify date dose changed. 
• If treatment interrupted please specify number of days missed 
• Please complete blood test results if Indapamide or Perindopril started at previous 
visit 
Other current drugs including aspirin other analgesics and laxatives etc:  
• Please give GENERIC drug name and dose, if known. 
Current symptoms 
• Please do not write in the boxes 'office use only'. 
Pate 
Smoking and drinking habits 
If patient is an ex or current smoker please give details of consumption per day of 
cigarettes, cigars &/or pipes. 
If patient drinks alcohol please give consumption of spirits, wine &/or beer per 
week 
Living arrangements  
• Please choose only one box 
Blood pressure 




The ECG will be recorded as follows: 
• A calibration mark should be recorded, in each channel. This calibration mark 
has to be adjusted to exactly 10mm. Leads recorded with a reduced calibration 
should be preceded by a calibration mark of exactly 5mm. 
• The tracings will be recorded at a paper speed of 25mm per second and for each 
lead, I, II, III, aVR, aVL, aVF, V 1 to V6 a strip of at least 5 seconds should be 
obtained. 
• Baseline drift and noise should be avoided. 
• Each ECG should be identified as follows: 
• Patient number 
• Date of birth 
• Initials 
322 
- 	Date of recording 
The calibration signal is measured from the top margin of the baseline to the top 
of the square wave. (See figure 1) 
Figure 1: Calibration wave 
• 
R-waves are measured to the nearest whole millimetre in the next to last 
complete normal beat in the appropriate leads. The R-wave amplitude is the 
vertical distance between the upper margin of the P-R baseline at the onset of 
the QRS complex and the peak of the R-wave, even if the R-wave is preceded 
by a Q-wave (See figures 2 and 3). 
The maximum S-wave is measured in the same way as the maximum R-wave. 
Figures 2&3 Below. 
10. 
Figure.2 Measure vertically from the onset of the QRS 
to the peak of the R 
V 
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Figure.3 Measure vertically from the onset 





• Please complete blood test results according to the number of decimal places 
provided and in the units specified. 
• NB because the data is read electronically, do not write extra numbers outside the 
boxes, or more than one number per box 
• See below for conversion table 









HDL Cholesterol  
(g/dl) x 0.62 = (mmo1/1) 
(mg/di) x 59 = (jtmol/1) 
(mg/dl) x 88.4 = (jAmol/1) 
(meq/1) x 1 = (mmo1/1) 
(meq/1) x 1 = (nuno1/1) 
(mg/100m1) x 0.17 = (mmo1/1) 
(mg/d1) x 0.056 = (mmo1/1) 
(mg/dl) x 0.026 = (mmo1/1) 
(mg/dl) x 0.026 = (mmo1/1) 
Ref: see Bold A., Wilding P. 1976 Clinical Chemistry. Conversion scales for SI units 
with normal adult reference values. Blackwell Scientific Publications (Oxford). 
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Page 5 
Orientation Memory Concentration test (OMC)  
• Please mark whether patient correctly names the year and month 
• Do not mark in the box marked 'office use only' 
• Memory phrase, 
D when asking the patient to remember a name and address please 
choose an appropriate name and address according to your country. 
D There are two fields to be remembered for the name 
- in english 'Forename & Surname' 
D There are three fields to be remembered for the address 
- 'Number, Street/Road & Town/City' 
Pages 6& 7 
Mini Mental State Exam (MMSE)  
Please use templates provided to administer the MMSE in the appropriate language. 
The MMSE has several sections, 
D Orientation, 
D Registration, 
➢ Attention & Calculation 
ONLY ATTEMPT PART B IF PATIENT UNABLE TO COMPLETE PART A 
➢ Recall 
D Language, Naming and Repeating, 
D Reading, 
D Writing, 
D Three stage command, 
Use a separate sheet of paper, not the questionnaire, this is because if the 
questionnaire is folded it will be difficult to scan electronically. 
D Construction. 
D Extra question. 
We would like to know if patient was unable to do some parts of the MMSE 
because they have a physical problem rather than because they have a memory 
problem. 
** PLEASE SIGN THE TOP RIGHT CORNER OF PAGE 1 AFTER FORM IS 
COMPLETE. 
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Patient initials:  
• Please write the initial of patient's 
• Given name first 
• Additional name 
• Family name last 
For example: Dr Nigel Stanley Becket 
N S B 
Cardiovascular Event Form  [CE] 
• 1 page form 
• Survey number 59 
• To be completed if patient suffers a cardiovascular event that requires 
antihypertensive treatment other than trial medication for less than three 
months. 
• NB. events requiring more than 3months treatment with antihypertensives other 
than trial medication require withdrawal from double blind treatment and the 
completion of a Terminating event form [T] 
Pare 1  
Patient number:  
• Please complete full patient number. 
Name of Doctor 
• Please complete in full 
Centre name  
• Please complete in full 
Date of birth 
• Please complete in full 
Sex 
• Please complete 
Date of event 
• Please complete in full 
Type of event 
)=. Myocardial Infarction 
If yes please speck clinical details 
➢ Angina  
If yes please specify clinical details 
➢ Congestive cardiac failure 
If yes please specify clinical details 
➢ Transient Ischaemic Attack 
If yes please speck clinical details 
➢ Other cardiovascular event 
Please give details of the event in the box provided. 
** PLEASE SIGN THE TOP RIGHT CORNER OF PAGE 1 AFTER FORM IS 
COMPLETE. 
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Patient initials:  
Please write the initial of patient's 
Given name first 
Additional name 
• Family name last 
For example: Dr Nigel Stanley Becket 
N S B 
Hyvet Serious Adverse Event Form  [AE] 
• 5 page form 
• Survey number 25 
To be completed if patient suffers any serious adverse event which occurs after 
randomisation, 
This form must be completed and white pages 2,3&4 faxed to the co- 
ordinating centre within 48hours of the event. 
For full details and instructions please see first page of form [AE] 
Page 1  
• Instructions regarding the completion of the form. 
Page 2 
Patient number:  
• Please complete full patient number. 
Name of Doctor  
• Please complete in full 
Centre name  
• Please complete in full 
Date of birth  
• Please complete in full 
Sex 
• Please complete 
Date of event 
• Please complete in full 
Date of entry into study 
• Please complete in full 
Study medication when event occurred 
• Please choose one box only 
If treatment has been interrupted?  
• Please give date stopped and restarted if applicable. 
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Other Drugs 
• Please give details of drugs and dates other than those used to treat adverse event or 
trial medication 
• NB please give generic names of drugs if known 
Pare 3  
Drugs continued  
Symptoms and Diagnoses 
• Please give details of patients symptoms and diagnoses in the boxes provided 
Details  
• Please give further details for example of laboratory tests in the box provided 
Page 4 
Action  





Give details of end result: 
• Full recovery 
• Death 
• Withdrawal (From double blind part of the trial) 
• Other 
Adverse event related to trial medication in the opinion of the investigator 
• Please complete and sign page 4 
❑ SIGN TOP RIGHT OF PAGE 2 
❑ FAX WHITE PAGES 2,3& 4 TO HAMMERSMITH CO-ORDINATING CENTRE 
WITHIN 48 HOURS. 
❑ POST WHITE PAGES 2,3& 4 TO HAMMERSMITH CO-ORDINATING 
CENTRE WITHIN 48 HOURS. 
**Please complete page 5 as applicable 
Pare 5 
328 
Additional information,  
• To be completed when patient's condition is clinically stable 
Details 
• Give details of laboratory tests or investigations etc: in the box provided. 
Outcome 
• Give details of end result 
Related to trial medication in the opinion of the investigator 
• Please complete 
Name and position of person who completed the form  
• Give details of person completing the form, date completed & 
❑ ** PLEASE SIGN TOP RIGHT HAND CORNER OF PAGE 5 
• Post page 5 to co-ordinating centre when completed. 
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Terminating Event Report Form (Double Blind) IT]  
This is identical to the Serious Event Form (Open Follow Up) 
• 2 page form 
• Survey number 26 
• This form is completed whenever a terminating event occurs. Patient continues 
in the open follow up 
Page 1  
Patient number:  
• Complete full patient number 
1) Information for those alive.  
• Give date of event 
• Non-fatal terminating events 
• Withdrawal Events 
• **Please give information about the event even if patient has already withdrawn 
from the double blind part of the trial. 
Page 2 
2) Information on those who have died.  
• Please give both immediate and underlying cause of death. 
For those dead or alive  
Other diseases/events since last visit 
• Please give details and dates of events/diseases not already mentioned 
Study medication at time of event 
• Please mark only one box 
• If treatment changed since last visit choose box next to current treatment, 
and tick yes under 'Dose change since last visit' and specify date dose changed. 
• If treatment interrupted please specify number of days missed 
Page 3 
Other current drugs at time of the event including aspirin other analgesics and laxatives 
etc: 
• Please give GENERIC drug name and dose, if known. 
Most recent blood pressure before event 
• Please record the most recent blood pressure values from before the event. 
Please record evidence of the above events (Blood tests, X rays etc)  
Give any results from blood tests etc: In the box provided. 
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Page 4 
Orientation Memory Concentration test (OMC)  
Please mark whether patient correctly names the year and month 
Do not mark in the box marked 'office use only' 
Memory phrase, 
➢ when asking the patient to remember a name and address please 
choose an appropriate name and address according to your country. 
➢ There are two fields to be remembered for the name 
- in english  'Forename & Surname' 
➢ There are three fields to be remembered for the address 
- 'Number, Street/Road & Town/City' 
Pages 5&6 
Mini Mental State Exam (MMSE)  
Please use templates provided to administer the MMSE in the appropriate language. 
The MMSE has several sections, 
D Orientation, 
D Registration, 
D Attention & Calculation 
ONLY ATTEMPT PART B IF PATIENT UNABLE TO COMPLETE PART A 
➢ Recall 
➢ Language, Naming and Repeating, 
➢ Reading, 
D Writing, 
D Three stage command, 
Use a separate sheet of paper, not the questionnaire, this is because if the 
questionnaire is folded it will be difficult to scan electronically. 
D Construction. 
➢ Extra question. 
We would like to know if patient was unable to do some parts of the MMSE 
because they have a physical problem rather than because they have a memory 
problem. 
** PLEASE SIGN THE TOP RIGHT CORNER OF PAGE 1 AFTER FORM IS 
COMPLETE 
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Open Follow Up Interim Report Form  [FI] 
• 2 page form 
• Survey number 26 
• To be completed instead of the Interim Report Form [I] after the patient has left 
the double blind part of the trial 
Page 1  
Patient number:  
• Complete full patient number, 
Have any of the following occurred since last visit 
If since the last HYVET visit, any of the events listed below have occurred, a 






Stroke - site not known 
Aortic dissecting aneurysm 
Retinal haemorrhages exudates and papilloedema 
If alive, the patient should be followed in the open follow up. 
If the patient has had an event but not required antihypertensive treatment for 
more than three months a Cardiovascular Event Form [CE] must be completed. 
Other diseases/events since last visit including any fractures or operations 
Please do not write in the boxes 'office use only'. 
Page 2 
Current symptoms.  
• Please do not write in the boxes 'office use only'. 
Other current drugs including aspirin other analgesics and laxatives etc:  
• Please give GENERIC drug name and dose, if known. 
Living arrangement:  
• Choose one box only 
Falls:  
• If patient has fallen since last visit please give number of falls 
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Blood pressure  
• Please record blood pressure results 
** PLEASE SIGN THE TOP RIGHT CORNER OF PAGE 1 AFTER FORM IS 
COMPLETE. 
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Open Follow Up Annual Report Form [FA] 
• 6 page form 
• Survey number 27 
• To be completed instead of the Annual Report Form [A] after the patient has left 
the double blind part of the trial 
Page 1  
Patient number:  
• Complete full patient number, 
Have any of the following occurred since last visit 
If since the last HYVET visit, any of the events listed below have occurred, a 






Stroke - site not known 
Aortic dissecting aneurysm 
Retinal haemorrhages exudates and papilloedema 
If alive patient should be followed in open follow up. 
If the patient has had an event but not required antihypertensive treatment for 
more than three months a Cardiovascular Event Form ICE] must be completed. 
Other diseases/events since last visit including any fractures or operations 
• Please do not write in the boxes 'office use only'. 
Page 2 
Other current drugs including aspirin other analgesics and laxatives etc:  
• Please give GENERIC drug name and dose, if known. 
Current symptoms  
• Please do not write in the boxes 'office use only'. 
Living arrangement:  
• Choose one box only 
Falls:  
• If patient has fallen since last visit please give number of falls 
334 
Blood pressure  
Please record blood pressure results 
Page 3 
Electrocardiogram 
The ECG will be recorded as follows: 
• A calibration mark should be recorded, in each channel. This calibration mark 
has to be adjusted to exactly 10mm. Leads recorded with a reduced calibration 
should be preceded by a calibration mark of exactly 5mm. 
• The tracings will be recorded at a paper speed of 25mm per second and for each 
lead, I, II, III, aVR, aVL, aVF, VI to V6 , a strip of at least 5 seconds should be 
obtained. 
• Baseline drift and noise should be avoided. 
• Each ECG should be identified as follows: 
• Patient number 
• Date of birth 
• Initials 
• Date of recording 
The calibration signal is measured from the top margin of the baseline to the top 
of the square wave. (See figure 1) 
Figure 1: Calibration wave 
• 
R-waves are measured to the nearest whole millimetre in the next to last 
complete normal beat in the appropriate leads. The R-wave amplitude is the 
vertical distance between the upper margin of the P-R baseline at the onset of 
the QRS complex and the peak of the R-wave, even if the R-wave is preceded 
by a Q-wave (See figures 2 and 3). 
The maximum S-wave is measured in the same way as the maximum R-wave. 
Figures 2&3 Below. 
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Figure.2 Measure vertically from the onset of the QRS 





Figure.3 Measure vertically from the onset 
of the QRS to the peak of the R 
P 
S 
Blood tests  
• Please complete blood test results according to the number of decimal places 
provided and in the units specified. 
• NB because the data is read electronically, do not write extra numbers outside the 
boxes, or more than one number per box. 
• See below for conversion table 
• Table: Conversion of SI units to conventional units. 
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Haemoglobin: 	(g/dl) x 0.62 = (mmo1/1) 
Uric acid: 	(mg/di) x 59 = (Ino1/1) 
Creatinine (mg/di) x 88.4 = (jimol/1) 
Sodium 	 (meq/1) x 1 = (mmo1/1) 
Potassium (meq/1) x 1 = (mmo1/1) 
Urea 	 (mg/100m1) x 0.17 = (mmo1/1) 
Glucose (mg/di) x 0.056 = (mmol/1) 
Total cholesterol 	(mg/di) x 0.026 = (mmo1/1) 
HDL Cholesterol 	(mg/di) x 0.026 = (mmo1/1) 
Ref: see Bold A., Wilding P. 1976 Clinical Chemistry. Conversion scales for SI units 
with normal adult reference values. Blackwell Scientific Publications (Oxford). 
Smoking and drinking habits  
If patient is an ex or current smoker please give details of consumption per day of 
cigarettes, cigars &/or pipes. 
If patient drinks alcohol please give consumption of spirits, wine &/or beer per 
week 
Page 4 
Orientation Memory Concentration test (OMC)  
Please mark whether patient correctly names the year and month 
Do not mark in the box marked 'office use only' 
Memory phrase, 
D when asking the patient to remember a name and address please 
choose an appropriate name and address according to your country. 
D There are two fields to be remembered for the name 
- in english  'Forename & Surname' 
D There are three fields to be remembered for the address 
- 'Number, Street/Road & Town/City' 
Pages 5&6 
Mini Mental State Exam (MMSE)  
Please use templates provided to administer the MMSE in the appropriate language. 
The MMSE has several sections, 
D Orientation, 
D Registration, 
D Attention & Calculation 
ONLY ATTEMPT PART B IF PATIENT UNABLE TO COMPLETE PART A 
D Recall 
➢ Language, Naming and Repeating, 
➢ Reading, 
D Writing, 
D Three stage command, 
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Use a separate sheet of paper, not the questionnaire, this is because if the 
questionnaire is folded it will be difficult to scan electronically. 
➢ Construction. 
➢ Extra question. 
We would like to know if patient was unable to do some parts of the MMSE 
because they have a physical problem rather than because they have a memory 
problem. 
** PLEASE SIGN THE TOP RIGHT CORNER OF PAGE 1 AFTER FORM IS 
COMPLETE 
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Patient initials:  
• Please write the initial of patient's 
• Given name first 
• Additional name 
• Family name last 
For example: Dr Nigel Stanley Becket 
N S B 
HYVET LOG BOOK 
• 1 page form 
• Survey number 58 
• To be completed during M-2, M-1 & M=0 
• Log book form is to be completed for each patient started on 
placebo irrespective of subsequent randomisation. 
Page 1  
Sex 
• Please complete 
Date of birth  
• Please complete in full 
Consent 
• Please complete 
Log book number  
• Number patients sequentially as they are seen 
• NB the maximum number of patients for any one investigator is 100 
Previous antihypertensive treatment 
• Please state whether patient has been taking antihypertensives prior to beginning the 
trial 'run-in' phase at M-2 
Antihypertensive treatment stopped 
• If patient was taking antihypertensives prior to M-2 have they stopped taking them? 
• NB Patient cannot continue in trial run-in if taking antihypertensives 
Country number 
• As provided by the Co-ordinating centre 
Centre number  
• As provided by the Co-ordinating centre 
Name of Doctor  
• Please complete in full 
Date of visits. 
• Please give date of M-2 (please complete a 4 digit year) 
• Please give date of M-1 (Please complete a 2 digit year) 
• Please give date of M=0 (Please complete a 2 digit year) 
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Blood pressures at ditferent visits  
• Please give sitting blood pressure at M-2 
• Please give sitting blood pressure at M-1 
• Please give sitting and standing blood pressure at M=0 
If not randomised, REASON FOR NON RANDOMISATION 
• If Patient is not put forward for randomisation i.e. entry form not completed please 
state reason why in the box provided. 




• Complete patient details 
• Each time patient is given a box of medication remove the small perforated 
part of the label and stick to the label form 
• Write the relevant visit number and date of visit next to the label 
• Store in patient files for 2 years 
• Return label forms to co-ordinating centre every 2 years 
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When to return forms to co-ordinatinq centre 
Log Book Form 
Entry Form 
randomisation 
Interim Report Form 




Adverse Event Form 
Terminating Event 
Form 
Open Follow Up 
Interim Report Form 
Open Follow Up 
Annual Report Form  
-Send forms to co-ordinating centre annually 
-Send to co-ordinating centre as soon as complete 
NB can be faxed then posted for faster 
-As soon as complete 
-As soon as complete 
-Complete and send as close to time of event as 
possible 
-Complete immediately fax and post to co-ordinating 
centre within 48hrs 
-Complete and send as close to time of event as 
possible 
-As soon as complete 
-As soon as complete 
NB If there is a problem with postage the staples can be removed and the 
forms faxed. They must still be posted however as we need the original 
white copy to enter the data. 
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10.2. Appendix 5: A copy of the portion of the case report 
form where the MMSE data was recorded is available 
from the author (it is based within specialist software and 
cannot be included electronically) 
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10.3. Appendix 6: Copies of the instructions used to guide 
investigators in the administration of the MMSE (Copies 
of the translated MMSE tests are confidential and cannot 
be included as the HYVET trial is still ongoing) 
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Instructions for the Mini Mental State Exam (MMSE)  
Scoring:  
The MMSE consists of 30 questions. For each question there are two answer boxes 
provided. Mark whether the patient's response to the question was 'incorrect' or 'correct' 
in the appropriate boxes. 
Orientation. 
Ensure that there is no calendar visible to the patient. 
Ask for the date. Then ask specifically for parts omitted, e.g., "Can you also tell me 
what season it is?" 
(The official dates for the four seasons in the UK and northern Europe in 2001 are as 
follows; 
spring begins March 20th, summer begins June 215t, autumn begins September 22nd  
and winter begins on December 21g. However, it is expected that the investigator will 
use their discretion according to their situation when the question is asked)  
The date must be exactly right to be scored 'correct'. The day before or after the current 
date is wrong. 
If the date is the last day of the month and the patient states the first day of the next 
month - both the day and month must be scored incorrect. 
Ask in turn "Can you tell me the name of this hospital?" (town, country, etc.). One point 
for each correct. 
Registration.  
Ask the patient if you may test his/her memory. Then say the names of 3 unrelated 
objects (see questionnaire), clearly and slowly, about one second for each. After you 
have said all three, ask him/her to repeat them. This first repetition determines his/her 
score that is each item that the patient repeats correctly the first time is scored correct -
each item that the patient fails to repeat correctly the first time is scored incorrect. After 
the initial scoring keep saying the three items until he/she can repeat all three - up to 6 
trials. If the patient does not learn all three after 6 trials recall (see below) cannot be 
meaningfully tested. 
Attention and calculation. 
• ALWAYS ATTEMPT PART A 
• If the patient cannot complete part A (serial subtraction) because of a lack of 
numeracy. Part B - spelling may be attempted. 
• It must be emphasized that part A must always be attempted 
• If the patient completes part A but is incorrect for some or all of the numbers these 
numbers should be marked as incorrect. If part A is abandoned after one or two tries 
part B must be used to increase the time before recall of the three words. 
• If the patient completes part A correctly part B must not be attempted. 
A: Subtraction. 
Ask the patient to begin with 100 and count backwards by 7. Stop after 5 subtractions 
Mark answers correct or incorrect. Do not provide feedback to the patient about their 
answers. 
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If the patient is unable to complete subtraction - for example because of lack of 
numeracy Part B may be attempted. 
Further assessments of the same patient must be made using the same 
question - that is if patient completes part A on their Entry form they must complete 
part A for all future assessments, Annual forms, Terminating event form, Follow up 
Annual forms etc: 
B: Spelling. 
The letters are only correct if they are in the correct order. Each letter is scored 
accordingly. 
If a letter is omitted/added or substituted into the word but the remaining letters are in 
the correct order, the remaining letters are correct. 
If letters are given in the wrong order they are incorrect. 
Recall. 
Ask the patient if he/she can recall the three words you previously asked him to 
remember. 
Each object to be recalled in any order is marked correct. 
Language.  
If patient is physically unable to complete this part of the test e.g.; is blind or suffering 
from a movement disorder etc: leave the boxes blank and mark the box at the bottom of 
the page to indicate this. 
Naming.  
Show the patient a wrist watch and ask him what it is. 
Repeat for pencil 
These must be exact to be scored correct. 
Repetition .  
Ask the patient to repeat the sentence after you. 
Allow only one trial. 
This must be exact to be scored correct. 
Reading 
Show a previously prepared card or write 'close your eyes' on a separate piece of paper. 
The writing should be large enough and clear enough for the patient to be able to see 
clearly 
(Please do not write on the questionnaire) 
Ask the patient to read the card aloud and do what is written on it all at once: do not 
repeat the instructions. The question is marked correct if the patient closes his/her eyes. 
Writing 
Ask the patient to write a short sentence. The patient may write in the box provided or 
the sentence may be copied into the box by the person completing the form. 
Do not dictate a sentence, it is to be written spontaneously. It must contain a subject and 
a verb and be sensible. Correct grammar and punctuation are not necessary. 
Three stage command. 
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Provide the patient with a sheet of paper - please do not use the questionnaire. 
Warn the patient that they need to pay attention, as the command will not be repeated. 
The whole command must be given at once - it cannot be repeated either whole or in 
parts. 
The response must be exact to be scored correct. 
Copying 
Ask the patient to copy the two pentagons shown on the left of the page. The pentagons 
must be drawn in the box provided on the questionnaire by the patient. The other 
questions may be covered if necessary to prevent the patient seeing their results. 
To be correct the pentagons must 	have 5 angles each 
have five sides each 
their intersection must form a four sided figure 
Drawing in front of the patient is not allowed. 
Tremor and rotation are ignored. 
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10.4. Appendix 7: Programs used to calculate the MMSE 
scores, missing values and to create risk factor variables 
available from the author on request 
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